
<html lang="en"     class="pb-page"  data-request-id="d9dfd68f-302d-4b34-bf23-6c443629b0a7"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.1c00703;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease" /></meta><meta name="dc.Creator" content="Ramakrishna  Nirogi" /></meta><meta name="dc.Creator" content="Abdul Rasheed  Mohammed" /></meta><meta name="dc.Creator" content="Anil Karbhari  Shinde" /></meta><meta name="dc.Creator" content="Shankar Reddy  Gagginapally" /></meta><meta name="dc.Creator" content="Durga Malleshwari  Kancharla" /></meta><meta name="dc.Creator" content="Srinivasa Rao  Ravella" /></meta><meta name="dc.Creator" content="Narsimha  Bogaraju" /></meta><meta name="dc.Creator" content="Vanaja Reddy  Middekadi" /></meta><meta name="dc.Creator" content="Ramkumar  Subramanian" /></meta><meta name="dc.Creator" content="Raghava Choudary  Palacharla" /></meta><meta name="dc.Creator" content="Vijay  Benade" /></meta><meta name="dc.Creator" content="Nageswararao  Muddana" /></meta><meta name="dc.Creator" content="Renny  Abraham" /></meta><meta name="dc.Creator" content="Rajesh Babu  Medapati" /></meta><meta name="dc.Creator" content="Jagadeesh Babu  Thentu" /></meta><meta name="dc.Creator" content="Venkat Reddy  Mekala" /></meta><meta name="dc.Creator" content="Surendra  Petlu" /></meta><meta name="dc.Creator" content="Bujji Babu  Lingavarapu" /></meta><meta name="dc.Creator" content="Sivasekhar  Yarra" /></meta><meta name="dc.Creator" content="Narendra  Kagita" /></meta><meta name="dc.Creator" content="Vinod Kumar  Goyal" /></meta><meta name="dc.Creator" content="Santosh Kumar  Pandey" /></meta><meta name="dc.Creator" content="Venkat  Jasti" /></meta><meta name="dc.Description" content="A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer’s dis..." /></meta><meta name="Description" content="A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer’s dis..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 12, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00703" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00703" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00703" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00703" /></link>
        
    
    

<title>Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00703" /></meta><meta property="og:title" content="Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0016.jpeg" /></meta><meta property="og:description" content="A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer’s disease. Starting from a reported 5-HT4R antagonist, a systematic structure–activity relationship was conducted, which led to the discovery of potent and selective 5-HT4R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, 12l). It showed balanced physicochemical–pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00703"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00703">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00703&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00703&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00703&amp;href=/doi/10.1021/acs.jmedchem.1c00703" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00412" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.1c00847" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT<sub>4</sub> Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Ramakrishna Nirogi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ramakrishna Nirogi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#7f11090c0d143f0c0a091a11511c1012"><span class="__cf_email__" data-cfemail="c2acb4b1b0a982b1b7b4a7aceca1adaf">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ramakrishna++Nirogi">Ramakrishna Nirogi</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2045-0784" title="Orcid link">https://orcid.org/0000-0002-2045-0784</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Abdul Rasheed Mohammed</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Abdul Rasheed Mohammed</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Abdul+Rasheed++Mohammed">Abdul Rasheed Mohammed</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7873-4600" title="Orcid link">https://orcid.org/0000-0001-7873-4600</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anil Karbhari Shinde</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anil Karbhari Shinde</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anil+Karbhari++Shinde">Anil Karbhari Shinde</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shankar Reddy Gagginapally</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shankar Reddy Gagginapally</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shankar+Reddy++Gagginapally">Shankar Reddy Gagginapally</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Durga Malleshwari Kancharla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Durga Malleshwari Kancharla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Durga+Malleshwari++Kancharla">Durga Malleshwari Kancharla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Srinivasa Rao Ravella</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Srinivasa Rao Ravella</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Srinivasa+Rao++Ravella">Srinivasa Rao Ravella</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Narsimha Bogaraju</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Narsimha Bogaraju</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Narsimha++Bogaraju">Narsimha Bogaraju</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vanaja Reddy Middekadi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vanaja Reddy Middekadi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vanaja+Reddy++Middekadi">Vanaja Reddy Middekadi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ramkumar Subramanian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ramkumar Subramanian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ramkumar++Subramanian">Ramkumar Subramanian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Raghava Choudary Palacharla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Raghava Choudary Palacharla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Raghava+Choudary++Palacharla">Raghava Choudary Palacharla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vijay Benade</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vijay Benade</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vijay++Benade">Vijay Benade</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nageswararao Muddana</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nageswararao Muddana</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nageswararao++Muddana">Nageswararao Muddana</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Renny Abraham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Renny Abraham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Renny++Abraham">Renny Abraham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rajesh Babu Medapati</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rajesh Babu Medapati</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rajesh+Babu++Medapati">Rajesh Babu Medapati</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jagadeesh Babu Thentu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jagadeesh Babu Thentu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jagadeesh+Babu++Thentu">Jagadeesh Babu Thentu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Venkat Reddy Mekala</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Venkat Reddy Mekala</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Venkat+Reddy++Mekala">Venkat Reddy Mekala</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Surendra Petlu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Surendra Petlu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Surendra++Petlu">Surendra Petlu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bujji Babu Lingavarapu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bujji Babu Lingavarapu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bujji+Babu++Lingavarapu">Bujji Babu Lingavarapu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sivasekhar Yarra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sivasekhar Yarra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sivasekhar++Yarra">Sivasekhar Yarra</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Narendra Kagita</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Narendra Kagita</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Narendra++Kagita">Narendra Kagita</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vinod Kumar Goyal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vinod Kumar Goyal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vinod+Kumar++Goyal">Vinod Kumar Goyal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Santosh Kumar Pandey</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Santosh Kumar Pandey</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Santosh+Kumar++Pandey">Santosh Kumar Pandey</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Venkat Jasti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Venkat Jasti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Venkat++Jasti">Venkat Jasti</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00703&amp;href=/doi/10.1021%2Facs.jmedchem.1c00703" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 12, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 April 2021</li><li><span class="item_label"><b>Published</b> online</span>12 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00703" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00703</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRamakrishna%2BNirogi%252C%2BAbdul%2BRasheed%2BMohammed%252C%2BAnil%2BKarbhari%2BShinde%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00703%26title%3DDiscovery%2Band%2BPreclinical%2BCharacterization%2Bof%2BUsmarapride%2B%2528SUVN-D4010%2529%253A%2BA%2BPotent%252C%2BSelective%2B5-HT4%2BReceptor%2BPartial%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BCognitive%2BDeficits%2BAssociated%2Bwith%2BAlzheimer%25E2%2580%2599s%2BDisease%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D25%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00703"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">484</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00703" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer’s Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Ramakrishna&quot;,&quot;last_name&quot;:&quot;Nirogi&quot;},{&quot;first_name&quot;:&quot;Abdul&quot;,&quot;last_name&quot;:&quot;Rasheed Mohammed&quot;},{&quot;first_name&quot;:&quot;Anil&quot;,&quot;last_name&quot;:&quot;Karbhari Shinde&quot;},{&quot;first_name&quot;:&quot;Shankar&quot;,&quot;last_name&quot;:&quot;Reddy Gagginapally&quot;},{&quot;first_name&quot;:&quot;Durga&quot;,&quot;last_name&quot;:&quot;Malleshwari Kancharla&quot;},{&quot;first_name&quot;:&quot;Srinivasa&quot;,&quot;last_name&quot;:&quot;Rao Ravella&quot;},{&quot;first_name&quot;:&quot;Narsimha&quot;,&quot;last_name&quot;:&quot;Bogaraju&quot;},{&quot;first_name&quot;:&quot;Vanaja&quot;,&quot;last_name&quot;:&quot;Reddy Middekadi&quot;},{&quot;first_name&quot;:&quot;Ramkumar&quot;,&quot;last_name&quot;:&quot;Subramanian&quot;},{&quot;first_name&quot;:&quot;Raghava&quot;,&quot;last_name&quot;:&quot;Choudary Palacharla&quot;},{&quot;first_name&quot;:&quot;Vijay&quot;,&quot;last_name&quot;:&quot;Benade&quot;},{&quot;first_name&quot;:&quot;Nageswararao&quot;,&quot;last_name&quot;:&quot;Muddana&quot;},{&quot;first_name&quot;:&quot;Renny&quot;,&quot;last_name&quot;:&quot;Abraham&quot;},{&quot;first_name&quot;:&quot;Rajesh&quot;,&quot;last_name&quot;:&quot;Babu Medapati&quot;},{&quot;first_name&quot;:&quot;Jagadeesh&quot;,&quot;last_name&quot;:&quot;Babu Thentu&quot;},{&quot;first_name&quot;:&quot;Venkat&quot;,&quot;last_name&quot;:&quot;Reddy Mekala&quot;},{&quot;first_name&quot;:&quot;Surendra&quot;,&quot;last_name&quot;:&quot;Petlu&quot;},{&quot;first_name&quot;:&quot;Bujji&quot;,&quot;last_name&quot;:&quot;Babu Lingavarapu&quot;},{&quot;first_name&quot;:&quot;Sivasekhar&quot;,&quot;last_name&quot;:&quot;Yarra&quot;},{&quot;first_name&quot;:&quot;Narendra&quot;,&quot;last_name&quot;:&quot;Kagita&quot;},{&quot;first_name&quot;:&quot;Vinod&quot;,&quot;last_name&quot;:&quot;Kumar Goyal&quot;},{&quot;first_name&quot;:&quot;Santosh&quot;,&quot;last_name&quot;:&quot;Kumar Pandey&quot;},{&quot;first_name&quot;:&quot;Venkat&quot;,&quot;last_name&quot;:&quot;Jasti&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00703&quot;},&quot;abstract&quot;:&quot;A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT4R) partial agonists for the treatment of cognitive deficits associated with Alzheimer’s disease. Starting from a reported 5-HT4R antagonist, a systematic structure–activity relationship was conducted, which led to the discovery of potent and selective 5-HT4R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, 12l). It showed balanced physicochemical–pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00703&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00703" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00703&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00703" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00703&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00703" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00703&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00703&amp;href=/doi/10.1021/acs.jmedchem.1c00703" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00703" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00703" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00703%26sid%3Dliteratum%253Aachs%26pmid%3D34251799%26genre%3Darticle%26aulast%3DNirogi%26date%3D2021%26atitle%3DDiscovery%2Band%2BPreclinical%2BCharacterization%2Bof%2BUsmarapride%2B%2528SUVN-D4010%2529%253A%2BA%2BPotent%252C%2BSelective%2B5-HT4%2BReceptor%2BPartial%2BAgonist%2Bfor%2Bthe%2BTreatment%2Bof%2BCognitive%2BDeficits%2BAssociated%2Bwith%2BAlzheimer%25E2%2580%2599s%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of oxadiazole derivatives were synthesized and evaluated as 5-hydroxytryptamine-4 receptor (5-HT<sub>4</sub>R) partial agonists for the treatment of cognitive deficits associated with Alzheimer’s disease. Starting from a reported 5-HT<sub>4</sub>R antagonist, a systematic structure–activity relationship was conducted, which led to the discovery of potent and selective 5-HT<sub>4</sub>R partial agonist 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (Usmarapride, <b>12l</b>). It showed balanced physicochemical–pharmacokinetic properties with robust nonclinical efficacy in cognition models. It also showed disease-modifying potential, as it increased neuroprotective soluble amyloid precursor protein alpha levels, and dose-dependent target engagement and correlation of efficacy with oral exposures. Phase 1 clinical studies have been completed and projected efficacious concentration was achieved without any major safety concerns. Phase 2 enabling long-term safety studies have been completed with no concerns for further development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62028" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62028" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Alzheimer’s disease (AD) is a debilitating progressive neurodegenerative disorder, affecting mostly the aging population. AD is characterized by the presence of Aβ plaques and pathologic tau deposits with clinical symptoms like confusion, memory loss, and dementia. Dysfunction of acetylcholine containing neurons in the brain contributes substantially to the symptoms. The current pharmacotherapy provides only symptomatic relief through augmentation of cholinergic function with several undesired side effects such as nausea, vomiting, and bradycardia. Moreover, no disease-modifying therapy is available to the patients to date. Thus, there is a need to explore new therapies through different modes of action. 5-Hydroxytryptamine-4 receptor (5-HT<sub>4</sub>R) is one of such targets which have attracted the attention of scientific community.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The 5-HT<sub>4</sub>R belongs to a superfamily of seven transmembrane G-protein coupled receptors (GPCRs) and is coupled to a G-protein containing Gαs subunit.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The 5-HT<sub>4</sub>R is reported to have a potential role in many central nervous system (CNS) disorders such as AD<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> and peripherally mediated disorders such as irritable bowel syndrome<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and gastroparesis.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The 5-HT<sub>4</sub> receptor is present at a high density in brain regions like the hippocampus, amygdala, and cerebral cortex, suggesting the possible involvement of this receptor in cognitive processes.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The 5-HT<sub>4</sub>R agonists modulate amyloid precursor protein (APP)-derived peptides, amyloid-beta (Aβ), and soluble amyloid precursor protein alpha (sAPPα).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The sAPPα is a soluble nonamyloidogenic protein, and it is reported to have a potent neuroprotective role against the neurotoxic effects of glutamate and β-amyloid.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Human 5-HT<sub>4</sub>R isoforms are positively coupled to adenylyl cyclase production. Thus, activation of this G-protein coupled receptor activates adenylyl cyclase, consequently increasing the production of cyclic adenosine monophosphate (cAMP). The increased cAMP, in turn, increases sAPPα release. The stimulatory effect of 5-HT<sub>4</sub>R on sAPPα release is mimicked by forskolin, a direct activator of adenylyl cyclase, and 8-bromo-cAMP (membrane-permeant cAMP analog), suggesting the involvement of adenylyl cyclase and cAMP in modulating sAPPα by 5-HT<sub>4</sub>R.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The 5-HT<sub>4</sub>R also increases the neuronal acetylcholine (ACh) levels in the brain.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, prolonged exposure of GPCRs to a full agonist can result in receptor desensitization, thereby limiting the compound’s therapeutic usefulness. Partial agonists have shown to minimize the potential for desensitization while retaining the desired activity.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Thus, 5-HT<sub>4</sub>R partial agonists may be of use for both disease modifying and symptomatic treatment of cognitive disorders associated with AD.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Several structurally diverse heteroaromatic derivatives<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17 ref18">(13−18)</a> as 5-HT<sub>4</sub>R agonists/partial agonists/antagonists have been explored for CNS and peripheral indications. The 5-HT<sub>4</sub>R partial agonist PRX-03140 showed significant improvement in cognition assessed by the Alzheimer’s Disease Assessment Scale-Cognition (ADAS-Cog) score in a phase 2a study for AD.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Apart from this compound, several other 5-HT<sub>4</sub>R compounds such as BIMU-1,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> RS-67333,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> prucalopride,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> capeserod (SL65.0155),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and PF-04995274<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> are in development (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reported 5-HT<sub>4</sub>R ligands along with the current series of compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In our continuous efforts of discovering novel small molecules for the potential treatment of AD with a diverse mechanism of actions,<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a> the 5-HT<sub>4</sub>R agonists attracted our attention as they have a dual mechanism of action in treating AD<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and availability of positive proof-of-concept phase 2 clinical results of PRX-03140. Most of the reported 5-HT<sub>4</sub>R ligands which have been explored for both CNS and peripheral indications belong to benzamide, imidazole, imidazopyridine, pyrazolopyridine, 2-oxoquinoline, and indazole derivatives. Previous work from our group disclosed a series of imidazo[1,5-<i>a</i>]pyridine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and pyrazolo[1,5-<i>a</i>]pyridine derivatives<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> represented by compounds <b>5a</b> and <b>4o</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), respectively, as 5-HT<sub>4</sub>R partial agonists with procognitive effects in animal models. While selected compounds from these series are at various stages of development, we focused on earlier reported indazole derivatives<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> represented by compound <b>11ab</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Compound <b>11ab</b> was reported as a 5-HT<sub>4</sub>R antagonist, and its structure can also be envisaged from 5-HT<sub>4</sub>R partial agonist <b>5a</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> based on the structural similarity (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We aimed to identify a structurally diverse 5-HT<sub>4</sub>R partial agonist as a lead compound with an adequate brain penetration, acceptable pharmacokinetics, robust nonclinical efficacy, and sufficient safety margin for the treatment of AD and associated disorders. Selective 5-HT<sub>4</sub>R partial agonists are reported to have the potential to modulate the centrally located 5-HT<sub>4</sub> receptors while showing minimal effects on the gastrointestinal system through peripheral 5-HT<sub>4</sub>R. Activation of peripheral 5-HT<sub>4</sub>R is implicated in modulating gastric intestinal motility and cardiac function. The structural modifications were done keeping in mind the 5-HT<sub>4</sub>R pharmacophore requirements such as an aromatic moiety, a coplanar carbonyl group, or its bioisosteres like oxadiazole, and a voluminous substituent in the basic amino framework of the molecule.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> The basic amino framework part of reported indazole derivative <b>11ab</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> was modified appropriately by implementing earlier understandings.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The well-optimized<a onclick="showRef(event, 'ref24 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref27">(24,27)</a><i>N</i>-isopropyl group on indazole nitrogen was kept constant throughout the structure–activity relationship (SAR) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Modifications in the basic amino framework led to chemical scaffolds showing desired partial agonistic activity at 5-HT<sub>4</sub>R. The successive modifications led to 1-isopropylindazole-carboxamide derivatives (<b>7a</b>–<b>7ai</b>), 1-isopropylindazole-1,3,4-oxadiazole derivatives (<b>12a</b>–<b>12ad</b>), and 1-isopropylindazole-1,2,4-oxadiazole derivatives (<b>17a</b>–<b>17c</b> and <b>23a</b>–<b>23c</b>). The SAR covering <i>in vitro</i> binding affinity, hERG affinity, metabolic stability, CYP inhibition, pharmacokinetics, receptor occupancy, and <i>in vivo</i> efficacy resulted in clinical candidate 1-isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate (<b>12l</b>, Usmarapride). Compound <b>12l</b> has completed phase 1 clinical studies and achieved projected efficacious concentrations within the tested doses. Phase 2 enabling nonclinical safety studies for compound <b>12l</b> in rats and dogs were completed with no concerns for further development.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Genesis of ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">The general synthetic strategy used for the preparation of the present series of compounds is summarized in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch4" aria-label="4">4</a>. The starting material indazole-3-carboxylic acid was sourced from a commercial vendor, and other building blocks were synthesized as per the earlier reported<a onclick="showRef(event, 'ref24 ref27 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref24 ref27 ref31 ref32">(24,27,31,32)</a> protocols. Synthesis of compounds <b>7</b> commenced (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) with indazole-3-carboxylic acid <b>1</b> which on N-isopropylation reaction with 2-iodopropane in the presence of NaO<sup><i>t</i></sup>Bu afforded <i>N</i>-isopropylindazole-3-carboxylic acid <b>2</b> as a single isomer. The carboxylic acid <b>2</b> was then converted to acid chloride <b>3</b> by treating it with thionyl chloride. The acid chloride <b>3</b> was then reacted with different N-Boc protected cyclic amines <b>4</b> in the presence of K<sub>2</sub>CO<sub>3</sub> to afford N-Boc protected carboxamide derivatives <b>5</b>. Deprotection of Boc in compounds <b>5</b> in the presence of trifluoroacetic acid followed by basification with NaHCO<sub>3</sub> yielded compounds <b>6</b>. The N-alkylation of compounds <b>6</b> by reacting with alkyl halides yielded N-alkylated carboxamide derivatives <b>7</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>7a</b>–<b>7ai</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaO<sup><i>t</i></sup>Bu, 2-iodopropane, DMF, r.t., 16.0 h, 60%. (b) SOCl<sub>2</sub>, 1,2-dichloroethane, 0 °C-reflux, 1.0 h, 100%. (c) K<sub>2</sub>CO<sub>3</sub>, Boc protected amine <b>4a</b>–<b>4h</b>, DCM, 0 °C-r.t., 16.0 h. (d) TFA, DCM, 0 °C-r.t., 16.0 h, H<sub>2</sub>O, NaHCO<sub>3</sub>. (e) K<sub>2</sub>CO<sub>3</sub>, acetonitrile, R–X, r.t.-reflux, 7.0–16.0 h.</p></p></figure><div class="NLM_p">The 1,3,4-oxadiazole derivatives <b>12</b> were prepared as mentioned in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The hydrazides <b>9</b> were prepared from the corresponding esters <b>8</b> by refluxing with hydrazine in methanol. The esters <b>8</b> were either sourced commercially or prepared by reported procedures. The hydrazides <b>9</b> were then reacted with acid chloride <b>3</b> in DCM to afford compounds <b>10</b> after basification with NaHCO<sub>3</sub>. Cyclization of compounds <b>10</b> with thionyl chloride in 1,2-dichloroethane at reflux temperature afforded compounds <b>11</b> with concomitant Boc deprotection. The N-alkylation of compounds <b>11</b> with appropriate alkyl halides in the presence of K<sub>2</sub>CO<sub>3</sub> afforded 1,3,4-oxadiazole derivatives <b>12</b>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>12a</b>–<b>12ad</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, Et<sub>3</sub>N, DMAP, DCM, 0 °C-r.t., 16 h. (b) Hydrazine-hydrate, MeOH, r.t.-reflux, 10.0 h. (c) (i) DCM, acid chlroride 3, 0 °C-r.t., 4.0 h; (ii) H<sub>2</sub>O, NaHCO<sub>3</sub>, 2 h. (d) SOCl<sub>2</sub>, 1,2-dichloroethane, r.t.-reflux, 6.0–10.0 h. (e) K<sub>2</sub>CO<sub>3</sub>, acetonitrile, R–X, r.t-reflux, 7.0–16.0 h.</p></p></figure><div class="NLM_p">The 1,2,4-oxadiazoles <b>17</b> were prepared as mentioned in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Commercially available 4-cyanopiperidine <b>13</b> was alkylated using a standard N-alkylation procedure to obtain compounds <b>14</b>. Compounds <b>14</b> on treatment with hydroxylamine in ethanol in the presence of K<sub>2</sub>CO<sub>3</sub> afforded compounds <b>15</b>. The <i>N</i>-isopropylindazole-3-carboxylic acid <b>2</b> was converted to its methyl ester <b>16</b> by reacting with methanol in the presence of dry HCl. The desired 1,2,4-oxadiazole derivatives <b>17</b> were obtained upon treatment of compounds <b>15</b> with ester <b>16</b> in DMF in the presence of NaH.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>17a</b>–<b>17c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, R–X, acetonitrile, r.t-reflux, 7.0–16.0 h. (b) NH<sub>2</sub>-OH·HCl, K<sub>2</sub>CO<sub>3</sub>, EtOH, r.t.-reflux, 16.0 h. (c) SOCl<sub>2</sub>, CH<sub>3</sub>OH, 0 °C-r.t., 6.0 h. (d) NaH, DMF, 120 °C 0.5 h.</p></p></figure><div class="NLM_p">1,2,4-Oxadiazoles <b>23</b> were prepared as mentioned in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The <i>N</i>-isopropyl-indazole-3-carboxylic acid <b>2</b> was converted to <i>N</i>-isopropyl-indazole-3-carboxamide <b>18</b> with Boc anhydride and NH<sub>4</sub>HCO<sub>3</sub>. The carboxamide derivative <b>18</b> was subjected to dehydration using TFAA and triethylamine to afford nitrile <b>19</b>. The commercially available ethyl isonipecotate <b>21</b> was alkylated ith appropriate alkyl halides using a standard N-alkylation procedure to obtain compounds <b>22a</b>–<b>22c</b>. The desired 1,2,4-oxadiazole derivatives <b>23a</b>–<b>23c</b> were obtained upon treatment of compounds <b>22</b> with compound <b>20</b> in DMF in the presence of NaH.</div><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0011.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>23a</b>–<b>23c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, pyridine, NH<sub>4</sub>HCO<sub>3</sub>, acetonitrile, r.t., 16.0 h, 83%. (b) TFAA, Et<sub>3</sub>N, THF, 0 °C-r.t., 2.0 h, 86%. (c) NH<sub>2</sub>-OH·HCl, K<sub>2</sub>CO<sub>3</sub>, EtOH, r.t.-reflux, 16.0 h, 100%. (d) K<sub>2</sub>CO<sub>3</sub>, R–X, acetonitrile, r.t-reflux, 7.0–16.0 h. (e) NaH, DMF, 120 °C, 16.0 h.</p></p></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66665" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66665" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The newly synthesized compounds were screened in the cell-based luciferase reporter gene assay that measures the levels of cAMP inside cells upon activation or inhibition of the receptor, the results of which are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Among the first prepared 1-isopropylindazole-carboxamide derivatives, <b>7a</b>–<b>7c</b>, consisting of aminopiperidine <b>4a</b>, 1-hydroxypropyl derivative <b>7a</b> and 1-fluoroethyl derivative <b>7c</b> showed potent <i>in vitro</i> efficacies (EC<sub>50</sub>) of 6.4 and 5.8 nM with intrinsic activity (<i>E</i><sub>max</sub>) values of 60 and 71%, respectively. Compound <b>7b</b> with a 1-hydroxyethyl group showed a modest EC<sub>50</sub> of 38 nM and <i>E</i><sub>max</sub> of 39%. The observed partial agonist activity was in contrast with the antagonist activity reported<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> for structurally similar types of indazole derivatives (<b>11ab</b>)<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> with bigger alkyl groups on the piperidine ring (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Encouraged by these findings, additional analogs (<b>7d</b>–<b>7g</b>) with branched alkyl groups with fluoro, hydroxy, or methoxy group substitutions were synthesized and evaluated. These compounds were 5–7-fold less potent as compared to normal alkyl group derivatives (<b>7a</b>–<b>7c</b>). Compounds with cyclic ethers such as pyran, methylpyranyl groups (<b>7h</b>–<b>7k</b>) showed 2–3-fold more potency than the branched alkyl-substituted compounds (<b>7d</b>–<b>7g</b>) but were 2–4-fold less potent than the alkyl-substituted derivatives (<b>7a</b> and <b>7c</b>). Overall, the straight alkoxyalkyl or fluoroalkyl-substituted piperidine derivatives were more potent than other branched alkyl or oxy-cyclic-substituted piperidine derivatives. In the next change in the compounds, a methylene linker was introduced between piperidine and indazolyl-3-carboxamide moiety. The methylpiperidine derivatives <b>7l</b> and <b>7n</b> consisting of aminopiperidine <b>4b</b> showed very weak activity with higher EC<sub>50</sub> and lower <i>E</i><sub>max</sub> (∼10%) values, indicating the linker was not tolerated. Introducing hydroxy and fluoro groups at the fourth position of the piperidine ring (aminopiperidine <b>4c</b> and <b>4d</b>) yielded compounds <b>7o</b>–<b>7q</b>. Though this modification resulted in compounds with potent EC<sub>50</sub> values (<50 nM), the <i>E</i><sub>max</sub> was on the lower side as compared to <b>7a</b> and <b>7c</b>. The methylpiperidine was then replaced with morpholine methylamine (<b>4e</b>) derivative <b>7r</b> with an EC<sub>50</sub> value of 3906 nM. Introducing the bicyclic 3-aza-bicyclo[3.1.0]hexane ring in place of piperidine resulted in less potent derivatives <b>7s</b>–<b>7u</b>. Bringing the methylene linker in 3-aza-bicyclo[3.1.0]hexane group (<b>4g</b>) dramatically increased the potency of the synthesized compounds (<b>7v</b>–<b>7z</b>) with EC<sub>50</sub> values <12 nM, albeit with weak agonist activity (<i>E</i><sub>max</sub> < 20%). The bicyclic 3-aza-bicyclo[3.1.0]hexane group was replaced with 8-aza-bicyclo[3.2.1]octan (<b>4h</b>) which resulted in potent compounds (<b>7aa</b>–<b>7ai</b>) with EC<sub>50</sub> values ranging from 3 nM to 62 nM and the agonist activity ranging from partial (<i>E</i><sub>max</sub>, 64%) to full agonist (<i>E</i><sub>max</sub>, 98%). Noteworthy in these compounds is barring branched <i>N</i>-alkyl derivatives (<b>7aa</b>, <b>7ad</b>, <b>7ae</b>, and <b>7ai</b>), all other compounds showed <10 nM EC<sub>50</sub> values with >50% agonist activity. Compound <b>7ac</b> showing a EC<sub>50</sub> value of 3 nM with 66% <i>E</i><sub>max</sub> value stands out to be the most potent partial agonist from the indazole 3-carboxamide derivatives synthesized.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. 5-HT<sub>4</sub>R Functional Activity of Indazole Carboxamide Derivatives <b>7a</b>–<b>7ai</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0012.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0013.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data represent mean ± SD. Functional activity determined in CHO cells stably expressing the human 5HT<sub>4E</sub> isoform and a reporter gene was used. EC<sub>50</sub> values were determined from average of two independent experiments tested in duplicate. The in-house data are consistent with reported values of PRX-03140 (17–52 nM/30–61%), PF-04995274 (0.26 nM/7%), and prucalopride (26 nM/52%) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf" class="ext-link">Supporting Information</a>); NA, not applicable.</p></div></div><div></div></div><div class="NLM_p">Bioisosteres have been explored in the past to improve potency, enhance selectivity, and optimize pharmacokinetic (PK) profiles or alter toxicophores in addition to being a source of novel intellectual property.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> To have compounds with improved potency and favorable pharmacokinetics, the symmetrical 1,3,4-oxadiazole and asymmetrical 1,2,4-oxadiazole derivatives were envisaged<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> as carboxamide bioisosteres (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <b>12a</b> without any alkyl substitution on piperidine nitrogen showed very weak activity with EC<sub>50</sub> of 1507 nM, however; it retained partial agonist activity showing an <i>E</i><sub>max</sub> value of 43% (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The alkyl-substituted derivatives <b>12b</b>–<b>12i</b> showed EC<sub>50</sub> values between 23 nM and 199 nM with moderate <i>E</i><sub>max</sub> values ranging from 28% to 56%. Among the lot, the isopropyl derivative <b>12b</b> and phenethyl derivative <b>12d</b> showed potent EC<sub>50</sub> values of 23 nM and 24 nM, respectively. The fluoroethyl derivative <b>12j</b> showed very weak activity with an EC<sub>50</sub> value of 1814 nM, as against its carboxamide counterpart <b>7c</b> which showed a potent EC<sub>50</sub> value of 5.8 nM. The other heteroalkyl derivatives <b>12k</b>–<b>12t</b> showed moderate EC<sub>50</sub> values ranging between 22 nM and 172 nM. These compounds showed a weak agonist activity ranging from (<i>E</i><sub>max</sub>, 17%) to moderate (<i>E</i><sub>max</sub>, 53%) partial agonist activity. The heteroalicyclic-substituted derivatives <b>12o</b> and <b>12p</b> showed EC<sub>50</sub> values of 79 nM and 84 nM, respectively, whereas compound <b>12u</b> having a methylpyranyl group with junction hydroxy showed a weak EC<sub>50</sub> value of 210 nM. The higher EC<sub>50</sub> value for compound <b>12u</b> is in sharp contrast to the corresponding carboxamide derivative <b>7j</b> with the same substitution that showed a potent EC<sub>50</sub> value of 15 nM. Compound <b>12v</b> showed very weak <i>in vitro</i> potency with an EC<sub>50</sub> value of 675 nM with a hydroxy group on the junction of piperidine. The introduction of an additional methylene group between 1,3,4-oxadiazole and piperidine resulted in compounds <b>12w</b>–<b>12y</b> with weak <i>in vitro</i> potency. The bicyclic 3-aza-bicyclo[3.1.0]hexane 1,3,4-oxadiazole derivatives <b>12z</b>–<b>12ab</b> turned out to be inactive. The similar carboxamide derivative <b>7v</b> was potent albeit with weak partial agonist activity as compared to inactive 1,3,4-oxadiazole derivative <b>12ab</b>. The tropane derivatives <b>12ac</b> and <b>12ad</b> showed weak potency with an EC<sub>50</sub> value of 695 nM and 1060 nM respectively.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. 5-HT<sub>4</sub>R Functional Activity of Indazole Carboxamide Derivatives <b>12a</b>–<b>12ad, 17a</b>–<b>17c</b>, <b>23a</b>–<b>23c</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0014.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0015.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data represent mean ± SD. Functional activity determined in CHO cells stably expressing the human 5HT<sub>4E</sub> isoform, and a reporter gene was used. EC<sub>50</sub> values were determined from average of two independent experiments tested in duplicate. The in-house data are consistent with reported values of PRX-03140 (17–52 nM/30–61%), PF-04995274 (0.26 nM/7%), and prucalopride (26 nM/52%) (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf" class="ext-link">Supporting Information</a>); NA, not applicable.</p></div></div><div></div></div><div class="NLM_p">The 1,2,4-oxadiazole derivatives were made to compare their activity with that of 1,3,4-oxadiazole counterparts. The 1,2,4-oxadiazole derivative <b>17a</b> having a methoxypropyl group on the piperidine ring which is at the 5-position of oxadiazole showed an EC<sub>50</sub> value of 156 nM which is ∼3-fold less than that of 1,3,4-oxadiazole derivative <b>12l</b>. However, the other synthesized derivatives <b>17b</b> and <b>17c</b> showed 2–4-fold more potency than their corresponding 1,3,4-oxadiazole derivatives<b>12p</b> and <b>12b</b> respectively. On the other hand, 1,2,4-oxadiazole derivative <b>23a</b> with an EC<sub>50</sub> value of 21 nM showed 2-fold more potency than 1,3,4-oxadiazole derivative <b>12l</b>. The other synthesized derivatives <b>23b</b> and <b>23c</b> from this series showed a weaker potency with EC<sub>50</sub> values of 106 and 297 nM, respectively.</div><div class="NLM_p">Several <i>in vitro</i> potent compounds which represent structural diversity during the SAR were further evaluated for their rat and human liver microsomal metabolic stability, metabolizing enzymes cytochrome P450 (CYP) 3A4 and 2D6 inhibition, time-dependent inhibition (TDI) for CYP 3A4 enzyme, and the human ether-a-go-go related gene (hERG) inhibition and <i>in vivo</i> rat pharmacokinetics, bioavailability, and brain penetration (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Metabolic Stability, CYP and hERG Inhibition, Pharmacokinetics, Brain Penetration of Selected 5-HT<sub>4</sub>R Compounds<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">rat liver microsomes %metabolized @ 30 min</th><th class="colsep0 rowsep0" align="center" char="±">human liver microsomes %metabolized @ 30 min</th><th class="colsep0 rowsep0" align="center" char=".">hERG IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">hERG % inhibition (%)</th><th class="colsep0 rowsep0" align="center" char=".">CYP3A4 inhibition IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">CYP2D6 inhibition IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">CYP 3A4 TDI (at 30 min) %inhibition</th><th class="colsep0 rowsep0" align="center" char="±">%<i>F</i></th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="±">AUC (ng·hr/mL)</th><th class="colsep0 rowsep0" align="center" char="±"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="±"><i>V</i><sub>dss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char="±">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="±"><i>C</i><sub>brain</sub>/<i>C</i><sub>plasma</sub> @ 1 h</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>PRX-03140</b></td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 0</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 0</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">62 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7c</b></td><td class="colsep0 rowsep0" align="char" char="±">87.5 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">45.8 ± 0.2</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">3 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">26 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">59 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">3.2 ± 1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7d</b></td><td class="colsep0 rowsep0" align="char" char="±">30.5 ± 4.4</td><td class="colsep0 rowsep0" align="char" char="±">16.7 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">177 ± 36</td><td class="colsep0 rowsep0" align="char" char="±">269 ± 30</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 1.3</td><td class="colsep0 rowsep0" align="char" char="±">7.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">32 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">3.3 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7f</b></td><td class="colsep0 rowsep0" align="char" char="±">90.9 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char="±">2 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">36 ± 50</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 17</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">70 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7o</b></td><td class="colsep0 rowsep0" align="char" char="±">15.6 ± 11.1</td><td class="colsep0 rowsep0" align="char" char="±">20.2 ± 3.1</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char="±">26 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">99 ± 83</td><td class="colsep0 rowsep0" align="char" char="±">242 ± 118</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">53 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">0.4 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7v</b></td><td class="colsep0 rowsep0" align="char" char="±">36.6 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">17.9 ± 1.8</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">36.4</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">7.9 ± 5.7</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">69 ± 11</td><td class="colsep0 rowsep0" align="char" char="±">102 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">0.9 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">95 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7w</b></td><td class="colsep0 rowsep0" align="char" char="±">44.8 ± 3.6</td><td class="colsep0 rowsep0" align="char" char="±">45.1 ± 4.1</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">20.4</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">12.5 ± 1.7</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">64 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">110 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 0.6</td><td class="colsep0 rowsep0" align="char" char="±">92 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">2.1 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7x</b></td><td class="colsep0 rowsep0" align="char" char="±">42.7 ± 12.5</td><td class="colsep0 rowsep0" align="char" char="±">27.4 ± 0.3</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">65 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">144 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">6.6 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">62 ± 19</td><td class="colsep0 rowsep0" align="char" char="±">2.4 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7ad</b></td><td class="colsep0 rowsep0" align="char" char="±">98.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">26.9 ± 1.4</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7ag</b></td><td class="colsep0 rowsep0" align="char" char="±">74.8 ± 3.1</td><td class="colsep0 rowsep0" align="char" char="±">21.4 ± 6.2</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char=".">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td><td class="colsep0 rowsep0" align="char" char="±">N.A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7ah</b></td><td class="colsep0 rowsep0" align="char" char="±">62.9 ± 3.8</td><td class="colsep0 rowsep0" align="char" char="±">31.7 ± 4.3</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">26.7</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">2.2 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">106 ± 2</td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="char" char="±">35.7 ± 2.9</td><td class="colsep0 rowsep0" align="char" char="±">15.3 ± 1.9</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">9 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">91 ± 40</td><td class="colsep0 rowsep0" align="char" char="±">133 ± 61</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">10.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">105 ± 6</td><td class="colsep0 rowsep0" align="char" char="±">3.6 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="char" char="±">98.5 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">76.0 ± 2.7</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">11.2</td><td class="colsep0 rowsep0" align="char" char=".">13.9</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">151 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">520 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">28 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">1.3 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="char" char="±">55.1 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">62.5 ± 1.4</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">2.6 ± 1.8</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 8.0</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 11</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.8</td><td class="colsep0 rowsep0" align="char" char="±">4.9 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">81 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">0.0 ± 0.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="char" char="±">83.8 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">43.6 ± 1.8</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">5.9 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">179 ± 80</td><td class="colsep0 rowsep0" align="char" char="±">394 ± 174</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 14</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12h</b></td><td class="colsep0 rowsep0" align="char" char="±">64.9 ± 4.3</td><td class="colsep0 rowsep0" align="char" char="±">64.8 ± 0.5</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">37</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">22 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">248 ± 43</td><td class="colsep0 rowsep0" align="char" char="±">392 ± 103</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">10.0 ± 3.0</td><td class="colsep0 rowsep0" align="char" char="±">96 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12k</b></td><td class="colsep0 rowsep0" align="char" char="±">79.2 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">53.8 ± 2.1</td><td class="colsep0 rowsep0" align="char" char=".">>10</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">19 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">43 ± 11</td><td class="colsep0 rowsep0" align="char" char="±">74 ± 12</td><td class="colsep0 rowsep0" align="char" char="±">1.2 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">12.7 ± 1.1</td><td class="colsep0 rowsep0" align="char" char="±">126 ± 17</td><td class="colsep0 rowsep0" align="char" char="±">0.8 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12l</b></td><td class="colsep0 rowsep0" align="char" char="±">25.1 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">26.2 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">34 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">360 ± 46</td><td class="colsep0 rowsep0" align="char" char="±">709 ± 120</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">76 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12p</b></td><td class="colsep0 rowsep0" align="char" char="±">43.0 ± 0.4</td><td class="colsep0 rowsep0" align="char" char="±">33.6 ± 0.6</td><td class="colsep0 rowsep0" align="char" char=".">8.5</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">66 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">587 ± 340</td><td class="colsep0 rowsep0" align="char" char="±">1323 ± 364</td><td class="colsep0 rowsep0" align="char" char="±">1.4 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">8.5 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">82 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12s</b></td><td class="colsep0 rowsep0" align="char" char="±">81.5 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">74.1 ± 2.9</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">91</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12t</b></td><td class="colsep0 rowsep0" align="char" char="±">62.1 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">36.4 ± 3.0</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17a</b></td><td class="colsep0 rowsep0" align="char" char="±">89.0 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">29.3 ± 12.3</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">75</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17b</b></td><td class="colsep0 rowsep0" align="char" char="±">64.1 ± 3.1</td><td class="colsep0 rowsep0" align="char" char="±">40.4 ± 0.8</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17c</b></td><td class="colsep0 rowsep0" align="char" char="±">73.0 ± 3.8</td><td class="colsep0 rowsep0" align="char" char="±">44.4 ± 3.8</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">7 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 4</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">19.5 ± 7.7</td><td class="colsep0 rowsep0" align="char" char="±">124 ± 38</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="char" char="±">95.4 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">56.49 ± 2.3</td><td class="colsep0 rowsep0" align="char" char=".">0.95</td><td class="colsep0 rowsep0" align="char" char=".">88</td><td class="colsep0 rowsep0" align="char" char=".">>45</td><td class="colsep0 rowsep0" align="char" char=".">37.7</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 7</td><td class="colsep0 rowsep0" align="char" char="±">157 ± 22</td><td class="colsep0 rowsep0" align="char" char="±">303 ± 100</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">35 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="char" char="±">52.5 ± 1.6</td><td class="colsep0 rowsep0" align="char" char="±">32.0 ± 9.9</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23c</b></td><td class="colsep0 rowsep0" align="char" char="±">46.7 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">40.9 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char=".">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td><td class="colsep0 rowsep0" align="char" char="±">NA</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Data represent mean ± SD. RLM, rat liver microsomes; HLM, human liver microsomes; hERG, human ether-a-go-go related gene; CYP, cytochrome P450; TDI, time-dependent inhibition. Doses used for PK experiments: 3.0 mg/kg for p.o. dosing, 1.0 mg/kg for i.v. dosing. %<i>F</i>, oral bioavailability; <i>C</i><sub>max</sub>, maximum systemic concentration; AUC, area under the curve; <i>t</i><sub>1/2</sub>, elimination half-life; <i>V</i><sub>dss</sub>, volume of distribution; CL, intravenous clearance; <i>C</i><sub>brain</sub>/<i>C</i><sub>plasma</sub>, brain to plasma concentration ratio; NA, not available.</p></div></div></div><div class="NLM_p">A compound’s metabolic stability is an important parameter to consider during the early stages of SAR. The metabolic stability of the compound is its susceptibility to biotransformation, which helps in predicting the compound’s PK properties which in turn helps in designing compounds with favorable PK properties. The metabolic stability results are usually reported as measures of intrinsic clearance, from which secondary PK parameters such as bioavailability and half-life can be calculated if the data on the volume of distribution and fraction absorbed are available. Since these parameters are very important in defining the PK and toxicological profile of the compound, the researchers need to give more emphasis on the metabolic stability during SAR optimization. The metabolic stability of the compounds reported here both in rat and human liver microsomes was found to be low (∼5%) to high (>70%). The carboxamide derivatives showed suboptimal ADME properties, as given in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. The carboxamides <b>7c</b> with fluoroethyl group <b>7f</b>, <b>7ad</b> with a branched hydroxy-alkyl group, and <b>7ag</b>, <b>7ah</b> with a pyranyl-methyl group on piperidine nitrogen were extensively metabolized in rat liver microsomes; whereas, in human liver microsomes, the metabolism was low to moderate. The high metabolism of these compounds in rat liver microsomes is very well reflected in their poor <i>in vivo</i> exposures and bioavailability in rats for the tested analogs <b>7c</b>, <b>7f</b>, and <b>7ah</b>. Low to moderate microsomal metabolism observed with the select carboxamide derivatives such as <b>7d</b>, <b>7v</b>, <b>7w</b>, and <b>7x</b> is well correlated with modest oral exposure and bioavailability in rats. Compound <b>7o</b>, however, was the exception, as its good metabolic stability both in rat and human microsomes did not translate into good <i>in vivo</i> exposures and bioavailability in rats.</div><div class="NLM_p">The 1,3,4-oxadiazole derivatives <b>12h</b>, <b>12l</b>, and <b>12p</b> showed good microsomal stability both in rats and humans that translated into good oral exposures, good bioavailability, and good brain exposures in rats. The 1,2,4-oxadiazole derivatives <b>17c</b> and <b>23a</b> showed poor rat microsomal metabolic stability. Rat PK data for <b>17c</b> indicated poor oral exposures and bioavailability, but that was not the case for <b>23a</b>. The 1,2,4-oxadiazole derivative <b>23a</b> showed moderate oral exposures and bioavailability. Good brain penetration property is essential for the compounds intended to treat brain disorders. Most of the compounds such as <b>7d</b>, <b>12d</b>, <b>12f</b>, <b>12h</b>, <b>12l</b>, <b>12p</b>, and <b>23a</b> showed very good brain penetration properties. Selected compounds were further evaluated for their CYP and hERG inhibiting properties. Cytochrome P450 (P450) is a family of enzymes that play a major role in the metabolism of drugs. Evaluation of the compound’s potential to inhibit a specific P450 enzyme is important, as coadministration of compounds may result in one or both inhibiting the other’s metabolism. This may affect the compound’s plasma exposures and potentially lead to adverse drug–drug interactions (DDI) or toxicity. The CYP enzyme inhibition liability of the selected compounds is remote, as most of them showed IC<sub>50</sub> values of >45 μM. The TDI of CYP enzyme refers to a change in compound’s potency during an <i>in vitro</i> incubation or <i>in vivo</i> dosing period. Potential mechanisms include the formation of inhibitory metabolites and mechanism-based inhibition. TDI is of particular concern as it is irreversible, and typically <i>de novo</i> synthesis of the enzyme is required to restore the activity. The consequences of TDI can be drug withdrawal or serious restrictions of use. Gratifyingly, the tested compounds either showed minimal or no TDI against CYP3A4 enzyme, therefore discharging them from the potential for DDI liability in a clinical setup. There is a literature precedent that disclosed the cardiovascular adverse events associated with 5-HT<sub>4</sub>R agonists. For instance, Cisapride, a 5-HT<sub>4</sub>R agonist, was withdrawn from the market due to the risk of fatal cardiac arrhythmias.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> The hERG affinity may have detrimental effects on cardiac safety which prompted us to identify 5-HT<sub>4</sub>R agonists having minimal hERG liability. Compounds <b>7d</b> and <b>12k</b> showed hERG IC<sub>50</sub> values >10 μM, compounds <b>12p</b> and <b>12l</b> showed IC<sub>50</sub> values of 8.5 μM and 3.0 μM respectively, and compound <b>12h</b> showed an IC<sub>50</sub> of 2.4 μM. Compounds <b>7d</b>, <b>12h</b>, <b>12k</b>, <b>12l</b>, and <b>12p</b>, based on their moderate to good metabolic stability, good <i>in vivo</i> exposures in rats, and modest affinity for hERG channel, were evaluated in the object recognition test (ORT), long-term memory deficit assay. The ORT<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> is regarded as a spontaneous delayed nonmatching-to-sample (DNMS) test. The test is based on spontaneous behavior. The main assumption of this test is that access to novelty (object or environment) can elicit approach behaviors in animals. The “unconditioned preference” of animals for novelty has been used in the ORT to study memory functions, assessing the ability of animals to recognize a novel object in a familiar environment. ORT does not involve reference memory components, thus it can be considered as a “pure” recognition memory test and a valid task to assess working memory. Additionally, ORT does not involve positive or negative reinforces (food or electric shocks), and this makes it comparable to memory tests currently used in the clinic. These advantages make the ORT efficacy model, quick, and simple.Thus, the ORT model has been widely used for assessing procognitive effects in preclinical models. In this set of experiments, the rats were treated with compounds <b>7d</b>, <b>12h</b>, <b>12k</b>, <b>12l</b>, and <b>12p</b> which also included reported 5-HT<sub>4</sub>R partial agonist RS-67333<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> as a positive control (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). The reference compound, RS-67333, evaluated at 0.3, 1.0, and 3.0 mg/kg i.p. showed statistically significant activity at 0.3 and 1.0 mg/kg, and the effects faded at 3.0 mg/kg dose, which is in line with literature reports. Compound <b>7d</b> showed activity only at 10 mg/kg p.o. dose. Compound <b>12h</b> showed activity at all tested doses; however, procognitive activity reduced as the dose increased. Compound <b>12k</b> did not show activity at any of the tested doses. Compound <b>12l</b> showed activity at 1 and 3 mg/kg p.o. doses. Compound <b>12p</b> showed activity at 3 and 10 mg/kg p.o. doses. Compound <b>12k</b> did not show activity probably due to its poor brain penetration and lower plasma exposures. The difference in the efficacy for the other tested compounds could be due to differences in the free fractions which could have led to a difference in receptor occupancy thereby a difference in the ORT.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of compounds <b>7d</b>, <b>12h</b>, <b>12k</b>, <b>12l</b>, <b>12p</b>, and RS-67333 on attenuation of long-term memory deficits in ORT. Data represent mean ± SEM of exploration time in seconds; (<i>N</i> = 7–8); *<i>p</i> < 0.05, **<i>p</i> < 0.01, ***<i>p</i> < 0.001. Paired–<i>t</i>-test comparison of novel vs familiar object.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on efficacy observed in ORT assay and good PK properties, compounds <b>12h</b> and <b>12l</b> were shortlisted for further evaluation. Compounds <b>12h</b> and <b>12l</b> were evaluated in another cognitive assay, the radial arm maze task (RAM).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The RAM is a popular test of working memory in rodents. RAM exploits the natural tendency of rodents to explore, learn, and remember different locations of food reinforcement. RAM in rodents requires rats to explore a series of visually identical arms arranged around a central start location. Each arm will be baited with a reward, and the rat is required to remember which arms it has visited. A rat returning to a previously visited arm is recorded as an error, and one can infer how the rat is using various cues based on the pattern of navigation and errors. In this assay, compound <b>12h</b> at tested doses of 1, 3, and 10 mg/kg p.o. did not reverse the scopolamine-induced cognitive deficits; whereas, compound <b>12l</b> significantly reversed the scopolamine-induced amnesia at the tested doses of 1, 3, and 10 mg/kg p.o. (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compounds <b>12h</b> and <b>12l</b> in RAM. Data represent mean ± SEM of % choice accuracy or total error compared to vehicle (F<sub>4,103</sub> = 19.54 for choice accuracy and F<sub>4,103</sub> = 14.81 for total error for compound <b>12h</b> and F<sub>4,105</sub> = 36.16 for choice accuracy and F<sub>4,105</sub> = 32.88 for total error for compound <b>12l</b>); <i>n</i> = 7–8; *<i>p</i> < 0.05, **<i>p</i> < 0.01, ***<i>p</i> < 0.001,****<i>p</i> < 0.0001 vs scopolamine (ANOVA followed by Dunnett’s test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to see correlation between dose and efficacy, compound <b>12l</b> was evaluated in ORT at doses 0.03, 0.1, 0.3, 1.0, 3.0, and 10.0 mg/kg p.o. In this study, compound <b>12l</b> did not show activity at 0.03 and 0.1 mg/kg, however did show significant efficacy from 0.3 to 3.0 mg/kg. The efficacy of compound <b>12l</b> in ORT assay at doses of 0.1–10 mg/kg, p.o. along with the recognition index is depicted in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A,B (exploration time and recognition index, respectively). Compound <b>12l</b> showed a statistically significant effect at 3.0 mg/kg on both exploration time and recognition index.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0005.jpeg" id="GRAPHIC-d7e3122-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Attenuation of long-term memory deficits in ORT by compound <b>12l</b>. Data represent (mean ± SEM) of exploration time compared to vehicle (<i>n</i> = 8–11/group). **<i>p</i> < 0.01, ***<i>p</i> < 0.001 (Paired–<i>t</i>-test comparison of novel vs familiar object). (B) Effect of compound <b>12l</b> on attenuation of long-term memory deficits in ORT assay. Data represent mean ± SEM of discrimination index. **<i>P</i> < 0.01 vs vehicle group (H<sub>7,74</sub> = 14.12; Kruskal–Wallis test followed by Dunn’s post hoc).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An inverted U-shaped dose–response curve has been observed with procognitive compounds and approved procognitive drugs.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The exact reason for such a phenomenon is not quite well understood. One school of thought is that an optimal level of acetylcholine is required for cognition. An increase in acetylcholine levels beyond optimal levels did not show improvement in cognition. One reason could be that moderate arousal is beneficial to cognition; whereas too much activation leads to cognitive impairment.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Another reason could be due to an off-target activity at higher doses which may make the rat uncomfortable. It is believed that in case there is an activation of presynaptic autoreceptors, it may result in reducing the efficacy at higher doses.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> This could be the reason that <b>12l</b> did not show efficacy at 10 mg/kg dose.</div><div class="NLM_p">To show the relationship between compound <b>12l</b> efficacy and its target engagement at 5-HT<sub>4</sub>R, it was evaluated for 5-HT<sub>4</sub> receptor occupancy (R.O.).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Gratifyingly, compound <b>12l</b> showed significant R.O. at tested doses ranging from 0.1 mg/kg to 30 mg/kg. The absolute ED<sub>50</sub> value was found to be 2.75 mg/kg, p.o. Brain EC<sub>50</sub> was found to be 184.8 ng/g, and plasma EC<sub>50</sub> was found to be 59.3 ng/mL (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The observed R.O. suggests that the <i>in vivo</i> efficacy for this compound may be mediated through 5-HT<sub>4</sub>R. The 5-HT<sub>4</sub>R partial agonist PF-04995274 showed dose-dependent R.O. with ED<sub>50</sub> value of 0.033 mg/kg, s.c. which was comparable with the reported value (0.01 mg/kg, s.c.).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Another 5-HT<sub>4</sub>R partial agonist RS-67333 showed an ED<sub>50</sub> value of 15.15 mg/kg, p.o. which was also in close agreement with the reported value.<a onclick="showRef(event, 'ref11 ref43'); return false;" href="javascript:void(0);" class="ref ref11 ref43">(11,43)</a> The <i>in vivo</i> efficacy doses of compound <b>12l</b> were very well correlated with observed R.O. data. The effective doses (0.3, 1.0, and 3 mg/kg, p.o.) of <b>12l</b> showed R.O. from 27% to 60% (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. 5-HT<sub>4</sub>R occupancy of compound <b>12l</b> and correlation with plasma and brain concentrations. Data shown are the mean ± SEM (<i>n</i> = 4–6 animals).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The 5-HT<sub>4</sub>R agonists can shift the equilibrium of amyloid precursor protein (APP) processing from an amyloidogenic to nonamyloidogenic form, showing disease-modifying potential.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The APP processing shifts equilibrium from an amyloidogenic to nonamyloidogenic form by generating sAPPα which is reported to provide neuroprotective effects.<a onclick="showRef(event, 'ref9 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref9 ref46 ref47">(9,46,47)</a> The 5-HT<sub>4</sub>R-mediated regulation of sAPPα secretion has been demonstrated <i>in vitro</i> using primary neuronal cultures and recombinant cells.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> It is reported that the endogenous ligand serotonin (5-HT) enhances the level of secreted sAPPα in a time and dose-dependent manner in Chinese hamster ovary (CHO) cells stably expressing the h5-HT<sub>4E</sub> receptor isoform.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> It is also reported that the 5-HT<sub>4</sub>R agonists increase sAPPα levels in the cortex and hippocampus of male C57BL/6j mice and the effects were blocked with selective 5-HT<sub>4</sub>R antagonist GR-113808.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> In agreement with the published results, activation of the 5-HT<sub>4E</sub> receptor isoform dose dependently increased expression levels of nonamyloidogenic sAPPα in tsa201 cells transiently transfected with the 5-HT<sub>4E</sub> receptor and APP695. At 10 μM concentration, 5-HT, RS-67333, and compound <b>12l</b> increased sAPPα secretion by 2.9 and 1.5 and 1.8 fold, respectively. The increase in sAPPα secretion by 5-HT and compound <b>12l</b> was completely blocked by GR-113808 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), suggesting compound <b>12l</b> has disease-modifying potential and the activity is arising from the selective activation of the 5-HT<sub>4</sub> receptor. RS-67333 was not subjected to blockade with GR-113808.</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0007.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>5-HT</b>, <b>12l</b>, and RS-67333 on sAPPα secretion in the absence or presence of selective 5-HT<sub>4</sub>R antagonist GR-113808 by Western blot. Data represent mean of duplicates of fold over basal of sAPPα levels. Compound <b>5-HT</b> and 5-HT<sub>4</sub> receptor partial agonist compound <b>12l</b> and RS-67333 evoked stimulation of sAPPα secretion <i>in vitro</i> were monitored using tsa201 cells transiently transfected with human 5-HT<sub>4E</sub> receptor and human APP695.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The protein binding experiment was done in rat, dog, and human liver microsomes to ascertain the free fraction available for <b>12l</b>. Compound <b>12l</b> showed 11.3, 9.2, and 7.3% free fraction in rat dog and human plasma, respectively. The free fraction in rat brain homogenate for <b>12l</b> was 5.9% (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. <i>In Vitro</i> Plasma Protein Binding for Compound <b>12l</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">%unbound</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">%bound</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char=".">replicate 1</th><th class="colsep0 rowsep0" align="center" char=".">replicate 2</th><th class="colsep0 rowsep0" align="center" char=".">replicate 1</th><th class="colsep0 rowsep0" align="center" char=".">replicate 2</th><th class="colsep0 rowsep0" align="center" char=".">%bound<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="center">Plasma Binding</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="char" char=".">93.6</td><td class="colsep0 rowsep0" align="char" char=".">91.8</td><td class="colsep0 rowsep0" align="char" char=".">92.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">beagle dog</td><td class="colsep0 rowsep0" align="char" char=".">8.3</td><td class="colsep0 rowsep0" align="char" char=".">10.0</td><td class="colsep0 rowsep0" align="char" char=".">91.7</td><td class="colsep0 rowsep0" align="char" char=".">90.0</td><td class="colsep0 rowsep0" align="char" char=".">90.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Wistar rat</td><td class="colsep0 rowsep0" align="char" char=".">11.8</td><td class="colsep0 rowsep0" align="char" char=".">10.9</td><td class="colsep0 rowsep0" align="char" char=".">88.2</td><td class="colsep0 rowsep0" align="char" char=".">89.1</td><td class="colsep0 rowsep0" align="char" char=".">88.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="center">Brain Homogenate Binding</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Wistar rat</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">94.5</td><td class="colsep0 rowsep0" align="char" char=".">93.8</td><td class="colsep0 rowsep0" align="char" char=".">94.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Data represent mean, and experiment was done in duplicates.</p></div></div></div><div class="NLM_p">Compound <b>12l</b> showed comparable potencies at tested 5-HT<sub>4</sub>R isoforms (5-HT<sub>4A</sub>, 5-HT<sub>4D</sub>, and 5-HT<sub>4E</sub>) with EC<sub>50</sub> values ranging from 32 to 114 nM. Compound <b>12l</b> showed excellent selectivity against 5-HT receptors (5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>3</sub>, 5-HT<sub>6</sub>, 5-HT<sub>7</sub>), adrenergic receptors (Adα<sub>1B</sub> and Adα<sub>2C</sub>), adenosine receptor A<sub>2A</sub>, cannabinoid receptors (CB<sub>1</sub> and CB<sub>2</sub>), dopamine (D<sub>1</sub>, D<sub>2S</sub>, D<sub>3</sub>, and D<sub>5</sub>), histamine (H<sub>1</sub> and H<sub>3</sub>), muscarinic receptors (M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub>, M<sub>4</sub>, and M<sub>5</sub>), and serotonin transporter (SERT). Compound <b>12l</b> did not show any significant binding up to the highest tested concentration of 10 μM toward GPCRs, ion channels, and transporters (see <a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf" class="ext-link">Supporting Information</a>). Compound <b>12l</b> did not show any agonist activity at the 5-HT<sub>2B</sub> receptor when evaluated in rat fundus assay<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> (See <a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf" class="ext-link">Supporting Information</a>). Compound <b>12l</b> did not show any activity at GPCRs or ion channels other than 5-HT<sub>4</sub>R, which are implicated in cognition. Compound <b>12l</b> is a nonhygroscopic and crystalline oxalate salt with excellent water solubility (17.1 mg/mL). The solubility of <b>12l</b> in buffer solutions from pH 2 to 7.0 is about 20–75 mg/mL at 37 °C. The highest possible dose of <b>12l</b> is soluble in 250 mL in the entire pH range. Compound <b>12l</b> demonstrated high permeability in Caco-2 experiments at a tested concentration (10 μM) with an apparent permeability coefficient (<i>P</i><sub>app</sub>) of 38 × 10<sup>–6</sup> cm·s<sup>–1</sup>. The high solubility and high permeability suggest that <b>12l</b> belongs to class I of the Biopharmaceutics Classification System (BCS). Compound <b>12l</b> showed an acid dissociation constant (p<i>K</i><sub>a</sub>) value of 8.4 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_p">Pharmacokinetics of compound <b>12l</b> was assessed in male beagle dogs (<i>n</i> = 3) at 1 mg/kg, p.o., and 1 mg/kg, i.v., doses. Compound <b>12l</b> showed rapid oral absorption (<i>T</i><sub>max</sub> in the range of 0.5–0.75 h) with oral exposures (AUC<sub>0–24h</sub> = 711 ± 369 ng·h/mL) and showed longer terminal i.v. half-life (6.0 ± 1.5 h). The moderate intravenous clearance (18 ± 6 mL/min/kg) and volume of distribution (5.1 ± 0.6 L/kg) indicate a higher tissue distribution. The observed absolute oral bioavailability (%<i>F</i>) was 72 ± 11%. Compound <b>12l</b> was evaluated for cardiovascular toxicity using dog telemetry assay as per ICH 7A guidelines. In this study, compound <b>12l</b> was administered orally to freely moving conscious male dogs. Gratifyingly, it did not show any adverse effect on QT interval prolongation up to the tested dose of 24 mg/kg p.o.</div><div class="NLM_p">Compound <b>12l</b> was found to be nonmutagenic in all four strains of <i>Salmonella typhimurium</i> TA1537, TA1535, TA98, and TA100 and <i>Escherichia coli</i> WP2 uvrA both in the absence and presence of metabolic activation. It was found to be nonclastogenic in <i>in vitro</i> chromosomal aberration tests in human peripheral blood lymphocytes and in <i>in vivo</i> micronucleus assay done on mice bone marrow. These studies were conducted per the standard protocols and in line with regulatory guidance documents (OECD 471 and 474 and ICH S2R1). The CYP enzyme inhibition, CYP3A4 TDI assay, CYP induction, and transporter assays were performed as described earlier.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Compound <b>12l</b> was not an inhibitor of P450 enzymes with IC<sub>50</sub> values >45 μM against major P450 isoforms. It did not show any TDI liability at CYP3A4 or CYP induction liability at CYP1A2, CYP2B6, and CYP3A4. Compound <b>12l</b> was neither an inhibitor (IC<sub>50</sub> > 100 μM) nor substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3 uptake transporters. The likelihood of drug–drug interaction potential of compound <b>12l</b> as an inhibitor/inducer is remote.</div><div class="NLM_p last">Compound <b>12l</b> as a clinical candidate has completed regulatory safety assessment studies in rats and dogs with excellent safety margins which supported its progression to first in human phase 1 clinical studies including pharmacokinetics, safety, and tolerability under US IND (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a>, identifiers: NCT02575482 and NCT03031574).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Compound <b>12l</b> showed a favorable safety and PK profile in a single ascending dose in healthy male and multiple ascending doses for 14 days in healthy male subjects. Gender, age, and food did not have any significant effect on the pharmacokinetics. It was well-tolerated in humans with adequate plasma exposures and a favorable half-life for once-a-day dosing. Phase 2 enabling long-term animal safety evaluation to support repeat dosing has also been completed. Compound <b>12l</b> will be evaluated in phase 2 proof of concept studies in patients with cognitive deficits associated with AD in due course of time.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41025" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41025" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, indazole-3-carboxamide, indazole 1,2,4-oxadiazole, and indazole 1,3,4-oxadiazole derivatives have been synthesized and tested for their <i>in vitro</i> affinity at 5-HT<sub>4</sub>R. The focused structure–activity relationships for <i>in vitro</i> affinity at 5-HT<sub>4</sub>R combined with microsomal metabolic stability, PK evaluation, efficacy in cognitive models, target engagement, and safety assessments resulted in a safe, potent, and selective 5-HT<sub>4</sub>R clinical candidate (<b>12l</b>, Usmarapride). Compound <b>12l</b> showed high selectivity against ganglionic 5-HT<sub>3</sub>R and other closely related receptors and good pharmacokinetics in rats, dogs, and healthy humans. It also showed promising <i>in vivo</i> efficacy in animal models of cognition. Additionally, compound <b>12l</b> increased neuroprotective sAPPα levels and may possess disease-modifying potential. Further, <b>12l</b> showed a dose-dependent receptor occupancy which correlates well with efficacy doses in tested cognition models. When evaluated in safety models, <b>12l</b> did not show any cardiotoxicity in dog telemetry studies. Based on its robust efficacy in cognition models and a wide margin of safety in preclinical species, it was evaluated in healthy human subjects in phase 1 clinical trials for tolerability and PK properties. Compound <b>12l</b> was found to be well tolerated and showed good pharmacokinetics. Further evaluation of compound <b>12l</b> for its efficacy in cognitive deficits associated with AD in a phase 2 proof-of-concept study is being planned.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31861" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31861" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unless stated otherwise, all reagents, commercially available building blocks, and solvents were purchased from common commercial suppliers and were used without further purification. Synthesized compounds were purified wherever required by passing through 100–200 mesh silica gel using appropriate solvent systems. <sup>1</sup>H NMR spectra were recorded at 400 MHz and <sup>13</sup>C NMR at 100 MHz on a Bruker NMR spectrometer instrument (Fallanden, Switzerland). All <sup>1</sup>HNMR shifts are reported in δ units (ppm) relative to the signals for chloroform (7.27 ppm), DMSO (2.50 ppm), and MeOH (3.31 ppm). All coupling constants (<i>J</i> values) are reported in hertz (Hz). NMR abbreviations are as follows: bs, broadened singlet; s, singlet; d, doublet; t,triplet; q, quartet; m, multiplet and dd, doublet of doublets. Thin-layer chromatography (TLC) was performed on Merck silica gel 60 F<sub>254</sub> plates. Electrospray ionization mass spectra were recorded on API 4000 triple quadrupole instrument (MDS-SCIEX, Concord, Ontario, Canada). Infrared spectra were recorded on KBr disc and in solid state using PerkinElmer model 1600 FT-IR spectrophotometer (PerkinElmer, Norwalk, CT, USA). Elemental analyses were carried out in an “Elementar” GmbH, Vario microcube instrument, and the analyses indicated by the symbols of the elements were within ±0.4% of the theoretical values. Column chromatography was performed using 100–200 mesh silica gel. The purity of all final compounds was established by HPLC (Agilant, Model-1100 series). All final compounds’ HPLC purity was found to be ≥95%. DSC was recorded on Waters DSC Q100 instrument. Melting points of synthesized compounds were determined using an Electro Derman open capillary apparatus and are uncorrected. The reference standards PRX-03140, RS-67333, PF-04995274, GR-113808, prucalopride, and others were synthesized and characterized in-house using respective reported procedures. The purity of all final compounds was determined using HPLC methods unless stated otherwise.</div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> General Procedure 1 (Boc Protection)</h3><div class="NLM_p last">To the solution of amine/amide (1.0 mmol) in DCM (2.0 mL) stirred at room temperature (r.t.), Boc anhydride (1.1 mmol), DMAP (0.05 mmol), and triethylamine (1.5 mmol) were added. The reaction mixture was stirred for 16 h at r.t. Upon completion of reaction, it was diluted with EtOAc, washed with water and brine, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. Volatiles were removed under reduced pressure to obtain the crude product, which was triturated with hexanes to obtain titled compound.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Procedure 2 (Boc Deprotection)</h3><div class="NLM_p last">To a Boc protected compound (1.0 mmol) in DCM (4.0 mL) under nitrogen at 0 °C, TFA (5.0 mmol) was added. The reaction was gradually warmed to r.t. and stirred for 16 h. The mixture was concentrated under vacuum to obtain a crude product, which was basified with aqueous NaHCO<sub>3</sub> solution. The reaction mass was diluted with DCM (10 mL), and the two layers were separated. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum which afforded amino compound.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure 3 (N-Alkylation)</h3><div class="NLM_p last">To the stirred solution of amino compound (1.0 mmol) in acetonitrile (4.0 mL) at r.t., K<sub>2</sub>CO<sub>3</sub> (1.5 mmol) and alkyl halide (1.05 mmol) were added. The reaction mixture was gradually heated to reflux (82–85 °C) for 7–16 h. After completion of the reaction, volatiles were removed under reduced pressure. The crude mass was diluted with DCM and water and allowed to stir for 15 min, then two layers were separated. The organic layer was washed with brine,and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and volatiles were removed under pressure to get gummy mass of N-alkylated compound.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure 4 (Acid Chloride and Amine Coupling Reaction)</h3><div class="NLM_p last">To a stirred solution of 1-isopropyl-1H-indazole-3-carbonyl chloride (<b>3</b>, 1.0 mmol) in DCM (2.0 mL) under nitrogen atmosphere at 0 °C, triethylamine (1.5 mmol) and a solution of amine (<b>4</b>, 1.02 mmol) in DCM (2.0 mL) were added. The reaction mixture was gradually warmed to r.t. and stirred for 16 h. After completion of the reaction, the reaction mixture was diluted with water and DCM. The separated organic layer was washed with brine and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated under vacuum to obtain crude carboxamide derivative, which was purified by silica gel column chromatography with appropriate solvent system.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General Procedure 5 (Hydrazide Formation)</h3><div class="NLM_p last">To a stirred solution of ester <b>8a</b>–<b>8f</b> (1.0 mmol) in methanol (2.0 mL) at r.t., hydrazine hydrate (80% w/v, 3.0 mmol) was added. The reaction mixture was heated to reflux for 4 h. An additional amount of hydrazine (80% w/v, 3.0 mmol) was added, and the reaction was heated until (6 h) all of the ester was consumed. Solvent methanol was evaporated under reduced pressure, and the residue was dissolved in DCM. The two layers were separated, the organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated under vacuum to obtain hydrazide derivative (<b>9a</b>–<b>9f</b>), which was used in the next reaction without further purification.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> General Procedure 6 (Acid Chloride-Hydrazide Coupling)</h3><div class="NLM_p last">To a stirred solution of hydrazide <b>9a</b>–<b>9f</b> (1.0 mmol) in DCM (2.0 mL) cooled at 0 °C, a solution of 1-isopropyl-1H-indazole-3-carbonyl chloride <b>3</b> (1.1 mmol) in DCM (2.0 mL) was added over a period of 5 min. The reaction was gradually warmed to r.t. and was stirred for 2 h. The progress of the reaction was monitored by TLC, which showed an absence of hydrazide. The reaction mixture was then diluted with water, and the two layers were separated. The aqueous layer was washed with EtOAc, cooled to 0 °C, and cautiously basified to pH 7.6 with 10% aqueous NaHCO<sub>3</sub> solution. The basified aqueous layer was then extracted with DCM. The combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure. The residue was then cooled to r.t. and diluted with hexane. The slurry, thus obtained, was filtered at r.t. under nitrogen atmosphere, and the wet product cake was washed with hexanes to obtain respective compounds <b>10a</b>–<b>10f</b> in quantitative yields.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure 7 (1,3,4-Oxadiazole Formation)</h3><div class="NLM_p last">To a stirred solution of compounds <b>10a</b>–<b>10f</b> (1.0 mmol) in 1,2-dichloroethane (4.0 mL) under nitrogen atmosphere at r.t., thionyl chloride (2.0 mmol) was added over a period of 15 min. The reaction temperature was then gradually raised, and the reaction mass was refluxed for 6–10 h until all starting material was consumed. The excess thionyl chloride and solvent 1,2-dichloroethane were distilled off under reduced pressure. The reaction mass was cooled to r.t. and diluted with water and solvent ether. The resulting mass was stirred for 15 min, and the two layers were separated. The pH of the aqueous layer was adjusted to 9–10 by adding an aqueous NaOH (2.5 N). The basified aqueous layer was then extracted multiple times with DCM. The combined organic layer was washed with cold (5–10 °C) aqueous NaOH (0.6 N) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure to afford 1,3,4-oxadiazole derivatives <b>11a</b>–<b>11f</b>.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure 8 (Salt formation)</h3><div class="NLM_p last">To the stirred solution of N-alkylated carboxamide derivative/oxadiazole derivative (1.0 mmol) in isopropanol (8.0 mL), respective acid (1.0 mmol) was added. The reaction mass was stirred for 1 h before the volatiles were evaporated under reduced pressure. The crude salt was triturated with copious amounts of ether and ethyl acetate to obtain the respective salts. The salts were recrystallized from isopropanol or mixture of solvents wherever required to obtain the desired purity.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedure 9 (Reductive Amination)</h3><div class="NLM_p">To a stirred mixture of carboxamide derivatives (1.0 mmol), aldehyde/ketone (1.5 mmol), and acetic acid (0.1 mL) in DCM (4.0 mL) cooled at 0 °C, sodium triacetoxyborohydride (2.0 mmol) was added. The reaction mass was gradually warmed to r.t and stirred for 16 h. The reaction mass was diluted with saturated aqueous NaHCO<sub>3</sub> solution and extracted with DCM. The combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure. The crude product was purified by silica gel column chromatography to obtain the N-alkylated derivatives.</div><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 1-Isopropyl-l<i>H</i>-indazole-3-carboxylic Acid (<b>2</b>)</h4><div class="NLM_p last">To the stirred DMF (50.0 mL) under nitrogen atmosphere at r.t., sodium <i>tert</i>-butoxide (6.0 g, 62.43 mmol) was added over a period of 15 min. The reaction mixture was stirred for 10 min after which it was cooled to 0 to 5 °C. A solution of indazole-3-carboxylic acid (4.0 g, 24.67 mmol) in DMF (50 mL) was added slowly into the reactor over a period of 45 min, maintaining the reaction mass temperature between 0 to 5 °C. The cooling was removed, and the reaction temperature was gradually raised to r.t. over a period of 30 min. After stirring at this temperature for 1 h, the reaction mixture was cooled to 0 °C, and isopropyl iodide (37.18 mmol) was added over a period of 30 min. The cooling was removed, and the reaction temperature was warmed to r.t. After 16 h of stirring, the HPLC analysis of the reaction mixture revealed l0% of indazole-7-carboxylicacid remaining. The reaction mass was quenched cautiously by adding cold water and extracted with EtOAc. The separated aqueous layer was acidified to pH 4.0 with aqueous HCl solution (6 N). The acidified reaction mass was then extracted with EtOAc. The combined organic layer was washed with water, brine, and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure to obtain a crude mass. The obtained crude mass was diluted with DCM (28.0 L) and stirred for 15 min. The solids precipitated (unreacted indazole-7-carboxylic acid) were filtered, and the filter bed was washed once with DCM. The combined filtrate was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and distilled under reduced pressure which yielded a crude mass. The crude mass was triturated with ether, and the solids were filtered to obtain the wet cake which was dried further under reduced pressure to obtain the title compound (3.0 g) in 60% yield. HPLC purity: 99.86%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 8.27 (d, <i>J</i> = 8.1 Hz, l H), 7.55 (d, <i>J</i> = 8.4 Hz, lH), 7.46 (t, <i>J</i> = 7.6 Hz, lH), 7.34 (t, <i>J</i> = 7.4 Hz, lH), 5.01–4.95 (m, lH), 1.68 (d, <i>J</i> = 6.6 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 167.6, 139.9, 133.7, 126.6, 124.1, 123.4, 122.3, 109.8, 51.8, 22.0; DSC: (RAMP 5 °C/min): 163.0 °C; mass (<i>m</i>/<i>z</i>): 205.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 1-Isopropyl-1<i>H</i>-indazole-3-carbonyl Chloride (<b>3</b>)</h4><div class="NLM_p last">To a stirred solution of 1-isopropyl-lH-indazole-3-carboxylic acid <b>2</b> (1.0 g, 4.90 mmol) in 1,2-dichloroethane (19.6 mL) cooled at 0 °C under nitrogen atmosphere, thionyl chloride (0.42 mL, 5.88 mmol) was added. The reaction mixture was gradually raised to r.t. and then refluxed for 1 h. After completion of the reaction, volatiles were evaporated which yielded title compound <b>3</b> (1.0 g) in quantitative yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.21 (d, <i>J</i> = 8.4 Hz, l H), 7.57 (d, <i>J</i> = 8.4 Hz, l H), 7.49 (t, <i>J</i> = 6.8 Hz, l H), 7.41 (t, <i>J</i> = 7.6 Hz, l H), 5.01–4.96 (m, l H), 1.68 (d, <i>J</i> = 6.6 Hz, 6H); mass (<i>m</i>/<i>z</i>): 223.1, 225.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 4-[(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5a</b>)</h4><div class="NLM_p last">By following general procedure 4, 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (500 mg, 2.25 mmol) was reacted with 4-amino-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>4a</b> (450.0 mg, 2.25 mmol) to obtain title compound <b>5a</b> (825.8 mg) in 95.1% yield with HPLC purity 97.0%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.37 (d, <i>J</i> = 8.0 Hz, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (t, <i>J</i> = 8.4 Hz, 1H), 7.18 (t, <i>J</i> = 7.6 Hz, 1H), 4.90–4.84 (m, 1H), 4.13 (bs, 3H), 2.75 (t, <i>J</i> = 12.0 Hz, 2H), 1.88 (d, <i>J</i> = 17.6 Hz, 4H), 1.64 (d, <i>J</i> = 6.8 Hz, 6H), 1.46 (s, 9H); mass (<i>m</i>/<i>z</i>): 387.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-{[(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5b</b>)</h4><div class="NLM_p last">By following general procedure 4, 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (200 mg, 0.9 mmol) was reacted with 4-aminomethylpiperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>4b</b> (192.6 mg, 0.9 mmol) to obtain title compound <b>5b</b> (324.0 mg) in 90.1% yield with HPLC purity 95.0%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (t, <i>J</i> = 8.4 Hz, 1H), 7.26 (t, <i>J</i> = 7.6 Hz, 1H), 4.90–4.84 (m, 1H), 4.13 (bs, 3H), 3.49 (bs, 2H), 2.71 (t, <i>J</i> = 12.0 Hz, 2H), 1.84 (d, <i>J</i> = 17.6 Hz, 4H), 1.61 (d, <i>J</i> = 6.8 Hz, 6H), 1.45 (s, 9H); mass (<i>m</i>/<i>z</i>): 401.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-Hydroxy-4-{[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5c</b>)</h4><div class="NLM_p last">By following general procedure 4, 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (1.0 g, 4.50 mmol) was reacted with 4-aminomethyl-4-hydroxy-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>4c</b> (1.03 g, 4.50 mmol) to obtain title compound <b>5c</b> (1.7 g) in 95.0% yield with HPLC purity 97.0%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.37 (d, <i>J</i> = 8.1 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (t, <i>J</i> = 8.4 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 4.20 (bs, 3H), 3.54 (bs, 2H), 2.73 (t, <i>J</i> = 12.0 Hz, 2H), 1.81 (d, <i>J</i> = 17.6 Hz, 4H), 1.64 (d, <i>J</i> = 6.8 Hz, 6H), 1.46 (s, 9H); mass (<i>m</i>/<i>z</i>): 417.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 4-Fluoro-4-{[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5d</b>)</h4><div class="NLM_p last">By following general procedure 4, 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (500 mg, 2.25 mmol) was reacted with 4-aminomethyl-4-fluoro-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>4d</b> (522.5 mg, 2.25 mmol) to obtain title compound <b>5d</b> (904.2 mg) in 96.1% yield with HPLC purity 94.0%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.42 (d, <i>J</i> = 8.0 Hz, 1H), 7.42 (d, <i>J</i> = 8.4 Hz, 2H), 7.21 (t, <i>J</i> = 8.4 Hz, 1H), 7.14 (t, <i>J</i> = 7.6 Hz, 1H), 4.25 (bs, 3H), 3.49 (bs, 2H), 2.71 (t, <i>J</i> = 12.0 Hz, 2H), 1.84 (d, <i>J</i> = 17.6 Hz, 4H), 1.64 (d, <i>J</i> = 6.8 Hz, 6H), 1.46 (s, 9H); mass (<i>m</i>/<i>z</i>): 419.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 6-{[(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-[1,3]oxazinane-3-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5e</b>)</h4><div class="NLM_p last">By following general procedure 4, 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (750.0 mg, 3.37 mmol) was reacted with 2-aminomethyl-morpholine-4-carboxylic acid <i>tert</i>-butyl ester <b>4e</b> (729.7 mg, 3.37 mmol) to obtain title compound <b>5e</b> (1.2 g) in 90.1% yield with HPLC purity 90.0%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.15 (d, <i>J</i> = 7.6 Hz, 2H), 7.76 (d, <i>J</i> = 8.4 Hz, 1H), 7.43 (t, <i>J</i> = 7.6 Hz, 1H), 7.22 (t, <i>J</i> = 7.6 Hz, 1H), 5.07–5.04 (m, 1H), 3.80–3.44 (m, 3H), 2.65–2.62 (m, 2H), 2.37–2.29 (m, 2H), 1.53 (d, <i>J</i> = 6.8 Hz, 6H), 1.44 (s, 9H), 1.22 (m, 2H); mass (<i>m</i>/<i>z</i>): 403.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 6-[(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-3-aza-bicyclo[3.1.0]hexane-3-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5f</b>)</h4><div class="NLM_p last">By following general procedure 4, 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (1.0 g, 4.50 mmol) was reacted with 6-amino-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid <i>tert</i>-butyl ester <b>4f</b> (892.3 mg, 4.50 mmol) to obtain title compound <b>5f</b> (1.5 g) in 90.1% yield with HPLC purity 95.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.95 (d, <i>J</i> = 8.4 Hz, 1H), 7.77 (d, <i>J</i> = 8.8 Hz, 1H), 7.43 (t, <i>J</i> = 7.6 Hz, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 5.07–5.04 (m, 1H), 2.49–2.42 (m 1H), 2.20 (t, <i>J</i> = 11.2 Hz, 2H), 1.68–1.63 (m, 2H), 1.54 (d, <i>J</i> = 6.4 Hz, 6H), 1.44 (s, 9H), 1.23 (m, 2H); mass (<i>m</i>/<i>z</i>): 385.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 6-{[(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-3-aza-bicyclo[3.1.0]hexane-3-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5g</b>)</h4><div class="NLM_p last">By following general procedure 4, 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (500 mg, 2.25 mmol) was reacted with 6-aminomethyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid <i>tert</i>-butyl ester <b>4g</b> (477.4 mg, 2.25 mmol) to obtain title compound <b>5g</b> (806.7 mg) in 90.1% yield with HPLC purity 93.4%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.95 (d, <i>J</i> = 8.4 Hz, 1H), 7.77 (d, <i>J</i> = 8.8 Hz, 1H), 7.43 (t, <i>J</i> = 7.6 Hz, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 5.07–5.04 (m, 1H), 2.91 (d, <i>J</i> = 11.6 Hz, 2H), 2.71 (d, <i>J</i> = 12.0 Hz, 2H), 2.49–2.42 (m, 1H), 2.20 (t, <i>J</i> = 11.2 Hz, 2H), 1.68–1.63 (m, 2H), 1.53 (d, <i>J</i> = 6.4 Hz, 6H), 1.44 (s, 9H); mass (<i>m</i>/<i>z</i>): 399.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-[(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-8-aza-bicyclo[3.2.1]octane-8-carboxylic Acid <i>tert</i>-Butyl Ester (<b>5h</b>)</h4><div class="NLM_p last">By following general procedure 4, 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (500 mg, 2.25 mmol) was reacted with 3-amino-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid <i>tert</i>-butyl ester <b>4h</b> (509.6 mg, 2.25 mmol) to obtain title compound <b>5h</b> (750.7 mg) in 80.8% yield with HPLC purity 92.4%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.37 (d, <i>J</i> = 8.4 Hz, 1H), 7.52 (d, <i>J</i> = 6.0 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 1H), 7.41 (t, <i>J</i> = 6.8 Hz, 1H), 4.91–4.86 (m, 1H), 4.35–4.34 (m, 1H), 3.65 (bs, 1H), 2.85–2.75 (m, 1H), 2.72–2.65 (m, 1H), 2.41–2.25 (m, 2H), 2.21–2.08 (m, 2H), 2.05–1.9 (m, 2H), 1.83–1.80 (m, 2H), 1.62 (d, <i>J</i> = 6.4 Hz, 6H), 1.44 (s, 9H); mass (<i>m</i>/<i>z</i>): 413.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid Piperidin-4-ylamide (<b>6a</b>)</h4><div class="NLM_p last">Following the procedure of Boc deprotection as mentioned in general procedure 2, compound 4-[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>5a</b> (825.8 mg, 2.13 mmol) was converted to title compound <b>6a</b> (580.7 mg) in 95.1% yield with HPLC purity 91.4%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.45 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (t, <i>J</i> = 8.4 Hz, 1H), 7.28 (t, <i>J</i> = 7.6 Hz, 1H), 5.01- 4.97 (m, 1H), 4.13 (bs, 2H), 2.97 (t, <i>J</i> = 12.0 Hz, 3H), 2.05 (m, 2H), 1.92 (d, <i>J</i> = 17.6 Hz, 4H), 1.61 (d, <i>J</i> = 6.8 Hz, 6H) ; mass (<i>m</i>/<i>z</i>): 287.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid (Piperidin-4-ylmethyl)-amide (<b>6b</b>)</h4><div class="NLM_p last">Following the procedure of Boc deprotection as mentioned in general procedure 2, compound 4-{[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>5b</b> (260.0 mg, 0.65 mmol) was converted to title compound <b>6b</b> (190.0 mg) in 97.4% yield with HPLC purity 95.21%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.39 (d, <i>J</i> = 8.0 Hz, 1H), 7.45 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (t, <i>J</i> = 8.4 Hz, 1H), 7.28 (t, <i>J</i> = 7.6 Hz, 1H), 5.01- 4.97 (m, 1H), 4.13 (bs, 3H), 2.97 (t, <i>J</i> = 12.0 Hz, 3H), 2.05 (m, 1H), 1.92 (d, <i>J</i> = 17.6 Hz, 4H), 1.61 (d, <i>J</i> = 6.8 Hz, 6H); mass (<i>m</i>/<i>z</i>): 301.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid (4-Hydroxy-piperidin-4-ylmethyl)-amide (<b>6c</b>)</h4><div class="NLM_p last">Following the procedure of Boc deprotection as mentioned in general procedure 2, compound 4-hydroxy-4-{[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>5c</b> (1.7 g, 4.08 mmol) was converted to title compound <b>6c</b> (1.1 g) in 98.0% yield with HPLC purity 97.15%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.37 (d, <i>J</i> = 8.1 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 2H), 7.38 (t, <i>J</i> = 8.4 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 4.21 (bs, 3H), 3.54 (bs, 2H), 2.73 (t, <i>J</i> = 12.0 Hz, 2H), 1.81 (d, <i>J</i> = 17.6 Hz, 4H), 1.64 (d, <i>J</i> = 6.8 Hz, 6H); mass (<i>m</i>/<i>z</i>): 317.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid (4-Fluoro-piperidin-4-ylmethyl)-amide (<b>6d</b>)</h4><div class="NLM_p last">Following the procedure of Boc deprotection as mentioned in general procedure 2, compound 4-fluoro-4-{[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>5d</b> (1.32 g, 3.15 mmol) was converted to title compound <b>6d</b> (0.97 g) in 97.7% yield with HPLC purity 96.2%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.36 (d, <i>J</i> = 8.2 Hz, 1H), 7.45 (d, <i>J</i> = 8.1 Hz, 2H), 7.38 (t, <i>J</i> = 8.4 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 4.26 (bs, 3H), 3.55 (bs, 2H), 2.73 (t, <i>J</i> = 12.0 Hz, 2H), 1.81 (d, <i>J</i> = 17.6 Hz, 4H), 1.64 (d, <i>J</i> = 6.8 Hz, 6H); mass (<i>m</i>/<i>z</i>): 319.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid (Morpholin-2-ylmethyl)-amide (<b>6e</b>)</h4><div class="NLM_p last">Following the procedure of Boc deprotection as mentioned in general procedure 2, compound 2-{[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-morpholine-4-carboxylic acid <i>tert</i>-butyl ester <b>5e</b> (1.2 g, 2.98 mmol) was converted to title compound <b>6e</b> (827.4 g) in 93.4% yield with HPLC purity 94.15%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.15 (d, <i>J</i> = 7.6 Hz, 2H), 7.76 (d, <i>J</i> = 8.4 Hz, 1H), 7.43 (t, <i>J</i> = 7.6 Hz, 1H), 7.22 (t, <i>J</i> = 7.6 Hz, 1H), 5.07–5.04 (m, 1H), 3.80–3.44 (m, 3H), 2.71 (t, <i>J</i> = 12.0 Hz, 2H), 2.65–2.62 (m, 2H), 2.37–2.29 (m, 2H), 1.53 (d, <i>J</i> = 6.8 Hz, 6H); mass (<i>m</i>/<i>z</i>): 303.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid (3-Aza-bicyclo[3.1.0]hex-6-yl)-amide (<b>6f</b>)</h4><div class="NLM_p last">Following the procedure of Boc deprotection as mentioned in general procedure 2, compound 6-[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid <i>tert</i>-butyl ester <b>5f</b> (1.5 g, 3.90 mmol) was converted to title compound (998.0 mg) <b>6f</b> in 90.0% yield with HPLC purity 94.1%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.95 (d, <i>J</i> = 8.4 Hz, 1H), 7.77 (d, <i>J</i> = 8.8 Hz, 1H), 7.43 (t, <i>J</i> = 7.6 Hz, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 5.07–5.04 (m, 1H), 2.91 (d, <i>J</i> = 11.6 Hz, 2H), 2.49–2.42 (m 1H), 2.20 (t, <i>J</i> = 11.2 Hz, 2H), 1.68–1.63 (m, 2H), 1.53 (d, <i>J</i> = 6.4 Hz, 6H); mass (<i>m</i>/<i>z</i>): 285.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid (3-Aza-bicyclo[3.1.0]hex-6-ylmethyl)-amide (<b>6g</b>)</h4><div class="NLM_p last">Following the procedure of Boc deprotection as mentioned in general procedure 2, compound 6-{[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-methyl}-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid <i>tert</i>-butyl ester <b>5g</b> (806.7 mg, 3.90 mmol) was converted to title compound <b>6g</b> (555.0 mg) in 92.0% yield with HPLC purity 96.8%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.95 (d, <i>J</i> = 8.4 Hz, 1H), 7.77 (d, <i>J</i> = 8.8 Hz, 1H), 7.43 (t, <i>J</i> = 7.6 Hz, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 5.07–5.04 (m, 1H), 2.91 (d, <i>J</i> = 11.6 Hz, 2H), 2.71 (d, <i>J</i> = 12.0 Hz, 2H), 2.49–2.42 (m, 1H), 2.20 (t, <i>J</i> = 11.2 Hz, 2H), 1.68–1.63 (m, 2H), 1.53 (d, <i>J</i> = 6.4 Hz, 6H); mass (<i>m</i>/<i>z</i>): 299.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid (8-Aza-bicyclo[3.2.1]oct-3-yl)-amide (<b>6h</b>)</h4><div class="NLM_p last">Following the procedure of Boc deprotection as mentioned in general procedure 2, compound 3-[(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-amino]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid <i>tert</i>-butyl ester <b>5h</b> (340.7 mg, 1.82 mmol) was converted to title compound <b>6h</b> (340.7 mg) in 90.0% yield with HPLC purity 97.1%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.37 (d, <i>J</i> = 8.4 Hz, 1H), 7.52 (d, <i>J</i> = 6.0 Hz, 1H), 7.43 (d, <i>J</i> = 8.4 Hz, 1H), 7.41 (t, <i>J</i> = 6.8 Hz, 1H), 4.91–4.86 (m, 1H), 4.35–4.34 (m, 1H), 3.65 (bs, 1H), 2.85–2.75 (m, 1H), 2.72–2.65 (m, 1H), 2.41–2.25 (m, 2H), 2.21–2.08 (m, 2H), 2.05–1.9 (m, 2H), 1.83–1.80 (m, 2H), 1.62 (d, <i>J</i> = 6.4 Hz, 6H); mass (<i>m</i>/<i>z</i>): 313.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid [1-(3-Hydroxy-propyl)-piperidin-4-yl]-amide Tartarate (<b>7a</b>)</h4><div class="NLM_p last">1-Isopropyl-1<i>H</i>-indazole-3-carboxylic acid piperidin-4-ylamide <b>6a</b> (580.0 mg, 2.02 mmol) was N-alkylated with 3-bromo-propan-1-ol by following general procedure 3 to obtain title compound <b>7a</b> free base which was converted to its tartarate salt by using the general procedure 8 to obtain title compound (685.6 mg) as cream color solid in 88.2% yield with HPLC purity 95.7%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.15 (t, <i>J</i> = 8.0 Hz, 2H), 7.78 (d, <i>J</i> = 8.8 Hz, 1H), 7.44 (t, <i>J</i> = 7.6 Hz, 1H), 7.26 (t, <i>J</i> = 7.6 Hz, 1H), 5.10–5.03 (m,1H), 4.05 (s, 2H), 3.98–3.96 (m, 1H), 3.90 (bs, 1H), 3.49 (t, <i>J</i> = 7.2 Hz, 2H), 3.20 (d, <i>J</i> = 11.2 Hz, 2H), 2.72 (d, <i>J</i> = 6.4 Hz, 2H), 2.52 (bs, 2H), 1.91 (d, <i>J</i> = 10.8 Hz, 2H), 1.81 (d, <i>J</i> = 11.2 Hz, 2H), 1.67 (t, <i>J</i> = 6.0 Hz, 2H), 1.54 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 174.4, 167.3, 160.6, 139.6, 129.1, 127.0, 122.8, 122.5, 121.9, 109.6, 81.0, 62.7, 57.9, 52.1, 51.6, 31.9, 28.2, 27.0, 22.0; DSC: (RAMP 5 °C/min): 143.2 °C; mass (<i>m</i>/<i>z</i>): 345.1 (M + H)<sup>+</sup>; C<sub>23</sub>H<sub>34</sub>N<sub>4</sub>O<sub>8</sub>; % C, H, N: calculated C; 55.86, H; 6.93, N; 11.33; found C; 55.62, H; 6.93, N; 11.52.</div></div><div id="sec4_9_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid [1-(3-Methoxy-propyl)-piperidin-4-ylmethyl]-amide Oxalate (<b>7l</b>)</h4><div class="NLM_p last">By following general procedure 3, 1-isopropyl-1<i>H</i>-indazole-3-carboxylic acid (piperidin-4-ylmethyl)-amide <b>6b</b> (190.0 mg, 0.63 mmol) was N-alkylated with 1-bromo-3-methoxypropane to obtain <b>7l</b> free base as a gummy mass which was converted to its oxalate salt by using the general procedure 8 to obtain title compound <b>7l</b> (188.6 mg) as off-white solid in 80.0% yield with HPLC purity 98.7%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.16 (d, <i>J</i> = 7.6 Hz, 1H), 7.79 (d, <i>J</i> = 7.6 Hz, 1H), 7.44 (t, <i>J</i> = 7.6 Hz, 1H), 7.26 (t, <i>J</i> = 7.6 Hz, 1H), 5.10–5.06 (m, 1H), 4.11–3.99 (m, 1H), 3.80 (d, <i>J</i> = 10.8 Hz, 1H), 3.62–3.50 (m, 1H), 3.34 (t, <i>J</i> = 9.6 Hz, 2H), 3.18 (s, 3H), 2.79 (d, <i>J</i> = 10.4 Hz, 2H), 2.69 (d, <i>J</i> = 10.4 Hz, 4H), 2.29 (bs, 2H), 1.97–1.76 (m, 2H), 1.64–1.61 (m, 1H), 1.53 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 167.9, 160.6, 139.6, 129.1, 127.0, 122.8, 122.5, 121.9, 109.6, 69.9, 57.9, 52.1, 51.6, 31.9, 28.2, 27.0, 22.0; DSC: (RAMP 5 °C/min): 157.1 °C; mass (<i>m</i>/<i>z</i>): 373.0 (M + H)<sup>+</sup>; C<sub>23</sub>H<sub>34</sub>N<sub>4</sub>O<sub>6</sub>; % C, H, N: calculated C; 59.72, H; 7.41, N; 12.11; found C; 59.81, H; 7.61, N; 12.23.</div></div><div id="sec4_9_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid [4-Hydroxy-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide Oxalate (<b>7o</b>)</h4><div class="NLM_p last">1-Isopropyl-1<i>H</i>-indazole-3-carboxylic acid (4-hydroxy-piperidin-4-ylmethyl)-amide <b>6c</b> (1.1 g, 3.47 mmol) was N-alkylated with 1-bromo-3-methoxy-propane by following general procedure 3 to obtain <b>7o</b> free base as a gummy mass which was converted to its oxalate salt by using the general procedure 8 to obtain title compound in 92.1% yield (1.32 g) with HPLC purity 97.5%. <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.31 (bs, 1H), 8.22 (d, <i>J</i> = 8.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.4 Hz, 1H), 7.47 (t, <i>J</i> = 7.6 Hz, 1H), 7.28 (t, <i>J</i> = 7.6 Hz, 1H), 5.08–5.02 (m, 1H), 3.65 (bs, 2H), 3.54 (s, 3H), 3.51- 3.46 (m, 6H), 3.23–2.219 (m, 2H), 2.02–1.95 (m, 6H), 1.62 (d, <i>J</i> = 6.4 Hz, 6H); mass (<i>m</i>/<i>z</i>): 389.2 (M + H)<sup>+</sup>; C<sub>23</sub>H<sub>34</sub>N<sub>4</sub>O<sub>6</sub>; % C, H, N: calculated C; 59.72, H; 7.41, N; 12.11; found C; 59.39, H; 7.61, N; 12.23.</div></div><div id="sec4_9_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid [4-Fluoro-1-(3-methoxy-propyl)-piperidin-4-ylmethyl]-amide (<b>7q</b>)</h4><div class="NLM_p last">1-Isopropyl-1<i>H</i>-indazole-3-carboxylic acid (4-hydroxy-piperidin-4-ylmethyl)-amide <b>6d</b> (0.5 g, 1.67 mmol) was N-alkylated with 1-bromo-3-methoxy-propane by following general procedure 3 to obtain <b>7q</b> as off-white powder in 88.2% yield (0.49 g) with HPLC purity 95.8%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.36 (d, <i>J</i> = 8.2 Hz, 1H), 7.45 (d, <i>J</i> = 8.1 Hz, 2H), 7.38 (t, <i>J</i> = 8.4 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 4.26 (bs, 3H), 3.55–3.43 (m, 4H), 3.54 (s, 3H), 2.73 (m, 2H), 2.04–1.88 (m, 6H), 1.64 (d, <i>J</i> = 6.8 Hz, 6H); mass (<i>m</i>/<i>z</i>): 391.1 (M + H)<sup>+</sup>; C<sub>21</sub>H<sub>31</sub>FN<sub>4</sub>O<sub>2</sub>; % C, H, N: calculated C; 64.59, H; 8.0, N; 14.35; found C; 64.02, H; 7.69, N; 14.26.</div></div><div id="sec4_9_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid [4-(3-Methoxypropyl)-morpholin-2-ylmethyl]-amide Tartarate (<b>7r</b>)</h4><div class="NLM_p last">1-Isopropyl-1<i>H</i>-indazole-3-carboxylic acid (4-fluoro-piperidin-4-ylmethyl)-amide was N-alkylated with 1-bromo-3-methoxy-propane by following general procedure 3 to obtain compound <b>7r</b> free base as a gummy mass which was converted to its tartarate salt using general procedure 8 to obtain title compound <b>7r</b> (851.8 mg) in 83% yield with HPLC purity 95.5%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.16 (d, <i>J</i> = 7.6 Hz, 2H), 7.79 (d, <i>J</i> = 8.4 Hz, 1H), 7.44 (t, <i>J</i> = 7.6 Hz, 1H), 7.26 (t, <i>J</i> = 7.6 Hz, 1H), 5.08–5.05 (m, 1H), 3.80–3.44 (m, 3H), 3.35–3.29 (m, 2H), 3.18 (s, 3H), 2.79–2.76 (m, 2H), 2.65–2.62 (m, 4H), 2.37–2.29 (m, 2H), 1.64–1.61 (m, 2H), 1.53 (d, <i>J</i> = 6.8 Hz, 6H); mass (<i>m</i>/<i>z</i>): 375.1 (M + H)<sup>+</sup>; C<sub>24</sub>H<sub>36</sub>N<sub>4</sub>O<sub>9</sub>; % C, H, N: calculated C; 54.95, H; 6.92, N; 10.68; found C; 55.01, H; 6.73, N; 10.43.</div></div><div id="sec4_9_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid [3-(3-Methoxy-propyl)-3-aza-bicyclo[3.1.0]hex-6-yl]-amide Oxalate (<b>7s</b>)</h4><div class="NLM_p last">1-Isopropyl-1<i>H</i>-indazole-3-carboxylic acid (3-aza-bicyclo[3.1.0]hex-6-yl)-amide <b>6f</b> (998.4 mg, 3.51 mmol) was N-alkylated with 1-bromo-3-methoxy-propane by following general procedure 3 to obtain compound <b>7s</b> free base as a gummy mass which was converted to its oxalate salt using general procedure 8 to obtain title compound <b>7s</b> (1.1 g) as off-white powder in 93% yield with HPLC purity 95.5%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.37 (d, <i>J</i> = 3.2 Hz, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 1H), 7.78 (d, <i>J</i> = 8.4 Hz, 1H), 7.44 (t, <i>J</i> = 7.2 Hz, 1H), 7.27 (t, <i>J</i> = 7.6 Hz, 1H), 5.07–5.04 (m, 1H), 3.75 (s, 3H), 3.68 (t, <i>J</i> = 9.2 Hz, 2H), 3.52–3.33 (m, 4H), 3.22- 3.14 (m, 6H), 3.14–2.99 (m, 2H), 2.06 (s, 2H), 1.81–1.78 (m, 2H), 1.52 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.2, 163.0, 139.9, 136.4, 126.3, 122.9, 122.6, 122.5, 109.3, 69.0, 58.7, 55.9, 54.3, 51.0, 39.8, 26.1, 22.1, 21.1; DSC: (RAMP 5 °C/min): 172.6 °C; mass (<i>m</i>/<i>z</i>): 357.2 (M + H)<sup>+</sup>; C<sub>22</sub>H<sub>30</sub>N<sub>4</sub>O<sub>6</sub>; % C, H, N: calculated C; 59.18, H; 6.77, N; 12.55; found C; 59.01, H; 6.71, N; 12.83.</div></div><div id="sec4_9_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid [3-(3-Methoxy-propyl)-3-aza-bicyclo[3.1.0]hex-6-ylmethyl]-amide Oxalate (<b>7v</b>)</h4><div class="NLM_p last">1-Isopropyl-1<i>H</i>-indazole-3-carboxylic acid (3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-amide <b>6g</b> (555.0 mg, 1.86 mmol) was N-alkylated with 1-bromo-3-methoxy-propane by following general procedure 3 to obtain compound <b>7v</b> free base as a gummy mass which was converted to its oxalate salt using general procedure 8 to obtain title compound <b>7v</b> (640.0 mg) as a gummy mass in 91.7% yield with HPLC purity 97.2%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.41 (bs, 1H), 8.17 (d, <i>J</i> = 8.0 Hz, 1H), 7.80 (d, <i>J</i> = 8.3 Hz, 1H), 7.45 (t, <i>J</i> = 7.21 Hz, 1H), 7.27 (t, <i>J</i> = 7.5 Hz, 1H), 5.09–5.06 (m, 1H), 3.32 (t, <i>J</i> = 11.0 Hz, 4H), 3.19 (s, 6H), 3.05 (bs, 4H), 1.75 (bs, 4H), 1.54 (d, <i>J</i> = 6.4 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 163.9, 163.1, 139.9, 136.4, 126.3, 122.9, 122.6, 122.5, 109.3, 69.0, 58.7, 55.9, 54.3, 51.0, 47.1, 39.8, 26.1, 22.1, 21.0; DSC: (RAMP 5 °C/min): 163.8 °C; mass (<i>m</i>/<i>z</i>): 371.2 (M + H)<sup>+</sup>; C<sub>22</sub>H<sub>33</sub>N<sub>4</sub>O<sub>6</sub>; % C, H, N: calculated C; 59.99, H; 7.00, N; 12.17; found C; 60.20, H; 6.98, N; 12.23.</div></div><div id="sec4_9_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid [8-(2-Fluoro-ethyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-amide (<b>7aa</b>)</h4><div class="NLM_p last">1-Isopropyl-1<i>H</i>-indazole-3-carboxylic acid (8-aza-bicyclo[3.2.1]oct-3-yl)-amide <b>6h</b> (340.0 mg, 1.08 mmol) was N-alkylated with 1-bromo-3-methoxy-propane by following general procedure 3 to obtain title compound <b>7aa</b> (351.0 mg) as off-white color powder in 90% yield with HPLC purity 96.7%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.38 (d, <i>J</i> = 8.4 Hz, 1H), 7.58 (d, <i>J</i> = 6.0 Hz, 1H), 7.46 (d, <i>J</i> = 8.4 Hz, 1H), 7.41 (t, <i>J</i> = 6.8 Hz, 1H), 4.91–4.86 (m, 1H), 4.70–4.60 (m, 1H), 4.55–4.48 (m, 1H), 4.35–4.34 (m, 1H), 3.65 (bs, 1H), 3.34 (bs, 2H), 2.85–2.75 (m, 1H), 2.72–2.65 (m, 1H), 2.41–2.25 (m, 2H), 2.21–2.08 (m, 2H), 2.05–1.9 (m, 2H), 1.83–1.80 (m, 2H), 1.62 (d, <i>J</i> = 6.4 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 166.9, 139.8, 136.4, 126.3, 122.9, 122.6, 122.5, 109.3, 84.1, 58.7, 55.9, 54.3, 51.0, 39.8, 26.1, 22.1, 21.8; DSC: (RAMP 5 °C/min): 159.2 °C; mass (<i>m</i>/<i>z</i>): 359.2 (M + H)<sup>+</sup>; C<sub>20</sub>H<sub>27</sub>FN<sub>4</sub>O; % C, H, N: calculated C; 67.01, H; 7.59, N; 15.63; found C; 67.18, H; 7.23, N; 15.61.</div></div><div id="sec4_9_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Piperidine-1,4-dicarboxylic Acid 1-<i>tert</i>-Butyl Ester 4-Ethyl Ester (<b>8a</b>)</h4><div class="NLM_p last">By following general procedure 1, ethyl isonipecotate (6.5 g, 41.35 mmol) was converted to the title compound <b>8</b> (9.54 g) in 90% yield with GC purity 98.8%. <sup>1</sup>H NMR (CDCI<sub>3</sub>): δ 4.16–4.11 (m, 2H), 2.86 (t, <i>J</i> = 12.0 Hz, 2H), 2.43–2.43 (m, 1H), 1.88–1.85 (bs, 2H), 1.67–1.57 (m, 4H), 1.47 (s, 9H), 1.27 (t, <i>J</i> = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 175.0, 159.3, 71.1, 51.2, 30.9, 28.4, 26.5; mass (<i>m</i>/<i>z</i>): 258.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-Hydrazinocarbonyl-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>9a</b>)</h4><div class="NLM_p last">By following general procedure 5, compound <b>8a</b> (5.0 g, 19.45 mmol) was converted to the titled compound <b>9a</b> (4.1 g) as an off-white crystalline powder in 87.2% yield with GC purity 99.79%. <sup>1</sup>H NMR (CDCI<sub>3</sub>): δ 8.12 (bs, 1H), 2.86 (t, <i>J</i> = 12.0 Hz, 2H), 2.43–2.43 (m, 1H), 2.05 (bs, 2H), 1.88–1.85 (bs, 2H), 1.67–1.57 (m, 4H), 1.47 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 177.9, 159.3, 69.2, 51.0, 30.5, 28.4, 26.5; DSC: (RAMP 5 °C/min): 102.1 °C; mass (<i>m</i>/<i>z</i>): 244.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 4-[<i>N</i>′-(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazinocarbonyl]-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>10a</b>)</h4><div class="NLM_p last">By following general procedure 6, 4-hydrazinocarbonyl-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>9a</b> (3.2 g, 13.48 mmol) was reacted with 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (3.0 g, 13.48 mmol) to obtain the above titled compound <b>10a</b> (5.3 g) as an off-white crystalline powder in 92% yield with HPLC purity 98.75%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 2.80 (bs, 2H), 2.71 (bs, 3H), 1.76 (d, <i>J</i> = 6.8 Hz, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.40 (s, 9H), 1.28 (t, <i>J</i> = 10.8 Hz, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 177.9, 167.3, 159.3, 139.9, 128.9, 127.5, 123.5, 121.9, 121.3, 111.1, 69.2, 53.7, 51.0, 30.5, 28.4, 26.5, 22.2; DSC: (RAMP 5 °C/min): 123.2 °C; mass (<i>m</i>/<i>z</i>): 430.5 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-Hydroxy-4-[<i>N</i>′-(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazinocarbonyl]-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>10b</b>)</h4><div class="NLM_p last">By following general procedure 6, 4-hydrazinocarbonyl-4-hydroxy-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>9b</b> (2.0 g, 8.98 mmol) was reacted with 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (2.3 g, 8.98 mmol) to obtain the above titled compound <b>10b</b> (1.2 g) as an off-white crystalline powder in 63.1% yield with HPLC purity 98.7%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 2.80 (bs, 2H), 2.71 (bs, 4H), 1.76 (d, <i>J</i> = 6.8 Hz, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.40 (s, 9H), 1.28 (t, <i>J</i> = 10.8 Hz, 2H); mp: 106.1–107.2 °C; mass (<i>m</i>/<i>z</i>): 446.3 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 4-{2-[<i>N</i>′-(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazino]-2-oxo-ethyl}-piperidine-1-carboxylic Acid <i>tert</i>-Butyl Ester (<b>10c</b>)</h4><div class="NLM_p last">By following general procedure 6, 4-hydrazinocarbonylmethylpiperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>9c</b> (3.4 g, 13.47 mmol) was reacted with 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (3.0 g, 13.47 mmol) to obtain the above titled compound <b>10c</b> (4.7 g) as brown color gummy mass in 80.0% yield with HPLC purity 95.6%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 3.98 (d, <i>J</i> = 12.0 Hz, 2H), 2.80 (bs, 2H), 2.71 (bs, 4H), 2.45 (bs, 2H),1.76 (d, <i>J</i> = 6.8 Hz, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.40 (s, 9H), 1.28 (t, <i>J</i> = 10.8 Hz, 2H); mass (<i>m</i>/<i>z</i>): 444.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 6-[<i>N</i>′-(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazinocarbonyl]-3-aza-bicyclo[3.1.0]hexane-3-carboxylic Acid <i>tert</i>-Butyl Ester (<b>10d</b>)</h4><div class="NLM_p last">By following general procedure 6, 6-hydrazinocarbonyl-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid <i>tert</i>-butyl ester <b>9d</b> (1.01 g, 4.50 mmol) was reacted with 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (1.0 g, 4.50 mmol) to obtain the above titled compound <b>10d</b> (1.5 g) as crystalline solid in 78% yield with HPLC purity 95.2%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 3.98 (d, <i>J</i> = 12.0 Hz, 2H), 2.80 (bs, 2H), 2.71 (bs, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.40 (s, 9H), 1.28 (t, <i>J</i> = 10.8 Hz, 2H); mp: 152.3–154.1 °C; mass (<i>m</i>/<i>z</i>): 428.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 3-[<i>N</i>′-(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazinocarbonyl]-8-aza-bicyclo[3.2.1]octane-8-carboxylic Acid <i>tert</i>-Butyl Ester (<b>10e</b>)</h4><div class="NLM_p last">By following general procedure 6, 3-hydrazinocarbonyl-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid <i>tert</i>-butyl ester <b>9d</b> (2.4 g, 8.98 mmol) was reacted with 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (2.4 g, 8.98 mmol) to obtain the above titled compound <b>10e</b> (3.89 g) as an off-white crystalline powder in 95.1% yield with HPLC purity 98.7%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 3.98 (d, <i>J</i> = 12.0 Hz, 2H), 2.71 (bs, 4H), 1.76 (d, <i>J</i> = 6.8 Hz, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.40 (s, 9H), 1.35–1.28 (m, 3H); mp: 117.9–118.8 °C; mass (<i>m</i>/<i>z</i>): 456.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1-Aza-bicyclo[2.2.2]octane-3-carboxylic Acid <i>N</i>′-(1-Isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazide (<b>10f</b>)</h4><div class="NLM_p last">By following general procedure 6, 1-aza-bicyclo[2.2.2]octane-3-carboxylic acid hydrazide <b>9f</b> (3.0 g, 12.34 mmol) reacts with 1-isopropyl-1<i>H</i>-indazole-3-carbonyl chloride <b>3</b> (2.7 g, 12.34 mmol) to obtain the above titled compound <b>10f</b> (4.24 g) as an off-white crystalline powder in 74.5% yield with HPLC purity 96.2%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 2.80 (m, 4H), 2.71 (m, 3H), 1.76 (d, <i>J</i> = 6.8 Hz, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.28 (m, 3H); mp: 137.3–138.8 °C; mass (<i>m</i>/<i>z</i>): 356.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-Isopropyl-3-(5-piperidin-4-yl-[1,3,4]oxadiazol-2-yl)-1<i>H</i>-indazole (<b>11a</b>)</h4><div class="NLM_p last">By following general procedure 7, 4-[<i>N</i>′-(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazinocarbonyl]-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>10a</b> (5.3 g, 12.33 mmol) was converted to above titled compound <b>11a</b> (3.6 g) as brown color solid in 95% yield with HPLC purity 99.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.91 (d, <i>J</i> = 8.8 Hz, 1H), 7.56 (t, <i>J</i> = 7.6 Hz, 1H), 7.40 (t, <i>J</i> = 7.6 Hz, 1H), 5.20–5.13 (m,1H), 3.22–3.16 (m, 1H), 3.02 (d, <i>J</i> = 12.4 Hz, 2H), 2.67 (d, <i>J</i> = 8.8 Hz, 2H), 2.01(d, <i>J</i> = 10.8 Hz, 2H), 1.73–1.65 (m, 2H), 1.56 (d, <i>J</i> = 6.4 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 160.1, 139.8, 128.6, 127.5, 123.4, 121.9, 121.3, 111.0, 51.0, 45.4, 33.4, 30.3, 22.2; DSC: (RAMP 5 °C/min): 109.6 °C; mass (<i>m</i>/<i>z</i>): 312.1(M + H)<sup>+</sup>.</div></div><div id="sec4_9_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 4-[5-(1-Isopropyl-1<i>H</i>-indazol-3-yl)-[1,3,4]oxadiazol-2-yl]-piperidin-4-ol (<b>11b</b>)</h4><div class="NLM_p last">By following general procedure 7, 4-hydroxy-4-[<i>N</i>′-(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazinocarbonyl]-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>10b</b> (1.2 g, 2.69 mmol) was converted to above titled compound <b>11b</b> (705.4 mg) which was isolated as a gummy mass in 90.0% yield with HPLC purity 92.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.12 (bs, 1H), 9.84 (bs, 1H), 8.10 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 2.80 (bs, 2H), 2.71 (bs, 2H), 1.76 (d, <i>J</i> = 6.8 Hz, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.28 (t, <i>J</i> = 10.8 Hz, 2H); mass (<i>m</i>/<i>z</i>): 328.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 1-Isopropyl-3-(5-piperidin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-1<i>H</i>-indazole (<b>11c</b>)</h4><div class="NLM_p last">By following general procedure 7, 4-{2-[<i>N</i>′-(1-isopropyl-1H-indazole-3-carbonyl)-hydrazino]-2-oxo-ethyl}-piperidine-1-carboxylic acid <i>tert</i>-butyl ester <b>10c</b> (4.7 g, 10.6 mmol) was converted to above titled compound <b>11c</b> (3.1 g) as brown color solid compound in 89% yield with HPLC purity 99.3%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 2.80 (bs, 2H), 2.71 (bs, 2H), 2.45 (bs, 2H),1.76 (d, <i>J</i> = 6.8 Hz, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.28 (t, <i>J</i> = 10.8 Hz, 2H); mp: 134.6–134.9 °C; mass (<i>m</i>/<i>z</i>): 325.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 3-[5-(3-Aza-bicyclo[3.1.0]hex-6-ylmethyl)-[1,3,4]oxadiazol-2-yl]-1-isopropyl-1<i>H</i>-indazole (<b>11d</b>)</h4><div class="NLM_p last">By following general procedure 7, 6-[<i>N</i>′-(1-isopropyl-1H-indazole-3-carbonyl)-hydrazinocarbonyl]-3-aza-bicyclo[3.1.0]hexane-3-carboxylic acid <i>tert</i>-butyl ester <b>10d</b> (1.5 g, 3.51 mmol) was converted to above titled compound <b>11d</b> (1.0 g) as a gummy mass in 93.2% yield with HPLC purity 95.2%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 2.80 (bs, 2H), 2.71 (bs, 4H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.28 (t, <i>J</i> = 10.8 Hz, 2H); mp: 127.3–128.9 °C; mass (<i>m</i>/<i>z</i>): 324.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 3-[5-(8-Aza-bicyclo[3.2.1]oct-3-yl)-[1,3,4]oxadiazol-2-yl]-1-isopropyl-1<i>H</i>-indazole (<b>11e</b>)</h4><div class="NLM_p last">By following general procedure 7, 3-[<i>N</i>′-(1-isopropyl-1<i>H</i>-indazole-3-carbonyl)-hydrazinocarbonyl]-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid <i>tert</i>-butyl ester <b>10e</b> (3.8 g, 8.342 mmol) was converted to above titled compound <b>11e</b> (2.71 g) as white color solid in 98% yield with HPLC purity 95.2%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 10.02 (bs, 1H), 9.86 (bs, 1H), 8.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (d, <i>J</i> = 8.4 Hz, 1H), 7.45 (t, <i>J</i> = 7.6 Hz, 1H), 7.30 (t, <i>J</i> = 7.6 Hz, 1H), 5.13–5.06 (m, 1H), 2.71 (bs, 4H), 1.76 (d, <i>J</i> = 6.8 Hz, 2H), 1.55 (d, <i>J</i> = 6.4 Hz, 6H), 1.35–1.28 (m, 3H); mp: 123.1–124.1 °C; mass (<i>m</i>/<i>z</i>): 339.5 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 1-Isopropyl-3-{5-[1-(3-methoxypropyl)-piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1<i>H</i>-indazole oxalate (<b>12l</b>)</h4><div class="NLM_p last">By following general procedure 3, 1-isopropyl-3-(5-piperidin-4-yl-[1,3,4]oxadiazol-2-yl)-1<i>H</i>-indazole <b>11a</b> (1.8 g, 6.07 mmol) was N-alkylated with 1-bromo-3-methoxypropane to obtain 1-isopropyl-3-{5-[1-(3-methoxypropyl)-piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1<i>H</i>-indazole (1.84 g) as light yellow gummy mass in 80.0% yield with HPLC purity 99.0%. The obtained free base was converted to oxalate salt by following general procedure 8 to obtain the titled compound <b>12l</b> as off-white crystalline powder with HPLC purity 99.83%. IR (cm<sup>–1</sup>): 3435, 2974, 2932, 2890, 2697, 2537, 1710, 1604, 1564, 1465, 1193, 1113, 992, 750; <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.20 (d, <i>J</i> = 8.4 Hz, 1H), 7.92 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (t, <i>J</i> = 7.2 Hz, 1H), 7.39 (t, <i>J</i> = 7.6 Hz, 1H), 5.25–5.12 (m, 1H), 3.50–3.37 (m, 5H), 3.24 (s, 3H), 3.08–2.97 (m, 4H), 2.37–2.27 (m, 2H), 2.18–2.05 (m, 2H), 1.95–1.85 (m, 2H), 1.56 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.2, 164.9 (2C), 160.3, 139.9, 128.8, 127.6, 123.5, 121.9, 121.3, 111.2, 69.5, 58.3, 54.1 (2C), 51.0, 50.7, 30.5, 26.6 24.3 (2C), 22.4 (2C); DSC: (RAMP 5 °C/min): 208.2 °C; mass (<i>m</i>/<i>z</i>): 384.2 (M + H)<sup>+</sup>; oxalic acid content 18.34% (average of two titration experiments; corresponds to mono oxalate); C<sub>23</sub>H<sub>31</sub>N<sub>5</sub>O<sub>6</sub>; % C, H, N: calculated C; 58.34, H; 6.60, N; 14.79; found C; 58.49, H; 6.49, N; 14.54.</div></div><div id="sec4_9_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 4-[5-(1-Isopropyl-1<i>H</i>-indazol-3-yl)-[1,3,4]oxadiazol-2-yl]-1-(3-methoxypropyl)-piperidin-4-ol (<b>12v</b>)</h4><div class="NLM_p last">By following general procedure 3, 4-[5-(1-isopropyl-1<i>H</i>-indazol-3-yl)-[1,3,4]oxadiazol-2-yl]-piperidin-4-ol <b>11b</b> (705.0 mg, 2.15 mmol) was N-alkylated with 1-bromo-3-methoxypropane to obtain above titled compound <b>12v</b> (585.6 mg) as cream color powder in 68% yield with HPLC purity 98.2%. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.37 (d, <i>J</i> = 8.1 Hz, 1H), 7.53 (d, <i>J</i> = 8.4 Hz, 1H), 7.47 (t, <i>J</i> = 6.9 Hz, 1H), 7.33 (t, <i>J</i> = 7.6 Hz, 1H), 5.0–4.93 (m, 1H), 3.10–2.98 (m, 2H), 1.67 (d, <i>J</i> = 6.6 Hz, 6H), 1.45–1.40 (m, 2H), 0.92 (d, <i>J</i> = 6.5 Hz, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 167.1, 164.9, 160.4, 139.8, 128.8, 127.6, 123.5, 121.9, 121.3, 111.0, 74.1, 69.5, 58.3, 54.1, 51.0, 50.7, 26.6 24.3, 22.4; DSC: (RAMP 5 °C/min): 197.3 °C; mass (<i>m</i>/<i>z</i>): 400.1 (M + H)<sup>+</sup>; C<sub>21</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub>; % C, H, N: calculated C; 63.14, H; 7.32, N; 17.53; found C; 62.91, H; 7.51, N; 17.64.</div></div><div id="sec4_9_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 3-[5-(1-Cyclobutyl-piperidin-4-ylmethyl)-[1,3,4]oxadiazol-2-yl]-1-isopropyl-1<i>H</i>-indazole Oxalate (<b>12x</b>)</h4><div class="NLM_p last">By following general procedure 3, 1-isopropyl-3-(5-piperidin-4-ylmethyl-[1,3,4]oxadiazol-2-yl)-1<i>H</i>-indazole <b>11c</b> (3.1 g, 9.53 mmol) was N-alkylated using general reductive amination procedure 9 with cyclobutane to obtain compound <b>12x</b> free base which was converted to its oxalate salt by following the general procedure 8 to obtain above titled compound <b>12x</b> (2.5 g) as light yellow color powder in 72.0% yield with HPLC purity 99.1%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.56 (t, <i>J</i> = 7.6 Hz, 1H), 7.40 (t, <i>J</i> = 7.6 Hz, 1H), 5.19–5.15 (m, 1H), 3.15–3.09 (m, 5H), 3.01 (d, <i>J</i> = 6.8 Hz, 2H), 2.06–1.99 (m, 5H), 1.88–1.85 (m, 2H), 1.69–1.62 (m, 2H), 1.55 (d, <i>J</i> = 6.8 Hz, 6H), 1.48–1.42 (m, 2H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 174.4, 170.6, 165.0, 161.5, 160.3, 139.9, 139.8, 135.5, 128.8, 127.6, 126.9, 123.5, 123.0, 122.9, 121.8, 121.8, 121.3, 111.2, 110.9, 72.5, 58.5, 51.0, 50.7, 48.4, 48.2, 32.0, 31.2, 30.7, 28.4, 25.4, 25.3, 22.4, 22.4, 13.7; DSC: (RAMP 5 °C/min): 179.1 °C; mass (<i>m</i>/<i>z</i>): 380.2 (M + H)<sup>+</sup>; C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>5</sub>; % C, H, N: calculated C; 61.39, H; 6.65, N; 14.92; found C; 61.74, H; 6.49, N; 14.78.</div></div><div id="sec4_9_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-Isopropyl-3-[5-(3-isopropyl-3-aza-bicyclo[3.1.0]hex-6-yl)-[1,3,4]oxadiazol-2-yl]-1<i>H</i>-indole Oxalate (<b>12z</b>)</h4><div class="NLM_p last">By following general procedure 3, 3-[5-(3-aza-bicyclo[3.1.0]hex-6-yl)-[1,3,4]oxadiazol-2-yl]-1-isopropyl-1<i>H</i>-indole <b>11d</b> (1.0 g, 3.26 mmol) was N-alkylated with 2-iodo propane compound <b>12z</b> free base which was converted to its oxalate salt by following the general procedure 8 to obtain above titled compound <b>12z</b> (758.6 mg) as pale yellow color powder in 70.0 yield with HPLC purity 96.8%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): 8.16 (d, <i>J</i> = 8.0 Hz, 1H), 7.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (t, <i>J</i> = 7.6 Hz, 1H), 7.39 (t, <i>J</i> = 7.6 Hz, 1H), 5.18–5.15 (m, 1H), 3.79–3.73 (m, 1H), 3.28–3.23 (m, 4H), 2.68 (bs, 1H), 1.54 (d, <i>J</i> = 6.4 Hz, 6H), 1.22 (d, <i>J</i> = 6.0 Hz, 6H), 1.03 (d, <i>J</i> = 6.0 Hz, 2H); DSC: (RAMP 5 °C/min): 184.2 °C; mass (<i>m</i>/<i>z</i>): 351.0 (M + H)<sup>+</sup>; C<sub>23</sub>H<sub>28</sub>N<sub>4</sub>O<sub>5</sub>; % C, H, N: calculated C; 62.71, H; 6.41, N; 12.72; found C; 63.04, H; 6.23, N; 12.44.</div></div><div id="sec4_9_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 1-Isopropyl-3-[5-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-[1,3,4]oxadiazol-2-yl]-1<i>H</i>-indazole Oxalate (<b>12ac</b>)</h4><div class="NLM_p last">By following general procedure 3, 3-[5-(8-aza-bicyclo[3.2.1]oct-3-yl)-[1,3,4]oxadiazol-2-yl]-1-isopropyl-1<i>H</i>-indazole <b>11e</b> (2.7 g, 8.00 mmol) was N-alkylated with iodomethane to obtain <b>12ac</b> free base which was converted to its oxalate salt by following the general procedure 8 to obtain above titled compound <b>12ac</b> (2.5 g) as off-white color powder in 90.0% yield with HPLC purity 97.9%. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.20 (d, <i>J</i> = 8.0 Hz, 1H), δ 7.92 (d, <i>J</i> = 8.8 Hz, 1H), 7.56 (t, <i>J</i> = 7.2 Hz, 1H), 7.40 (t, <i>J</i> = 7.2 Hz, 1H), 5.19–5.16 (m, 1H), 2.67 (s, 3H), 2.53–2.49 (m, 2H), 2.34–2.27 (m, 4H), 2.13–2.06 (m, 4H), 1.99–1.93 (m, 1H), 1.55 (d, <i>J</i> = 6.8 Hz, 6H); <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 175.4, 174.1, 172.7, 171.2, 161.4, 161.2, 139.8, 135.6, 126.8, 124.4, 123.1, 123.0, 122.9, 121.8, 10.8, 73.3, 72.3, 72.2, 62.5, 61.4, 61.2, 50.6, 32.3, 32.0, 31.5, 30.7, 24.4, 24.2, 24.0, 22.4, 17.1; DSC: (RAMP 5 °C/min): 178.1 °C; mass (<i>m</i>/<i>z</i>): 352.0 (M + H)<sup>+</sup>; C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>5</sub>; % C, H, N: calculated C; 59.85, H; 6.16, N; 15.86; found C; 60.01, H; 6.02, N; 15.43.</div></div><div id="sec4_9_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 1-(3-Methoxypropyl)-piperidine-4-carbonitrile (<b>14a</b>)</h4><div class="NLM_p last">By following general procedure 3, piperidine-4-carbonitrile <b>13</b> (2.0 g, 18.18 mmol) was N-alkylated using 1-bromo-3-methoxy propane (3.0 g, 20.01 mmol) to obtain titled compound <b>14a</b> in 63.6% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.42 (t, <i>J</i> = 6.3 Hz, 2 H), 3.32 (s, 3H), 2.64 (bs, 3H), 2.43 (t, <i>J</i> = 7.3 Hz, 2 H), 1.96–1.83 (m, 4 H), 1.77–1.70 (m, 2 H); mass (<i>m</i>/<i>z</i>): 183.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 1-(Tetrahydropyran-4-ylmethyl)-piperidine-4-carbonitrile (<b>14b</b>)</h4><div class="NLM_p last">By following general procedure 3, piperidine-4-carbonitrile <b>13</b> (1.0 g, 9.09 mmol) was N-alkylated using 4-bromomethyltetrahydropyran (1.7 g, 9.54 mmol) to obtain titled compound <b>14b</b> in 59.2% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 3.92–3.86 (m, 2H), 3.86–3.82 (m, 2H), 2.69–2.63 (m, 3H), 2.46–2.42 (m, 4H), 2.42–2.39 (m, 1H), 1.98–1.81 (m, 4H) 1.77–1.70 (m, 4H); mass (<i>m</i>/<i>z</i>): 209.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 1-Isopropyl-piperidine-4-carbonitrile (<b>14c</b>)</h4><div class="NLM_p last">By following general procedure 3, piperidine-4-carbonitrile <b>13</b> (1.0 g, 9.09 mmol) was N-alkylated using 2-iodopropane (1.62 g, 9.54 mmol) to obtain titled compound <b>14c</b> in 77.8% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 4.32–4.22 (m, 1H), 2.71–2.65 (m, 3H), 2.49–2.43 (m, 1H), 1.96–1.83 (m, 3H), 1.76–1.71 (m, 2H), 1.23 (d, <i>J</i> = 6.2 Hz, 6H); mass (<i>m</i>/<i>z</i>): 153.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> <i>N</i>-Hydroxy-1-(3-methoxypropyl)-piperidine-4-carboxamidine (<b>15a</b>)</h4><div class="NLM_p last">To the stirred solution of compound <b>14a</b> (800.0 mg, 4.39 mmol) in ethanol (20.0 mL) at r.t., hydroxylamine hydrochloride (636.0 mg, 9.21 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.27 g, 9.21 mmol) were added. The reaction was gradually heated to reflux for 16 h. After completion of the reaction, it was cooled to r.t. and filtered through a Celite bed. The filtrate was concentrated under vacuum to afford title compound <b>15a</b> in quantitative yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.77 (bs, 1H), 5.32 (s, 2H), 4.02–3.99 (m, 1H), 3.29 (bs, 2 H), 3.20 (s, 3 H), 2.85 (d, <i>J</i> = 11.2 Hz, 3H), 2.70 (t, <i>J</i> = 10.4 Hz, 3 H), 1.92 (d, <i>J</i> = 3.6 Hz, 2H), 1.83 (t, <i>J</i> = 1.8 Hz, 4H); mass (<i>m</i>/<i>z</i>): 216.4 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i>-Hydroxy-1-(tetrahydropyran-4-ylmethyl)-piperidine-4-carboxamidine (<b>15b</b>)</h4><div class="NLM_p last">By following the procedure as mentioned for compound <b>15a</b>, compound <b>15b</b> was prepared. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.72 (bs, 1H), 5.34 (bs, 2H), 3.92–3.86 (m, 2H), 3.86–3.82 (m, 2H), 2.69–2.63 (m, 3H), 2.46–2.42 (m, 4H), 2.42–2.39 (m, 1H), 1.98–1.81 (m, 4H) 1.77–1.70 (m, 4H); mass (<i>m</i>/<i>z</i>): 242.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> <i>N</i>-Hydroxy-1-(isopropyl)-piperidine-4-carboxamidine (<b>15c</b>)</h4><div class="NLM_p last">By following the procedure as mentioned for compound <b>15a</b>, compound <b>15c</b> was prepared. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.92 (bs, 1H), 5.27 (bs, 2H), 4.32–4.22 (m, 1H), 2.71–2.65 (m, 3H), 2.49–2.43 (m, 1H), 1.96–1.83 (m, 3H), 1.76–1.71 (m, 2H), 1.23 (d, <i>J</i> = 6.2 Hz, 6H); mass (<i>m</i>/<i>z</i>): 186.3 (M + H).</div></div><div id="sec4_9_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic acid methyl ester (<b>16</b>)</h4><div class="NLM_p last">To the stirred solution of compound <b>2</b> (1.0 g, 4.91 mmol) in methanol (20.0 mL) cooled at 0 °C, thionyl chloride (1.2 mL, 17.22 mmol) was added. The reaction temperature was gradually warmed to r.t., and the reaction was stirred for 6 h. After completion of the reaction, the volatiles were evaporated. The crude mass thus obtained was quenched with aqueous NaHCO<sub>3</sub> and diluted with ethyl acetate, and the two layers were separated. The organic layer was washed with brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated under vacuum to afford the title compound <b>16</b> in quantitative yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.25 (d, <i>J</i> = 8.1 Hz, l H), 7.53 (d, <i>J</i> = 8.4 Hz, l H), 7.45 (t, <i>J</i> = 7.1 Hz, 1H), 7.33 (t, <i>J</i> = 7.6 Hz, 1H), 5.02–4.93 (m, l H), 4.04 (s, 3H) 1.67 (d, <i>J</i> = 6.7 Hz, 6H); mass (<i>m</i>/<i>z</i>): 219 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 1-Isopropyl-3-{3-[1-(3-methoxy-propyl)-piperidin-4-yl]-[1,2,4]oxadiazol-5-yl}-1<i>H</i>-indazole (<b>17a</b>)</h4><div class="NLM_p last">To a stirred solution of compound <b>15a</b> (500.0 mg, 2.32 mmol) in DMF (10.0 mL) at r.t., a DMF (5.0 mL) solution of sodium hydride (116.0 mg, 3.0 mmol) followed by compound <b>16</b> (659.0 mg, 3.02 mmol) was added, and the reaction mass was stirred at 120 °C for 16 h. After completion of the reaction, the reaction mass was quenched with ice cold water and extracted with ethyl acetate, and two layers were separated. The organic layer was washed with brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated under vacuum to afford above titled compound <b>17a</b> in quantitative yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.33 (d, <i>J</i> = 8.1 Hz, 1H), 7.57 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (t, <i>J</i> = 7.2 Hz, 1H), 7.38 (t, <i>J</i> = 7.6 Hz, 1H), 5.03–4.97 (m, 1H), 3.47 (t, <i>J</i> = 6.4 Hz, 2H), 3.35 (s, 3H), 3.06–3.03 (m, 2H), 2.88 (s, 1H), 2.43–2.40 (m, 2H), 2.17 (bs, 1H), 2.05 (bs, 2H), 1.85–1.84 (m, 2H), 1.76 (d, <i>J</i> = 6.4 Hz, 6H), 1.68–1.60 (m, 4H) in 17.9% yield with HPLC purity 98.1%. DSC: (RAMP 5 °C/min): 154.7 °C; mass (<i>m</i>/<i>z</i>): 384.1 (M + H)<sup>+</sup>; C<sub>21</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>; % C, H, N: calculated C; 65.77, H; 7.62, N; 18.26; found C; 65.39, H; 7.33, N; 18.18.</div></div><div id="sec4_9_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 1-Isopropyl-1<i>H</i>-indazole-3-carboxylic Acid Amide (<b>18</b>)</h4><div class="NLM_p last">To a stirred solution of compound <b>2</b> (1.0 g, 4.91 mmol) in acetonitrile (20.0 mL) at r.t., pyridine (425.9 mg, 5.39 mmol) and Boc anhydride (1.28 g, 5.88 mmol) were added. After stirring for 1 h at r.t., NH<sub>4</sub>HCO<sub>3</sub> (627.0 mg, 7.93 mmol) was added to the reaction mixture, and the reaction was stirred for 16 h. The reaction mass was diluted with ethylaceate and water, and the two layers were separated. The organic layer was washed with 1 N HCl followed by 1 N NaOH solution and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated under vacuum to obtain title compound <b>18</b> (830.0 mg) in 83.4% yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 8.17 (d, <i>J</i> = 8.2 Hz, l H), 7.89 (d, <i>J</i> = 8.6 Hz, 1H), 7.57 (bs, 1H), 7.44 (t, <i>J</i> = 7.4 Hz, 1H), 7.34 (bs, 1 H), 7.24 (t, <i>J</i> = 7.3 Hz, 1H), 5.09–5.03 (m, 1H), 1.53 (d, <i>J</i> = 6.5 Hz, 6H); mass (<i>m</i>/<i>z</i>): 204.0 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 1-Isopropyl-1<i>H</i>-indazole-3-carbonitrile (<b>19</b>)</h4><div class="NLM_p last">To a stirred solution of compound <b>18</b> (1.0 g, 5.71 mmol) in THF (22.0 mL) at 0 °C, trimethylamine (1.73 g, 17.1 mmol) followed by trifluoroacetic anhydride (1.79 g, 8.55 mmol) were added. The reaction temperature was gradually warmed to r.t., and the reaction was stirred for 2 h. The reaction was quenched by adding ice cold water and ethyl acetate. The two layers were separated and the organic layer was washed with sat. NaHCO<sub>3</sub> solution and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under vacuum to obtain title compound <b>19</b> (933.0 mg) in 86% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.85 (d, <i>J</i> = 8.1 Hz, l H), 7.57 (d, <i>J</i> = 8.5 Hz, l H), 7.50 (t, <i>J</i> = 7.0 Hz, l H), 7.36 (t, <i>J</i> = 7.5 Hz, l H), 5.09–5.03 (m, l H), 1.64 (d, <i>J</i> = 6.6 Hz, 6H); mass (<i>m</i>/<i>z</i>): 186.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> <i>N</i>-Hydroxy-1-isopropyl-1<i>H</i>-indazole-3-carboxamidine (<b>20</b>)</h4><div class="NLM_p last">To a stirred solution of compound <b>19</b> (770.0 mg, 4.16 mmol) in ethanol (16.0 mL) at r.t., hydroxylamine hydrochloride (603.0 mg, 8.74 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.2 g, 8.74 mmol) were added. The reaction mixture was gradually heated to reflux for 16 h. The reaction mass was cooled to r.t. and filtered through Celite, and the filtrate was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under vacuum to afford title compound <b>20</b> (923.6 mg) in quantitative yield. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 9.76 (bs, 1H), 8.09 (d, <i>J</i> = 8.1 Hz, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 1H), 7.40 (t, <i>J</i> = 7.3 Hz, 1H), 7.18 (t, <i>J</i> = 7.5 Hz, 1H), 5.60 (bs, 2H), 5.03- 4.96 (m, 1H), 1.51 (d, <i>J</i> = 6.5 Hz, 6H); mass (<i>m</i>/<i>z</i>): 219.0 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 1-(3-Methoxypropyl)-piperidine-4-carboxylic Acid Ethyl Ester (<b>22a</b>)</h4><div class="NLM_p last">By following general procedure 3, ethylisonipecotate <b>21</b> was alkylated using 1-bromo-3-methoxy propane to obtain compound <b>22a</b> as a gummy liquid. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 4.12 (q, 2H), 3.41 (t, <i>J</i> = 6.4 Hz, 2H), 2.90–2.85 (m, 2H), 2.38 (t, <i>J</i> = 7.4 Hz, 2H), 2.34–2.20 (m, 1H), 2.05–1.93 (m, 2H), 1.92–1.85 (m, 2H), 1.80–1.70 (m, 2H), 1.23 (t, <i>J</i> = 7.1 Hz, 3H); mass (<i>m</i>/<i>z</i>): 230.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 1-(Tetrahydropyran-4-ylmethyl)-piperidine-4-carboxylic Acid Ethyl Ester (<b>22b</b>)</h4><div class="NLM_p last">By following general procedure 3, ethylisonipecotate <b>21</b> was alkylated using 4-bromomethyltetrahydropyran to obtain compound <b>22b</b> as a gummy liquid. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 4.12 (q, 2H), 3.89 (t, <i>J</i> = 6.1 Hz, 2H), 3.81 (t, <i>J</i> = 6.1 Hz, 2H), 3.20–3.12 (m, 3H), 2.90–2.85 (m, 3H), 2.36–2.26 (m, 1H), 2.11–2.07, (m, 1H), 2.05–1.93 (m, 4H), 1.92–1.85 (m, 2H), 1.80–1.70 (m, 2H), 1.25 (t, <i>J</i> = 6.5 Hz, 3H); mass (<i>m</i>/<i>z</i>): 256.3 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 1-(Isopropyl)-piperidine-4-carboxylic Acid Ethyl Ester (<b>22c</b>)</h4><div class="NLM_p last">By following general procedure 3, ethylisonipecotate <b>21</b> was alkylated using 2-iodopropane to obtain compound <b>22c</b> as a gummy liquid. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 4.12 (q, 2H), 4.02–3.98 (m, 1H), 3.20–3.12 (m, 3H), 2.90–2.85 (m, 1H), 2.36–2.26 (m, 1H), 1.92–1.85 (m, 2H), 1.80–1.70 (m, 2H), 1.62 (d, <i>J</i> = 6.7 Hz, 6H), 1.21 (t, <i>J</i> = 6.5 Hz, 3H); mass (<i>m</i>/<i>z</i>): 200.2 (M + H)<sup>+</sup>.</div></div><div id="sec4_9_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 1-Isopropyl-3-{5-[1-(3-methoxypropyl)-piperidin-4-yl]-[1,2,4]oxadiazol-3-yl}-1<i>H</i>-indazole (<b>23a</b>)</h4><div class="NLM_p last">To a stirred solution of compound <b>22a</b> (685.0 mg, 2.9 mmol) in DMF (6.0 mL) at 0 °C, a DMF solution of sodium hydride (119.0 mg, 2.9 mmol) followed by compound <b>20</b> (500.0 mg, 2.29 mmol) was added. The reaction temperature was gradually raised to 120 °C for 16 h. The reaction mass was cooled to r.t. and filtered through Celite, the filtrate was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was evaporated under vacuum to afford title compound <b>23a</b> (105.6 mg) in 95% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.31 (d, <i>J</i> = 8.1 Hz, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 1H), 7.46 (t, <i>J</i> = 7.1 Hz, 1H), 7.32 (t, <i>J</i> = 7.5 Hz, 1H), 5.01–4.96 (m, 1H), 3.46 (t, <i>J</i> = 6.3 Hz, 2H), 3.35 (s, 3H), 3.01 (bs, 2H), 2.48 (t, <i>J</i> = 7.2 Hz, 2H), 2.20–2.10 (m, 2H), 2.05 (bs, 1H), 1.83–1.76 (m, 2H), 1.69 (d, <i>J</i> = 6.7 Hz, 6H), 1.25–1.23 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 172.4, 170.7, 164.9, 139.9, 128.8, 127.7, 124.1, 122.4, 121.1, 111.5, 69.5, 58.3, 54.2, 51.3, 51.1, 31.3, 27.1, 24.4, 22.4; DSC: (RAMP 5 °C/min): 167.3 °C; mass (<i>m</i>/<i>z</i>): 384.4 (M + H)<sup>+</sup>; C<sub>21</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>; % C, H, N: calculated C; 65.77, H; 7.62, N; 18.26; found C; 65.93, H; 7.84, N; 18.01.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Animals and Ethics</h3><div class="NLM_p last">Adult male Wistar rats (8–12 weeks; 200–300 g; in-house bred) were used in all the studies. Naive animals were used for experimentation. Rats were housed in groups of 3–4 in hanging polycarbonate cages (dimension: length, 43.2 cm × width, 25.4 in. × height, 21.2 cm) with a bedding of clean corn cob. For all the experiments, animals were introduced to the animal house at least 7 days prior to the commencement of the study. The animal house was maintained at 21 ± 3 °C, 30–70% relative humidity and 12 h light/dark cycle (lights on at 7:00 AM and off at 7:00 PM). Food (pelleted rodent feed, Rayan’s Biotechnologies Pvt. Ltd. Hyderabad) and water were made available <i>ad libitum</i> unless specified otherwise for the experiment. The test compound was administered orally, and scopolamine was administered through the intraperitoneal route. For the object recognition task, each group had 12 rats, and in the radial arm maze, each group had 6 rats. All experimental procedures were performed in accordance with the Institutional Animal Ethics Committee of Suven Life Sciences Ltd., Hyderabad, constituted as per the directions of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), India.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Determination of EC<sub>50</sub> Values for 5-HT<sub>4</sub>R</h3><div class="NLM_p">The compounds were screened in the cell-based luciferase reporter gene luminescence assay which measures the levels of cAMP inside cells upon activation or inhibition of the receptor. Serotonin (5-HT) and luciferin was purchased from Sigma-Aldrich (St. Louis, Missouri, USA). T4 DNA ligase and high fidelity Taq polymerase were procured from Roche (Basel, Switzerland). Superscript reverse transcriptase and mammalian expression vector pcDNA3.1 were purchased from Invitrogen (Carlsbad, California, USA). CRE-Luc reporter gene construct was supplied by Strata gene (La Jolla, California, USA). Cell culture media and sera were procured from Invitrogen (Carlsbad, California, USA). All other DNA restriction and modification enzymes were from New England Biolabs (Ipswich, Massachusetts, USA). All other reagents and common chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Human 5-HT<sub>4</sub>R cDNA clone was purchased from Origene (Rockville, Maryland, USA). The coding sequence was amplified by PCR using gene specific primers. Amplified DNA was cloned in to mammalian expression vector pcDNA 3.1. The authenticity of the cloned genes was determined by restriction analysis and nucleotide sequencing. CHO cell line was purchased from American Type Culture Collection, Manassas, Virginia, USA. The cells were routinely cultured in Hams F12 medium supplemented with 10% fetal bovine serum (FBS) at 37 °C in 5% CO<sub>2</sub>. The cells were transfected with 5-HT<sub>4</sub>R isoforms along with 3-fold excess of CRE-Luc reporter gene using lipofectamine as recommended by the supplier. Cells were further cultured in the same medium supplemented with 800 μg/mL G418. Individual colonies were picked up after 2 weeks of selection and screened for serotonin-induced luciferase activity. Colonies exhibiting maximum serotonin-induced luciferase activity were selected and amplified for further investigations. The recombinant CHO cells were plated in 96-well clear bottom white plates (Corning) and cultured overnight as described above. Cells were grown overnight in serum-free medium before incubation with compounds to prevent receptor desensitization due to presence of endogenous ligands in the serum.</div><div class="NLM_p">The reference endogenous agonist serotonin and test compounds in Opti-MEM medium at 11 different test concentrations, starting from 10 μM until 0.1 nM in 3-fold serial dilutions, were incubated with the cells separately in individual wells for 4 h at 37 °C in 5% CO<sub>2</sub>. Compounds whose potency was <1 nM were tested in a dose–response study with concentrations starting from 1 μM to 0.01 nM. After incubation, the medium was removed, and the cells were washed with phosphate buffered saline and lysed in lysis buffer (Tris, 10 mM (pH-8.0); NaCl, 50 mM; DTT, 1 mM; protease inhibitor cocktail 1×, NP 40–0.1%). The luciferase activity was measured in individual wells using luciferin substrate in a Victor Light Luminometer, PerkinElmer.</div><div class="NLM_p last">The maximum response produced by each drug was normalized to the 5-HT-induced maximum response. Data were analyzed using Graphpad prism software to derive EC<sub>50</sub> values that corresponded to the concentration of agonists required to obtain half-maximal stimulation of adenylyl cyclase. Values were expressed as the mean of two independent experiments performed in duplicates. Reference compound PF-04995274, a reported partial agonist<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a>, showed partial agonist activity in our 5-HT<sub>4E</sub> cell-based reporter gene assay with an EC<sub>50</sub> value of 1.3 nM and <i>E</i><sub>max</sub> 18%, which was very well in agreement with published data of EC<sub>50</sub>/<i>E</i><sub>max</sub>: 0.26 nM/7%. Some of other reported compounds EC<sub>50</sub> values were also determined using our assay and compared with the published data. The EC<sub>50</sub> values obtained versus reported values are tabulated in the <a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf" class="ext-link">Supporting Information</a> of this manuscript.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Microsomal Metabolic Stability</h3><div class="NLM_p last">Compounds were incubated with microsomes at 0.5 mg protein/mL in 100 mM phosphate buffer pH 7.4 at 37 °C. Reactions were initiated by addition of NADPH. All incubations were carried out for 30 min. At 30 min, an aliquot of the sample was removed and transferred into 300 μL of acetonitrile. The samples were stored at −20 °C until analysis. Samples were analyzed using LC-MS/MS. Results were expressed as % metabolized at 30 min postincubation.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Protein Binding</h3><div class="NLM_p last">Unbound fractions of test compound in plasma, brain homogenate, and liver microsomes were determined using high-throughput dialysis (HT dialysis). Briefly, dialysis membranes were soaked in deionized water for 20 min, then in deionized water with 30% ethanol for 15 min, and finally in phosphate buffer until use. Membranes were rinsed in phosphate buffer before assembling. The membranes were layered between Teflon bars of dialysis assembly. Stock solution of test compound was prepared at 10 mM in DMSO, diluted to 1 mM in acetonitrile, and further diluted to 100 μM in mixture of water and acetonitrile (1:1 v/v). Rat blood and brains were isolated on the day of the study, and brains were homogenized with two volumes of phosphate buffer. The blood was centrifuged at 4000 rpm for 10 min to obtain plasma. Human plasma (pool of 3) was prepared from human blood (3 donors) by centrifuging at 4000 rpm for 10 min at 4 °C. Suspension of liver microsomes was prepared at 0.5 in phosphate buffer (100 mM, pH 7.4). The dialysate chambers were loaded with 150 μL of 100 mM phosphate buffer (pH 7.4) in triplicates. The matrix chambers were loaded with 150 μL of the plasma or brain homogenate or microsomal suspension spiked with test compound at a final concentration of 1 μM. 50 μL of the sample was removed from both of the chambers at 0 h. The plate was sealed and incubated at 37 °C for 6 h at 100 rpm. After 6 h, 50 μL of the sample was removed from both the chambers. Equal volumes of buffer or matrix were added to the matrix and buffer samples, respectively, to create identical sample matrices for analysis. The supernatants were transferred to vials and were analyzed by LC-MS/MS.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Pharmacokinetic Study in Rats</h3><div class="NLM_p last">Male Wistar rats (225 ± 25 g) were used for evaluation of pharmacokinetics. Three animals were housed in each cage. Two days prior to dosing day, male Wistar rats were anesthetized with isoflurane for surgical placement of jugular vein catheter. Animals were fasted overnight before oral dosing (p.o.), and food pellets were allowed 2 h postdosing, whereas during intravenous dosing food and water were provided as <i>ad libitum</i>. Three rats were dosed with test compound orally (3 mg/kg) or intravenously (i.v., 1 mg/kg). Dose formulation was prepared by using water as a vehicle (10 mL/kg for oral and 2 mL/kg for intravenous dosing). At each time point, 200 μL of blood was collected through jugular vein cannula and immediately replenished with an equivalent volume of normal saline in freely moving rats. Collected blood was transferred into a labeled eppendorf tube containing 10 μL of heparin as anticoagulant. The time points for blood collection were predose and 0.08 (only i.v.), 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h postdose (<i>n</i> = 3). The collected blood was centrifuged at 4000 rpm for 10 min at 4 °C. Plasma was separated in prelabeled tubes and stored below −70 °C until analysis. The test compound concentrations were extracted from plasma samples by protein precipitation using four volumes of acetonitrile (v/v) containing predetermined internal standard. The precipitants were centrifuged (at 11292×<i>g</i> and 10 °C for 10 min), and supernatant was transferred and injected in LC-MS/MS. The analytes of interest were quantified using a suitable multiple reaction monitoring mode in the range of 2–2000 ng/mL or ng/g against a set of calibration standards and quality control samples. Study samples were analyzed using calibration samples in the batch and quality control samples spread across the batch. Pharmacokinetic parameters were determined by using standard noncompartmental analysis (Phoenix WinNonLin 6.2 version or higher software) using linear trapezoidal with linear interpolation method.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Rodent Brain Penetration Study</h3><div class="NLM_p last">Male Wistar rats (225 ± 25 g) were used as experimental animals. Three animals were housed in each cage. Animals were given water and food <i>ad libitum</i> throughout the experiment and maintained on a 12 h light/dark cycle. Brain penetration was determined in a discrete manner in the rats. The compounds were formulated in water and administered orally at 10 mg/kg (free base equivalent). Blood samples were removed via cardiac puncture under isoflurane anesthesia at 1 h postdose. The animals were sacrificed to collect the brain tissue. Plasma was separated, and brain samples were homogenized and stored at −70 °C until analysis. The concentrations of the compound in plasma and brain were determined using a LC-MS/MS method. The test compound was extracted from brain homogenate by protein precipitation using four volumes of acetonitrile (v/v) containing predetermined internal standard. The precipitants were centrifuged (at 11292<i>g</i> at 10 °C for 10 min), and the supernatant was transferred and injected in LC-MS/MS. The compounds were quantified in the calibration range of 1–2000 ng/mL in plasma and brain homogenate. Study samples were analyzed using calibration samples in the batch and quality control samples spread across the batch. The extent of brain to plasma ratio was calculated (<i>C</i><sub>brain</sub>/<i>C</i><sub>plasma</sub>).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> <i>In Vivo</i> PK Profile in Male Beagle Dogs</h3><div class="NLM_p last">A single dose, crossover study design with 7 days washout period between the treatments was used to administer compound <b>12l</b> to three male beagle dogs. All dogs were fasted overnight, food was offered at regular time intervals for an intravenous route of administration, and food was offered after 4 h of postoral dose. On the day of dosing (day 0), each dog was administered intravenously as 5 min infusion at 1 mg/kg and oral administration as gavage at 3 mg/kg on day 7. Dose formulations were prepared on the day of treatment. At each time point, 0.5 mL of blood sample was collected from saphenous/cephalic vein at designated time points, and collected blood samples were transferred to prelabeled sodium heparin-coated sampling tubes. The time points for blood collection from each animal were predose and 0.08 (only i.v.), 0.16 (only i.v.), 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h post dose (n = 3). The collected blood samples were centrifuged at 4000 rpm for 10 min at 4 °C within 30 min of collection, and plasma was separated in prelabeled tubes and stored at −70 °C until analysis. Compound <b>12l</b> concentrations in plasma samples were determined using a qualified LC-MS/MS method with ACN protein precipitation technique and quantified in the calibration range of 1.013–1013 ng/mL. The PK evaluation was performed using noncompartmental analysis (WinNonLin version 5.0.3 Pharsight Corporation, Mountain View, California 94040/USA) and using the linear trapezoidal with linear interpolation calculation method.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> CYP 3A4 and 2D6 Inhibition<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></h3><div class="NLM_p last">CYP 3A4 and 2D6 inhibitory potential of the test compounds was studied using human liver microsomes. Inhibitory activity was evaluated by incubating the test compound (0.1–45 μM) in duplicates for 2 (3A4) and 12 min (2D6) with human liver microsomes in the presence of isoform-specific substrate (midazolam-3A4 or dextromethorphan-2D6) and NADPH regeneration system. Incubations were terminated by adding ice-cold acetonitrile containing an internal standard, and metabolites were quantified using LC-MS/MS. Peak area ratios of analyte versus internal standards were used for calculating IC<sub>50</sub>.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> hERG Patch Clamp Assay IC<sub>50</sub> Determination<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></h3><div class="NLM_p last">The HEK293-hERG cells for patch clamp assay were cultured in Dulbecco’s modified Eagle’s medium (DMEM):Ham’s F12 (1:1 ratio) with 10% FBS containing 0.5 mg/mL of selective antibiotic, G-418 sulfate (Calbiochem), and 0.1% penicillin and streptomycin (Thermofisher, MA, USA) in a T-75 flask. Cells were harvested at 70–80% confluency by washing with HBSS lacking Mg<sup>2+</sup> and Ca<sup>2+</sup> ions and subsequent addition of accumax (2.5 mL) (Sigma-Aldrich, MO, USA) and incubated in the flask at 5% CO<sub>2</sub> and 37 °C until cells start sliding on the surface. After cells have completely detached from the surface, about 10 mL of complete media without selective antibiotic was added and pipetted to detach the cell clumps. Additional 7.5 mL of complete media was added to collect the residual cells in the flask, and cell suspension was incubated at 5% CO<sub>2</sub> and 37 °C for 30 min. Centrifuged at 200<i>g</i> for 2 min, the supernatant was discarded, and the cell pellet was resuspended in external solution which was used for the patch clamp assay. hERG patch clamp assay was performed using the external solution of 140 mM NaCl, 4 mM KCl, 1 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 5 mM <span class="smallcaps smallerCapital">d</span>-glucose monohydrate, 10 mM HEPES/NaOH, pH 7.4, osmolarity: 298 mOsmol and internal solution of 50 mM KCl, 10 mM NaCl, 60 mM KF, 20 mM EGTA, 10 mM HEPES/KOH, pH 7.2, osmolarity 285 mOsmol. Whole cell patch clamp recordings were performed by using the <i>I</i>–<i>V</i> protocol of holding HEK293-hERG cells at −80 mV and stepping to +40 mV for 500 ms and followed by 500 ms step to −40 mV before stepping back to the holding potential. The peak current is measured at −40 mV tail currents using the Patchliner instrument. The <i>I</i>–<i>V</i> pulse protocol was pulsed every 10 s, online analyses were recorded by substituting the leak current from the peak current, and IC<sub>50</sub> values were calculated from IGOR PRO software (WaveMetrics, Inc. Portland, OR, USA).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> Determination of <i>In Vivo</i> Receptor Occupancy</h3><div class="NLM_p last">Male Wistar rats (<i>n</i> = 4–6/group) were administered with vehicle or test compounds (compound <b>12l</b> (0.1, 0.3, 1, 3, 10, and 30 mg/kg, p.o.), PF-04995274 (0.003, 0.01, 0.03, 0.1, 0.3, 1, and 3 mg/kg, s.c.) or RS-67333 (1, 3, 10, 20, and 30 mg/kg, p.o.). After 1 h of treatment with test compounds or vehicle, rats were restrained and administered with tracer (SB207145, 1 μg/kg) intravenously. After 30 min of tracer administration, rats were sacrificed, and the brain was separated for isolation of cerebellum (nonspecific region) and striatum (specific region). Isolated brain tissues were transferred to prelabeled tubes and stored on dry ice until quantification of tracer concentrations using LC-MS/MS. Blood and remaining brain were also collected from the rats treated with compound <b>12l</b> for measurement of test compound concentrations. Percentage R.O. of test compound was calculated using the concentrations of tracer in the striatum and cerebellum.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Object Recognition Task</h3><div class="NLM_p last">Male Wistar rats 10–12 weeks old were used. The arena was an open field made up of acrylic (50 × 50 × 50 cm). Twenty-4 h prior to testing, the rats were habituated to individual test arenas for 20 min in the absence of any objects. Twenty-4 h after the habituation, rats (12 animals per group) were administered respective treatments. After the post-treatment interval of 30 min, rats were subjected to familiarization phase (T1). Rats were placed individually in the open field for 3 min, containing two identical objects (a1 and a2). Choice trial (T2) was carried out after 24 h after the T1 trial. Rats were administered respective treatments. After the post treatment interval of 30 min rats were subjected to choice trial (T2). Rats were allowed to explore the open field for 3 min in the presence of one familiar object (a3) and one novel object (b). Exploration time was noted. Recognition index was calculated as time spent with the novel object and time spent with the familiar object in the choice trial. Rats which did not explore the familiar object for ≥15 s in the familiarization trial and ≥10 s in the recognition trial were not considered for statistical evaluation. The object was such that it could not be moved from its place. The familiar object was a bright yellow colored bottle of dimension 12 × 4 cm, while the novel object was an ambered colored bottle of dimension 11 × 3.5 cm. After each of the familiarization or recognition trials, the bottles were cleaned with 20% alcohol to mask olfactory cues.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> Radial Arm Maze</h3><div class="NLM_p last">Rats were fasted until they reached 85% of their body weight and then trained to eat pelleted food in the home cage. On days 1 and 2, the rats were habituated in the radial arm maze to find and eat the pellets. On the subsequent 4 days, the rats had to find and eat the pellets which were exclusively placed in the hopper of the arm. Each hopper was baited once. Re-entry into an arm from which the food was retrieved or exited from an arm without eating the pellet was considered as an error. % Choice accuracy was calculated as<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_m001.gif" alt="" id="_i95" /></img></span>where TE is the total error and TA is the total number of choices made. A rat could make a total of 16 arm visits. The trial was ended when all the pellets were retrieved or 16 arms were visited or a time of 10 min had elapsed. Total error was calculated as sum of number of repeat entries into an arm after food retrieval + number of arms omitted + exit from an arm without food retrieval. Following each trial, the radial maze was cleaned with soap solution to mask olfactory cues.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Estimation of sAPPα Levels Secreted by Cell Line</h3><div class="NLM_p">The measurement of sAPPα by Western blot was performed according to Fei Shen<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> with slight modifications. 5-HT<sub>4</sub>R agonist-evoked stimulation of sAPPα secretion <i>in vitro</i> was monitored using tsa201 cells transiently transfected with h5-HT<sub>4E</sub> receptor and human APP695. The amount of sAPPα released into the culture medium was determined using a semiquantitative Western blot assay with an antibody purified anti-β-amyloid, 1–16 monoclonal antibody (clone 6E10) to amino acid residues 1–17 of amyloid beta (Aβ) in the C terminus of sAPPα.</div><div class="NLM_p last">Cell culture medium, serum, and transfection reagent were purchased from Invitrogen (Carlsbad, California, USA). The human kidney cell line tsa201 was purchased from ECACC Sigma-Aldrich (St. Louis, Missouri, USA). Primary antibody clone 6E10 was purchased from Covance (Princeton, New Jersey, USA). Secondary antibody antimouse IgG-alkaline phosphatase, detection reagent, protease inhibitor, and chemicals were purchased from Sigma-Aldrich (St. Louis, Missouri, USA).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Cell Culture and Transient Transfection</h3><div class="NLM_p last">The human kidney cell line tsa201 was grown at 37 °C and 5% CO<sub>2</sub> in DMEM supplemented with 10% FBS, 2 mM glutamine, and antibiotics. For transient transfection experiments, tsa201 cells were transfected with expression constructs encoding the human APP695 gene and 5-HT<sub>4E</sub> gene using lipofectamine 2000 according to the manufacturer’s instructions. Briefly, 50–60% confluent cell cultures were incubated for 4 h in a mixture of a cationic transfection reagent and expression constructs. At the end of the incubation period, media were changed, and cells were cultured for an additional period of 40 h before the determination of sAPPα.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> Measurement of sAPPα by Western Blot</h3><div class="NLM_p last">Cells were cultured as described above and 40 h prior to assay were seeded into 6-well poly-<span class="smallcaps smallerCapital">d</span>-lysine-coated multiwell dishes and incubated in a humidified 5% CO<sub>2</sub> incubator at 37 °C. Cells were grown to approximately 90% confluency and, following aspiration of the growth medium, incubated in serum-free DMEM for 4 h. Cells then were washed with phosphate-buffered saline prior to incubation with test compound (0.001–10 μM in DMEM) for 30 min at 37 °C. For antagonist study, the cells were preincubated for 15 min and then treated with 5-HT<sub>4</sub>R agonist for 30 min. A buffer control and 5-HT (1 μM) were included as controls on every plate. For each condition, determinations were made in duplicate. At the end of the assay incubation period, an aliquot of extracellular medium was transferred from the respective wells into a tube containing protease inhibitor cocktail. The sample was centrifuged, and the supernatant collected into a new tube and stored at −80 °C prior to assay by Western blot. Samples were separated on SDS-PAGE 10% and transferred to PVDF membrane from Millipore (Burlington, Massachusetts, USA) in a mini trans blot cell apparatus from Bio-Rad (Hercules, California, USA) with transfer conditions of 10–15 V for overnight at 2–8 °C using transfer buffer (25 mM Tris, 192 mM glycine and 10% methanol). Membrane was preactivated in 100% methanol for 20 s and equilibrated in transfer buffer for 5 min before subjecting for transfer. After transfer, membrane was washed for 5 min in Tris buffered saline (TBS). The membrane was blocked in blocking buffer (TBS containing 0.1% Tween 20 and 5% nonfat dry milk) for 1 h at r.t. After blocking, the membrane was incubated with primary antibody purified anti-β-amyloid, 1–16 monoclonal antibody (clone 6E10) raised in a mouse for overnight at 2–8 °C. Membrane was washed three times each for 5 min in wash buffer (TBS containing 0.1% Tween 20). Membrane was incubated with secondary antibody antimouse IgG-alkaline phosphatase raised in a goat for 1 h at r.t. Membrane was washed three times each for 5 min in wash buffer (TBS containing 0.1% Tween 20). Membrane was developed with BCIP/NBT detection reagent, and images were captured in GelDoc imaging System (Bio-Rad). Electrophoresis molecular weight markers were used to verify the size of the protein, that is, sAPPα 98 kDa. Images were analyzed using ImageJ software (NIH).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00703" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03340" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03340" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00703?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00703</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Characterization data of final compounds, comparative <i>in vitro</i> affinities of 5-HT<sub>4</sub>R reference standards, data from functional assays, selectivity profile and elemental analysis (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Additional data (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_002.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_003.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Additional data (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_004.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf">jm1c00703_si_001.pdf (947.53 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_002.pdf">jm1c00703_si_002.pdf (637.53 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_003.csv">jm1c00703_si_003.csv (8.84 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_004.pdf">jm1c00703_si_004.pdf (216.63 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00703" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramakrishna Nirogi</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-2045-0784" title="Orcid link">https://orcid.org/0000-0002-2045-0784</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9ff1e9ecedf4dfeceae9faf1b1fcf0f2"><span class="__cf_email__" data-cfemail="4f21393c3d240f3c3a392a21612c2022">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Abdul Rasheed Mohammed</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-7873-4600" title="Orcid link">https://orcid.org/0000-0001-7873-4600</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anil Karbhari Shinde</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shankar Reddy Gagginapally</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Durga Malleshwari Kancharla</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Srinivasa Rao Ravella</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Narsimha Bogaraju</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vanaja Reddy Middekadi</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramkumar Subramanian</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Raghava Choudary Palacharla</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vijay Benade</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nageswararao Muddana</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renny Abraham</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajesh Babu Medapati</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jagadeesh Babu Thentu</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Venkat Reddy Mekala</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Surendra Petlu</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bujji Babu Lingavarapu</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sivasekhar Yarra</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Narendra Kagita</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vinod Kumar Goyal</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Santosh Kumar Pandey</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Venkat Jasti</span> - <span class="hlFld-Affiliation affiliation">Suven Life Sciences Limited, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e7955-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i100">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54324" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54324" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The support of the scientists from Analytical Chemistry, <i>In Vitro</i> and <i>In Vivo</i> Pharmacology, Drug Metabolism, and Pharmacokinetics Departments and the moral and financial support from Mr. Venkateswarlu Jasti, CEO, Suven Life Sciences Ltd., Hyderabad are greatly acknowledged.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">5-HT<sub>4</sub>R</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine 4 receptor</p></td></tr><tr><td class="NLM_term">p.o.</td><td class="NLM_def"><p class="first last">per oral</p></td></tr><tr><td class="NLM_term">s.c.</td><td class="NLM_def"><p class="first last">subcutaneous</p></td></tr><tr><td class="NLM_term">i.v.</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute</p></td></tr><tr><td class="NLM_term">mm</td><td class="NLM_def"><p class="first last">millimeter</p></td></tr><tr><td class="NLM_term">rpm</td><td class="NLM_def"><p class="first last">rotations per minute</p></td></tr><tr><td class="NLM_term">cps</td><td class="NLM_def"><p class="first last">counts per second</p></td></tr><tr><td class="NLM_term">mp</td><td class="NLM_def"><p class="first last">melting point</p></td></tr><tr><td class="NLM_term">DSC</td><td class="NLM_def"><p class="first last">differential scanning calorimetry</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-à-go-go-related gene</p></td></tr><tr><td class="NLM_term">sAPPα</td><td class="NLM_def"><p class="first last">soluble amyloid precursor protein α</p></td></tr><tr><td class="NLM_term">R.O.</td><td class="NLM_def"><p class="first last">receptor occupancy</p></td></tr><tr><td class="NLM_term">LC-MS/MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">Ach</td><td class="NLM_def"><p class="first last">acetylcholine</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">concentration giving a 50% response</p></td></tr><tr><td class="NLM_term">ED<sub>50</sub></td><td class="NLM_def"><p class="first last">dose giving a 50% response</p></td></tr><tr><td class="NLM_term"><i>E</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximal effect</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">HEK</td><td class="NLM_def"><p class="first last">human embryonic kidney</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyran</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin-layer chromatography</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">isopropanol</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last">2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic anhydride</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylaminopyridine</p></td></tr><tr><td class="NLM_term">ICH</td><td class="NLM_def"><p class="first last">International Council for Harmonization</p></td></tr><tr><td class="NLM_term">OECD</td><td class="NLM_def"><p class="first last">Organization for Economic Cooperation and Development</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecoutey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochais, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic modulators of the serotonin 5-HT<sub>4</sub> receptor: a patent review (2014-present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1080/13543776.2020.1767587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1080%2F13543776.2020.1767587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=32400221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSgsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=495-508&author=C.+Lanthierauthor=P.+Dallemagneauthor=C.+Lecouteyauthor=S.+Claeysenauthor=C.+Rochais&title=Therapeutic+modulators+of+the+serotonin+5-HT4+receptor%3A+a+patent+review+%282014-present%29&doi=10.1080%2F13543776.2020.1767587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present)</span></div><div class="casAuthors">Lanthier, Caroline; Dallemagne, Patrick; Lecoutey, Cedric; Claeysen, Sylvie; Rochais, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">495-508</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A Review.  IntroductionNumerous chemotypes have been described over time in order to generate potent and selective 5-HT4R ligands.  Both agonists and antagonists have demonstrated their interest in several disease models.  This culminates with the FDA approval of tegaserod and prucalopride in the recent years.  Areas coveredThis review summarizes the patent applications from 2014 to present, dedicated to the use or the description of novel 5-HT4R modulators.  Several novel ligands and scaffolds have been industrially protected mainly in the field of central nervous system (CNS) pathologies as well as gastrointestinal disorders, including the combination with other drugs or for veterinary uses.  Expert opinionThe therapeutic potential of 5-HT4R modulators has been explored for several years in animal models, but also linked to potential safety issues with initial ligands.  The current use of prucalopride in humans demonstrates that its toxicity is not linked to the target and that 5-HT4R modulators are safe in humans.  Therefore, an important no. of studies and patents has continued in the recent years to expand the use of 5-HT4R modulators, not only to treat gastrointestinal disorders, but also for CNS pathologies.  This article details current efforts in this development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Q6zEPQKyZrVg90H21EOLACvtfcHk0liDru6NVpVysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSgsLbM&md5=c9d6fa1474a9f3242dc0b029b3d2cf05</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1080%2F13543776.2020.1767587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2020.1767587%26sid%3Dliteratum%253Aachs%26aulast%3DLanthier%26aufirst%3DC.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DLecoutey%26aufirst%3DC.%26aulast%3DClaeysen%26aufirst%3DS.%26aulast%3DRochais%26aufirst%3DC.%26atitle%3DTherapeutic%2520modulators%2520of%2520the%2520serotonin%25205-HT4%2520receptor%253A%2520a%2520patent%2520review%2520%25282014-present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D495%26epage%3D508%26doi%3D10.1080%2F13543776.2020.1767587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laz, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysse, P. J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartig, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branchek, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinshank, R. L.</span></span> <span> </span><span class="NLM_article-title">The 5-HT<sub>4</sub> receptor: molecular cloning and pharmacological characterization of two splice variants</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2815</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1995.tb07280.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1002%2Fj.1460-2075.1995.tb07280.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=7796807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2MXms1Ckt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=2806-2815&author=C.+Geraldauthor=N.+Adhamauthor=H.+T.+Kaoauthor=M.+A.+Olsenauthor=T.+M.+Lazauthor=L.+E.+Schechterauthor=J.+A.+Bardauthor=P.+J.-J.+Vaysseauthor=P.+R.+Hartigauthor=T.+A.+Branchekauthor=R.+L.+Weinshank&title=The+5-HT4+receptor%3A+molecular+cloning+and+pharmacological+characterization+of+two+splice+variants&doi=10.1002%2Fj.1460-2075.1995.tb07280.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants</span></div><div class="casAuthors">Gerald, Christophe; Adham, Nika; Kao, Hung-Teh; Olsen, Michael A.; Laz, Thomas M.; Schechter, Lee E.; Bard, Jonathan A.; Vaysse, Pierre J.-J.; Hartig, Paul R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2806-15</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mol. cloning efforts have provided primary amino acid sequence and signal transduction data for a large collection of serotonin receptor subtypes.  These include five 5-HT1-like receptors, three 5-HT2 receptors, one 5-HT3 receptor, two 5-HT5 receptors, one 5-HT6 receptor and one 5-HT7 receptor.  Mol. biol. information on the 5-HT4 receptor is notably absent from this list.  The authors now report the cloning of the pharmacol. defined 5-HT4 receptor.  Using degenerate oligonucleotide primers, the authors identified a rat brain PCR fragment which encoded a '5-HT receptor-like' amino acid sequence.  The corresponding full-length cDNA was isolated from a rat brain cDNA library.  Transiently expressed in COS-7 cells, this receptor stimulates adenylyl cyclase activity and is sensitive to the benzamide deriv. cisapride.  The response is also blocked by ICS-205930.  Interestingly, the authors isolated two splice variants of the receptor, 5-HT4L and 5-HT4S, differing in the length and sequence of their C-termini.  In rat brain, the 5-HT4S transcripts are restricted to the striatum, but the 5-HT4L transcripts are expressed throughout the brain, except in the cerebellum where it was barely detectable.  In peripheral tissues, differential expression was also obsd. in the atrium of the heart where only the 5-HT4S isoform was detectable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDLjGTNqkbC7Vg90H21EOLACvtfcHk0liDru6NVpVysg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1Ckt7Y%253D&md5=1bfa665fe162f63a50a5b083152bfa21</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1995.tb07280.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1995.tb07280.x%26sid%3Dliteratum%253Aachs%26aulast%3DGerald%26aufirst%3DC.%26aulast%3DAdham%26aufirst%3DN.%26aulast%3DKao%26aufirst%3DH.%2BT.%26aulast%3DOlsen%26aufirst%3DM.%2BA.%26aulast%3DLaz%26aufirst%3DT.%2BM.%26aulast%3DSchechter%26aufirst%3DL.%2BE.%26aulast%3DBard%26aufirst%3DJ.%2BA.%26aulast%3DVaysse%26aufirst%3DP.%2BJ.-J.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26aulast%3DBranchek%26aufirst%3DT.%2BA.%26aulast%3DWeinshank%26aufirst%3DR.%2BL.%26atitle%3DThe%25205-HT4%2520receptor%253A%2520molecular%2520cloning%2520and%2520pharmacological%2520characterization%2520of%2520two%2520splice%2520variants%26jtitle%3DEMBO%2520J.%26date%3D1995%26volume%3D14%26spage%3D2806%26epage%3D2815%26doi%3D10.1002%2Fj.1460-2075.1995.tb07280.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manahan-Vaughan, D.</span></span> <span> </span><span class="NLM_article-title">The serotonergic 5-HT<sub>4</sub> receptor: a unique modulator of hippocampal synaptic information processing and cognition</span>. <i>Neurobiol. Learn. Mem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.nlm.2016.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.nlm.2016.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=27317942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSitb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=145-153&author=H.+Hagenaauthor=D.+Manahan-Vaughan&title=The+serotonergic+5-HT4+receptor%3A+a+unique+modulator+of+hippocampal+synaptic+information+processing+and+cognition&doi=10.1016%2Fj.nlm.2016.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The serotonergic 5-HT4 receptor: A unique modulator of hippocampal synaptic information processing and cognition</span></div><div class="casAuthors">Hagena, Hardy; Manahan-Vaughan, Denise</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Learning and Memory</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145-153</span>CODEN:
                <span class="NLM_cas:coden">NLMEFR</span>;
        ISSN:<span class="NLM_cas:issn">1074-7427</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Serotonin (5-hydroxytryptamine, 5-HT) contributes in multifarious ways to the regulation of brain function, spanning key aspects such as the sleep-wake cycle, appetite, mood and mental health.  The 5-HT receptors comprise seven receptor families (5-HT1-7) that are further subdivided into 14 receptor subtypes.  The role of the 5-HT receptor in the modulation of neuronal excitability has been well documented.  Recently, however, it has become apparent that the 5-HT4 receptor may contribute significantly to cognition and regulates less ostensible aspects of brain function: it engages in metaplastic regulation of synaptic responsiveness in key brain structures such as the hippocampus, thereby specifically promoting persistent forms of synaptic plasticity, and influences the direction of change in synaptic strength in selected hippocampal subfields.  This highly specific neuromodulatory control by the 5-HT4 receptor may in turn explain the reported role for this receptor in hippocampus-dependent cognition.  In this review article, we describe the role of the 5-HT4 receptor in hippocampal function, and describe how this receptor plays a unique and highly specialised role in synaptic information storage and cognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Zi8OATIdmrVg90H21EOLACvtfcHk0lh9XFrT8wXAMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSitb3O&md5=1e8be03017f92c9a815f094abc48f535</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.nlm.2016.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nlm.2016.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DHagena%26aufirst%3DH.%26aulast%3DManahan-Vaughan%26aufirst%3DD.%26atitle%3DThe%2520serotonergic%25205-HT4%2520receptor%253A%2520a%2520unique%2520modulator%2520of%2520hippocampal%2520synaptic%2520information%2520processing%2520and%2520cognition%26jtitle%3DNeurobiol.%2520Learn.%2520Mem.%26date%3D2017%26volume%3D138%26spage%3D145%26epage%3D153%26doi%3D10.1016%2Fj.nlm.2016.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maillet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc’h, F.</span></span> <span> </span><span class="NLM_article-title">New insights into serotonin 5-HT<sub>4</sub> receptors: a novel therapeutic target for Alzheimer’s disease?</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.2174/1567205043332252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.2174%2F1567205043332252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=15975071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvF2jt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=79-85&author=M.+Mailletauthor=S.+J.+Robertauthor=F.+Lezoualc%E2%80%99h&title=New+insights+into+serotonin+5-HT4+receptors%3A+a+novel+therapeutic+target+for+Alzheimer%E2%80%99s+disease%3F&doi=10.2174%2F1567205043332252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into serotonin 5-HT4 receptors: A novel therapeutic target for Alzheimer's disease?</span></div><div class="casAuthors">Maillet, Marjorie; Robert, Sylvain J.; Lezoualc'h, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">79-85</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The serotonin 5-HT4 receptor mediates many physiol. effects in the central nervous system.  The recent mol. identification of 5-HT4 receptors and the development of selective 5-HT4 receptor ligands have led to many important new insights into the signalling pathways and the physiol. roles of these G protein-coupled-receptors in neurons.  With respect to neurodegenerative disorders, it is suggested that 5-HT4 agonists may represent a new avenue for the treatment of Alzheimer's disease.  This mini-review will focus on recent in vitro and in vivo pharmacol. and biochem. studies showing the involvement of 5-HT4 receptors in cognitive processes and the amyloid precursor protein processing.  The potential use of 5-HT4 agonists for the treatment of AD will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEEiivpw5diLVg90H21EOLACvtfcHk0lh9XFrT8wXAMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvF2jt70%253D&md5=6e42fa1b968fffe34f6ee96ed37bc957</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F1567205043332252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205043332252%26sid%3Dliteratum%253Aachs%26aulast%3DMaillet%26aufirst%3DM.%26aulast%3DRobert%26aufirst%3DS.%2BJ.%26aulast%3DLezoualc%25E2%2580%2599h%26aufirst%3DF.%26atitle%3DNew%2520insights%2520into%2520serotonin%25205-HT4%2520receptors%253A%2520a%2520novel%2520therapeutic%2520target%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253F%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2004%26volume%3D1%26spage%3D79%26epage%3D85%26doi%3D10.2174%2F1567205043332252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, F.</span></span> <span> </span><span class="NLM_article-title">Drugs acting on serotonin receptors for the treatment of functional GI disorders</span>. <i>Dig Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1159/000090309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1159%2F000090309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=16699264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A280%3ADC%252BD283msl2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=59-69&author=M.+Toniniauthor=F.+Pace&title=Drugs+acting+on+serotonin+receptors+for+the+treatment+of+functional+GI+disorders&doi=10.1159%2F000090309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs acting on serotonin receptors for the treatment of functional GI disorders</span></div><div class="casAuthors">Tonini Marcello; Pace Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Digestive diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">59-69</span>
        ISSN:<span class="NLM_cas:issn">0257-2753</span>.
    </div><div class="casAbstract">In the gut, serotonin (5-hydroxytryptamine: 5-HT) exerts a variety of effects on intrinsic enteric neurons, extrinsic afferents, enterocytes and smooth muscle cells, which are related to the expression of multiple 5-HT receptor types and subtypes regulating motility, vascular tone, secretion and perception.  Agonists and antagonists at 5-HT receptors have gained access to the market for the two major variants of the irritable bowel syndrome (IBS), a functional disorder characterized by abdominal pain associated with diarrhea and/or constipation in the absence of any organic abnormality.  Indeed, the 5-HT3 receptor antagonist alosetron is available in the US market for the treatment of women with severe, diarrhea-predominant IBS (D-IBS) refractory to conventional therapy, whereas tegaserod, a partial 5-HT4 receptor agonist, has been approved by the FDA and other regulatory agencies for the treatment of women with constipation-predominant IBS (C-IBS) or functional constipation.  This review is mainly intended to discuss the role of non-neuronal (paracrine) and neuronal 5-HT in the pathophysiology of functional gastrointestinal disorders (FGIDs), such as IBS and functional dyspepsia, and the mechanisms through which drugs acting on 5-HT receptors regulate visceral motility, perception and secretion in these two conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSq9uzlmfvkOmx8TEN9K18QfW6udTcc2ea88K5rE_lT8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283msl2msA%253D%253D&md5=dda3f4f7c10a3e874dbeec3da1d316eb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1159%2F000090309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000090309%26sid%3Dliteratum%253Aachs%26aulast%3DTonini%26aufirst%3DM.%26aulast%3DPace%26aufirst%3DF.%26atitle%3DDrugs%2520acting%2520on%2520serotonin%2520receptors%2520for%2520the%2520treatment%2520of%2520functional%2520GI%2520disorders%26jtitle%3DDig%2520Dis.%26date%3D2006%26volume%3D24%26spage%3D59%26epage%3D69%26doi%3D10.1159%2F000090309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouras, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camilleri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mckinzie, S.</span></span> <span> </span><span class="NLM_article-title">Selective stimulation of colonic transit by the benzofuran 5-HT<sub>4</sub> agonist prucalopride, in healthy humans</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.1136/gut.44.5.682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1136%2Fgut.44.5.682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10205205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK1MXjtF2ktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1999&pages=682-686&author=E.+P.+Bourasauthor=M.+Camilleriauthor=D.+D.+Burtonauthor=S.+Mckinzie&title=Selective+stimulation+of+colonic+transit+by+the+benzofuran+5-HT4+agonist+prucalopride%2C+in+healthy+humans&doi=10.1136%2Fgut.44.5.682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans</span></div><div class="casAuthors">Bouras, E. P.; Camilleri, M.; Burton, D. D.; McKinzie, S.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">682-686</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Prucalopride (R093877) is a selective and specific 5HT4 agonist, the first of a new chem. class of benzo-furans, with gastrointestinal prokinetic activities in vitro.  To evaluate the effects of prucalo-pride on gastrointestinal and colonic transit.  A validated scintigraphic technique was used to measure gastrointestinal and colonic transit over 48 h in 50 healthy volunteers.  For seven days, each subject received a daily dose of 0.5, 1, 2, or 4 mg prucalopride, or placebo in a double blind, randomized fashion.  The transit test was performed over the last 48 h.  There were significant accelerations of overall colonic transit at 4, 8, 24, and 48 h (p<0.05) and proximal colonic emptying t1/2 (p<0.05).  The 0.5, 2, and 4 mg doses of prucalopride were almost equally effective and accelerated colonic transit compared with placebo.  Prucalopride did not significantly alter gastric emptying (p>0.5) or small bowel transit (overall p=0.12).  The medication appeared to be well tolerated during the seven day treatment of healthy subjects.  Prucalopride accelerates colonic transit, partly by stimulating proximal colonic emptying, but does not alter gastric or small bowel transit in healthy human subjects.  Prucalopride deserves further study in patients with constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0h8xd_-Aq1bVg90H21EOLACvtfcHk0lh9XFrT8wXAMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtF2ktrg%253D&md5=a2d3dd4271c784729e9fb49d4d6f74ab</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1136%2Fgut.44.5.682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.44.5.682%26sid%3Dliteratum%253Aachs%26aulast%3DBouras%26aufirst%3DE.%2BP.%26aulast%3DCamilleri%26aufirst%3DM.%26aulast%3DBurton%26aufirst%3DD.%2BD.%26aulast%3DMckinzie%26aufirst%3DS.%26atitle%3DSelective%2520stimulation%2520of%2520colonic%2520transit%2520by%2520the%2520benzofuran%25205-HT4%2520agonist%2520prucalopride%252C%2520in%2520healthy%2520humans%26jtitle%3DGut%26date%3D1999%26volume%3D44%26spage%3D682%26epage%3D686%26doi%3D10.1136%2Fgut.44.5.682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumuis, A.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptors, a place in the sun: act two</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2011.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.coph.2011.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=21342787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=87-93&author=J.+Bockaertauthor=S.+Claeysenauthor=V.+Companauthor=A.+Dumuis&title=5-HT4+receptors%2C+a+place+in+the+sun%3A+act+two&doi=10.1016%2Fj.coph.2011.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptors, a place in the sun: act two</span></div><div class="casAuthors">Bockaert, Joel; Claeysen, Sylvie; Compan, Valerie; Dumuis, Aline</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-93</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  5-HT4 receptors control brain physiol. functions such as learning and memory, feeding and mood behavior as well as gastro-intestinal transit. 5-HT4 receptors are one of the 5-HT receptors for which the available drugs and signalling knowledge are the most advanced.  Several therapeutic 5-HT4 receptor drugs have been commercialized.  Therefore, the hope that 5-HT4 receptors could also be the target for brain diseases is reasonable.  Several major devastating illnesses could benefit from 5-HT4 receptors-directed therapy such as Alzheimer's disease, feeding-assocd. diseases such as anorexia and major depressive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe-9UQID9lqbVg90H21EOLACvtfcHk0lhzguL2cy_UOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7Y%253D&md5=6f136864149bddba0ec1f0ed3b153968</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2011.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2011.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DClaeysen%26aufirst%3DS.%26aulast%3DCompan%26aufirst%3DV.%26aulast%3DDumuis%26aufirst%3DA.%26atitle%3D5-HT4%2520receptors%252C%2520a%2520place%2520in%2520the%2520sun%253A%2520act%2520two%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D87%26epage%3D93%26doi%3D10.1016%2Fj.coph.2011.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc’h, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, S. J.</span></span> <span> </span><span class="NLM_article-title">The serotonin 5-HT<sub>4</sub> receptor and the amyloid precursor protein processing</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/S0531-5565(02)00157-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2FS0531-5565%2802%2900157-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=12543273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=159-166&author=F.+Lezoualc%E2%80%99hauthor=S.+J.+Robert&title=The+serotonin+5-HT4+receptor+and+the+amyloid+precursor+protein+processing&doi=10.1016%2FS0531-5565%2802%2900157-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The serotonin 5-HT4 receptor and the amyloid precursor protein processing</span></div><div class="casAuthors">Lezoualc'h, Frank; Robert, Sylvain J.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">159-166</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A large body of evidence supports a major role for the serotonin 5-HT4 receptor in learning and memory and it is suggested that 5-HT4 agonists may be beneficial for memory disorders such as Alzheimer's disease (AD).  The 5-HT4 receptors are members of the G protein-coupled receptor superfamily and are pos. coupled to adenylyl cyclase.  In this communication the authors show that a neuronal isoform of the human 5-HT4 receptor, h5-HT4(g) regulates the metab. of the amyloid precursor protein (APP695).  This process is obsd. in Chinese hamster ovary (CHO) cells stably coexpressing the neuronal h5-HT4(g) receptor isoform as well as the human APP695.  The 5-HT4 agonists strongly stimulate the release of the non-amyloidogenic sol. amyloid precursor protein sAPPα as detected by immunoblot.  Prucalopride was more potent than serotonin (5-HT) with regard to enhanced of sAPPα secretion.  This process was blocked by a selective 5-HT4 antagonist, GR113808.  Furthermore, 5-HT4 ligands enhance sAPPα secretion via cAMP-dependent and PKA-independent signaling pathways indicating there are alternative pathways by which the h5-HT4 receptor via cAMP regulates APP metab.  Because the α-cleavage event may preclude the formation of amyloidogenic peptides, and secreted sAPPα has putative neuroprotective and enhancing-memory properties, our present data suggest the 5-HT4 receptor as a novel target for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobwRXVEkZwfLVg90H21EOLACvtfcHk0ljJKdQ6XD9tZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFWmsw%253D%253D&md5=b4e047f7299a56f139389894c3a3060c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0531-5565%2802%2900157-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0531-5565%252802%252900157-2%26sid%3Dliteratum%253Aachs%26aulast%3DLezoualc%25E2%2580%2599h%26aufirst%3DF.%26aulast%3DRobert%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520serotonin%25205-HT4%2520receptor%2520and%2520the%2520amyloid%2520precursor%2520protein%2520processing%26jtitle%3DExp.%2520Gerontol.%26date%3D2003%26volume%3D38%26spage%3D159%26epage%3D166%26doi%3D10.1016%2FS0531-5565%2802%2900157-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugaza, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc’h, F.</span></span> <span> </span><span class="NLM_article-title">The human serotonin 5-HT<sub>4</sub> receptor regulates secretion of non-amyloidogenic precursor protein</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">44881</span>– <span class="NLM_lpage">44888</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109008200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1074%2Fjbc.M109008200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=11584021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFegurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=44881-44888&author=S.+J.+Robertauthor=J.+L.+Zugazaauthor=R.+Fischmeisterauthor=A.+M.+Gardierauthor=F.+Lezoualc%E2%80%99h&title=The+human+serotonin+5-HT4+receptor+regulates+secretion+of+non-amyloidogenic+precursor+protein&doi=10.1074%2Fjbc.M109008200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein</span></div><div class="casAuthors">Robert, Sylvain J.; Zugaza, Jose L.; Fischmeister, Rodolphe; Gardier, Alain M.; Lezoualc'h, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">44881-44888</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The serotonin 5-HT4 receptor has recently gained a lot of attention for its functional roles in central processes such as memory and cognition.  In this study, we show that activation of the human 5-HT4 (h5-HT4) receptor stimulates the secretion of the non-amyloidogenic sol. form of the amyloid precursor protein (sAPPα).  5-HT enhanced the level of secreted sAPPα in a time- and dose-dependent manner in Chinese hamster ovary cells stably expressing the h5-HT4(e) receptor isoform.  The increase was inhibited by the selective 5-HT4 receptor antagonist, GR 113808.  The 5-HT4 selective agonists, prucalopride and renzapride, also increased secreted sAPPα in IMR32 human neuroblastoma cells.  The stimulatory effect of 5-HT was mimicked by forskolin, a direct activator of adenylyl cyclase, and 8-bromo-cAMP, a membrane-permeant cAMP analog.  On the contrary, inhibition of protein kinase A (PKA) by H 89 potentiated the 5-HT-induced increase in both secreted and cellular sAPPα.  This phenomenon involves a novel PKA-independent stimulatory process that overcomes a PKA-dependent inhibitory one.  Finally, activation of the h5-HT4(e) receptor did not modify extracellular amyloid β-protein in Chinese hamster ovary cells transfected with the human APP695.  Given the neuroprotective and enhancing memory effects of sAPPα, our results may open a new avenue for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZXW1Ib2lqw7Vg90H21EOLACvtfcHk0ljJKdQ6XD9tZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFegurk%253D&md5=bf4cbeb9c1c76976cde9ce9579a7ffc5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109008200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109008200%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DS.%2BJ.%26aulast%3DZugaza%26aufirst%3DJ.%2BL.%26aulast%3DFischmeister%26aufirst%3DR.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26aulast%3DLezoualc%25E2%2580%2599h%26aufirst%3DF.%26atitle%3DThe%2520human%2520serotonin%25205-HT4%2520receptor%2520regulates%2520secretion%2520of%2520non-amyloidogenic%2520precursor%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D44881%26epage%3D44888%26doi%3D10.1074%2Fjbc.M109008200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumuis, A.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptors</span>. <i>Curr. Drug Targets: CNS Neurol. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.2174/1568007043482615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.2174%2F1568007043482615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=14965243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFWksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=39-51&author=J.+Bockaertauthor=S.+Claeysenauthor=V.+Companauthor=A.+Dumuis&title=5-HT4+receptors&doi=10.2174%2F1568007043482615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptors</span></div><div class="casAuthors">Bockaert, J.; Claeysen, S.; Compan, V.; Dumuis, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: CNS & Neurological Disorders</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">CDTCCC</span>;
        ISSN:<span class="NLM_cas:issn">1568-007X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Serotonin 4 receptors (5-HT4Rs) were discovered 15 yr ago.  They are coded by a very complex gene (700Kb, 38 exons) which generates 8 C-terminal variants (a, b, c, d, e, f, g, and n).  Their sequences differ after position L358.  Another variant is characterized by a 14 residue insertion within the extracellular loop 2.  Highly selective potent 5-HT4 receptor antagonists and partial agonists which cross the blood-brain barrier have been synthesized, but a specific full agonist for brain studies is still missing.  Based on physiol. and behavioral expts., 5-HT4Rs may be targets to treat cognitive deficits, abdominal pain, and feeding disorders.  One 5-HT4R-directed drug (SL65.0155) is already in phase II to treat patients suffering from memory deficits or dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoemFXFD0xNLrVg90H21EOLACvtfcHk0ljJKdQ6XD9tZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFWksrc%253D&md5=b9139c95c9d832dd89b51d45fc3bde96</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568007043482615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568007043482615%26sid%3Dliteratum%253Aachs%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DClaeysen%26aufirst%3DS.%26aulast%3DCompan%26aufirst%3DV.%26aulast%3DDumuis%26aufirst%3DA.%26atitle%3D5-HT4%2520receptors%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520CNS%2520Neurol.%2520Disord.%26date%3D2004%26volume%3D3%26spage%3D39%26epage%3D51%26doi%3D10.2174%2F1568007043482615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubitski, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutzman-Engwall, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorczyca, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siok, C. J.</span></span> <span> </span><span class="NLM_article-title">The 5-HT<sub>4</sub> receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.192351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1124%2Fjpet.112.192351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=22408061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=681-691&author=D.+E.+Johnsonauthor=E.+Drummondauthor=S.+Grimwoodauthor=A.+Sawant-Basakauthor=E.+Millerauthor=E.+Tsengauthor=L.+L.+McDowellauthor=M.+A.+Vanase-Frawleyauthor=K.+E.+Fisherauthor=D.+M.+Rubitskiauthor=K.+J.+Stutzman-Engwallauthor=R.+T.+Nelsonauthor=W.+E.+Hornerauthor=R.+R.+Gorczycaauthor=M.+Hajosauthor=C.+J.+Siok&title=The+5-HT4+receptor+agonists+prucalopride+and+PRX-03140+increase+acetylcholine+and+histamine+levels+in+the+rat+prefrontal+cortex+and+the+power+of+stimulated+hippocampal+%CE%B8+oscillations&doi=10.1124%2Fjpet.112.192351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations</span></div><div class="casAuthors">Johnson, David E.; Drummond, Elena; Grimwood, Sarah; Sawant-Basak, Aarti; Miller, Emily; Tseng, Elaine; McDowell, Laura L.; Vanase-Frawley, Michelle A.; Fisher, Katherine E.; Rubitski, David M.; Stutzman-Engwall, Kim J.; Nelson, Robin T.; Horner, Weldon E.; Gorczyca, Roxanne R.; Hajos, Mihaly; Siok, Chester J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">681-691</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">5-Hydroxytryptamine (5-HT)4 receptor agonists reportedly stimulate brain acetylcholine (ACh) release, a property that might provide a new pharmacol. approach for treating cognitive deficits assocd. with Alzheimer's disease.  The purpose of this study was to compare the binding affinities, functional activities, and effects on neuropharmacol. responses assocd. with cognition of two highly selective 5-HT4 receptor agonists, prucalopride and 6,7-dihydro-4-hydroxy-7-isopropyl-6-oxo-N-[3-(piperidin-1-yl)propyl]thieno[2,3-b]pyridine-5-carboxamide (PRX-03140).  In vitro, prucalopride and PRX-03140 bound to native rat brain 5-HT4 receptors with Ki values of 30 nM and 110 nM, resp., and increased cAMP prodn. in human embryonic kidney-293 cells expressing recombinant rat 5-HT4 receptors.  In vivo receptor occupancy studies established that prucalopride and PRX-03140 were able to penetrate the brain and bound to 5-HT4 receptors in rat brain, achieving 50% receptor occupancy at free brain exposures of 330 nM and 130 nM, resp.  Rat microdialysis studies revealed that prucalopride maximally increased ACh and histamine levels in the prefrontal cortex at 5 and 10 mg/kg, whereas PRX-03140 significantly increased cortical histamine levels at 50 mg/kg, failing to affect ACh release at doses lower than 150 mg/kg.  In combination studies, donepezil-induced increases in cortical ACh levels were potentiated by prucalopride and PRX-03140.  Electrophysiol. studies in rats demonstrated that both compds. increased the power of brainstem-stimulated hippocampal θ oscillations at 5.6 mg/kg.  These findings show for the first time that the 5-HT4 receptor agonists prucalopride and PRX-03140 can increase cortical ACh and histamine levels, augment donepezil-induced ACh increases, and increase stimulated-hippocampal θ power, all neuropharmacol. parameters consistent with potential pos. effects on cognitive processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYkki5FaX4E7Vg90H21EOLACvtfcHk0ljzpKPCxVx8DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWltL4%253D&md5=a85101ee05a17788379fad99a454347b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.192351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.192351%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BE.%26aulast%3DDrummond%26aufirst%3DE.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DMcDowell%26aufirst%3DL.%2BL.%26aulast%3DVanase-Frawley%26aufirst%3DM.%2BA.%26aulast%3DFisher%26aufirst%3DK.%2BE.%26aulast%3DRubitski%26aufirst%3DD.%2BM.%26aulast%3DStutzman-Engwall%26aufirst%3DK.%2BJ.%26aulast%3DNelson%26aufirst%3DR.%2BT.%26aulast%3DHorner%26aufirst%3DW.%2BE.%26aulast%3DGorczyca%26aufirst%3DR.%2BR.%26aulast%3DHajos%26aufirst%3DM.%26aulast%3DSiok%26aufirst%3DC.%2BJ.%26atitle%3DThe%25205-HT4%2520receptor%2520agonists%2520prucalopride%2520and%2520PRX-03140%2520increase%2520acetylcholine%2520and%2520histamine%2520levels%2520in%2520the%2520rat%2520prefrontal%2520cortex%2520and%2520the%2520power%2520of%2520stimulated%2520hippocampal%2520%25CE%25B8%2520oscillations%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D681%26epage%3D691%26doi%3D10.1124%2Fjpet.112.192351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castro-Alvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chávez-Ángel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, R.</span></span> <span> </span><span class="NLM_article-title">Understanding the molecular basis of 5-HT <sub>4</sub> receptor partial agonists through 3D-QSAR studies</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3602</span>, <span class="refDoi"> DOI: 10.3390/ijms22073602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.3390%2Fijms22073602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=33808456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3MXht1GktLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2021&pages=3602&author=A.+Castro-Alvarezauthor=E.+Ch%C3%A1vez-%C3%81ngelauthor=R.+Nelson&title=Understanding+the+molecular+basis+of+5-HT+4+receptor+partial+agonists+through+3D-QSAR+studies&doi=10.3390%2Fijms22073602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the molecular basis of 5-HT4 receptor partial agonists through 3D-QSAR studies</span></div><div class="casAuthors">Castro-Alvarez, Alejandro; Chavez-Angel, Emigdio; Nelson, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3602</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disorder whose prevalence has an incidence in senior citizens.  Unfortunately, current pharmacotherapy only offers symptom relief for patients with side effects such as bradycardia, nausea, and vomiting.  Therefore, there is a present need to provide other therapeutic alternatives for treatments for these disorders.  The 5-HT4 receptor is an attractive therapeutic target since it has a potential role in central and peripheral nervous system disorders such as AD, irritable bowel syndrome, and gastroparesis.  Quant. structure-activity relationship anal. of a series of 62 active compds. in the 5-HT4 receptor was carried out in the present work.  The structure-activity relationship was estd. using three-dimensional quant. structure-activity relationship (3D-QSAR) techniques based on these structures' field mol. (force and Gaussian field).  The best force-field QSAR models achieve a value for the coeff. of detn. of the training set of R2training = 0.821, and for the test set R2test = 0.667, while for Gaussian-field QSAR the training and the test were R2training = 0.898 and R2test = 0.695, resp.  The obtained results were validated using a coeff. of correlation of the leave-one-out crossvalidation of Q2 LOO = 0.804 and Q2 LOO = 0.886 for force- and Gaussian-field QSAR, resp.  Based on these results, novel 5-HT4 partial agonists with potential biol. activity (pEC50 8.209-9.417 for force-field QSAR and 9.111-9.856 for Gaussian-field QSAR) were designed.  In addn., for the new analogs, their absorption, distribution, metab., excretion, and toxicity properties were also analyzed.  The results show that these new derivs. also have reasonable pharmacokinetics and drug-like properties.  Our findings suggest novel routes for the design and development of new 5-HT4 partial agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwmigHC7VPuLVg90H21EOLACvtfcHk0ljzpKPCxVx8DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXht1GktLrK&md5=783dda0da13a8ee8867b280bb120bf75</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3390%2Fijms22073602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms22073602%26sid%3Dliteratum%253Aachs%26aulast%3DCastro-Alvarez%26aufirst%3DA.%26aulast%3DCh%25C3%25A1vez-%25C3%2581ngel%26aufirst%3DE.%26aulast%3DNelson%26aufirst%3DR.%26atitle%3DUnderstanding%2520the%2520molecular%2520basis%2520of%25205-HT%25204%2520receptor%2520partial%2520agonists%2520through%25203D-QSAR%2520studies%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2021%26volume%3D22%26spage%3D3602%26doi%3D10.3390%2Fijms22073602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waizumi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papanikolaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutzman-Engwall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubitski, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span> <span> </span><span class="NLM_article-title">Identification of multiple 5-HT<sub>4</sub> partial agonist clinical candidates for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9240</span>– <span class="NLM_lpage">9254</span>, <span class="refDoi"> DOI: 10.1021/jm300953p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300953p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGhsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9240-9254&author=M.+A.+Brodneyauthor=D.+E.+Johnsonauthor=A.+Sawant-Basakauthor=K.+J.+Coffmanauthor=E.+M.+Drummondauthor=E.+L.+Hudsonauthor=K.+E.+Fisherauthor=H.+Noguchiauthor=N.+Waizumiauthor=L.+L.+McDowellauthor=A.+Papanikolaouauthor=B.+A.+Pettersenauthor=A.+W.+Schmidtauthor=E.+Tsengauthor=K.+Stutzman-Engwallauthor=D.+M.+Rubitskiauthor=M.+A.+Vanase-Frawleyauthor=S.+Grimwood&title=Identification+of+multiple+5-HT4+partial+agonist+clinical+candidates+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm300953p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Multiple 5-HT4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Brodney, Michael A.; Johnson, David E.; Sawant-Basak, Aarti; Coffman, Karen J.; Drummond, Elena M.; Hudson, Emily L.; Fisher, Katherine E.; Noguchi, Hirohide; Waizumi, Nobuaki; McDowell, Laura L.; Papanikolaou, Alexandros; Pettersen, Betty A.; Schmidt, Anne W.; Tseng, Elaine; Stutzman-Engwall, Kim; Rubitski, David M.; Vanase-Frawley, Michelle A.; Grimwood, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9240-9254</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cognitive impairments obsd. in Alzheimer's disease (AD) are in part a consequence of reduced acetylcholine (ACh) levels resulting from a loss of cholinergic neurons.  Preclinically, serotonin 4 receptor (5-HT4) agonists are reported to modulate cholinergic function and therefore may provide a new mechanistic approach for treating cognitive deficits assocd. with AD.  Herein the authors communicate the design and synthesis of potent, selective, and brain penetrant 5-HT4 agonists.  The overall goal of the medicinal chem. strategy was identification of structurally diverse clin. candidates with varying intrinsic activities.  The exposure-response relationships between binding affinity, intrinsic activity, receptor occupancy, drug exposure, and pharmacodynamic activity in relevant preclin. models of AD were utilized as key selection criteria for advancing compds.  On the basis of their excellent balance of pharmacokinetic attributes and safety, two lead 5-HT4 partial agonist candidates PF-04995274 and PF-03382792 were chosen for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqT9o-N9H9KbVg90H21EOLACvtfcHk0liPEWDtSoslPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGhsLzJ&md5=269b3b0ff783eafbaa8f45a90f320a46</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm300953p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300953p%26sid%3Dliteratum%253Aachs%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DD.%2BE.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DCoffman%26aufirst%3DK.%2BJ.%26aulast%3DDrummond%26aufirst%3DE.%2BM.%26aulast%3DHudson%26aufirst%3DE.%2BL.%26aulast%3DFisher%26aufirst%3DK.%2BE.%26aulast%3DNoguchi%26aufirst%3DH.%26aulast%3DWaizumi%26aufirst%3DN.%26aulast%3DMcDowell%26aufirst%3DL.%2BL.%26aulast%3DPapanikolaou%26aufirst%3DA.%26aulast%3DPettersen%26aufirst%3DB.%2BA.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DStutzman-Engwall%26aufirst%3DK.%26aulast%3DRubitski%26aufirst%3DD.%2BM.%26aulast%3DVanase-Frawley%26aufirst%3DM.%2BA.%26aulast%3DGrimwood%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520multiple%25205-HT4%2520partial%2520agonist%2520clinical%2520candidates%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9240%26epage%3D9254%26doi%3D10.1021%2Fjm300953p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptor agonists for the treatment of Alzheimer’s disease</span>. <i>Neurosci. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>02</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.4236/nm.2011.22013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.4236%2Fnm.2011.22013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=02&publication_year=2011&pages=87-92&author=I.+Ahmadauthor=R.+Nirogi&title=5-HT4+receptor+agonists+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.4236%2Fnm.2011.22013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptor agonists for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Ahmad, Ishtiyaque; Nirogi, Ramakrishna</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience & Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">NMEEBO</span>;
        ISSN:<span class="NLM_cas:issn">2158-2912</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a progressive neurol. disorder primarily affecting new memory formation as well as retrieval of previously acquired memories.  According to World Health Organization, current global population suffering from cognitive impairment is estd. to 37 million.  The no. is projected to double in next one and half decade.  Half of the population afflicted with dementia is represented by AD patients.  Current therapies, which provide marginal symptomatic relief to AD patients, are effective only in half of the patient population.  In depth understanding of the mol. mechanism of the disease is urgently required to develop more effective therapies.  Therapies in clin. development may either offer symptomatic relief to patients or provide pure disease modifications, thus limiting benefit to patients.  5-HT4 receptor agonists offer an attractive option for the treatment of AD patients.  Activation of 5-HT4 receptor under preclin. conditions is demonstrated to improve neurotransmission and enhance the release of acetylcholine resulting in the memory formation.  In various cell based and animal models, partial 5-HT4 receptor agonists are demonstrated to promote the release of sol. amyloid precursor protein alpha and block the release of amyloid beta peptide offering suitable candidates as disease modification agents.  Remarkably, 5-HT4 receptor agonists are also reported to induce neurogenesis in hippocampus as well as enteric system through the activation of cAMP response element binding protein in rodents.  Taken together, 5-HT4 agonists address all major facets of Alzheimer's disease and may provide therapeutic potential for other neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuyo7_gJ-VqrVg90H21EOLACvtfcHk0liPEWDtSoslPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht77M&md5=641e27dc6f84024df4874cbf50bb4598</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4236%2Fnm.2011.22013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fnm.2011.22013%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DNirogi%26aufirst%3DR.%26atitle%3D5-HT4%2520receptor%2520agonists%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Med.%26date%3D2011%26volume%3D02%26spage%3D87%26epage%3D92%26doi%3D10.4236%2Fnm.2011.22013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptor ligands: applications and new prospects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1021/jm020099f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020099f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1ejsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=319-344&author=M.+Langloisauthor=R.+Fischmeister&title=5-HT4+receptor+ligands%3A+applications+and+new+prospects&doi=10.1021%2Fjm020099f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 Receptor Ligands: Applications and New Prospects</span></div><div class="casAuthors">Langlois, Michel; Fischmeister, Rodolphe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-344</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The present paper describes the recent advances made in medicinal chem. and in the mechanisms proposed to explain the physiol. role of 5-HT4 receptors in the different tissues where they are present and the putative clin. applications of the agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0XyIrWuAGRLVg90H21EOLACvtfcHk0liPEWDtSoslPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1ejsg%253D%253D&md5=a812f9e611bcea02f0e819783fa2f1c9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm020099f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020099f%26sid%3Dliteratum%253Aachs%26aulast%3DLanglois%26aufirst%3DM.%26aulast%3DFischmeister%26aufirst%3DR.%26atitle%3D5-HT4%2520receptor%2520ligands%253A%2520applications%2520and%2520new%2520prospects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D319%26epage%3D344%26doi%3D10.1021%2Fjm020099f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modica, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittala, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siracusa, M. A.</span></span> <span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>3</sub> and 5-HT<sub>4</sub> ligands: an update of medicinal chemistry research in the past few years</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.2174/092986710790192730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.2174%2F092986710790192730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=20015043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=334-362&author=M.+N.+Modicaauthor=V.+Pittalaauthor=G.+Romeoauthor=L.+Salernoauthor=M.+A.+Siracusa&title=Serotonin+5-HT3+and+5-HT4+ligands%3A+an+update+of+medicinal+chemistry+research+in+the+past+few+years&doi=10.2174%2F092986710790192730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT3 and 5-HT4 ligands: an update of medicinal chemistry research in the last few years</span></div><div class="casAuthors">Modica, M. N.; Pittala, V.; Romeo, G.; Salerno, L.; Siracusa, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-362</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The biogenic amine serotonin (5-hydroxytryptamine, 5-HT) is one of the most studied neurotransmitters in the central nervous system.  It acts through the activation of at least fourteen 5-HT receptor subtypes.  Over the last two decades, high attention was devoted to the 5-HT3 and 5-HT4 receptors due to their colocalization in the gastrointestinal tract and because their ligands are useful in the treatment of intestinal serotonergic system dysfunctions.  The focus of this review is to discuss the literature concerning recent advances on 5-HT3R and 5-HT4R ligands and their structure-activity relationships from a medicinal chem. perspective.  During the last few years, new and significant progresses have been made in the field of novel potent and selective ligands, mixed ligands, agonists, partial agonists, and antagonists, and a no. of patents have been filed.  Furthermore several ligands targeting the 5-HT3R and 5-HT4R have been proposed for novel therapeutic indications such as the treatment of various psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdNfYoWkWpJbVg90H21EOLACvtfcHk0lhzDs2yhZGsKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSlsr0%253D&md5=7031f777b035675f1c562ec72c054f85</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F092986710790192730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710790192730%26sid%3Dliteratum%253Aachs%26aulast%3DModica%26aufirst%3DM.%2BN.%26aulast%3DPittala%26aufirst%3DV.%26aulast%3DRomeo%26aufirst%3DG.%26aulast%3DSalerno%26aufirst%3DL.%26aulast%3DSiracusa%26aufirst%3DM.%2BA.%26atitle%3DSerotonin%25205-HT3%2520and%25205-HT4%2520ligands%253A%2520an%2520update%2520of%2520medicinal%2520chemistry%2520research%2520in%2520the%2520past%2520few%2520years%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D334%26epage%3D362%26doi%3D10.2174%2F092986710790192730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castriconi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennuni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caselli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rienzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menziani, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbraccia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelli, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies in serotonin 5-HT<sub>4</sub> receptor ligands based on a benzo[<i>de</i>][2,6]naphthridine scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.ejmech.2014.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=24871995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCqurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=36-46&author=F.+Castriconiauthor=M.+Paolinoauthor=G.+Giulianiauthor=M.+Anziniauthor=G.+Campianiauthor=L.+Mennuniauthor=C.+Sabatiniauthor=M.+Lanzaauthor=G.+Caselliauthor=F.+De+Rienzoauthor=M.+C.+Menzianiauthor=M.+Sbracciaauthor=P.+Molinariauthor=T.+Costaauthor=A.+Cappelli&title=Synthesis+and+structure-activity+relationship+studies+in+serotonin+5-HT4+receptor+ligands+based+on+a+benzo%5Bde%5D%5B2%2C6%5Dnaphthridine+scaffold&doi=10.1016%2Fj.ejmech.2014.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthyridine scaffold</span></div><div class="casAuthors">Castriconi, Federica; Paolino, Marco; Giuliani, Germano; Anzini, Maurizio; Campiani, Giuseppe; Mennuni, Laura; Sabatini, Chiara; Lanza, Marco; Caselli, Gianfranco; De Rienzo, Francesca; Menziani, Maria Cristina; Sbraccia, Maria; Molinari, Paola; Costa, Tommaso; Cappelli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36-46</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A small series of serotonin 5-HT4 receptor ligands has been designed from flexible 2-methoxyquinoline compds. by applying the conformational constraint approach.  2-Methoxyquinoline compds., e.g., I, and the corresponding conformationally constrained analogs, e.g., II, were synthesized and their interactions with the 5-HT4 receptor were examd. by measuring both binding affinity and the ability to promote or inhibit receptor-G protein coupling.  Ester deriv. I and conformationally constrained compd. II were demonstrated to be the most interesting compds. showing a nanomolar 5-HT4R affinity similar to that shown by ref. ligands cisapride (III) and RS-23,597-190 (IV).  The result was rationalized by docking studies in term of high similarity in the binding modalities of flexible I and conformationally constrained II.  The intrinsic efficacy of some selected ligands was detd. by evaluating the receptor-G protein coupling and the results obtained demonstrated that the nature and the position of substituents play a crit. role in the interaction of these ligands with their receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr3OLUrCRSLVg90H21EOLACvtfcHk0lhzDs2yhZGsKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCqurfF&md5=f638b3b57a0130f99d4bd9095e53ce9e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DCastriconi%26aufirst%3DF.%26aulast%3DPaolino%26aufirst%3DM.%26aulast%3DGiuliani%26aufirst%3DG.%26aulast%3DAnzini%26aufirst%3DM.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DMennuni%26aufirst%3DL.%26aulast%3DSabatini%26aufirst%3DC.%26aulast%3DLanza%26aufirst%3DM.%26aulast%3DCaselli%26aufirst%3DG.%26aulast%3DDe%2BRienzo%26aufirst%3DF.%26aulast%3DMenziani%26aufirst%3DM.%2BC.%26aulast%3DSbraccia%26aufirst%3DM.%26aulast%3DMolinari%26aufirst%3DP.%26aulast%3DCosta%26aufirst%3DT.%26aulast%3DCappelli%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520in%2520serotonin%25205-HT4%2520receptor%2520ligands%2520based%2520on%2520a%2520benzo%255Bde%255D%255B2%252C6%255Dnaphthridine%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D82%26spage%3D36%26epage%3D46%26doi%3D10.1016%2Fj.ejmech.2014.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, J.P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medhurst, A.D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehmi, S.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calver, A.R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, A.D.</span></span> <span> </span><span class="NLM_article-title">Modulation of hippocampal excitability by 5-HT<sub>4</sub> receptor agonists persists in a transgenic model of Alzheimer’s disease</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2004.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.neuroscience.2004.06.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=15489027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1yktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2004&pages=49-54&author=J.P.+Spencerauthor=J.T.+Brownauthor=J.C.+Richardsonauthor=A.D.+Medhurstauthor=S.S.+Sehmiauthor=A.R.+Calverauthor=A.D.+Randall&title=Modulation+of+hippocampal+excitability+by+5-HT4+receptor+agonists+persists+in+a+transgenic+model+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neuroscience.2004.06.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease</span></div><div class="casAuthors">Spencer, J. P.; Brown, J. T.; Richardson, J. C.; Medhurst, A. D.; Sehmi, S. S.; Calver, A. R.; Randall, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-54</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">5-HT4 receptors are widely distributed in both peripheral and central nervous systems where they couple, via a G-protein, to the activation of adenylate cyclase.  In the brain, the highest 5-HT4 receptor densities are found in the limbic system, including the hippocampus and frontal cortex.  It has been suggested that activation of these receptors may be of therapeutic benefit in diseases that produce cognitive deficits such as Alzheimer's disease (AD).  Previous electrophysiol. studies have shown that the 5-HT4 agonist, Zacopride, can increase population spike amplitude recorded in region CA1 of rat hippocampal slices in a cAMP/cAMP-dependent protein kinase A-dependent manner.  The authors report here that the 5-HT4 agonist, prucalopride, and the 5-HT4 partial agonist, SL65.0155, produce a similar effect in rat hippocampal slices and that the specific 5-HT4 antagonist, GR113808, blocks these effects.  To investigate the potential use of 5-HT4 agonists in the treatment of AD, Prucalopride was applied to hippocampal slices from a transgenic mouse line that overexpresses the Aβ peptide.  Despite the deficit in synaptic transmission present in these mice, the percentage increase of the CA1 population spike induced by Prucalopride was the same as that obsd. in wild-type mice.  These data support 5-HT4 receptors as a target for cognitive enhancement and suggest that a partial agonist would be sufficient to produce benefits, while reducing potential peripheral side effects.  In addn., the authors show that 5-HT4 receptors remain functional in the presence of excess Aβ peptide and may therefore be a useful target in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM0T_aSjIK77Vg90H21EOLACvtfcHk0lhzDs2yhZGsKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1yktbo%253D&md5=5f313bb6ae0b51608fffea3c9c6d4eee</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2004.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2004.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DSpencer%26aufirst%3DJ.P.%26aulast%3DBrown%26aufirst%3DJ.T.%26aulast%3DRichardson%26aufirst%3DJ.C.%26aulast%3DMedhurst%26aufirst%3DA.D.%26aulast%3DSehmi%26aufirst%3DS.S.%26aulast%3DCalver%26aufirst%3DA.R.%26aulast%3DRandall%26aufirst%3DA.D.%26atitle%3DModulation%2520of%2520hippocampal%2520excitability%2520by%25205-HT4%2520receptor%2520agonists%2520persists%2520in%2520a%2520transgenic%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuroscience%26date%3D2004%26volume%3D129%26spage%3D49%26epage%3D54%26doi%3D10.1016%2Fj.neuroscience.2004.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span> </span><span class="NLM_article-title">EPIX Pharmaceuticals Reports Compelling
Clinical Results for PRX-03140
in Alzheimer's Disease</span>. <a href="https://www.fiercebiotech.com/biotech/press-release-epix-pharmaceuticals-reports-compelling-clinical-results-for-prx-03140" class="extLink">https://www.fiercebiotech.com/biotech/press-release-epix-pharmaceuticals-reports-compelling-clinical-results-for-prx-03140</a> (accessed 2021-04-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EPIX+Pharmaceuticals+Reports+Compelling%0AClinical+Results+for+PRX-03140%0Ain+Alzheimer%27s+Disease.+https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fpress-release-epix-pharmaceuticals-reports-compelling-clinical-results-for-prx-03140+%28accessed+2021-04-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEPIX%2520Pharmaceuticals%2520Reports%2520Compelling%250AClinical%2520Results%2520for%2520PRX-03140%250Ain%2520Alzheimer%2527s%2520Disease" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span> </span><span class="NLM_article-title">Therapeutics PRX-03140</span>. <a href="https://www.alzforum.org/therapeutics/prx-03140" class="extLink">https://www.alzforum.org/therapeutics/prx-03140</a> (accessed 2021-04-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Therapeutics+PRX-03140.+https%3A%2F%2Fwww.alzforum.org%2Ftherapeutics%2Fprx-03140+%28accessed+2021-04-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DTherapeutics%2520PRX-03140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti-Gauthier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumuis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumireu-Mourat, B.</span></span> <span> </span><span class="NLM_article-title">BIMU1 increases associative memory in rats by activating 5-HT<sub>4</sub> receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1016/S0028-3908(97)00058-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2FS0028-3908%2897%2900058-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=9225296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2sXktlSrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=697-706&author=E.+Marchetti-Gauthierauthor=F.+S.+Romanauthor=A.+Dumuisauthor=J.+Bockaertauthor=B.+Soumireu-Mourat&title=BIMU1+increases+associative+memory+in+rats+by+activating+5-HT4+receptors&doi=10.1016%2FS0028-3908%2897%2900058-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">BIMU1 increases associative memory in rats by activating 5-HT4 receptors</span></div><div class="casAuthors">Marchetti-Gauthier, E.; Roman, F. S.; Dumuis, A.; Bockaert, J.; Soumireu-Mourat, B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4/5</span>),
    <span class="NLM_cas:pages">697-706</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Olfactory assocn. learning was used to investigate the involvement of 5-HT4 receptors in learning and long-term memory.  The behavioral role of the 5-HT4 receptors was studied by using BIMU1 (3-ethyl-2,3-dihydro-N-[endo-8-methyl-8-azabicyclo(3.2.1)oct-3-yl]-2-oxo-1H-benzimidazole-1-carboxamide, hydrochloride (Boehringer Ingelheim, Italy)); a mixed 5-HT4 agonist/5-HT3 antagonist, and GR125487 (1-[2-[(Me sulfonyl)-amino]ethyl]-4-piperidinyl-Me 5-fluoro-2-methoxy-1H-indole-3-carboxylate; Glaxo Group Research, Hertfordshire, U.K.), a specific 5-HT4 antagonist.  The i.p. injections of BIMU1 at 1, 5, and 10 mg/kg were followed by an substantial improvement (>15% in percentage of correct responses at the dose of 10 mg/kg) in associative memory.  Difficulty rapidly reversing behavioral responses to previously learned assocn., 1 mo later indicated that the BIMU1 effect at 10 mg/kg was not transient, but correlated to long-term memory.  The effects of BIMU1 are most likely to be mediated by 5-HT4 receptors since they were blocked by GR125487 at 10 mg/kg.  These data suggest that activation of 5-HT4 receptors may modulate cognitive processes like learning and memory.  Also, 5-HT4 receptor agonists could be useful for treating mnesic deficits as displayed in patients with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzX-RtVuCgcbVg90H21EOLACvtfcHk0liJPhWmrWMAxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlSrtLc%253D&md5=c117d4166934db82f0295bc336555a12</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2897%2900058-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252897%252900058-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarchetti-Gauthier%26aufirst%3DE.%26aulast%3DRoman%26aufirst%3DF.%2BS.%26aulast%3DDumuis%26aufirst%3DA.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DSoumireu-Mourat%26aufirst%3DB.%26atitle%3DBIMU1%2520increases%2520associative%2520memory%2520in%2520rats%2520by%2520activating%25205-HT4%2520receptors%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D36%26spage%3D697%26epage%3D706%26doi%3D10.1016%2FS0028-3908%2897%2900058-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eglen, R.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonhaus, D.W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R.D.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of two novel and potent 5-HT<sub>4</sub> receptor agonists, RS 67333 and RS 67506, <i>in vitro</i> and <i>in vivo</i></span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1387</span>– <span class="NLM_lpage">1392</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1995.tb16628.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1111%2Fj.1476-5381.1995.tb16628.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=8564196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2MXns1Wgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1995&pages=1387-1392&author=R.M.+Eglenauthor=D.W.+Bonhausauthor=L.G.+Johnsonauthor=E.+Leungauthor=R.D.+Clark&title=Pharmacological+characterization+of+two+novel+and+potent+5-HT4+receptor+agonists%2C+RS+67333+and+RS+67506%2C+in+vitro+and+in+vivo&doi=10.1111%2Fj.1476-5381.1995.tb16628.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo</span></div><div class="casAuthors">Eglen, R. M.; Bonhaus, D. W.; Johnson, L. G.; Leung, E.; Clark, R. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1387-92</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Scientific & Medical Division</span>)
        </div><div class="casAbstract">The pharmacol. of two novel 5-HT4 receptor agonists, RS 67333 (1-(4-amino-5-chloro-2-methoxy phenyl)-3-[1(n-butyl)-4-piperidinyl]-1-propanone HCl) and RS 67506 (1-(4-amino-5-chloro-2-methoxy-phenyl)-3-[1-(2-Me sulfonylamino)ethyl-4-piperidinyl]-1-propanone HCl) have been assessed in vitro and in vivo.  RS 67333 and RS 67506 exhibited affinities (pKi = 8.7 and 8.8, resp.) for the 5-HT4 binding sites, labeled with [3H]-GR 113808, in guinea-pig striatum.  The Hill coeffs. from these displacement curves were not significantly different from unity.  The compds. exhibited lower affinities (<6.0) at several other receptors including 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2C, dopamine D1, D2 and muscarinic M1-M3 receptors.  However, RS 67333 and RS 67506 did exhibit affinities for the σ1 (pKi = 8.9 and 7.9, resp.) and σ2 (pKi = 8.0 and 7.3, resp.) binding sites.  At the 5-HT4 receptor mediating relaxation of the carbachol-precontracted esophagus, RS 67333 and RS 67506 acted as potent (pEC50 8.4 and 8.6, resp.) with respect to 5-HT.  Relaxant responses to RS 67333 or RS 67506 were surmountably antagonized by GR 113808 (10 nM), with apparent affinities (pKB) of 9.1 and 9.0, resp.  RS 67333 and RS 67506 induced dose-dependent increases in heart rate of the anesthetized micropig (ED50 4.9 and 5.4 μg kg-1, i.v.), with maximal increases of 35 and 47 beats min-1, resp.  RS 67333 and RS 67506, therefore, acted as potent, partial 5-HT4 receptor agonists in vitro and in vivo.  These compds., by virtue of their high potency and selectivity, may have some utility in elucidating the physiol. role of 5-HT4 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzNOdCScURALVg90H21EOLACvtfcHk0liJPhWmrWMAxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXns1Wgsrg%253D&md5=c35823f3865d177e00933fd35a779137</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1995.tb16628.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1995.tb16628.x%26sid%3Dliteratum%253Aachs%26aulast%3DEglen%26aufirst%3DR.M.%26aulast%3DBonhaus%26aufirst%3DD.W.%26aulast%3DJohnson%26aufirst%3DL.G.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DClark%26aufirst%3DR.D.%26atitle%3DPharmacological%2520characterization%2520of%2520two%2520novel%2520and%2520potent%25205-HT4%2520receptor%2520agonists%252C%2520RS%252067333%2520and%2520RS%252067506%252C%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D115%26spage%3D1387%26epage%3D1392%26doi%3D10.1111%2Fj.1476-5381.1995.tb16628.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moser, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergis, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lochead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duconseille, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terranova, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berque-Bestel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc'h, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumuis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scatton, B.</span></span> <span> </span><span class="NLM_article-title">SL65.0155, a novel 5-HT<sub>4</sub> receptor partial agonist with potent cognition-enhancing properties</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>302</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.034249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1124%2Fjpet.102.034249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=12130738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1OgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2002&pages=731-741&author=P.+C.+Moserauthor=O.+E.+Bergisauthor=S.+Jeghamauthor=A.+Locheadauthor=E.+Duconseilleauthor=J.-P.+Terranovaauthor=D.+Cailleauthor=I.+Berque-Bestelauthor=F.+Lezoualc%27hauthor=R.+Fischmeisterauthor=A.+Dumuisauthor=J.+Bockaertauthor=P.+Georgeauthor=P.+Soubrieauthor=B.+Scatton&title=SL65.0155%2C+a+novel+5-HT4+receptor+partial+agonist+with+potent+cognition-enhancing+properties&doi=10.1124%2Fjpet.102.034249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">SL65.0155, a novel 5-hydroxytryptamine4 receptor partial agonist with potent cognition-enhancing properties</span></div><div class="casAuthors">Moser, Paul C.; Bergis, Olivier E.; Jegham, Samir; Lochead, Alistair; Duconseille, Elee; Terranova, Jean-Paul; Caille, Dominique; Berque-Bestel, Isabelle; Lezoualc'h, Frank; Fischmeister, Rodolphe; Dumuis, Aline; Bockaert, Joel; George, Pascal; Soubrie, Philippe; Scatton, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">731-741</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">SL65.0155 [5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-[1-(2-phenylethyl)-4-piperidinyl]-1,3,4-oxadiazol-2(3H)-one monohydrochloride] is a novel benzodioxanoxadiazolone compd. with high affinity for human 5-hydroxytryptamine (5-HT)4 receptors (Ki of 0.6 nM) and good selectivity (greater than 100-fold for all other receptors tested).  In cells expressing the 5-HT4(b) and 5-HT4(e) splice variants, SL65.0155 acted as a partial agonist, stimulating cAMP prodn. with a maximal effect of 40 to 50% of serotonin.  However, in the rat esophagus prepn., SL65.0155 acted as a 5-HT4 antagonist with a pKb of 8.81.  In addn., SL65.0155 potently improved performance in several tests of learning and memory.  In the object recognition task, it improved retention at 24 h when administered i.p. or p.o. (0.001-0.1 mg/kg).  This effect was antagonized by the 5-HT4 antagonist SDZ 205,557, itself without effect, demonstrating that the promnesic effects of SL65.0155 are mediated by 5-HT4 agonism.  SL65.0155 also reversed the cognitive deficits of aged rats in the linear maze task and the scopolamine-induced deficit of mice in the water maze task.  Furthermore, the combined administration of an inactive dose of SL65.0155 with the cholinesterase inhibitor rivastigmine resulted in a significant promnesic effect, suggesting a synergistic interaction.  SL65.0155 was devoid of unwanted cardiovascular, gastrointestinal, or central nervous system effects with doses up to more than 100-fold higher than those active in the cognitive tests.  These results characterize SL65.0155 as a novel promnesic agent acting via 5-HT4 receptors, with an excellent preclin. profile.  Its broad range of activity in cognitive tests and synergism with cholinesterase inhibitors suggest that SL65.0155 represents a promising new agent for the treatment of dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Fd4FHsnTBrVg90H21EOLACvtfcHk0lg0ccTjuBGEPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1OgtLs%253D&md5=fdb2129c26cd2aa9bbc0ef4d63fbec1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.034249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.034249%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DP.%2BC.%26aulast%3DBergis%26aufirst%3DO.%2BE.%26aulast%3DJegham%26aufirst%3DS.%26aulast%3DLochead%26aufirst%3DA.%26aulast%3DDuconseille%26aufirst%3DE.%26aulast%3DTerranova%26aufirst%3DJ.-P.%26aulast%3DCaille%26aufirst%3DD.%26aulast%3DBerque-Bestel%26aufirst%3DI.%26aulast%3DLezoualc%2527h%26aufirst%3DF.%26aulast%3DFischmeister%26aufirst%3DR.%26aulast%3DDumuis%26aufirst%3DA.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DScatton%26aufirst%3DB.%26atitle%3DSL65.0155%252C%2520a%2520novel%25205-HT4%2520receptor%2520partial%2520agonist%2520with%2520potent%2520cognition-enhancing%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D302%26spage%3D731%26epage%3D741%26doi%3D10.1124%2Fjpet.102.034249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagginapalli, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravella, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kota, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, V. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of imidazo[1,5-<i>a</i>]pyridine derivatives as 5-HT<sub>4</sub> receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.08.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.ejmech.2015.08.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=26363507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2nsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2015&pages=289-301&author=R.+Nirogiauthor=A.+R.+Mohammedauthor=A.+K.+Shindeauthor=N.+Bogarajuauthor=S.+R.+Gagginapalliauthor=S.+R.+Ravellaauthor=L.+Kotaauthor=G.+Bhyrapuneniauthor=N.+R.+Muddanaauthor=V.+Benadeauthor=R.+C.+Palacharlaauthor=P.+Jayarajanauthor=R.+Subramanianauthor=V.+K.+Goyal&title=Synthesis+and+SAR+of+imidazo%5B1%2C5-a%5Dpyridine+derivatives+as+5-HT4+receptor+partial+agonists+for+the+treatment+of+cognitive+disorders+associated+with+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2015.08.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease</span></div><div class="casAuthors">Nirogi, Ramakrishna; Mohammed, Abdul Rasheed; Shinde, Anil K.; Bogaraju, Narsimha; Gagginapalli, Shankar Reddy; Ravella, Srinivasa Rao; Kota, Laxman; Bhyrapuneni, Gopinadh; Muddana, Nageswara Rao; Benade, Vijay; Palacharla, Raghava Chowdary; Jayarajan, Pradeep; Subramanian, Ramkumar; Goyal, Vinod Kumar</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289-301</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disease which has a higher prevalence and incidence in older people.  The need for improved AD therapies is unmet.  The 5-hydroxytryptamine4 receptor (5-HT4R) partial agonists may be of benefit for both the symptomatic and disease-modifying treatment of cognitive disorders assocd. with AD.  Herein, we report the design, synthesis and SAR of imidazo[1,5-a] pyridine derivs. as 5-HT4R partial agonists.  The focused SAR, optimization of ADME properties resulted the discovery of compd. I as potent, selective, brain penetrant 5-HT4 partial agonist as a lead compd. with good ADME properties and efficacy in both symptomatic and disease modifying animal models of cognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy8ulfS2opHrVg90H21EOLACvtfcHk0ljnJIlmr5Klxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2nsrzO&md5=5d43819ce00762e923aee113fb2721f4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.08.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.08.051%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DShinde%26aufirst%3DA.%2BK.%26aulast%3DBogaraju%26aufirst%3DN.%26aulast%3DGagginapalli%26aufirst%3DS.%2BR.%26aulast%3DRavella%26aufirst%3DS.%2BR.%26aulast%3DKota%26aufirst%3DL.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DMuddana%26aufirst%3DN.%2BR.%26aulast%3DBenade%26aufirst%3DV.%26aulast%3DPalacharla%26aufirst%3DR.%2BC.%26aulast%3DJayarajan%26aufirst%3DP.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DGoyal%26aufirst%3DV.%2BK.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520imidazo%255B1%252C5-a%255Dpyridine%2520derivatives%2520as%25205-HT4%2520receptor%2520partial%2520agonists%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%2520associated%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D103%26spage%3D289%26epage%3D301%26doi%3D10.1016%2Fj.ejmech.2015.08.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiriveedhi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kota, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badange, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R.</span></span> <span> </span><span class="NLM_article-title">Benzamide derivatives and their constrained analogs as histamine H<sub>3</sub> receptor antagonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.ejmech.2015.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=26731168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFaj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=655-662&author=R.+Nirogiauthor=A.+Shindeauthor=V.+K.+Tiriveedhiauthor=L.+Kotaauthor=S.+K.+Sarafauthor=R.+K.+Badangeauthor=A.+R.+Mohammedauthor=R.+Subramanianauthor=N.+R.+Muddanaauthor=G.+Bhyrapuneniauthor=R.+Abraham&title=Benzamide+derivatives+and+their+constrained+analogs+as+histamine+H3+receptor+antagonists&doi=10.1016%2Fj.ejmech.2015.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists</span></div><div class="casAuthors">Nirogi, Ramakrishna; Shinde, Anil; Tiriveedhi, Vinaykumar; Kota, Laxman; Saraf, Sangram Keshari; Badange, Rajesh Kumar; Mohammed, Abdul Rasheed; Subramanian, Ramkumar; Muddana, Nageshwararao; Bhyrapuneni, Gopinadh; Abraham, Renny</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of substituted [(4-piperidinyl)oxy]benzamides and substituted [(4-piperidinyl)oxy]-3,4-dihydro-2H-isoquinolin-1-one derivs. have been synthesized and tested for their binding affinity towards H3 receptor.  Most of these synthesized compds. have displayed potent binding affinity for H3 receptor when tested in in vitro binding assay.  Preliminary SAR studies, functional activity, pharmacokinetic profile and efficacy profile constitute the subject matter of this communication.  The synthesis of the target compds. was achieved using 4-[(4-piperidinyl)oxy]benzoic acid derivs. as intermediates.  Corresponding amide analogs included 1-isoquinolinone derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBGI2izDp8FLVg90H21EOLACvtfcHk0ljnJIlmr5Klxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFaj&md5=9d5fe398cfdaab5d6568cebb6aad27fc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DShinde%26aufirst%3DA.%26aulast%3DTiriveedhi%26aufirst%3DV.%2BK.%26aulast%3DKota%26aufirst%3DL.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26aulast%3DBadange%26aufirst%3DR.%2BK.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DMuddana%26aufirst%3DN.%2BR.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DAbraham%26aufirst%3DR.%26atitle%3DBenzamide%2520derivatives%2520and%2520their%2520constrained%2520analogs%2520as%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D655%26epage%3D662%26doi%3D10.1016%2Fj.ejmech.2015.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambhampati, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badange, R. k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyala, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reballi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasti, V.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylatemonohydrate (SUVN-502): a novel, potent, selective and orally active serotonin 6 (5-HT<sub>6</sub>) receptor antagonist for potential treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1859</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01662</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01662" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislyqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1843-1859&author=R.+Nirogiauthor=A.+Shindeauthor=R.+S.+Kambhampatiauthor=A.+R.+Mohammedauthor=S.+K.+Sarafauthor=R.+k.+Badangeauthor=T.+R.+Bandyalaauthor=V.+Bhattaauthor=K.+Bojjaauthor=V.+Reballiauthor=R.+Subramanianauthor=V.+Benadeauthor=R.+C.+Palacharlaauthor=G.+Bhyrapuneniauthor=P.+Jayarajanauthor=V.+Goyalauthor=V.+Jasti&title=Discovery+and+development+of+1-%5B%282-bromophenyl%29sulfonyl%5D-5-methoxy-3-%5B%284-methyl-1-piperazinyl%29methyl%5D-1H-indole+dimesylatemonohydrate+%28SUVN-502%29%3A+a+novel%2C+potent%2C+selective+and+orally+active+serotonin+6+%285-HT6%29+receptor+antagonist+for+potential+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.6b01662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Nirogi, Ramakrishna; Shinde, Anil; Kambhampati, Rama Sastry; Mohammed, Abdul Rasheed; Saraf, Sangram Keshari; Badange, Rajesh kumar; Bandyala, Thrinath Reddy; Bhatta, Venugopalarao; Bojja, Kumar; Reballi, Veena; Subramanian, Ramkumar; Benade, Vijay; Palacharla, Raghava Choudary; Bhyrapuneni, Gopinadh; Jayarajan, Pradeep; Goyal, Vinod; Jasti, Venkat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1843-1859</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of a novel series of 3-(piperazinylmethyl) indole derivs. as 5-hydroxytryptamine-6 receptor (5-HT6R) antagonists resulted in identification of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (5al, SUVN-502) as a clin. candidate for potential treatment of cognitive disorders.  It has high affinity at human 5-HT6R (Ki = 2.04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunol. factors, second messengers, and prostaglandins.  It has high selectivity over 5-HT2A receptor.  It is orally bioavailable and brain penetrant with robust preclin. efficacy.  The combination of 5al, donepezil, and memantine (triple combination) produces synergistic effects in extracellular levels of acetylcholine in the ventral hippocampus.  Preclin. efficacy in triple combination and high selectivity over 5-HT2A receptors are the differentiating features which culminated in selection of 5al for further development.  The Phase-1 evaluation of safety and pharmacokinetics has been completed, allowing for the initiation of a Phase-2 proof of concept study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_gw476vRgPbVg90H21EOLACvtfcHk0liVVztlqsf5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislyqsLk%253D&md5=26e4f0c1c34255ce2c2ef3bbf3c06a85</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01662%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DShinde%26aufirst%3DA.%26aulast%3DKambhampati%26aufirst%3DR.%2BS.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26aulast%3DBadange%26aufirst%3DR.%2Bk.%26aulast%3DBandyala%26aufirst%3DT.%2BR.%26aulast%3DBhatta%26aufirst%3DV.%26aulast%3DBojja%26aufirst%3DK.%26aulast%3DReballi%26aufirst%3DV.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DBenade%26aufirst%3DV.%26aulast%3DPalacharla%26aufirst%3DR.%2BC.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DJayarajan%26aufirst%3DP.%26aulast%3DGoyal%26aufirst%3DV.%26aulast%3DJasti%26aufirst%3DV.%26atitle%3DDiscovery%2520and%2520development%2520of%25201-%255B%25282-bromophenyl%2529sulfonyl%255D-5-methoxy-3-%255B%25284-methyl-1-piperazinyl%2529methyl%255D-1H-indole%2520dimesylatemonohydrate%2520%2528SUVN-502%2529%253A%2520a%2520novel%252C%2520potent%252C%2520selective%2520and%2520orally%2520active%2520serotonin%25206%2520%25285-HT6%2529%2520receptor%2520antagonist%2520for%2520potential%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1843%26epage%3D1859%26doi%3D10.1021%2Facs.jmedchem.6b01662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagginapally, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kancharla, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middekadi, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravella, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birangal, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarajan, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure–activity relationships, and preclinical evaluation of heteroaromatic amides and 1,3,4-oxadiazole derivatives as 5-HT<sub>4</sub> receptor partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4993</span>– <span class="NLM_lpage">5008</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00457</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00457" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVChsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4993-5008&author=R.+K.+Nirogiauthor=A.+R.+Mohammedauthor=A.+Shindeauthor=S.+R.+Gagginapallyauthor=D.+M.+Kancharlaauthor=V.+R.+Middekadiauthor=N.+Bogarajuauthor=S.+R.+Ravellaauthor=P.+Singhauthor=S.+R.+Birangalauthor=R.+Subramanianauthor=R.+C.+Palacharlaauthor=V.+Benadeauthor=N.+Muddanaauthor=P.+Jayarajan&title=Synthesis%2C+structure%E2%80%93activity+relationships%2C+and+preclinical+evaluation+of+heteroaromatic+amides+and+1%2C3%2C4-oxadiazole+derivatives+as+5-HT4+receptor+partial+agonists&doi=10.1021%2Facs.jmedchem.8b00457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists</span></div><div class="casAuthors">Nirogi, Ramakrishna; Mohammed, Abdul Rasheed; Shinde, Anil K.; Gagginapally, Shankar Reddy; Kancharla, Durga Malleshwari; Middekadi, Vanaja Reddy; Bogaraju, Narsimha; Ravella, Srinivasa Rao; Singh, Pooja; Birangal, Sumit Raosaheb; Subramanian, Ramkumar; Palacharla, Raghava Choudary; Benade, Vijay; Muddana, Nageswararao; Jayarajan, Pradeep</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4993-5008</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disorder that has a higher prevalence and incidence in people older than 60 years.  The need for improved AD therapies is unmet as the current therapies are symptomatic with modest efficacy.  Partial agonists of the 5-HT4 receptor (5-HT4R) offer both symptomatic and disease-modifying treatments as they shift amyloid-precursor-protein (APP) processing from the amyloidogenic pathway to the nonamyloidogenic pathway by activating the α-secretase enzyme.  In addn., they also offer symptomatic treatment by increasing levels of the neurotransmitter acetylcholine in the brain.  Because of this fascinating dual mechanism of action, several chem. scaffolds having 5-HT4R pharmacophores were designed and evaluated.  Most of the synthesized compds. showed potent in vitro affinities and in vivo efficacies.  Upon anal. of focused structure-activity relationships, compd. 4o was identified as a potent 5-HT4R partial agonist with favorable ADME properties and good in vivo efficacy.  GR-125487, a selective 5-HT4R antagonist, attenuated the activity of compd. 4o in the novel-object-recognition-test cognition model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk2z2YiR_ja7Vg90H21EOLACvtfcHk0liVVztlqsf5Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVChsLk%253D&md5=b8bacee142c07a4dbb433e95b86b1d07</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00457%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%2BK.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DShinde%26aufirst%3DA.%26aulast%3DGagginapally%26aufirst%3DS.%2BR.%26aulast%3DKancharla%26aufirst%3DD.%2BM.%26aulast%3DMiddekadi%26aufirst%3DV.%2BR.%26aulast%3DBogaraju%26aufirst%3DN.%26aulast%3DRavella%26aufirst%3DS.%2BR.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DBirangal%26aufirst%3DS.%2BR.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DPalacharla%26aufirst%3DR.%2BC.%26aulast%3DBenade%26aufirst%3DV.%26aulast%3DMuddana%26aufirst%3DN.%26aulast%3DJayarajan%26aufirst%3DP.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520preclinical%2520evaluation%2520of%2520heteroaromatic%2520amides%2520and%25201%252C3%252C4-oxadiazole%2520derivatives%2520as%25205-HT4%2520receptor%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4993%26epage%3D5008%26doi%3D10.1021%2Facs.jmedchem.8b00457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furlotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alisi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apicella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capezzone de Joannon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzolla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuzzucoli Crucitti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ombrato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pescatori, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polenzani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitiello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Santo, R.</span></span> <span> </span><span class="NLM_article-title">Discovery and pharmacological Profile of New 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-<i>c</i>]quinoline derivatives as selective serotonin-4 receptor ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9446</span>– <span class="NLM_lpage">9466</span>, <span class="refDoi"> DOI: 10.1021/jm300573d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300573d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOhs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9446-9466&author=G.+Furlottiauthor=M.+A.+Alisiauthor=C.+Apicellaauthor=A.+Capezzone+de+Joannonauthor=N.+Cazzollaauthor=R.+Costiauthor=G.+Cuzzucoli+Crucittiauthor=B.+Garroneauthor=A.+Iacovoauthor=G.+Magaroauthor=G.+Manganoauthor=G.+Mieleauthor=R.+Ombratoauthor=L.+Pescatoriauthor=L.+Polenzaniauthor=F.+Rosiauthor=M.+Vitielloauthor=R.+Di+Santo&title=Discovery+and+pharmacological+Profile+of+New+1H-indazole-3-carboxamide+and+2H-pyrrolo%5B3%2C4-c%5Dquinoline+derivatives+as+selective+serotonin-4+receptor+ligands&doi=10.1021%2Fjm300573d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Profile of New 1H-Indazole-3-carboxamide and 2H-Pyrrolo[3,4-c]quinoline Derivatives as Selective Serotonin 4 Receptor Ligands</span></div><div class="casAuthors">Furlotti, Guido; Alisi, Maria Alessandra; Apicella, Claudia; Capezzone de Joannon, Alessandra; Cazzolla, Nicola; Costi, Roberta; Cuzzucoli Crucitti, Giuliana; Garrone, Beatrice; Iacovo, Alberto; Magaro, Gabriele; Mangano, Giorgina; Miele, Gaetano; Ombrato, Rosella; Pescatori, Luca; Polenzani, Lorenzo; Rosi, Federica; Vitiello, Marco; Di Santo, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9446-9466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the discovery of the serotonin 4 receptor (5-HT4R), a large no. of receptor ligands have been studied.  The safety concerns and the lack of market success of these ligands have mainly been attributed to their lack of selectivity.  In this study we describe the discovery of N-[(4-piperidinyl)methyl]-1H-indazole-3-carboxamide and 4-[(4-piperidinyl)methoxy]-2H-pyrrolo[3,4-c]quinoline derivs. as new 5-HT4R ligands endowed with high selectivity over the serotonin 2A receptor and human ether-a-go-go-related gene potassium ion channel.  Within these series, two mols. (I and II) were identified as potent and selective 5-HT4R antagonists with good in vitro pharmacokinetic properties.  These compds. were evaluated for their antinociceptive action in two analgesia animal models; II showed a significant antinociceptive effect in both models and is proposed as an interesting lead compd. as a 5-HT4R antagonist with analgesic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnC05jFTxZArVg90H21EOLACvtfcHk0lip5z8Xl4YDNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOhs7jO&md5=120ddc3595ab221fa97fc1c5da5eccaf</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300573d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300573d%26sid%3Dliteratum%253Aachs%26aulast%3DFurlotti%26aufirst%3DG.%26aulast%3DAlisi%26aufirst%3DM.%2BA.%26aulast%3DApicella%26aufirst%3DC.%26aulast%3DCapezzone%2Bde%2BJoannon%26aufirst%3DA.%26aulast%3DCazzolla%26aufirst%3DN.%26aulast%3DCosti%26aufirst%3DR.%26aulast%3DCuzzucoli%2BCrucitti%26aufirst%3DG.%26aulast%3DGarrone%26aufirst%3DB.%26aulast%3DIacovo%26aufirst%3DA.%26aulast%3DMagaro%26aufirst%3DG.%26aulast%3DMangano%26aufirst%3DG.%26aulast%3DMiele%26aufirst%3DG.%26aulast%3DOmbrato%26aufirst%3DR.%26aulast%3DPescatori%26aufirst%3DL.%26aulast%3DPolenzani%26aufirst%3DL.%26aulast%3DRosi%26aufirst%3DF.%26aulast%3DVitiello%26aufirst%3DM.%26aulast%3DDi%2BSanto%26aufirst%3DR.%26atitle%3DDiscovery%2520and%2520pharmacological%2520Profile%2520of%2520New%25201H-indazole-3-carboxamide%2520and%25202H-pyrrolo%255B3%252C4-c%255Dquinoline%2520derivatives%2520as%2520selective%2520serotonin-4%2520receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9446%26epage%3D9466%26doi%3D10.1021%2Fjm300573d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulier, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicsic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathé-Allainmat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brémont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardamone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aureggi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, M.</span></span> <span> </span><span class="NLM_article-title">New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT<sub>4</sub> receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1021/jm960320m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960320m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVSktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=608-621&author=D.+Yangauthor=J.+L.+Soulierauthor=S.+Sicsicauthor=M.+Math%C3%A9-Allainmatauthor=B.+Br%C3%A9montauthor=T.+Crociauthor=R.+Cardamoneauthor=G.+Aureggiauthor=M.+Langlois&title=New+esters+of+4-amino-5-chloro-2-methoxybenzoic+acid+as+potent+agonists+and+antagonists+for+5-HT4+receptors&doi=10.1021%2Fjm960320m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">New Esters of 4-Amino-5-chloro-2-methoxybenzoic Acid as Potent Agonists and Antagonists for 5-HT4 Receptors</span></div><div class="casAuthors">Yang, Donglai; Soulier, Jean-Louis; Sicsic, Sames; Mathe-Allainmat, Monique; Bremont, Beatrice; Croci, Tiziano; Cardamone, Rosanna; Aureggi, Giulio; Langlois, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">608-621</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A no. of benzoates derived from 4-amino-5-chloro-2-methoxybenzoic acid and substituted 1-piperidineethanol were prepd. and found to be potent 5-HT4 receptor agonists in the elec.-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum and the rat esophagus muscle.  Monosubstitution of the piperidine ring with Me, OH, NH-Ac, or CONH2 groups gave compds. equipotent to 2-piperidinoethyl-4-amino-2-methoxybenzoate-HCl (I) (ML 10302), a 5-HT4 receptor agonist previously reported to have nanomolar affinity.  I and 2-(3-(S)-hydroxypiperidino)ethyl-4-amino-2-methoxybenzoate-HCl (II) were as potent as serotonin (5-HT) but had maximal responses which were only 60-80% of that of 5-HT, suggesting a partial agonist profile for these compds.  Binding assays were performed with [3H]GR 113808 in the rat striatum, and several of these compds. were found to have nanomolar affinity for 5-HT4 receptors (I, Ki = 1.07; II, Ki = 1.0 nM).  The introduction of 2 Me groups on the piperidine ring brought about a dramatic change in the pharmacol. profile of 2-[(cis- and trans-3,5-dimethylpiperidinyl)ethyl]-4-amino-5-chloro-2-methoxybenzoate (III-cis isomer).  III (Ki = 0.26 nM) inhibited the relaxant action of 5-HT in the rat esophagus muscle with a pA2 value of 8.6.  The advantage of the ester function was demonstrated by comparing the activity of several such compds. at 5-HT4 receptors with those of the corresponding amide derivs.  This difference was less marked when the basic moiety was sterically constrained as in the quinuclidine and tropane moieties.  Structural analyses of I and III were performed by detg. their X-ray crystal structures and by mol. modeling (SYBYL).  A relatively limited no. of min. energy conformers was found for both compds.  They were characterized by the cis folded conformation of the Et chain and by the orientation of the lone pair of the nitrogen atom pointing out of the mol. as seen in conformationally-constrained benzamides such as zacopride and renzapride.  A hypothetical model for the 5-HT4 receptor with 2 sites for the binding of agonist and antagonist mols. was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-i-Mdpx5yirVg90H21EOLACvtfcHk0lip5z8Xl4YDNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVSktb4%253D&md5=9a560dbfd938b39801cea1109316f80c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm960320m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960320m%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DD.%26aulast%3DSoulier%26aufirst%3DJ.%2BL.%26aulast%3DSicsic%26aufirst%3DS.%26aulast%3DMath%25C3%25A9-Allainmat%26aufirst%3DM.%26aulast%3DBr%25C3%25A9mont%26aufirst%3DB.%26aulast%3DCroci%26aufirst%3DT.%26aulast%3DCardamone%26aufirst%3DR.%26aulast%3DAureggi%26aufirst%3DG.%26aulast%3DLanglois%26aufirst%3DM.%26atitle%3DNew%2520esters%2520of%25204-amino-5-chloro-2-methoxybenzoic%2520acid%2520as%2520potent%2520agonists%2520and%2520antagonists%2520for%25205-HT4%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D608%26epage%3D621%26doi%3D10.1021%2Fjm960320m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecoutey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochais, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic modulators of the serotonin 5-HT <sub>4</sub> receptor: a patent review (2014-present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1080/13543776.2020.1767587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1080%2F13543776.2020.1767587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=32400221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSgsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=495-508&author=C.+Lanthierauthor=P.+Dallemagneauthor=C.+Lecouteyauthor=S.+Claeysenauthor=C.+Rochais&title=Therapeutic+modulators+of+the+serotonin+5-HT+4+receptor%3A+a+patent+review+%282014-present%29&doi=10.1080%2F13543776.2020.1767587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present)</span></div><div class="casAuthors">Lanthier, Caroline; Dallemagne, Patrick; Lecoutey, Cedric; Claeysen, Sylvie; Rochais, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">495-508</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A Review.  IntroductionNumerous chemotypes have been described over time in order to generate potent and selective 5-HT4R ligands.  Both agonists and antagonists have demonstrated their interest in several disease models.  This culminates with the FDA approval of tegaserod and prucalopride in the recent years.  Areas coveredThis review summarizes the patent applications from 2014 to present, dedicated to the use or the description of novel 5-HT4R modulators.  Several novel ligands and scaffolds have been industrially protected mainly in the field of central nervous system (CNS) pathologies as well as gastrointestinal disorders, including the combination with other drugs or for veterinary uses.  Expert opinionThe therapeutic potential of 5-HT4R modulators has been explored for several years in animal models, but also linked to potential safety issues with initial ligands.  The current use of prucalopride in humans demonstrates that its toxicity is not linked to the target and that 5-HT4R modulators are safe in humans.  Therefore, an important no. of studies and patents has continued in the recent years to expand the use of 5-HT4R modulators, not only to treat gastrointestinal disorders, but also for CNS pathologies.  This article details current efforts in this development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Q6zEPQKyZrVg90H21EOLACvtfcHk0lhuZE6h7N6lmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSgsLbM&md5=c9d6fa1474a9f3242dc0b029b3d2cf05</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1080%2F13543776.2020.1767587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2020.1767587%26sid%3Dliteratum%253Aachs%26aulast%3DLanthier%26aufirst%3DC.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DLecoutey%26aufirst%3DC.%26aulast%3DClaeysen%26aufirst%3DS.%26aulast%3DRochais%26aufirst%3DC.%26atitle%3DTherapeutic%2520modulators%2520of%2520the%2520serotonin%25205-HT%25204%2520receptor%253A%2520a%2520patent%2520review%2520%25282014-present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D495%26epage%3D508%26doi%3D10.1080%2F13543776.2020.1767587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span>; <span class="NLM_string-name">Mohammed, A. R.</span>; <span class="NLM_string-name">Yarlagadda, S.</span>; <span class="NLM_string-name">Ravella, S. R.</span>; <span class="NLM_string-name">Shinde, A. K.</span>; <span class="NLM_string-name">Kambhampati, R.</span>; <span class="NLM_string-name">Royapalley, P. K.</span>; <span class="NLM_string-name">Jayarajan, P.</span>; <span class="NLM_string-name">Bhyrapuneni, G.</span>; <span class="NLM_string-name">Patnala, S. M.</span>; <span class="NLM_string-name">Ravula, J.</span>; <span class="NLM_string-name">Jasti, V.</span></span> <span> </span><span class="NLM_article-title">Heteroaryl compounds as 5-HT<sub>4</sub> receptor ligands</span>. WIPO patent <span class="NLM_patent">WO2013042135A1</span>, March 28, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Nirogi&author=A.+R.+Mohammed&author=S.+Yarlagadda&author=S.+R.+Ravella&author=A.+K.+Shinde&author=R.+Kambhampati&author=P.+K.+Royapalley&author=P.+Jayarajan&author=G.+Bhyrapuneni&author=S.+M.+Patnala&author=J.+Ravula&author=V.+Jasti&title=Heteroaryl+compounds+as+5-HT4+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26atitle%3DHeteroaryl%2520compounds%2520as%25205-HT4%2520receptor%2520ligands%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span>; <span class="NLM_string-name">Shinde, A. K.</span>; <span class="NLM_string-name">Mohammed, A. R.</span>; <span class="NLM_string-name">Saraf, S. K.</span>; <span class="NLM_string-name">Bogaraju, N.</span>; <span class="NLM_string-name">Subramanian, R.</span>; <span class="NLM_string-name">Jayarajan, P.</span>; <span class="NLM_string-name">Bhyrapuneni, G.</span>; <span class="NLM_string-name">Jasti, V.</span></span> <span> </span><span class="NLM_article-title">Amide compounds as 5-HT<sub>4</sub> receptor agonists</span>. WIPO patent <span class="NLM_patent">WO2016128990A1</span>, Aug 18, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+Nirogi&author=A.+K.+Shinde&author=A.+R.+Mohammed&author=S.+K.+Saraf&author=N.+Bogaraju&author=R.+Subramanian&author=P.+Jayarajan&author=G.+Bhyrapuneni&author=V.+Jasti&title=Amide+compounds+as+5-HT4+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26atitle%3DAmide%2520compounds%2520as%25205-HT4%2520receptor%2520agonists%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0liH2Qtu-wrmpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span> <span> </span><span class="NLM_article-title">Oxadiazoles in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1817</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1021/jm2013248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1817-1830&author=J.+Bostromauthor=A.+Hognerauthor=A.+Llinasauthor=E.+Wellnerauthor=A.+T.+Plowright&title=Oxadiazoles+in+medicinal+chemistry&doi=10.1021%2Fjm2013248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Oxadiazoles in medicinal chemistry</span></div><div class="casAuthors">Bostrom Jonas; Hogner Anders; Llinas Antonio; Wellner Eric; Plowright Alleyn T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1817-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms.  Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities.  The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection.  In virtually all cases, the 1,3,4-oxadiazole isomer shows an order of magnitude lower lipophilicity (log D), as compared to its isomeric partner.  Significant differences are also observed with respect to metabolic stability, hERG inhibition, and aqueous solubility, favoring the 1,3,4-oxadiazole isomers.  The difference in profile between the 1,2,4 and 1,3,4 regioisomers can be rationalized by their intrinsically different charge distributions (e.g., dipole moments).  To facilitate the use of these heteroaromatic rings, novel synthetic routes for ready access of a broad spectrum of 1,3,4-oxadiazoles, under mild conditions, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO9RQiG9xFS2Zyxfu64m4ffW6udTcc2eZEzOAhpFMdSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D&md5=b934995431ced1be297e6f126262f3cb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm2013248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013248%26sid%3Dliteratum%253Aachs%26aulast%3DBostrom%26aufirst%3DJ.%26aulast%3DHogner%26aufirst%3DA.%26aulast%3DLlinas%26aufirst%3DA.%26aulast%3DWellner%26aufirst%3DE.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26atitle%3DOxadiazoles%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1817%26epage%3D1830%26doi%3D10.1021%2Fjm2013248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drici, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barhanin, J.</span></span> <span> </span><span class="NLM_article-title">Cardiac K+ channels and drug-acquired long QT syndrome</span>. <i>Therapie</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10860023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A280%3ADC%252BD3czhslKjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2000&pages=185-193&author=M.+D.+Driciauthor=J.+Barhanin&title=Cardiac+K%2B+channels+and+drug-acquired+long+QT+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac K+ channels and drug-acquired long QT syndrome</span></div><div class="casAuthors">Drici M D; Barhanin J</div><div class="citationInfo"><span class="NLM_cas:title">Therapie</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-93</span>
        ISSN:<span class="NLM_cas:issn">0040-5957</span>.
    </div><div class="casAbstract">The hallmark of long QT syndromes (LQTS) is an abnormal ventricular repolarization characterized by a prolonged QT interval on the electrocardiogram and a propensity to the occurrence of syncopes resulting from polymorphic ventricular tachycardia, called torsades de pointes.  They may degenerate to ventricular fibrillation, possibly causing sudden death.  Congenital LQTS, which implicates at least six chromosomal loci, LQT1 to LQT6, three of them corresponding to mutations concerning the coding of K+ channel proteins, give useful information about the mechanism underlying the arrhythmia.  One of the potassium channel genes implicated in congenital LQTS is HERG, which encodes the IKr current channel protein.  This current has provided a relevant insight into the occurrence of drug-acquired LQTS, since all drugs associated with torsades, such as erythromycin, terfenadine, haloperidol, or cisapride, also block IKr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpCXQeHUzr0-Q4Pl9hzjQhfW6udTcc2eZEzOAhpFMdSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3czhslKjtg%253D%253D&md5=8acf3350d6b38147e71426f03e20a7dd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrici%26aufirst%3DM.%2BD.%26aulast%3DBarhanin%26aufirst%3DJ.%26atitle%3DCardiac%2520K%252B%2520channels%2520and%2520drug-acquired%2520long%2520QT%2520syndrome%26jtitle%3DTherapie%26date%3D2000%26volume%3D55%26spage%3D185%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rampe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. M.</span></span> <span> </span><span class="NLM_article-title">A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel hERG</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(97)01249-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2FS0014-5793%2897%2901249-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=9395068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2sXntVOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=1997&pages=28-32&author=D.+Rampeauthor=M.+L.+Royauthor=A.+Dennisauthor=A.+M.+Brown&title=A+mechanism+for+the+proarrhythmic+effects+of+cisapride+%28Propulsid%29%3A+high+affinity+blockade+of+the+human+cardiac+potassium+channel+hERG&doi=10.1016%2FS0014-5793%2897%2901249-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG</span></div><div class="casAuthors">Rampe, David; Roy, Mary-Louise; Dennis, Adrienne; Brown, Arthur M.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-32</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cisapride (Propulsid) is a gastrointestinal prokinetic agent commonly used to treat nocturnal heartburn as well as a variety of other gastrointestinal disorders.  The use of cisapride has been assocd. with acquired long QT syndrome and ventricular arrhythmias such as torsades de pointes which produces sudden cardiac death.  These cardiotoxic effects can be due to blockade of one or more types of K+ channel currents in the human heart.  For this reason we compared the effects of cisapride on two cloned human cardiac K+ channels, Kv1.5 and the human ether-a-go-go-related gene (HERG) stably transfected into mammalian cells.  Using patch clamp electrophysiol., we found that cisapride was a potent inhibitor of HERG displaying an IC50 value of 44.5 nmol/l when tail currents at -40 mV were measured following a 2 s test depolarization to +20 mV.  When HERG currents were measured at the end of prolonged (20 s) depolarizing steps to +20 mV, the apparent affinity of cisapride was increased and measured 6.70 nmol/l.  The main effect of cisapride was to enhance the rate of HERG current decay thereby reducing current at the end of the voltage clamp pulse.  Furthermore, the potency of cisapride for the HERG channel was similar to that obsd. for the class III antiarrhythmic agent dofetilide (IC50 = 15.3 nmol/l) and the nonsedating antihistamine terfenadine (IC50 = 56.0 nmol/l).  In contrast to its effects on HERG, cisapride inhibited Kv1.5 channel currents weakly displaying an IC50 value of 21.2 μmol/l.  It is concluded that cisapride displays specific, high affinity block of the human cardiac K+ channel HERG.  It is likely that this interaction underlies the proarrhythmic effects of the drug obsd. under certain clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3R8aVmRVtG7Vg90H21EOLACvtfcHk0lhzpwoaekFelA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntVOhu74%253D&md5=26afd6fcc7834feab4620055da6376fd</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2897%2901249-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252897%252901249-0%26sid%3Dliteratum%253Aachs%26aulast%3DRampe%26aufirst%3DD.%26aulast%3DRoy%26aufirst%3DM.%2BL.%26aulast%3DDennis%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26atitle%3DA%2520mechanism%2520for%2520the%2520proarrhythmic%2520effects%2520of%2520cisapride%2520%2528Propulsid%2529%253A%2520high%2520affinity%2520blockade%2520of%2520the%2520human%2520cardiac%2520potassium%2520channel%2520hERG%26jtitle%3DFEBS%2520Lett.%26date%3D1997%26volume%3D417%26spage%3D28%26epage%3D32%26doi%3D10.1016%2FS0014-5793%2897%2901249-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursill, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyse, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breit, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, T. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the human ether-a-go-go-related gene (hERG) potassium channel by cisapride: affinity for open and inactivated states</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1038%2Fsj.bjp.0702774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10510456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFWgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=444-450&author=B.+D.+Walkerauthor=C.+B.+Singletonauthor=J.+A.+Bursillauthor=K.+R.+Wyseauthor=S.+M.+Valenzuelaauthor=M.+R.+Qiuauthor=S.+N.+Breitauthor=T.+J.+Campbell&title=Inhibition+of+the+human+ether-a-go-go-related+gene+%28hERG%29+potassium+channel+by+cisapride%3A+affinity+for+open+and+inactivated+states&doi=10.1038%2Fsj.bjp.0702774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states</span></div><div class="casAuthors">Walker, B. D.; Singleton, C. B.; Bursill, J. A.; Wyse, K. R.; Valenzuela, S. M.; Qiu, M. R.; Breit, S. N.; Campbell, T. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Cisapride is a prokinetic agent which has been assocd. with QT prolongation, torsades de pointes and cardiac arrest.  The cellular mechanism for these observations is high affinity blockade of IKr (encoded by HERG).  In a chronic transfection model using CHO-K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiol. temps. (IC50 16.4 nM at 20-22°C and 23.6 nM at 37°C).  Channel inhibition exhibited time-, voltage- and frequency-dependence.  In an envelope of tails test, channel blockade increased from 27±8% after a 120 ms depolarizing step to 50±4% after a 1.0 s step.  These findings suggested affinity for open and/or inactivated channel states.  Inactivation was significantly accelerated by cisapride in a concn.-dependent manner and there was a small (-7 mV) shift in the voltage dependence of steady state inactivation.  Channel blockade by cisapride was modulated by [K+]o, with a 26% redn. in the potency of channel blockade when [K+]o was increased from 1 to 10 mM.  In conclusion, HERG channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concn.  These features may have significant clin. implications with regard to the mechanism and treatment of cisapride-induced proarrhythmia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMulDrySVSiLVg90H21EOLACvtfcHk0lhzpwoaekFelA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFWgs7Y%253D&md5=1b8744d3cc1d71832de307061f3ab42a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702774%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DB.%2BD.%26aulast%3DSingleton%26aufirst%3DC.%2BB.%26aulast%3DBursill%26aufirst%3DJ.%2BA.%26aulast%3DWyse%26aufirst%3DK.%2BR.%26aulast%3DValenzuela%26aufirst%3DS.%2BM.%26aulast%3DQiu%26aufirst%3DM.%2BR.%26aulast%3DBreit%26aufirst%3DS.%2BN.%26aulast%3DCampbell%26aufirst%3DT.%2BJ.%26atitle%3DInhibition%2520of%2520the%2520human%2520ether-a-go-go-related%2520gene%2520%2528hERG%2529%2520potassium%2520channel%2520by%2520cisapride%253A%2520affinity%2520for%2520open%2520and%2520inactivated%2520states%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fsj.bjp.0702774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antunes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biala, G.</span></span> <span> </span><span class="NLM_article-title">The novel object recognition memory: neurobiology, test procedure, and its modifications</span>. <i>Cogn. Process.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1007/s10339-011-0430-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1007%2Fs10339-011-0430-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=22160349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A280%3ADC%252BC38zoslWlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=93-110&author=M.+Antunesauthor=G.+Biala&title=The+novel+object+recognition+memory%3A+neurobiology%2C+test+procedure%2C+and+its+modifications&doi=10.1007%2Fs10339-011-0430-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The novel object recognition memory: neurobiology, test procedure, and its modifications</span></div><div class="casAuthors">Antunes M; Biala G</div><div class="citationInfo"><span class="NLM_cas:title">Cognitive processing</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Animal models of memory have been considered as the subject of many scientific publications at least since the beginning of the twentieth century.  In humans, memory is often accessed through spoken or written language, while in animals, cognitive functions must be accessed through different kind of behaviors in many specific, experimental models of memory and learning.  Among them, the novel object recognition test can be evaluated by the differences in the exploration time of novel and familiar objects.  Its application is not limited to a field of research and enables that various issues can be studied, such as the memory and learning, the preference for novelty, the influence of different brain regions in the process of recognition, and even the study of different drugs and their effects.  This paper describes the novel object recognition paradigms in animals, as a valuable measure of cognition.  The purpose of this work was to review the neurobiology and methodological modifications of the test commonly used in behavioral pharmacology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQocv30hVI3YVf1XRtfYM0dfW6udTcc2eapKA_p_A8bjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zoslWlsQ%253D%253D&md5=4f73ed1bafb04056c5aef19b1b86c802</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10339-011-0430-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10339-011-0430-z%26sid%3Dliteratum%253Aachs%26aulast%3DAntunes%26aufirst%3DM.%26aulast%3DBiala%26aufirst%3DG.%26atitle%3DThe%2520novel%2520object%2520recognition%2520memory%253A%2520neurobiology%252C%2520test%2520procedure%252C%2520and%2520its%2520modifications%26jtitle%3DCogn.%2520Process.%26date%3D2012%26volume%3D13%26spage%3D93%26epage%3D110%26doi%3D10.1007%2Fs10339-011-0430-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medapati, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmuganathan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandikere, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irappanavar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saralaya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N.</span></span> <span> </span><span class="NLM_article-title">Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1453</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2012.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.brainres.2012.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=22464882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFeltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1453&publication_year=2012&pages=40-45&author=R.+Nirogiauthor=R.+Abrahamauthor=P.+Jayarajanauthor=R.+B.+Medapatiauthor=D.+Shanmuganathanauthor=V.+Kandikereauthor=S.+Irappanavarauthor=R.+Saralayaauthor=V.+Benadeauthor=G.+Bhyrapuneniauthor=N.+Muddana&title=Difference+in+the+norepinephrine+levels+of+experimental+and+non-experimental+rats+with+age+in+the+object+recognition+task&doi=10.1016%2Fj.brainres.2012.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task</span></div><div class="casAuthors">Nirogi, Ramakrishna; Abraham, Renny; Jayarajan, Pradeep; Medapati, Rajesh Babu; Shanmuganathan, Dhanalakshmi; Kandikere, Vishwottam; Irappanavar, Shantaveer; Saralaya, Ramanatha; Benade, Vijay; Bhyrapuneni, Gopinadh; Muddana, Nageswararao</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1453</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-45</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the present study, we investigated the performance of adult and juvenile rats in the Object Recognition Task (ORT).  While it is well known that the performance of rat in ORT differs with age, the reason for the difference as well as the underlying neurotransmitter that may have led to these differences were investigated.  In the present study, juvenile rats of postnatal day 40-45 (PND 40-45) and adult rats of postnatal day 60+ (PND 60+) were subjected to a two trial ORT.  The juvenile rats did not discriminate between the novel object and the familiar object, while the adult rats discriminated the novel from the familiar object.  On estg. brain concns. of norepinephrine (NE), it was obsd. that the NE level in MTL (medial temporal lobe) of adult exptl. rats was significantly higher than the adult non-exptl. rats.  In juvenile rats, no significant difference was obsd. in the NE levels of exptl. rats in comparison to its non-exptl. counterparts.  Administration of yohimbine (α2A adrenergic receptor antagonist) enhanced the level of NE in juvenile rats and reversed the difference seen with age.  From the present study, we conclude that the deficit in memory seen is likely due to the difference in NE levels with task and this can be reversed by yohimbine which enhance NE levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzGeFKjEr4j7Vg90H21EOLACvtfcHk0lgdYDEiqLi0lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFeltb0%253D&md5=8c0fea2283e6a5f57fd74ae28b94aee8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2012.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2012.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DAbraham%26aufirst%3DR.%26aulast%3DJayarajan%26aufirst%3DP.%26aulast%3DMedapati%26aufirst%3DR.%2BB.%26aulast%3DShanmuganathan%26aufirst%3DD.%26aulast%3DKandikere%26aufirst%3DV.%26aulast%3DIrappanavar%26aufirst%3DS.%26aulast%3DSaralaya%26aufirst%3DR.%26aulast%3DBenade%26aufirst%3DV.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DMuddana%26aufirst%3DN.%26atitle%3DDifference%2520in%2520the%2520norepinephrine%2520levels%2520of%2520experimental%2520and%2520non-experimental%2520rats%2520with%2520age%2520in%2520the%2520object%2520recognition%2520task%26jtitle%3DBrain%2520Res.%26date%3D2012%26volume%3D1453%26spage%3D40%26epage%3D45%26doi%3D10.1016%2Fj.brainres.2012.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olton, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuelson, R. J.</span></span> <span> </span><span class="NLM_article-title">Remembrance of places passed: spatial memory in rats</span>. <i>J. Exp. Psychol. Anim. Behav. Process</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1037/0097-7403.2.2.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1037%2F0097-7403.2.2.97" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1976&pages=97-116&author=D.+S.+Oltonauthor=R.+J.+Samuelson&title=Remembrance+of+places+passed%3A+spatial+memory+in+rats&doi=10.1037%2F0097-7403.2.2.97"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1037%2F0097-7403.2.2.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0097-7403.2.2.97%26sid%3Dliteratum%253Aachs%26aulast%3DOlton%26aufirst%3DD.%2BS.%26aulast%3DSamuelson%26aufirst%3DR.%2BJ.%26atitle%3DRemembrance%2520of%2520places%2520passed%253A%2520spatial%2520memory%2520in%2520rats%26jtitle%3DJ.%2520Exp.%2520Psychol.%2520Anim.%2520Behav.%2520Process%26date%3D1976%26volume%3D2%26spage%3D97%26epage%3D116%26doi%3D10.1037%2F0097-7403.2.2.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braida, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamperti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, M.</span></span> <span> </span><span class="NLM_article-title">An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>302</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00072-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2F0014-2999%2896%2900072-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=8790986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK28XjtlSksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=1996&pages=13-20&author=D.+Braidaauthor=E.+Paladiniauthor=P.+Griffiniauthor=M.+Lampertiauthor=A.+Maggiauthor=M.+Sala&title=An+inverted+U-shaped+curve+for+heptylphysostigmine+on+radial+maze+performance+in+rats%3A+comparison+with+other+cholinesterase+inhibitors&doi=10.1016%2F0014-2999%2896%2900072-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors</span></div><div class="casAuthors">Braida, Daniela; Paladini, Emma; Griffini, Pierluigi; Lamperti, Mariapia; Maggi, Antonio; Sala, Mariaelvina</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The potential of heptylphysostigmine tartrate (MF201), a new second-generation cholinesterase inhibitor, to antagonize scopolamine-induced amnesia in rats was assessed in an 8-arm radial maze.  Upon completing the training session, the rats were orally administered increasing doses of MF201 (2, 3, 4, 6 and 8 mg/kg) 60 min prior to a s.c. injection of scopolamine (0.25 mg/kg).  Tacrine (0.25, 0.37, 0.5, 1 and 2 mg/kg), 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]-Me piperidine (E2020) (0.125, 0.18, 0.25 and 0.5 mg/kg) and physostigmine (0.15, 0.25, 0.5 and 1 mg/kg) were orally administered and rats were tested in the same task.  As previously described, scopolamine induced an impairment in radial maze performance, measured in terms of total no. of errors, total time taken to complete the task and the percentage of amnesic animals.  The reversal of scopolamine-induced impairment was characterized by the presence of an inverted U-shaped dose-response curve.  A significant antagonistic effect was achieved with a dose (mg/kg) of 0.25 for E2020, 0.5 for tacrine and physostigmine and 3, 4 and 6 for MF201, the latter manifesting a broader spectrum of activity (3-6 mg/kg).  While the maximal active doses restored the scopolamine-induced modified pattern of arm entry, they were ineffective in reducing hypermotility, suggesting the drugs have a specific effect on cognitive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR3j3kxkBBC7Vg90H21EOLACvtfcHk0liWOyudwY_dqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtlSksb4%253D&md5=96b226b46ac6bd4470b8a02815f07d1e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900072-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900072-6%26sid%3Dliteratum%253Aachs%26aulast%3DBraida%26aufirst%3DD.%26aulast%3DPaladini%26aufirst%3DE.%26aulast%3DGriffini%26aufirst%3DP.%26aulast%3DLamperti%26aufirst%3DM.%26aulast%3DMaggi%26aufirst%3DA.%26aulast%3DSala%26aufirst%3DM.%26atitle%3DAn%2520inverted%2520U-shaped%2520curve%2520for%2520heptylphysostigmine%2520on%2520radial%2520maze%2520performance%2520in%2520rats%253A%2520comparison%2520with%2520other%2520cholinesterase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D302%26spage%3D13%26epage%3D20%26doi%3D10.1016%2F0014-2999%2896%2900072-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostaras, S. G.</span></span> <span> </span><span class="NLM_article-title">Psychostimulants and cognition: a continuum of behavioral and cognitive activation</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1124/pr.112.007054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1124%2Fpr.112.007054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=24344115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGnu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=193-221&author=S.+Woodauthor=J.+R.+Sageauthor=T.+Shumanauthor=S.+G.+Anagnostaras&title=Psychostimulants+and+cognition%3A+a+continuum+of+behavioral+and+cognitive+activation&doi=10.1124%2Fpr.112.007054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Psychostimulants and cognition: a continuum of behavioral and cognitive activation</span></div><div class="casAuthors">Wood, Suzanne; Sage, Jennifer R.; Shuman, Tristan; Anagnostaras, Stephan G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">193-221, 29 pp.</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Psychostimulants such as cocaine have been used as performance enhancers throughout recorded history.  Although psychostimulants are commonly prescribed to improve attention and cognition, a great deal of literature has described their ability to induce cognitive deficits, as well as addiction.  How can a single drug class be known to produce both cognitive enhancement and impairment.  Properties of the particular stimulant drug itself and individual differences between users have both been suggested to dictate the outcome of stimulant use.  A more parsimonious alternative, which we endorse, is that dose is the crit. detg. factor in cognitive effects of stimulant drugs.  Herein, we review several popular stimulants (cocaine, amphetamine, methylphenidate, modafinil, and caffeine), outlining their history of use, mechanism of action, and use and abuse today.  One common graphic depiction of the cognitive effects of psychostimulants is an inverted U-shaped dose-effect curve.  Moderate arousal is beneficial to cognition, whereas too much activation leads to cognitive impairment.  In parallel to this schematic, we propose a continuum of psychostimulant activation that covers the transition from one drug effect to another as stimulant intake is increased.  Low doses of stimulants effect increased arousal, attention, and cognitive enhancement; moderate doses can lead to feelings of euphoria and power, as well as addiction and cognitive impairment; and very high doses lead to psychosis and circulatory collapse.  This continuum helps account for the seemingly disparate effects of stimulant drugs, with the same drug being assocd. with cognitive enhancement and impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUCx_-Q7V6rVg90H21EOLACvtfcHk0liWOyudwY_dqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGnu73E&md5=ec43a4e0babb213d36455c2a070ba16e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fpr.112.007054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.112.007054%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DS.%26aulast%3DSage%26aufirst%3DJ.%2BR.%26aulast%3DShuman%26aufirst%3DT.%26aulast%3DAnagnostaras%26aufirst%3DS.%2BG.%26atitle%3DPsychostimulants%2520and%2520cognition%253A%2520a%2520continuum%2520of%2520behavioral%2520and%2520cognitive%2520activation%26jtitle%3DPharmacol.%2520Rev.%26date%3D2014%26volume%3D66%26spage%3D193%26epage%3D221%26doi%3D10.1124%2Fpr.112.007054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandikere, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saralaya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajjala, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleti, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasheed, M. A.</span></span> <span> </span><span class="NLM_article-title"><i>In vivo</i> rat striatal 5-HT<sub>4</sub> receptor occupancy using non-radiolabelled SB207145</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">704</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1111/jphp.12030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1111%2Fjphp.12030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=23600388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1Wks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=704-712&author=R.+Nirogiauthor=V.+Kandikereauthor=G.+Bhyrapuneniauthor=R.+Saralayaauthor=D.+R.+Ajjalaauthor=R.+R.+Aletiauthor=M.+A.+Rasheed&title=In+vivo+rat+striatal+5-HT4+receptor+occupancy+using+non-radiolabelled+SB207145&doi=10.1111%2Fjphp.12030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">In-vivo rat striatal 5-HT4 receptor occupancy using non-radiolabelled SB207145</span></div><div class="casAuthors">Nirogi, Ramakrishna; Kandikere, Vishwottam; Bhyrapuneni, Gopinadh; Saralaya, Ramanatha; Ajjala, Devender Reddy; Aleti, Raghupathi Reddy; Abdul Rasheed, Mohammed</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">704-712</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The objective of the current investigation was to develop a simple, rapid method for detg. in-vivo 5-hydroxytryptamine type 4 receptor (5-HT4R) occupancy in rat brain using non-radiolabeled SB207145 as a tracer for accelerating the drug discovery process.  In-vivo tracer optimization studies for tracer dose, survival intervals and brain distribution profile were carried out in rats.  The tracer was pharmacol. validated using potent well-characterized 5-HT4R ligands.  The brain regional concns. of tracer (SB207145); plasma and brain concns. of 5-HT4R ligands were quantified using high-performance liq. chromatog. coupled with a tandem mass spectrometric detector (LC-MS/MS).  SB207145 showed a higher specific binding in striatum (1.96 ng/g) and lower binding in cerebellum (0.66 ng/g), which is consistent with findings of other published 5-HT4R expression studies.  Pretreatment with potent 5-HT4 ligands dose-dependently reduced striatal SB207145 concn. and the ED to achieve 50% receptor occupancy (ED50) values were 4.8, 2.0, 7.4, 9.9, 3.8 and 0.02 mg/kg for GR113808, piboserod, prucalopride, RS67333, TD8954 and PF04995274, resp.  Results from the mass spectrometry approach to det. 5-HT4R occupancy in rat brain are comparable with those reported using radiolabeled scintillation spectroscopy methods.  In conclusion, the LC-MS/MS characterization permits use of tracer at a preclin. stage in high-throughput fashion as well as characterization of target expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBAD2h_4wjYrVg90H21EOLACvtfcHk0lj0e2OEmYsSig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1Wks7w%253D&md5=fdd50664c69a42cbdf1501a11582e591</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1111%2Fjphp.12030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjphp.12030%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DKandikere%26aufirst%3DV.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DSaralaya%26aufirst%3DR.%26aulast%3DAjjala%26aufirst%3DD.%2BR.%26aulast%3DAleti%26aufirst%3DR.%2BR.%26aulast%3DRasheed%26aufirst%3DM.%2BA.%26atitle%3DIn%2520vivo%2520rat%2520striatal%25205-HT4%2520receptor%2520occupancy%2520using%2520non-radiolabelled%2520SB207145%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2013%26volume%3D65%26spage%3D704%26epage%3D712%26doi%3D10.1111%2Fjphp.12030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span>; <span class="NLM_string-name">Drummond, E.</span>; <span class="NLM_string-name">Zasadny, K.</span>; <span class="NLM_string-name">Skaddan, M.</span>; <span class="NLM_string-name">Brodney, M.</span>; <span class="NLM_string-name">Coffman, K.</span>; <span class="NLM_string-name">Nicholas, T.</span>; <span class="NLM_string-name">Duvvuri, S.</span>; <span class="NLM_string-name">Raunig, D. L.</span>; <span class="NLM_string-name">Leurent, C.</span>; <span class="NLM_string-name">Rowinski, C.</span>; <span class="NLM_string-name">Park, Y.-S.</span>; <span class="NLM_string-name">Ogden, A.</span>; <span class="NLM_string-name">Sawant-Basak, A.</span>; <span class="NLM_string-name">Miller, E. L</span>; <span class="NLM_string-name">Rapp, T.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Planeta-Wilson, B.</span>; <span class="NLM_string-name">Ropchan, J.</span>; <span class="NLM_string-name">Carson, R.</span>; <span class="NLM_string-name">Morris, E.</span>; <span class="NLM_string-name">Ding, Y.-S.</span>; <span class="NLM_string-name">Katz, E.</span></span> <span> </span><span class="NLM_article-title">Translational receptor occupancy for the 5-HT<sub>4</sub> partial agonist PF-04995274 in rats, non-human primates and healthy volunteers</span>. Proceedings from the  <i>International Conference on Alzheimer’s Disease</i>, July 16–21, 2011, Paris, France; <span class="NLM_publisher-name">Alzforum</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2011</span>; poster no. 11818.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.jalz.2011.05.1875" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Grimwood&author=E.+Drummond&author=K.+Zasadny&author=M.+Skaddan&author=M.+Brodney&author=K.+Coffman&author=T.+Nicholas&author=S.+Duvvuri&author=D.+L.+Raunig&author=C.+Leurent&author=C.+Rowinski&author=Y.-S.+Park&author=A.+Ogden&author=A.+Sawant-Basak&author=E.+L+Miller&author=T.+Rapp&author=Y.+Wang&author=B.+Planeta-Wilson&author=J.+Ropchan&author=R.+Carson&author=E.+Morris&author=Y.-S.+Ding&author=E.+Katz&title=Translational+receptor+occupancy+for+the+5-HT4+partial+agonist+PF-04995274+in+rats%2C+non-human+primates+and+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2011.05.1875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26id%3Ddoi%3A10.1016%252Fj.jalz.2011.05.1875%26sid%3Dliteratum%253Aachs%26aulast%3DGrimwood%26aufirst%3DS.%26atitle%3DTranslational%2520receptor%2520occupancy%2520for%2520the%25205-HT4%2520partial%2520agonist%2520PF-04995274%2520in%2520rats%252C%2520non-human%2520primates%2520and%2520healthy%2520volunteers%26jtitle%3DInternational%2520Conference%2520on%2520Alzheimer%25E2%2580%2599s%2520Disease%26pub%3DAlzforum%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc’h, F.</span></span> <span> </span><span class="NLM_article-title">Distinct functional effects of human 5-HT<sub>4</sub> receptor isoforms on beta-amyloid secretion</span>. <i>Neurodegener. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1159/000113691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1159%2F000113691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=18322379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1Wht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=163-165&author=S.+J.+Robertauthor=F.+Lezoualc%E2%80%99h&title=Distinct+functional+effects+of+human+5-HT4+receptor+isoforms+on+beta-amyloid+secretion&doi=10.1159%2F000113691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Functional Effects of Human 5-HT4 Receptor Isoforms on β-Amyloid Secretion</span></div><div class="casAuthors">Robert, Sylvain J.; Lezoualc'h, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">163-165</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: The serotonin 5-HT4 receptor is of potential interest for the treatment of Alzheimer's disease because it increases memory and learning and influences amyloid precursor protein (APP) processing.  Several 5-HT4 receptor isoforms have been cloned in humans.  They all belong to the G-protein-coupled receptor superfamily and differ in compn. and length of their amino acid intracellular C-terminal sequence.  At present, it is still unknown whether 5-HT4 receptor isoforms may have distinct effects on APP processing.  Objective: In this study, we investigated the effect of an ultrashort isoform of the human 5-HT4 receptor (2 amino acids after the splicing site), the 5-HT4(d) receptor isoform (h5-HT4(d)), on APP processing in Chinese hamster ovary cells (CHO cells).  Methods: Non-amyloidogenic sol. sAPPα was detd. by immunoblot and β-amyloid peptides (Aβ1-40 and Aβ1-42) were assayed by ELISA in CHO cells stably expressing h5-HT4(d) and transiently transfected with human APP695.  Results: We show here that activation of h5-HT4(d) strongly stimulates the release of sAPPα and concomitantly decreases extracellular Aβ peptides.  These data contrast with our previous findings showing that the h5-HT4(e/g) receptor isoform, which has 20 amino acids after the splicing site, did not influence Aβ secretion.  Conclusion: We conclude that C-terminal tails of 5-HT4 receptor isoforms may influence their functional effect on Aβ secretion and that the pathways regulating either β- or γ-secretase may be differentially controlled by 5-HT4 receptor isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFF1W64EZATLVg90H21EOLACvtfcHk0lh-03XhON8Szg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Wht7s%253D&md5=c90b7775cd8805e5160a66689b8939ff</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1159%2F000113691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000113691%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DS.%2BJ.%26aulast%3DLezoualc%25E2%2580%2599h%26aufirst%3DF.%26atitle%3DDistinct%2520functional%2520effects%2520of%2520human%25205-HT4%2520receptor%2520isoforms%2520on%2520beta-amyloid%2520secretion%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2008%26volume%3D5%26spage%3D163%26epage%3D165%26doi%3D10.1159%2F000113691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cachard-Chastel, M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc'h, F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewachter, I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delomenie, C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croes, S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devijver, H</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicsic, S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A M</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptor agonists increase sAPPα levels in the cortex and hippo-campus of male C57BL/6j mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1038%2Fsj.bjp.0707178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=17325649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs12ntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2007&pages=883-892&author=M+Cachard-Chastelauthor=F+Lezoualc%27hauthor=I+Dewachterauthor=C+Delomenieauthor=S+Croesauthor=H+Devijverauthor=M+Langloisauthor=F+Van+Leuvenauthor=S+Sicsicauthor=A+M+Gardier&title=5-HT4+receptor+agonists+increase+sAPP%CE%B1+levels+in+the+cortex+and+hippo-campus+of+male+C57BL%2F6j+mice&doi=10.1038%2Fsj.bjp.0707178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptor agonists increase sAPPα levels in the cortex and hippocampus of male C57BL/6j mice</span></div><div class="casAuthors">Cachard-Chastel, M.; Lezoualc'h, F.; Dewachter, I.; Delomenie, C.; Croes, S.; Devijver, H.; Langlois, M.; Van Leuven, F.; Sicsic, S.; Gardier, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A strategy to treat Alzheimer's disease (AD) is to increase the sol. form of amyloid precursor protein (sAPPα), a promnesic protein, in the brain.  Because strong evidence supports beneficial effects of 5-hydroxytryptamine 5-HT4 receptor agonists in memory and learning, we investigated the role of 5-HT4 receptors on APP processing in 8 wk-old male C57BL/6j mice.  Mice were given, s.c., prucalopride or ML 10302 (s.c.), two highly selective 5-HT4 receptor agonists and, up to 240 min later, the hippocampus and cortex were analyzed by Western blot for sAPPα detn.  Prucalopride (5 or 10 mg kg-1) significantly increased sAPPα levels in the hippocampus and cortex, but did not modify the expression level of APP mRNA as detected by quant. RT-PCR.  A selective 5-HT4 receptor antagonist, GR125487 (1 mg kg-1, s.c.) inhibited prucalopride induced- increase in sAPPα levels.  In addn., levels of sAPPα were increased by ML10302 only at 20 mg kg-1 and was limited to the cortex.  Also, prucalopride increased sAPPα levels in the cortex of a transgenic mouse model of AD, expressing the London mutation of APP.  Furthermore, the combined injection of a selective acetylcholinesterase inhibitor, donepezil and prucalopride induced a synergic increase in sAPPα levels in the cortex and hippocampus.  The results demonstrate that the 5-HT4 receptor plays a key role in the non-amyloidogenic pathway of APP metab. in vivo and give support to the beneficial use of 5-HT4 agonists for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgDGVLDs3CMLVg90H21EOLACvtfcHk0lh-03XhON8Szg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs12ntbo%253D&md5=37636a905d062d15019a151f983ecebc</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707178%26sid%3Dliteratum%253Aachs%26aulast%3DCachard-Chastel%26aufirst%3DM%26aulast%3DLezoualc%2527h%26aufirst%3DF%26aulast%3DDewachter%26aufirst%3DI%26aulast%3DDelomenie%26aufirst%3DC%26aulast%3DCroes%26aufirst%3DS%26aulast%3DDevijver%26aufirst%3DH%26aulast%3DLanglois%26aufirst%3DM%26aulast%3DVan%2BLeuven%26aufirst%3DF%26aulast%3DSicsic%26aufirst%3DS%26aulast%3DGardier%26aufirst%3DA%2BM%26atitle%3D5-HT4%2520receptor%2520agonists%2520increase%2520sAPP%25CE%25B1%2520levels%2520in%2520the%2520cortex%2520and%2520hippo-campus%2520of%2520male%2520C57BL%252F6j%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D150%26spage%3D883%26epage%3D892%26doi%3D10.1038%2Fsj.bjp.0707178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Activation of 5-HT<sub>4</sub> receptors inhibits secretion of β-amyloid peptides and increases neuronal survival</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>203</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2006.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.expneurol.2006.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=16978609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Krt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2007&pages=274-278&author=S.+Choauthor=Y.+Hu&title=Activation+of+5-HT4+receptors+inhibits+secretion+of+%CE%B2-amyloid+peptides+and+increases+neuronal+survival&doi=10.1016%2Fj.expneurol.2006.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of 5-HT4 receptors inhibits secretion of β-amyloid peptides and increases neuronal survival</span></div><div class="casAuthors">Cho, Seongeun; Hu, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">274-278</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activation of 5-HT4 receptors has been shown to improve memory processes in preclin. cognition models, suggesting potential utility of 5-HT4 agonists for the symptomatic treatment of Alzheimer's disease (AD).  Recent studies have shown that 5-HT4 agonists also increase the secretion of the non-amyloidogenic sol. amyloid precursor protein-alpha (sAPPα).  In the present study, we demonstrated that a selective 5-HT4 partial agonist, RS67333, inhibited the generation of β-amyloid peptide (Aβ) in primary cortical cultures of Tg2576 transgenic mice expressing human APPK670N/M671L.  Furthermore, treatments with RS67333 selectively increased the survival of transgenic neurons in a dose-dependent manner, which was inhibited by 5-HT4 antagonists.  These and previous data collectively suggest that the 5-HT4 receptor may be an effective therapeutic target for AD, providing both symptomatic improvements and neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr94iComWBAYLVg90H21EOLACvtfcHk0lh-03XhON8Szg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Krt73K&md5=0b90d41ab8f752fb01c09cee2df2a429</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2006.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2006.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DActivation%2520of%25205-HT4%2520receptors%2520inhibits%2520secretion%2520of%2520%25CE%25B2-amyloid%2520peptides%2520and%2520increases%2520neuronal%2520survival%26jtitle%3DExp.%2520Neurol.%26date%3D2007%26volume%3D203%26spage%3D274%26epage%3D278%26doi%3D10.1016%2Fj.expneurol.2006.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruda, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obedencio, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D. T.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptor agonist mediated enhancement of cognitive function <i>in vivo</i> and amyloid precursor protein processing <i>in vitro</i>: A pharmacodynamics and pharmacokinetic assessment</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2011.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.neuropharm.2011.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=21392515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslyntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=69-79&author=F.+Shenauthor=J.+A.M.+Smithauthor=R.+Changauthor=D.+L.+Bourdetauthor=P.+R.+Tsurudaauthor=G.+P.+Obedencioauthor=D.+T.+Beattie&title=5-HT4+receptor+agonist+mediated+enhancement+of+cognitive+function+in+vivo+and+amyloid+precursor+protein+processing+in+vitro%3A+A+pharmacodynamics+and+pharmacokinetic+assessment&doi=10.1016%2Fj.neuropharm.2011.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment</span></div><div class="casAuthors">Shen, Fei; Smith, Jacqueline A. M.; Chang, Ray; Bourdet, David L.; Tsuruda, Pamela R.; Obedencio, Glenmar P.; Beattie, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">69-79</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There remains an urgent need for therapeutic agents that provide improved symptomatic treatment and attenuate disease progression in patients with Alzheimer's disease (AD).  5-HT4 receptors are widely expressed in those CNS areas which receive substantial cholinergic input and are involved in cognition.  The ability of 5-HT4 receptor agonists to increase acetylcholine (ACh) release and reduce cognitive impairment in both animals and humans was demonstrated.  In addn., 5-HT4 receptor agonist modulation of levels of the amyloid precursor protein (APP) derived peptides, sol. amyloid precursor protein (sAPPα), and amyloid beta protein (Aβ) in the CNS was reported.  In this study, the preclin. properties of 3 structurally-distinct 5-HT4 receptor selective agonists, PRX-03140, velusetrag, and TD-8954, were studied to assess their potential for symptomatic and disease-modifying benefit in the treatment of AD.  All 3 compds. exhibited high affinity for the rat 5-HT4 receptor but could be discriminated on the basis of their agonist activity.  In cAMP accumulation and sAPPα secretion assays using recombinant HEK293f-5-HT4(d)-APP695 cells, velusetrag and TD-8954 were potent, full agonists, relative to 5-HT, whereas PRX-03140 was a partial agonist (intrinsic activity 18%, relative to 5-HT).  In a guinea pig colon isolated tissue prepn., TD-8954 exhibited lower intrinsic activity than velusetrag, and PRX-03140 had negligible agonist activity.  In the rat Morris water maze (MWM) cognition test, velusetrag and TD-8954 (0.1 mg/kg), but not PRX-03140 (0.03-1 mg/kg), significantly reversed the scopolamine-induced spatial learning deficit via activation of 5-HT4 receptors.  Coadministration of subefficacious doses of the acetylcholinesterase inhibitor (AChEi), donepezil (0.1 mg/kg, i.p.), and either velusetrag or TD-8954 (0.01 mg/kg i.p.) resulted in reversal of the scopolamine-induced cognitive deficit.  Pharmacokinetic data indicated that the CNS penetration for all 3 5-HT4 receptor agonists was relatively low.  However, the pharmacodynamic-pharmacokinetic relationships in the MWM model for velusetrag and TD-8954 were consistent with their resp. receptor pharmacol. (binding affinity and intrinsic efficacy) and CNS penetration properties.  Collectively, these findings support a potential role for potent and efficacious 5-HT4 receptor agonists in the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHch3UQC1H5rVg90H21EOLACvtfcHk0lidh9LesjnhLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslyntrk%253D&md5=be19e02fdc4c73af70613f43cbc215b0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2011.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2011.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DF.%26aulast%3DSmith%26aufirst%3DJ.%2BA.M.%26aulast%3DChang%26aufirst%3DR.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26aulast%3DTsuruda%26aufirst%3DP.%2BR.%26aulast%3DObedencio%26aufirst%3DG.%2BP.%26aulast%3DBeattie%26aufirst%3DD.%2BT.%26atitle%3D5-HT4%2520receptor%2520agonist%2520mediated%2520enhancement%2520of%2520cognitive%2520function%2520in%2520vivo%2520and%2520amyloid%2520precursor%2520protein%2520processing%2520in%2520vitro%253A%2520A%2520pharmacodynamics%2520and%2520pharmacokinetic%2520assessment%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D61%26spage%3D69%26epage%3D79%26doi%3D10.1016%2Fj.neuropharm.2011.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, N. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological evidence for a functional serotonin-2b receptor in a human uterine smooth muscle cell line</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1261</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.100172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1124%2Fjpet.105.100172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=16517693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD28Xlt1eqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=1254-1261&author=C.+R.+Kellyauthor=N.+A.+Sharif&title=Pharmacological+evidence+for+a+functional+serotonin-2b+receptor+in+a+human+uterine+smooth+muscle+cell+line&doi=10.1124%2Fjpet.105.100172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological evidence for a functional serotonin-2B receptor in a human uterine smooth muscle cell line</span></div><div class="casAuthors">Kelly, Curtis R.; Sharif, Najam A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1254-1261</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present study investigated the serotonin-induced increase in phosphoinositide hydrolysis and mobilization of intracellular Ca2+ ([Ca2+]i) in human uterine smooth muscle cells (HUSMCs) to identify the serotonergic receptor pos. coupled to phospholipase C in these cells.  In phosphoinositide (PI) assays, serotonin (5-HT) and α-methyl-5-HT were potent, full agonists (EC50 = 20 and 4.1 nM, resp.), whereas the phenylethylamine, R-(-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane hydrochloride, was less active (EC50 = 63 nM).  Proposed 5-HT2B-selective agonists, BW-723C86 and (+)-norfenfluramine, exhibited strong agonist potency and efficacy comparable with 5-HT (EC50 = 18 and 33 nM, resp.) and ∼15-fold more potency than (-)-norfenfluramine (EC50 = 500 nM).  5-HT2C receptor agonists m-chlorophenylpiperazine and MK-212 were weak agonists in these cells, with potencies of 110 and 880 nM, resp.  A similar rank order of potency was obsd. in [Ca2+]i mobilization assays (r = 0.9) in the HUSMC and with contraction of rat stomach fundus strips that contain a 5-HT2B receptor (r = 0.9).  Antagonist studies revealed that a 5-HT2B-selective antagonist, RS-127445 (Ki = 0.13 nM), was significantly more effective at inhibiting 5-HT-induced activity than a 5-HT2A antagonist, M-100907 (Ki = 914 nM) and the 5-HT2C antagonists RS-102221 (Ki = 2.5 μM) and SB-242084 (Ki = 42.4 nM) in the HUSMC PI turnover assays.  Taken together, these studies strongly suggest the presence of a functionally active 5-HT2B receptor subtype in HUSMCs.  The physiol. role of this receptor in these cells remains to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWnAOFD_xYkrVg90H21EOLACvtfcHk0lidh9LesjnhLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xlt1eqtbY%253D&md5=52ea7805fe17184bad2816d80f4fe74a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.100172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.100172%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26atitle%3DPharmacological%2520evidence%2520for%2520a%2520functional%2520serotonin-2b%2520receptor%2520in%2520a%2520human%2520uterine%2520smooth%2520muscle%2520cell%2520line%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26spage%3D1254%26epage%3D1261%26doi%3D10.1124%2Fjpet.105.100172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padala, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajjala, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, V. R. C.</span></span> <span> </span><span class="NLM_article-title">Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">105425</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2020.105425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.ejps.2020.105425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=32534194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKntrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=105425&author=R.+Nirogiauthor=G.+Bhyrapuneniauthor=N.+R.+Muddanaauthor=A.+Manoharanauthor=A.+K.+Shindeauthor=A.+R.+Mohammedauthor=N.+P.+Padalaauthor=D.+R.+Ajjalaauthor=R.+Subramanianauthor=V.+R.+C.+Palacharla&title=Absorption%2C+distribution%2C+metabolism%2C+excretion+%28ADME%29%2C+drug-drug+interaction+potential+and+prediction+of+human+pharmacokinetics+of+SUVN-G3031%2C+a+novel+histamine+3+receptor+%28H3R%29+inverse+agonist+in+clinical+development+for+the+treatment+of+narcolepsy&doi=10.1016%2Fj.ejps.2020.105425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy</span></div><div class="casAuthors">Nirogi, Ramakrishna; Bhyrapuneni, Gopinadh; Muddana, Nageswara Rao; Manoharan, Arunkumar; Shinde, Anil K.; Mohammed, Abdul Rasheed; Padala, Nagasurya Prakash; Ajjala, Devender Reddy; Subramanian, Ramkumar; Palacharla, Veera Raghava Chowdary</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105425</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SUVN-G3031 is a potent and selective inverse agonist of Histmine-3 (H3) receptor that is being investigated for the treatment of narcolepsy.  SUVN-G3031 has high passive permeability, not a substrate for P-glycoprotein, has high plasma unbound fractions and was equally distributed between blood and plasma.  Major routes of metab. in vitro were cyclization (Metabolite A) in microsomes and dealkylation (Metabolite D) in hepatocytes.  Intrinsic clearance in liver microsomes and hepatocytes was low as monitored by metabolite formation approach.  CYP3A4 and MAO-A were the major enzymes involved in the formation of metabolite A and metabolite D resp.  The human hepatic clearance estd. by well-stirred model from hepatocytes was low (2.7 L.h -1) illustrating the importance of metabolite formation kinetics for prediction of human clearance for SUVN-G3031.  Renal clearance in humans (9.7 L.h -1) was predicted from dog renal clearance and accounts for ∼ 78% of the total clearance.  SUVN-G3031 was neither an inhibitor nor inducer of the P 450 enzymes at clin. relevant concns.  SUVN-G3031 did not inhibit the major uptake transporters and was not a substrate for the uptake transporters.  The potential of SUVN-G3031 as a victim and perpetrator of drug-drug interactions is remote.  The predicted human pharmacokinetic parameters were consistent with those obsd. in the first-in-human study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxMYCrhUw617Vg90H21EOLACvtfcHk0lh9x_5Se6qQxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKntrnK&md5=66d29d9d3f72695ac827e19458c16ebd</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2020.105425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2020.105425%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DMuddana%26aufirst%3DN.%2BR.%26aulast%3DManoharan%26aufirst%3DA.%26aulast%3DShinde%26aufirst%3DA.%2BK.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DPadala%26aufirst%3DN.%2BP.%26aulast%3DAjjala%26aufirst%3DD.%2BR.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DPalacharla%26aufirst%3DV.%2BR.%2BC.%26atitle%3DAbsorption%252C%2520distribution%252C%2520metabolism%252C%2520excretion%2520%2528ADME%2529%252C%2520drug-drug%2520interaction%2520potential%2520and%2520prediction%2520of%2520human%2520pharmacokinetics%2520of%2520SUVN-G3031%252C%2520a%2520novel%2520histamine%25203%2520receptor%2520%2528H3R%2529%2520inverse%2520agonist%2520in%2520clinical%2520development%2520for%2520the%2520treatment%2520of%2520narcolepsy%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2020%26volume%3D152%26spage%3D105425%26doi%3D10.1016%2Fj.ejps.2020.105425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jetta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, V. R. C.</span></span> <span> </span><span class="NLM_article-title">First-in-human studies to evaluate the safety, tolerability, and pharmacokinetics of a novel 5-HT<sub>4</sub> partial agonist, SUVN-D4010, in healthy adult and elderly subjects</span>. <i>Clin. Drug Investig.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1007/s40261-021-01027-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1007%2Fs40261-021-01027-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=33788154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtVars7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2021&pages=469-482&author=R.+Nirogiauthor=G.+Bhyrapuneniauthor=N.+R.+Muddanaauthor=V.+K.+Goyalauthor=S.+K.+Pandeyauthor=A.+R.+Mohammedauthor=J.+Ravulaauthor=S.+Jettaauthor=V.+R.+C.+Palacharla&title=First-in-human+studies+to+evaluate+the+safety%2C+tolerability%2C+and+pharmacokinetics+of+a+novel+5-HT4+partial+agonist%2C+SUVN-D4010%2C+in+healthy+adult+and+elderly+subjects&doi=10.1007%2Fs40261-021-01027-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects</span></div><div class="casAuthors">Nirogi, Ramakrishna; Bhyrapuneni, Gopinadh; Muddana, Nageswara Rao; Goyal, Vinod Kumar; Pandey, Santosh Kumar; Mohammed, Abdul Rasheed; Ravula, Jyothsna; Jetta, Satish; Palacharla, Veera Raghava Chowdary</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-482</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">SUVN-D4010 is a novel, potent, highly selective 5-HT4 partial agonist intended for the treatment of cognitive disorders.  The objective of the clin. study was to characterize the safety, tolerability, and pharmacokinetics of SUVN-D4010 in healthy adults after single and multiple doses, and to evaluate the effect of food, sex, and age on the pharmacokinetics.  Single-ascending dose and multiple-ascending dose studies for 14 days were conducted in healthy adults using a randomized, double-blind design.  The effects of food, sex, and age on SUVN-D4010 pharmacokinetics (25 mg single dose) were evaluated using an open-label, two-period, randomized, fed and fasted, crossover design.  Pharmacokinetics and safety assessments were conducted throughout the study.  SUVN-D4010 at a single dose up to 45 mg and multiple doses up to 40 mg once daily was found to be safe and well tolerated in healthy adults.  The most frequently reported adverse events were headache and nausea.  SUVN-D4010 exposure was dose proportional across the tested doses.  Steady state was achieved on day 2 after once-daily dosing for 14 days.  Food had no significant effect on the exposures but an increase in median time to attain the max. plasma concn. (tmax) from 2 h in a fasted state to 3.5 h in fed state was obsd.  The max. plasma concn. (Cmax) and the area under the concn.-time curve (AUC) of SUVN-D4010 was 37% and 39%, resp., lower in adult females compared to males following administration of a single 25 mg dose.  In the elderly population, Cmax and AUC of SUVN-D4010 were 42% and 37%, resp., lower compared to adult males following administration of a single 25 mg dose.  SUVN-D4010 was well tolerated and safe in elderly subjects (≥ 65 years) following a single 25 mg dose.  Conclusion: SUVN-D4010 was found to be safe and well tolerated in healthy human subjects.  SUVN-D4010 followed linear pharmacokinetics across the dose range.  Accumulation was in the range of 1.3- to 1.4-fold after multiple dosing.  Renal excretion is not the major route of elimination.  Food had no effect on the exposures but increased the tmax of SUVN-D4010.  Exposures were lower in females and elderly subjects suggesting sex and age effects on the pharmacokinetics of SUVN-D4010 and possible dose adjustment in these populations.  SUVN-D4010 was well tolerated and safe in elderly subjects after a single dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKWdz6etmtlLVg90H21EOLACvtfcHk0lh9x_5Se6qQxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtVars7nE&md5=1c6620287e3797ccd57aefaa49777e1a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs40261-021-01027-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40261-021-01027-4%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DMuddana%26aufirst%3DN.%2BR.%26aulast%3DGoyal%26aufirst%3DV.%2BK.%26aulast%3DPandey%26aufirst%3DS.%2BK.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DRavula%26aufirst%3DJ.%26aulast%3DJetta%26aufirst%3DS.%26aulast%3DPalacharla%26aufirst%3DV.%2BR.%2BC.%26atitle%3DFirst-in-human%2520studies%2520to%2520evaluate%2520the%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520a%2520novel%25205-HT4%2520partial%2520agonist%252C%2520SUVN-D4010%252C%2520in%2520healthy%2520adult%2520and%2520elderly%2520subjects%26jtitle%3DClin.%2520Drug%2520Investig.%26date%3D2021%26volume%3D41%26spage%3D469%26epage%3D482%26doi%3D10.1007%2Fs40261-021-01027-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santa, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sithiphong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guoliang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zozulya, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimmachack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghetti, A.</span></span> <span> </span><span class="NLM_article-title">Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1089/adt.2004.2.497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1089%2Fadt.2004.2.497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=15671647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVehtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=497-506&author=H.+Taoauthor=A.+D.+Santaauthor=A.+Guiaauthor=M.+Huangauthor=J.+Liguttiauthor=G.+Walkerauthor=K.+Sithiphongauthor=F.+Chanauthor=T.+Guoliangauthor=Z.+Zozulyaauthor=S.+Sayaauthor=R.+Phimmachackauthor=C.+Sieauthor=J.+Yuanauthor=L.+Wuauthor=J.+Xuauthor=A.+Ghetti&title=Automated+tight+seal+electrophysiology+for+assessing+the+potential+hERG+liability+of+pharmaceutical+compounds&doi=10.1089%2Fadt.2004.2.497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds</span></div><div class="casAuthors">Tao, Huimin; Ana, David Santa; Guia, Antonio; Huang, Mingxian; Ligutti, Joseph; Walker, George; Sithiphong, Khachonesine; Chan, Florence; Tao, Guoliang; Zozulya, Zoya; Saya, Steve; Phimmachack, Rick; Sie, Charles; Yuan, Julian; Wu, Lei; Xu, Jia; Ghetti, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">497-506</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.  Electrophysiol. is the most reliable in vitro screening method for identifying potential cardiac hERG liabilities, but only the recent advent of planar electrode-based voltage clamp electrophysiol. promises sufficient throughput to support the drug testing needs of most drug discovery programs.  The authors have assessed the reliability of this new format of the voltage clamp technol. in measuring the activity of small mols. on the hERG channel.  Based on the results herein of a screening against a panel of well-characterized hERG-active and -inactive mols., the authors demonstrate that planar electrode electrophysiol., utilizing the Sealchip and PatchXpress technol. platform (AVIVA Biosciences Corp., San Diego, CA), is comparable to traditional electrophysiol. based on glass micropipettes in its reliability and data content.  The new technol. will allow significantly higher throughput and more thorough testing of pharmaceutical compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX3rSpyKMUAbVg90H21EOLACvtfcHk0lgPdGLP5zdlQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVehtb7M&md5=40c3a9569d4e739551db6609173b3c58</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1089%2Fadt.2004.2.497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2004.2.497%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DH.%26aulast%3DSanta%26aufirst%3DA.%2BD.%26aulast%3DGuia%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DLigutti%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DG.%26aulast%3DSithiphong%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DF.%26aulast%3DGuoliang%26aufirst%3DT.%26aulast%3DZozulya%26aufirst%3DZ.%26aulast%3DSaya%26aufirst%3DS.%26aulast%3DPhimmachack%26aufirst%3DR.%26aulast%3DSie%26aufirst%3DC.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGhetti%26aufirst%3DA.%26atitle%3DAutomated%2520tight%2520seal%2520electrophysiology%2520for%2520assessing%2520the%2520potential%2520hERG%2520liability%2520of%2520pharmaceutical%2520compounds%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2004%26volume%3D2%26spage%3D497%26epage%3D506%26doi%3D10.1089%2Fadt.2004.2.497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reported 5-HT<sub>4</sub>R ligands along with the current series of compounds.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Genesis of ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>7a</b>–<b>7ai</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaO<sup><i>t</i></sup>Bu, 2-iodopropane, DMF, r.t., 16.0 h, 60%. (b) SOCl<sub>2</sub>, 1,2-dichloroethane, 0 °C-reflux, 1.0 h, 100%. (c) K<sub>2</sub>CO<sub>3</sub>, Boc protected amine <b>4a</b>–<b>4h</b>, DCM, 0 °C-r.t., 16.0 h. (d) TFA, DCM, 0 °C-r.t., 16.0 h, H<sub>2</sub>O, NaHCO<sub>3</sub>. (e) K<sub>2</sub>CO<sub>3</sub>, acetonitrile, R–X, r.t.-reflux, 7.0–16.0 h.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>12a</b>–<b>12ad</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, Et<sub>3</sub>N, DMAP, DCM, 0 °C-r.t., 16 h. (b) Hydrazine-hydrate, MeOH, r.t.-reflux, 10.0 h. (c) (i) DCM, acid chlroride 3, 0 °C-r.t., 4.0 h; (ii) H<sub>2</sub>O, NaHCO<sub>3</sub>, 2 h. (d) SOCl<sub>2</sub>, 1,2-dichloroethane, r.t.-reflux, 6.0–10.0 h. (e) K<sub>2</sub>CO<sub>3</sub>, acetonitrile, R–X, r.t-reflux, 7.0–16.0 h.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>17a</b>–<b>17c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, R–X, acetonitrile, r.t-reflux, 7.0–16.0 h. (b) NH<sub>2</sub>-OH·HCl, K<sub>2</sub>CO<sub>3</sub>, EtOH, r.t.-reflux, 16.0 h. (c) SOCl<sub>2</sub>, CH<sub>3</sub>OH, 0 °C-r.t., 6.0 h. (d) NaH, DMF, 120 °C 0.5 h.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0011.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>23a</b>–<b>23c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc<sub>2</sub>O, pyridine, NH<sub>4</sub>HCO<sub>3</sub>, acetonitrile, r.t., 16.0 h, 83%. (b) TFAA, Et<sub>3</sub>N, THF, 0 °C-r.t., 2.0 h, 86%. (c) NH<sub>2</sub>-OH·HCl, K<sub>2</sub>CO<sub>3</sub>, EtOH, r.t.-reflux, 16.0 h, 100%. (d) K<sub>2</sub>CO<sub>3</sub>, R–X, acetonitrile, r.t-reflux, 7.0–16.0 h. (e) NaH, DMF, 120 °C, 16.0 h.</p></p></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of compounds <b>7d</b>, <b>12h</b>, <b>12k</b>, <b>12l</b>, <b>12p</b>, and RS-67333 on attenuation of long-term memory deficits in ORT. Data represent mean ± SEM of exploration time in seconds; (<i>N</i> = 7–8); *<i>p</i> < 0.05, **<i>p</i> < 0.01, ***<i>p</i> < 0.001. Paired–<i>t</i>-test comparison of novel vs familiar object.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compounds <b>12h</b> and <b>12l</b> in RAM. Data represent mean ± SEM of % choice accuracy or total error compared to vehicle (F<sub>4,103</sub> = 19.54 for choice accuracy and F<sub>4,103</sub> = 14.81 for total error for compound <b>12h</b> and F<sub>4,105</sub> = 36.16 for choice accuracy and F<sub>4,105</sub> = 32.88 for total error for compound <b>12l</b>); <i>n</i> = 7–8; *<i>p</i> < 0.05, **<i>p</i> < 0.01, ***<i>p</i> < 0.001,****<i>p</i> < 0.0001 vs scopolamine (ANOVA followed by Dunnett’s test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0005.jpeg" id="rightTab-GRAPHIC-d7e3122-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Attenuation of long-term memory deficits in ORT by compound <b>12l</b>. Data represent (mean ± SEM) of exploration time compared to vehicle (<i>n</i> = 8–11/group). **<i>p</i> < 0.01, ***<i>p</i> < 0.001 (Paired–<i>t</i>-test comparison of novel vs familiar object). (B) Effect of compound <b>12l</b> on attenuation of long-term memory deficits in ORT assay. Data represent mean ± SEM of discrimination index. **<i>P</i> < 0.01 vs vehicle group (H<sub>7,74</sub> = 14.12; Kruskal–Wallis test followed by Dunn’s post hoc).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. 5-HT<sub>4</sub>R occupancy of compound <b>12l</b> and correlation with plasma and brain concentrations. Data shown are the mean ± SEM (<i>n</i> = 4–6 animals).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/medium/jm1c00703_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0007.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Effect of compound <b>5-HT</b>, <b>12l</b>, and RS-67333 on sAPPα secretion in the absence or presence of selective 5-HT<sub>4</sub>R antagonist GR-113808 by Western blot. Data represent mean of duplicates of fold over basal of sAPPα levels. Compound <b>5-HT</b> and 5-HT<sub>4</sub> receptor partial agonist compound <b>12l</b> and RS-67333 evoked stimulation of sAPPα secretion <i>in vitro</i> were monitored using tsa201 cells transiently transfected with human 5-HT<sub>4E</sub> receptor and human APP695.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00703/20210715/images/large/jm1c00703_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00703&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86725" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86725" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecoutey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochais, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic modulators of the serotonin 5-HT<sub>4</sub> receptor: a patent review (2014-present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1080/13543776.2020.1767587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1080%2F13543776.2020.1767587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=32400221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSgsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=495-508&author=C.+Lanthierauthor=P.+Dallemagneauthor=C.+Lecouteyauthor=S.+Claeysenauthor=C.+Rochais&title=Therapeutic+modulators+of+the+serotonin+5-HT4+receptor%3A+a+patent+review+%282014-present%29&doi=10.1080%2F13543776.2020.1767587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present)</span></div><div class="casAuthors">Lanthier, Caroline; Dallemagne, Patrick; Lecoutey, Cedric; Claeysen, Sylvie; Rochais, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">495-508</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A Review.  IntroductionNumerous chemotypes have been described over time in order to generate potent and selective 5-HT4R ligands.  Both agonists and antagonists have demonstrated their interest in several disease models.  This culminates with the FDA approval of tegaserod and prucalopride in the recent years.  Areas coveredThis review summarizes the patent applications from 2014 to present, dedicated to the use or the description of novel 5-HT4R modulators.  Several novel ligands and scaffolds have been industrially protected mainly in the field of central nervous system (CNS) pathologies as well as gastrointestinal disorders, including the combination with other drugs or for veterinary uses.  Expert opinionThe therapeutic potential of 5-HT4R modulators has been explored for several years in animal models, but also linked to potential safety issues with initial ligands.  The current use of prucalopride in humans demonstrates that its toxicity is not linked to the target and that 5-HT4R modulators are safe in humans.  Therefore, an important no. of studies and patents has continued in the recent years to expand the use of 5-HT4R modulators, not only to treat gastrointestinal disorders, but also for CNS pathologies.  This article details current efforts in this development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Q6zEPQKyZrVg90H21EOLACvtfcHk0lgsSxw1u5SQUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSgsLbM&md5=c9d6fa1474a9f3242dc0b029b3d2cf05</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1080%2F13543776.2020.1767587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2020.1767587%26sid%3Dliteratum%253Aachs%26aulast%3DLanthier%26aufirst%3DC.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DLecoutey%26aufirst%3DC.%26aulast%3DClaeysen%26aufirst%3DS.%26aulast%3DRochais%26aufirst%3DC.%26atitle%3DTherapeutic%2520modulators%2520of%2520the%2520serotonin%25205-HT4%2520receptor%253A%2520a%2520patent%2520review%2520%25282014-present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D495%26epage%3D508%26doi%3D10.1080%2F13543776.2020.1767587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adham, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kao, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laz, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schechter, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysse, P. J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartig, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branchek, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinshank, R. L.</span></span> <span> </span><span class="NLM_article-title">The 5-HT<sub>4</sub> receptor: molecular cloning and pharmacological characterization of two splice variants</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2815</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1995.tb07280.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1002%2Fj.1460-2075.1995.tb07280.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=7796807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2MXms1Ckt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=2806-2815&author=C.+Geraldauthor=N.+Adhamauthor=H.+T.+Kaoauthor=M.+A.+Olsenauthor=T.+M.+Lazauthor=L.+E.+Schechterauthor=J.+A.+Bardauthor=P.+J.-J.+Vaysseauthor=P.+R.+Hartigauthor=T.+A.+Branchekauthor=R.+L.+Weinshank&title=The+5-HT4+receptor%3A+molecular+cloning+and+pharmacological+characterization+of+two+splice+variants&doi=10.1002%2Fj.1460-2075.1995.tb07280.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants</span></div><div class="casAuthors">Gerald, Christophe; Adham, Nika; Kao, Hung-Teh; Olsen, Michael A.; Laz, Thomas M.; Schechter, Lee E.; Bard, Jonathan A.; Vaysse, Pierre J.-J.; Hartig, Paul R.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2806-15</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Mol. cloning efforts have provided primary amino acid sequence and signal transduction data for a large collection of serotonin receptor subtypes.  These include five 5-HT1-like receptors, three 5-HT2 receptors, one 5-HT3 receptor, two 5-HT5 receptors, one 5-HT6 receptor and one 5-HT7 receptor.  Mol. biol. information on the 5-HT4 receptor is notably absent from this list.  The authors now report the cloning of the pharmacol. defined 5-HT4 receptor.  Using degenerate oligonucleotide primers, the authors identified a rat brain PCR fragment which encoded a '5-HT receptor-like' amino acid sequence.  The corresponding full-length cDNA was isolated from a rat brain cDNA library.  Transiently expressed in COS-7 cells, this receptor stimulates adenylyl cyclase activity and is sensitive to the benzamide deriv. cisapride.  The response is also blocked by ICS-205930.  Interestingly, the authors isolated two splice variants of the receptor, 5-HT4L and 5-HT4S, differing in the length and sequence of their C-termini.  In rat brain, the 5-HT4S transcripts are restricted to the striatum, but the 5-HT4L transcripts are expressed throughout the brain, except in the cerebellum where it was barely detectable.  In peripheral tissues, differential expression was also obsd. in the atrium of the heart where only the 5-HT4S isoform was detectable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDLjGTNqkbC7Vg90H21EOLACvtfcHk0lgsSxw1u5SQUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1Ckt7Y%253D&md5=1bfa665fe162f63a50a5b083152bfa21</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1995.tb07280.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1995.tb07280.x%26sid%3Dliteratum%253Aachs%26aulast%3DGerald%26aufirst%3DC.%26aulast%3DAdham%26aufirst%3DN.%26aulast%3DKao%26aufirst%3DH.%2BT.%26aulast%3DOlsen%26aufirst%3DM.%2BA.%26aulast%3DLaz%26aufirst%3DT.%2BM.%26aulast%3DSchechter%26aufirst%3DL.%2BE.%26aulast%3DBard%26aufirst%3DJ.%2BA.%26aulast%3DVaysse%26aufirst%3DP.%2BJ.-J.%26aulast%3DHartig%26aufirst%3DP.%2BR.%26aulast%3DBranchek%26aufirst%3DT.%2BA.%26aulast%3DWeinshank%26aufirst%3DR.%2BL.%26atitle%3DThe%25205-HT4%2520receptor%253A%2520molecular%2520cloning%2520and%2520pharmacological%2520characterization%2520of%2520two%2520splice%2520variants%26jtitle%3DEMBO%2520J.%26date%3D1995%26volume%3D14%26spage%3D2806%26epage%3D2815%26doi%3D10.1002%2Fj.1460-2075.1995.tb07280.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hagena, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manahan-Vaughan, D.</span></span> <span> </span><span class="NLM_article-title">The serotonergic 5-HT<sub>4</sub> receptor: a unique modulator of hippocampal synaptic information processing and cognition</span>. <i>Neurobiol. Learn. Mem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1016/j.nlm.2016.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.nlm.2016.06.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=27317942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSitb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2017&pages=145-153&author=H.+Hagenaauthor=D.+Manahan-Vaughan&title=The+serotonergic+5-HT4+receptor%3A+a+unique+modulator+of+hippocampal+synaptic+information+processing+and+cognition&doi=10.1016%2Fj.nlm.2016.06.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The serotonergic 5-HT4 receptor: A unique modulator of hippocampal synaptic information processing and cognition</span></div><div class="casAuthors">Hagena, Hardy; Manahan-Vaughan, Denise</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Learning and Memory</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">145-153</span>CODEN:
                <span class="NLM_cas:coden">NLMEFR</span>;
        ISSN:<span class="NLM_cas:issn">1074-7427</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  Serotonin (5-hydroxytryptamine, 5-HT) contributes in multifarious ways to the regulation of brain function, spanning key aspects such as the sleep-wake cycle, appetite, mood and mental health.  The 5-HT receptors comprise seven receptor families (5-HT1-7) that are further subdivided into 14 receptor subtypes.  The role of the 5-HT receptor in the modulation of neuronal excitability has been well documented.  Recently, however, it has become apparent that the 5-HT4 receptor may contribute significantly to cognition and regulates less ostensible aspects of brain function: it engages in metaplastic regulation of synaptic responsiveness in key brain structures such as the hippocampus, thereby specifically promoting persistent forms of synaptic plasticity, and influences the direction of change in synaptic strength in selected hippocampal subfields.  This highly specific neuromodulatory control by the 5-HT4 receptor may in turn explain the reported role for this receptor in hippocampus-dependent cognition.  In this review article, we describe the role of the 5-HT4 receptor in hippocampal function, and describe how this receptor plays a unique and highly specialised role in synaptic information storage and cognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Zi8OATIdmrVg90H21EOLACvtfcHk0liHQ8q1U-aVxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSitb3O&md5=1e8be03017f92c9a815f094abc48f535</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.nlm.2016.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nlm.2016.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DHagena%26aufirst%3DH.%26aulast%3DManahan-Vaughan%26aufirst%3DD.%26atitle%3DThe%2520serotonergic%25205-HT4%2520receptor%253A%2520a%2520unique%2520modulator%2520of%2520hippocampal%2520synaptic%2520information%2520processing%2520and%2520cognition%26jtitle%3DNeurobiol.%2520Learn.%2520Mem.%26date%3D2017%26volume%3D138%26spage%3D145%26epage%3D153%26doi%3D10.1016%2Fj.nlm.2016.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maillet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc’h, F.</span></span> <span> </span><span class="NLM_article-title">New insights into serotonin 5-HT<sub>4</sub> receptors: a novel therapeutic target for Alzheimer’s disease?</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">85</span>, <span class="refDoi"> DOI: 10.2174/1567205043332252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.2174%2F1567205043332252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=15975071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjvF2jt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2004&pages=79-85&author=M.+Mailletauthor=S.+J.+Robertauthor=F.+Lezoualc%E2%80%99h&title=New+insights+into+serotonin+5-HT4+receptors%3A+a+novel+therapeutic+target+for+Alzheimer%E2%80%99s+disease%3F&doi=10.2174%2F1567205043332252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into serotonin 5-HT4 receptors: A novel therapeutic target for Alzheimer's disease?</span></div><div class="casAuthors">Maillet, Marjorie; Robert, Sylvain J.; Lezoualc'h, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">79-85</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The serotonin 5-HT4 receptor mediates many physiol. effects in the central nervous system.  The recent mol. identification of 5-HT4 receptors and the development of selective 5-HT4 receptor ligands have led to many important new insights into the signalling pathways and the physiol. roles of these G protein-coupled-receptors in neurons.  With respect to neurodegenerative disorders, it is suggested that 5-HT4 agonists may represent a new avenue for the treatment of Alzheimer's disease.  This mini-review will focus on recent in vitro and in vivo pharmacol. and biochem. studies showing the involvement of 5-HT4 receptors in cognitive processes and the amyloid precursor protein processing.  The potential use of 5-HT4 agonists for the treatment of AD will be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEEiivpw5diLVg90H21EOLACvtfcHk0liHQ8q1U-aVxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjvF2jt70%253D&md5=6e42fa1b968fffe34f6ee96ed37bc957</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F1567205043332252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205043332252%26sid%3Dliteratum%253Aachs%26aulast%3DMaillet%26aufirst%3DM.%26aulast%3DRobert%26aufirst%3DS.%2BJ.%26aulast%3DLezoualc%25E2%2580%2599h%26aufirst%3DF.%26atitle%3DNew%2520insights%2520into%2520serotonin%25205-HT4%2520receptors%253A%2520a%2520novel%2520therapeutic%2520target%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253F%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2004%26volume%3D1%26spage%3D79%26epage%3D85%26doi%3D10.2174%2F1567205043332252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tonini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, F.</span></span> <span> </span><span class="NLM_article-title">Drugs acting on serotonin receptors for the treatment of functional GI disorders</span>. <i>Dig Dis.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1159/000090309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1159%2F000090309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=16699264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A280%3ADC%252BD283msl2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=59-69&author=M.+Toniniauthor=F.+Pace&title=Drugs+acting+on+serotonin+receptors+for+the+treatment+of+functional+GI+disorders&doi=10.1159%2F000090309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs acting on serotonin receptors for the treatment of functional GI disorders</span></div><div class="casAuthors">Tonini Marcello; Pace Fabio</div><div class="citationInfo"><span class="NLM_cas:title">Digestive diseases (Basel, Switzerland)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">59-69</span>
        ISSN:<span class="NLM_cas:issn">0257-2753</span>.
    </div><div class="casAbstract">In the gut, serotonin (5-hydroxytryptamine: 5-HT) exerts a variety of effects on intrinsic enteric neurons, extrinsic afferents, enterocytes and smooth muscle cells, which are related to the expression of multiple 5-HT receptor types and subtypes regulating motility, vascular tone, secretion and perception.  Agonists and antagonists at 5-HT receptors have gained access to the market for the two major variants of the irritable bowel syndrome (IBS), a functional disorder characterized by abdominal pain associated with diarrhea and/or constipation in the absence of any organic abnormality.  Indeed, the 5-HT3 receptor antagonist alosetron is available in the US market for the treatment of women with severe, diarrhea-predominant IBS (D-IBS) refractory to conventional therapy, whereas tegaserod, a partial 5-HT4 receptor agonist, has been approved by the FDA and other regulatory agencies for the treatment of women with constipation-predominant IBS (C-IBS) or functional constipation.  This review is mainly intended to discuss the role of non-neuronal (paracrine) and neuronal 5-HT in the pathophysiology of functional gastrointestinal disorders (FGIDs), such as IBS and functional dyspepsia, and the mechanisms through which drugs acting on 5-HT receptors regulate visceral motility, perception and secretion in these two conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSq9uzlmfvkOmx8TEN9K18QfW6udTcc2eb8ot4NjOEjrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283msl2msA%253D%253D&md5=dda3f4f7c10a3e874dbeec3da1d316eb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1159%2F000090309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000090309%26sid%3Dliteratum%253Aachs%26aulast%3DTonini%26aufirst%3DM.%26aulast%3DPace%26aufirst%3DF.%26atitle%3DDrugs%2520acting%2520on%2520serotonin%2520receptors%2520for%2520the%2520treatment%2520of%2520functional%2520GI%2520disorders%26jtitle%3DDig%2520Dis.%26date%3D2006%26volume%3D24%26spage%3D59%26epage%3D69%26doi%3D10.1159%2F000090309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouras, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camilleri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mckinzie, S.</span></span> <span> </span><span class="NLM_article-title">Selective stimulation of colonic transit by the benzofuran 5-HT<sub>4</sub> agonist prucalopride, in healthy humans</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">682</span>– <span class="NLM_lpage">686</span>, <span class="refDoi"> DOI: 10.1136/gut.44.5.682</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1136%2Fgut.44.5.682" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10205205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK1MXjtF2ktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=1999&pages=682-686&author=E.+P.+Bourasauthor=M.+Camilleriauthor=D.+D.+Burtonauthor=S.+Mckinzie&title=Selective+stimulation+of+colonic+transit+by+the+benzofuran+5-HT4+agonist+prucalopride%2C+in+healthy+humans&doi=10.1136%2Fgut.44.5.682"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans</span></div><div class="casAuthors">Bouras, E. P.; Camilleri, M.; Burton, D. D.; McKinzie, S.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">682-686</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Prucalopride (R093877) is a selective and specific 5HT4 agonist, the first of a new chem. class of benzo-furans, with gastrointestinal prokinetic activities in vitro.  To evaluate the effects of prucalo-pride on gastrointestinal and colonic transit.  A validated scintigraphic technique was used to measure gastrointestinal and colonic transit over 48 h in 50 healthy volunteers.  For seven days, each subject received a daily dose of 0.5, 1, 2, or 4 mg prucalopride, or placebo in a double blind, randomized fashion.  The transit test was performed over the last 48 h.  There were significant accelerations of overall colonic transit at 4, 8, 24, and 48 h (p<0.05) and proximal colonic emptying t1/2 (p<0.05).  The 0.5, 2, and 4 mg doses of prucalopride were almost equally effective and accelerated colonic transit compared with placebo.  Prucalopride did not significantly alter gastric emptying (p>0.5) or small bowel transit (overall p=0.12).  The medication appeared to be well tolerated during the seven day treatment of healthy subjects.  Prucalopride accelerates colonic transit, partly by stimulating proximal colonic emptying, but does not alter gastric or small bowel transit in healthy human subjects.  Prucalopride deserves further study in patients with constipation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0h8xd_-Aq1bVg90H21EOLACvtfcHk0lg2vcTP5Rwb3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtF2ktrg%253D&md5=a2d3dd4271c784729e9fb49d4d6f74ab</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1136%2Fgut.44.5.682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgut.44.5.682%26sid%3Dliteratum%253Aachs%26aulast%3DBouras%26aufirst%3DE.%2BP.%26aulast%3DCamilleri%26aufirst%3DM.%26aulast%3DBurton%26aufirst%3DD.%2BD.%26aulast%3DMckinzie%26aufirst%3DS.%26atitle%3DSelective%2520stimulation%2520of%2520colonic%2520transit%2520by%2520the%2520benzofuran%25205-HT4%2520agonist%2520prucalopride%252C%2520in%2520healthy%2520humans%26jtitle%3DGut%26date%3D1999%26volume%3D44%26spage%3D682%26epage%3D686%26doi%3D10.1136%2Fgut.44.5.682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumuis, A.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptors, a place in the sun: act two</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2011.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.coph.2011.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=21342787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=87-93&author=J.+Bockaertauthor=S.+Claeysenauthor=V.+Companauthor=A.+Dumuis&title=5-HT4+receptors%2C+a+place+in+the+sun%3A+act+two&doi=10.1016%2Fj.coph.2011.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptors, a place in the sun: act two</span></div><div class="casAuthors">Bockaert, Joel; Claeysen, Sylvie; Compan, Valerie; Dumuis, Aline</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-93</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  5-HT4 receptors control brain physiol. functions such as learning and memory, feeding and mood behavior as well as gastro-intestinal transit. 5-HT4 receptors are one of the 5-HT receptors for which the available drugs and signalling knowledge are the most advanced.  Several therapeutic 5-HT4 receptor drugs have been commercialized.  Therefore, the hope that 5-HT4 receptors could also be the target for brain diseases is reasonable.  Several major devastating illnesses could benefit from 5-HT4 receptors-directed therapy such as Alzheimer's disease, feeding-assocd. diseases such as anorexia and major depressive disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe-9UQID9lqbVg90H21EOLACvtfcHk0ljFGAi41-XqzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXks1Wqs7Y%253D&md5=6f136864149bddba0ec1f0ed3b153968</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2011.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2011.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DClaeysen%26aufirst%3DS.%26aulast%3DCompan%26aufirst%3DV.%26aulast%3DDumuis%26aufirst%3DA.%26atitle%3D5-HT4%2520receptors%252C%2520a%2520place%2520in%2520the%2520sun%253A%2520act%2520two%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2011%26volume%3D11%26spage%3D87%26epage%3D93%26doi%3D10.1016%2Fj.coph.2011.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc’h, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, S. J.</span></span> <span> </span><span class="NLM_article-title">The serotonin 5-HT<sub>4</sub> receptor and the amyloid precursor protein processing</span>. <i>Exp. Gerontol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.1016/S0531-5565(02)00157-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2FS0531-5565%2802%2900157-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=12543273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD3sXkvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=159-166&author=F.+Lezoualc%E2%80%99hauthor=S.+J.+Robert&title=The+serotonin+5-HT4+receptor+and+the+amyloid+precursor+protein+processing&doi=10.1016%2FS0531-5565%2802%2900157-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The serotonin 5-HT4 receptor and the amyloid precursor protein processing</span></div><div class="casAuthors">Lezoualc'h, Frank; Robert, Sylvain J.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Gerontology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">159-166</span>CODEN:
                <span class="NLM_cas:coden">EXGEAB</span>;
        ISSN:<span class="NLM_cas:issn">0531-5565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A large body of evidence supports a major role for the serotonin 5-HT4 receptor in learning and memory and it is suggested that 5-HT4 agonists may be beneficial for memory disorders such as Alzheimer's disease (AD).  The 5-HT4 receptors are members of the G protein-coupled receptor superfamily and are pos. coupled to adenylyl cyclase.  In this communication the authors show that a neuronal isoform of the human 5-HT4 receptor, h5-HT4(g) regulates the metab. of the amyloid precursor protein (APP695).  This process is obsd. in Chinese hamster ovary (CHO) cells stably coexpressing the neuronal h5-HT4(g) receptor isoform as well as the human APP695.  The 5-HT4 agonists strongly stimulate the release of the non-amyloidogenic sol. amyloid precursor protein sAPPα as detected by immunoblot.  Prucalopride was more potent than serotonin (5-HT) with regard to enhanced of sAPPα secretion.  This process was blocked by a selective 5-HT4 antagonist, GR113808.  Furthermore, 5-HT4 ligands enhance sAPPα secretion via cAMP-dependent and PKA-independent signaling pathways indicating there are alternative pathways by which the h5-HT4 receptor via cAMP regulates APP metab.  Because the α-cleavage event may preclude the formation of amyloidogenic peptides, and secreted sAPPα has putative neuroprotective and enhancing-memory properties, our present data suggest the 5-HT4 receptor as a novel target for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobwRXVEkZwfLVg90H21EOLACvtfcHk0ljFGAi41-XqzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXkvFWmsw%253D%253D&md5=b4e047f7299a56f139389894c3a3060c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0531-5565%2802%2900157-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0531-5565%252802%252900157-2%26sid%3Dliteratum%253Aachs%26aulast%3DLezoualc%25E2%2580%2599h%26aufirst%3DF.%26aulast%3DRobert%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520serotonin%25205-HT4%2520receptor%2520and%2520the%2520amyloid%2520precursor%2520protein%2520processing%26jtitle%3DExp.%2520Gerontol.%26date%3D2003%26volume%3D38%26spage%3D159%26epage%3D166%26doi%3D10.1016%2FS0531-5565%2802%2900157-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugaza, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc’h, F.</span></span> <span> </span><span class="NLM_article-title">The human serotonin 5-HT<sub>4</sub> receptor regulates secretion of non-amyloidogenic precursor protein</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">44881</span>– <span class="NLM_lpage">44888</span>, <span class="refDoi"> DOI: 10.1074/jbc.M109008200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1074%2Fjbc.M109008200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=11584021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFegurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=44881-44888&author=S.+J.+Robertauthor=J.+L.+Zugazaauthor=R.+Fischmeisterauthor=A.+M.+Gardierauthor=F.+Lezoualc%E2%80%99h&title=The+human+serotonin+5-HT4+receptor+regulates+secretion+of+non-amyloidogenic+precursor+protein&doi=10.1074%2Fjbc.M109008200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein</span></div><div class="casAuthors">Robert, Sylvain J.; Zugaza, Jose L.; Fischmeister, Rodolphe; Gardier, Alain M.; Lezoualc'h, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">44881-44888</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The serotonin 5-HT4 receptor has recently gained a lot of attention for its functional roles in central processes such as memory and cognition.  In this study, we show that activation of the human 5-HT4 (h5-HT4) receptor stimulates the secretion of the non-amyloidogenic sol. form of the amyloid precursor protein (sAPPα).  5-HT enhanced the level of secreted sAPPα in a time- and dose-dependent manner in Chinese hamster ovary cells stably expressing the h5-HT4(e) receptor isoform.  The increase was inhibited by the selective 5-HT4 receptor antagonist, GR 113808.  The 5-HT4 selective agonists, prucalopride and renzapride, also increased secreted sAPPα in IMR32 human neuroblastoma cells.  The stimulatory effect of 5-HT was mimicked by forskolin, a direct activator of adenylyl cyclase, and 8-bromo-cAMP, a membrane-permeant cAMP analog.  On the contrary, inhibition of protein kinase A (PKA) by H 89 potentiated the 5-HT-induced increase in both secreted and cellular sAPPα.  This phenomenon involves a novel PKA-independent stimulatory process that overcomes a PKA-dependent inhibitory one.  Finally, activation of the h5-HT4(e) receptor did not modify extracellular amyloid β-protein in Chinese hamster ovary cells transfected with the human APP695.  Given the neuroprotective and enhancing memory effects of sAPPα, our results may open a new avenue for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZXW1Ib2lqw7Vg90H21EOLACvtfcHk0ljkVnQxG0ZOBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFegurk%253D&md5=bf4cbeb9c1c76976cde9ce9579a7ffc5</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109008200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109008200%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DS.%2BJ.%26aulast%3DZugaza%26aufirst%3DJ.%2BL.%26aulast%3DFischmeister%26aufirst%3DR.%26aulast%3DGardier%26aufirst%3DA.%2BM.%26aulast%3DLezoualc%25E2%2580%2599h%26aufirst%3DF.%26atitle%3DThe%2520human%2520serotonin%25205-HT4%2520receptor%2520regulates%2520secretion%2520of%2520non-amyloidogenic%2520precursor%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D44881%26epage%3D44888%26doi%3D10.1074%2Fjbc.M109008200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumuis, A.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptors</span>. <i>Curr. Drug Targets: CNS Neurol. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.2174/1568007043482615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.2174%2F1568007043482615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=14965243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisFWksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=39-51&author=J.+Bockaertauthor=S.+Claeysenauthor=V.+Companauthor=A.+Dumuis&title=5-HT4+receptors&doi=10.2174%2F1568007043482615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptors</span></div><div class="casAuthors">Bockaert, J.; Claeysen, S.; Compan, V.; Dumuis, A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets: CNS & Neurological Disorders</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">39-51</span>CODEN:
                <span class="NLM_cas:coden">CDTCCC</span>;
        ISSN:<span class="NLM_cas:issn">1568-007X</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Serotonin 4 receptors (5-HT4Rs) were discovered 15 yr ago.  They are coded by a very complex gene (700Kb, 38 exons) which generates 8 C-terminal variants (a, b, c, d, e, f, g, and n).  Their sequences differ after position L358.  Another variant is characterized by a 14 residue insertion within the extracellular loop 2.  Highly selective potent 5-HT4 receptor antagonists and partial agonists which cross the blood-brain barrier have been synthesized, but a specific full agonist for brain studies is still missing.  Based on physiol. and behavioral expts., 5-HT4Rs may be targets to treat cognitive deficits, abdominal pain, and feeding disorders.  One 5-HT4R-directed drug (SL65.0155) is already in phase II to treat patients suffering from memory deficits or dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoemFXFD0xNLrVg90H21EOLACvtfcHk0ljkVnQxG0ZOBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisFWksrc%253D&md5=b9139c95c9d832dd89b51d45fc3bde96</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F1568007043482615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568007043482615%26sid%3Dliteratum%253Aachs%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DClaeysen%26aufirst%3DS.%26aulast%3DCompan%26aufirst%3DV.%26aulast%3DDumuis%26aufirst%3DA.%26atitle%3D5-HT4%2520receptors%26jtitle%3DCurr.%2520Drug%2520Targets%253A%2520CNS%2520Neurol.%2520Disord.%26date%3D2004%26volume%3D3%26spage%3D39%26epage%3D51%26doi%3D10.2174%2F1568007043482615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubitski, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutzman-Engwall, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horner, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorczyca, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siok, C. J.</span></span> <span> </span><span class="NLM_article-title">The 5-HT<sub>4</sub> receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1124/jpet.112.192351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1124%2Fjpet.112.192351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=22408061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=681-691&author=D.+E.+Johnsonauthor=E.+Drummondauthor=S.+Grimwoodauthor=A.+Sawant-Basakauthor=E.+Millerauthor=E.+Tsengauthor=L.+L.+McDowellauthor=M.+A.+Vanase-Frawleyauthor=K.+E.+Fisherauthor=D.+M.+Rubitskiauthor=K.+J.+Stutzman-Engwallauthor=R.+T.+Nelsonauthor=W.+E.+Hornerauthor=R.+R.+Gorczycaauthor=M.+Hajosauthor=C.+J.+Siok&title=The+5-HT4+receptor+agonists+prucalopride+and+PRX-03140+increase+acetylcholine+and+histamine+levels+in+the+rat+prefrontal+cortex+and+the+power+of+stimulated+hippocampal+%CE%B8+oscillations&doi=10.1124%2Fjpet.112.192351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations</span></div><div class="casAuthors">Johnson, David E.; Drummond, Elena; Grimwood, Sarah; Sawant-Basak, Aarti; Miller, Emily; Tseng, Elaine; McDowell, Laura L.; Vanase-Frawley, Michelle A.; Fisher, Katherine E.; Rubitski, David M.; Stutzman-Engwall, Kim J.; Nelson, Robin T.; Horner, Weldon E.; Gorczyca, Roxanne R.; Hajos, Mihaly; Siok, Chester J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">681-691</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">5-Hydroxytryptamine (5-HT)4 receptor agonists reportedly stimulate brain acetylcholine (ACh) release, a property that might provide a new pharmacol. approach for treating cognitive deficits assocd. with Alzheimer's disease.  The purpose of this study was to compare the binding affinities, functional activities, and effects on neuropharmacol. responses assocd. with cognition of two highly selective 5-HT4 receptor agonists, prucalopride and 6,7-dihydro-4-hydroxy-7-isopropyl-6-oxo-N-[3-(piperidin-1-yl)propyl]thieno[2,3-b]pyridine-5-carboxamide (PRX-03140).  In vitro, prucalopride and PRX-03140 bound to native rat brain 5-HT4 receptors with Ki values of 30 nM and 110 nM, resp., and increased cAMP prodn. in human embryonic kidney-293 cells expressing recombinant rat 5-HT4 receptors.  In vivo receptor occupancy studies established that prucalopride and PRX-03140 were able to penetrate the brain and bound to 5-HT4 receptors in rat brain, achieving 50% receptor occupancy at free brain exposures of 330 nM and 130 nM, resp.  Rat microdialysis studies revealed that prucalopride maximally increased ACh and histamine levels in the prefrontal cortex at 5 and 10 mg/kg, whereas PRX-03140 significantly increased cortical histamine levels at 50 mg/kg, failing to affect ACh release at doses lower than 150 mg/kg.  In combination studies, donepezil-induced increases in cortical ACh levels were potentiated by prucalopride and PRX-03140.  Electrophysiol. studies in rats demonstrated that both compds. increased the power of brainstem-stimulated hippocampal θ oscillations at 5.6 mg/kg.  These findings show for the first time that the 5-HT4 receptor agonists prucalopride and PRX-03140 can increase cortical ACh and histamine levels, augment donepezil-induced ACh increases, and increase stimulated-hippocampal θ power, all neuropharmacol. parameters consistent with potential pos. effects on cognitive processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYkki5FaX4E7Vg90H21EOLACvtfcHk0ljkVnQxG0ZOBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWltL4%253D&md5=a85101ee05a17788379fad99a454347b</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.192351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.192351%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BE.%26aulast%3DDrummond%26aufirst%3DE.%26aulast%3DGrimwood%26aufirst%3DS.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DMcDowell%26aufirst%3DL.%2BL.%26aulast%3DVanase-Frawley%26aufirst%3DM.%2BA.%26aulast%3DFisher%26aufirst%3DK.%2BE.%26aulast%3DRubitski%26aufirst%3DD.%2BM.%26aulast%3DStutzman-Engwall%26aufirst%3DK.%2BJ.%26aulast%3DNelson%26aufirst%3DR.%2BT.%26aulast%3DHorner%26aufirst%3DW.%2BE.%26aulast%3DGorczyca%26aufirst%3DR.%2BR.%26aulast%3DHajos%26aufirst%3DM.%26aulast%3DSiok%26aufirst%3DC.%2BJ.%26atitle%3DThe%25205-HT4%2520receptor%2520agonists%2520prucalopride%2520and%2520PRX-03140%2520increase%2520acetylcholine%2520and%2520histamine%2520levels%2520in%2520the%2520rat%2520prefrontal%2520cortex%2520and%2520the%2520power%2520of%2520stimulated%2520hippocampal%2520%25CE%25B8%2520oscillations%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D681%26epage%3D691%26doi%3D10.1124%2Fjpet.112.192351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castro-Alvarez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chávez-Ángel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, R.</span></span> <span> </span><span class="NLM_article-title">Understanding the molecular basis of 5-HT <sub>4</sub> receptor partial agonists through 3D-QSAR studies</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3602</span>, <span class="refDoi"> DOI: 10.3390/ijms22073602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.3390%2Fijms22073602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=33808456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3MXht1GktLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2021&pages=3602&author=A.+Castro-Alvarezauthor=E.+Ch%C3%A1vez-%C3%81ngelauthor=R.+Nelson&title=Understanding+the+molecular+basis+of+5-HT+4+receptor+partial+agonists+through+3D-QSAR+studies&doi=10.3390%2Fijms22073602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding the molecular basis of 5-HT4 receptor partial agonists through 3D-QSAR studies</span></div><div class="casAuthors">Castro-Alvarez, Alejandro; Chavez-Angel, Emigdio; Nelson, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3602</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disorder whose prevalence has an incidence in senior citizens.  Unfortunately, current pharmacotherapy only offers symptom relief for patients with side effects such as bradycardia, nausea, and vomiting.  Therefore, there is a present need to provide other therapeutic alternatives for treatments for these disorders.  The 5-HT4 receptor is an attractive therapeutic target since it has a potential role in central and peripheral nervous system disorders such as AD, irritable bowel syndrome, and gastroparesis.  Quant. structure-activity relationship anal. of a series of 62 active compds. in the 5-HT4 receptor was carried out in the present work.  The structure-activity relationship was estd. using three-dimensional quant. structure-activity relationship (3D-QSAR) techniques based on these structures' field mol. (force and Gaussian field).  The best force-field QSAR models achieve a value for the coeff. of detn. of the training set of R2training = 0.821, and for the test set R2test = 0.667, while for Gaussian-field QSAR the training and the test were R2training = 0.898 and R2test = 0.695, resp.  The obtained results were validated using a coeff. of correlation of the leave-one-out crossvalidation of Q2 LOO = 0.804 and Q2 LOO = 0.886 for force- and Gaussian-field QSAR, resp.  Based on these results, novel 5-HT4 partial agonists with potential biol. activity (pEC50 8.209-9.417 for force-field QSAR and 9.111-9.856 for Gaussian-field QSAR) were designed.  In addn., for the new analogs, their absorption, distribution, metab., excretion, and toxicity properties were also analyzed.  The results show that these new derivs. also have reasonable pharmacokinetics and drug-like properties.  Our findings suggest novel routes for the design and development of new 5-HT4 partial agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwmigHC7VPuLVg90H21EOLACvtfcHk0ljRj83AVNtujQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXht1GktLrK&md5=783dda0da13a8ee8867b280bb120bf75</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3390%2Fijms22073602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms22073602%26sid%3Dliteratum%253Aachs%26aulast%3DCastro-Alvarez%26aufirst%3DA.%26aulast%3DCh%25C3%25A1vez-%25C3%2581ngel%26aufirst%3DE.%26aulast%3DNelson%26aufirst%3DR.%26atitle%3DUnderstanding%2520the%2520molecular%2520basis%2520of%25205-HT%25204%2520receptor%2520partial%2520agonists%2520through%25203D-QSAR%2520studies%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2021%26volume%3D22%26spage%3D3602%26doi%3D10.3390%2Fijms22073602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawant-Basak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waizumi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papanikolaou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersen, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutzman-Engwall, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubitski, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanase-Frawley, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span></span> <span> </span><span class="NLM_article-title">Identification of multiple 5-HT<sub>4</sub> partial agonist clinical candidates for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9240</span>– <span class="NLM_lpage">9254</span>, <span class="refDoi"> DOI: 10.1021/jm300953p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300953p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGhsLzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9240-9254&author=M.+A.+Brodneyauthor=D.+E.+Johnsonauthor=A.+Sawant-Basakauthor=K.+J.+Coffmanauthor=E.+M.+Drummondauthor=E.+L.+Hudsonauthor=K.+E.+Fisherauthor=H.+Noguchiauthor=N.+Waizumiauthor=L.+L.+McDowellauthor=A.+Papanikolaouauthor=B.+A.+Pettersenauthor=A.+W.+Schmidtauthor=E.+Tsengauthor=K.+Stutzman-Engwallauthor=D.+M.+Rubitskiauthor=M.+A.+Vanase-Frawleyauthor=S.+Grimwood&title=Identification+of+multiple+5-HT4+partial+agonist+clinical+candidates+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm300953p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Multiple 5-HT4 Partial Agonist Clinical Candidates for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Brodney, Michael A.; Johnson, David E.; Sawant-Basak, Aarti; Coffman, Karen J.; Drummond, Elena M.; Hudson, Emily L.; Fisher, Katherine E.; Noguchi, Hirohide; Waizumi, Nobuaki; McDowell, Laura L.; Papanikolaou, Alexandros; Pettersen, Betty A.; Schmidt, Anne W.; Tseng, Elaine; Stutzman-Engwall, Kim; Rubitski, David M.; Vanase-Frawley, Michelle A.; Grimwood, Sarah</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9240-9254</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cognitive impairments obsd. in Alzheimer's disease (AD) are in part a consequence of reduced acetylcholine (ACh) levels resulting from a loss of cholinergic neurons.  Preclinically, serotonin 4 receptor (5-HT4) agonists are reported to modulate cholinergic function and therefore may provide a new mechanistic approach for treating cognitive deficits assocd. with AD.  Herein the authors communicate the design and synthesis of potent, selective, and brain penetrant 5-HT4 agonists.  The overall goal of the medicinal chem. strategy was identification of structurally diverse clin. candidates with varying intrinsic activities.  The exposure-response relationships between binding affinity, intrinsic activity, receptor occupancy, drug exposure, and pharmacodynamic activity in relevant preclin. models of AD were utilized as key selection criteria for advancing compds.  On the basis of their excellent balance of pharmacokinetic attributes and safety, two lead 5-HT4 partial agonist candidates PF-04995274 and PF-03382792 were chosen for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqT9o-N9H9KbVg90H21EOLACvtfcHk0lhZNUvRy6Wndg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGhsLzJ&md5=269b3b0ff783eafbaa8f45a90f320a46</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm300953p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300953p%26sid%3Dliteratum%253Aachs%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DJohnson%26aufirst%3DD.%2BE.%26aulast%3DSawant-Basak%26aufirst%3DA.%26aulast%3DCoffman%26aufirst%3DK.%2BJ.%26aulast%3DDrummond%26aufirst%3DE.%2BM.%26aulast%3DHudson%26aufirst%3DE.%2BL.%26aulast%3DFisher%26aufirst%3DK.%2BE.%26aulast%3DNoguchi%26aufirst%3DH.%26aulast%3DWaizumi%26aufirst%3DN.%26aulast%3DMcDowell%26aufirst%3DL.%2BL.%26aulast%3DPapanikolaou%26aufirst%3DA.%26aulast%3DPettersen%26aufirst%3DB.%2BA.%26aulast%3DSchmidt%26aufirst%3DA.%2BW.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DStutzman-Engwall%26aufirst%3DK.%26aulast%3DRubitski%26aufirst%3DD.%2BM.%26aulast%3DVanase-Frawley%26aufirst%3DM.%2BA.%26aulast%3DGrimwood%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520multiple%25205-HT4%2520partial%2520agonist%2520clinical%2520candidates%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9240%26epage%3D9254%26doi%3D10.1021%2Fjm300953p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptor agonists for the treatment of Alzheimer’s disease</span>. <i>Neurosci. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>02</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.4236/nm.2011.22013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.4236%2Fnm.2011.22013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVKht77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=02&publication_year=2011&pages=87-92&author=I.+Ahmadauthor=R.+Nirogi&title=5-HT4+receptor+agonists+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.4236%2Fnm.2011.22013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptor agonists for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Ahmad, Ishtiyaque; Nirogi, Ramakrishna</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience & Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-92</span>CODEN:
                <span class="NLM_cas:coden">NMEEBO</span>;
        ISSN:<span class="NLM_cas:issn">2158-2912</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a progressive neurol. disorder primarily affecting new memory formation as well as retrieval of previously acquired memories.  According to World Health Organization, current global population suffering from cognitive impairment is estd. to 37 million.  The no. is projected to double in next one and half decade.  Half of the population afflicted with dementia is represented by AD patients.  Current therapies, which provide marginal symptomatic relief to AD patients, are effective only in half of the patient population.  In depth understanding of the mol. mechanism of the disease is urgently required to develop more effective therapies.  Therapies in clin. development may either offer symptomatic relief to patients or provide pure disease modifications, thus limiting benefit to patients.  5-HT4 receptor agonists offer an attractive option for the treatment of AD patients.  Activation of 5-HT4 receptor under preclin. conditions is demonstrated to improve neurotransmission and enhance the release of acetylcholine resulting in the memory formation.  In various cell based and animal models, partial 5-HT4 receptor agonists are demonstrated to promote the release of sol. amyloid precursor protein alpha and block the release of amyloid beta peptide offering suitable candidates as disease modification agents.  Remarkably, 5-HT4 receptor agonists are also reported to induce neurogenesis in hippocampus as well as enteric system through the activation of cAMP response element binding protein in rodents.  Taken together, 5-HT4 agonists address all major facets of Alzheimer's disease and may provide therapeutic potential for other neurol. disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuyo7_gJ-VqrVg90H21EOLACvtfcHk0lhZNUvRy6Wndg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVKht77M&md5=641e27dc6f84024df4874cbf50bb4598</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.4236%2Fnm.2011.22013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fnm.2011.22013%26sid%3Dliteratum%253Aachs%26aulast%3DAhmad%26aufirst%3DI.%26aulast%3DNirogi%26aufirst%3DR.%26atitle%3D5-HT4%2520receptor%2520agonists%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurosci.%2520Med.%26date%3D2011%26volume%3D02%26spage%3D87%26epage%3D92%26doi%3D10.4236%2Fnm.2011.22013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptor ligands: applications and new prospects</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">344</span>, <span class="refDoi"> DOI: 10.1021/jm020099f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020099f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhs1ejsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=319-344&author=M.+Langloisauthor=R.+Fischmeister&title=5-HT4+receptor+ligands%3A+applications+and+new+prospects&doi=10.1021%2Fjm020099f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 Receptor Ligands: Applications and New Prospects</span></div><div class="casAuthors">Langlois, Michel; Fischmeister, Rodolphe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">319-344</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The present paper describes the recent advances made in medicinal chem. and in the mechanisms proposed to explain the physiol. role of 5-HT4 receptors in the different tissues where they are present and the putative clin. applications of the agonists and antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0XyIrWuAGRLVg90H21EOLACvtfcHk0lhZNUvRy6Wndg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhs1ejsg%253D%253D&md5=a812f9e611bcea02f0e819783fa2f1c9</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm020099f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020099f%26sid%3Dliteratum%253Aachs%26aulast%3DLanglois%26aufirst%3DM.%26aulast%3DFischmeister%26aufirst%3DR.%26atitle%3D5-HT4%2520receptor%2520ligands%253A%2520applications%2520and%2520new%2520prospects%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D319%26epage%3D344%26doi%3D10.1021%2Fjm020099f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Modica, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittala, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siracusa, M. A.</span></span> <span> </span><span class="NLM_article-title">Serotonin 5-HT<sub>3</sub> and 5-HT<sub>4</sub> ligands: an update of medicinal chemistry research in the past few years</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">334</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.2174/092986710790192730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.2174%2F092986710790192730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=20015043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSlsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=334-362&author=M.+N.+Modicaauthor=V.+Pittalaauthor=G.+Romeoauthor=L.+Salernoauthor=M.+A.+Siracusa&title=Serotonin+5-HT3+and+5-HT4+ligands%3A+an+update+of+medicinal+chemistry+research+in+the+past+few+years&doi=10.2174%2F092986710790192730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Serotonin 5-HT3 and 5-HT4 ligands: an update of medicinal chemistry research in the last few years</span></div><div class="casAuthors">Modica, M. N.; Pittala, V.; Romeo, G.; Salerno, L.; Siracusa, M. A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">334-362</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The biogenic amine serotonin (5-hydroxytryptamine, 5-HT) is one of the most studied neurotransmitters in the central nervous system.  It acts through the activation of at least fourteen 5-HT receptor subtypes.  Over the last two decades, high attention was devoted to the 5-HT3 and 5-HT4 receptors due to their colocalization in the gastrointestinal tract and because their ligands are useful in the treatment of intestinal serotonergic system dysfunctions.  The focus of this review is to discuss the literature concerning recent advances on 5-HT3R and 5-HT4R ligands and their structure-activity relationships from a medicinal chem. perspective.  During the last few years, new and significant progresses have been made in the field of novel potent and selective ligands, mixed ligands, agonists, partial agonists, and antagonists, and a no. of patents have been filed.  Furthermore several ligands targeting the 5-HT3R and 5-HT4R have been proposed for novel therapeutic indications such as the treatment of various psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdNfYoWkWpJbVg90H21EOLACvtfcHk0lg5gWDJA5Wrow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSlsr0%253D&md5=7031f777b035675f1c562ec72c054f85</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F092986710790192730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710790192730%26sid%3Dliteratum%253Aachs%26aulast%3DModica%26aufirst%3DM.%2BN.%26aulast%3DPittala%26aufirst%3DV.%26aulast%3DRomeo%26aufirst%3DG.%26aulast%3DSalerno%26aufirst%3DL.%26aulast%3DSiracusa%26aufirst%3DM.%2BA.%26atitle%3DSerotonin%25205-HT3%2520and%25205-HT4%2520ligands%253A%2520an%2520update%2520of%2520medicinal%2520chemistry%2520research%2520in%2520the%2520past%2520few%2520years%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D334%26epage%3D362%26doi%3D10.2174%2F092986710790192730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castriconi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mennuni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caselli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rienzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menziani, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sbraccia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappelli, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationship studies in serotonin 5-HT<sub>4</sub> receptor ligands based on a benzo[<i>de</i>][2,6]naphthridine scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">36</span>– <span class="NLM_lpage">46</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.05.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.ejmech.2014.05.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=24871995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVCqurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=36-46&author=F.+Castriconiauthor=M.+Paolinoauthor=G.+Giulianiauthor=M.+Anziniauthor=G.+Campianiauthor=L.+Mennuniauthor=C.+Sabatiniauthor=M.+Lanzaauthor=G.+Caselliauthor=F.+De+Rienzoauthor=M.+C.+Menzianiauthor=M.+Sbracciaauthor=P.+Molinariauthor=T.+Costaauthor=A.+Cappelli&title=Synthesis+and+structure-activity+relationship+studies+in+serotonin+5-HT4+receptor+ligands+based+on+a+benzo%5Bde%5D%5B2%2C6%5Dnaphthridine+scaffold&doi=10.1016%2Fj.ejmech.2014.05.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and structure-activity relationship studies in serotonin 5-HT4 receptor ligands based on a benzo[de][2,6]naphthyridine scaffold</span></div><div class="casAuthors">Castriconi, Federica; Paolino, Marco; Giuliani, Germano; Anzini, Maurizio; Campiani, Giuseppe; Mennuni, Laura; Sabatini, Chiara; Lanza, Marco; Caselli, Gianfranco; De Rienzo, Francesca; Menziani, Maria Cristina; Sbraccia, Maria; Molinari, Paola; Costa, Tommaso; Cappelli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">36-46</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A small series of serotonin 5-HT4 receptor ligands has been designed from flexible 2-methoxyquinoline compds. by applying the conformational constraint approach.  2-Methoxyquinoline compds., e.g., I, and the corresponding conformationally constrained analogs, e.g., II, were synthesized and their interactions with the 5-HT4 receptor were examd. by measuring both binding affinity and the ability to promote or inhibit receptor-G protein coupling.  Ester deriv. I and conformationally constrained compd. II were demonstrated to be the most interesting compds. showing a nanomolar 5-HT4R affinity similar to that shown by ref. ligands cisapride (III) and RS-23,597-190 (IV).  The result was rationalized by docking studies in term of high similarity in the binding modalities of flexible I and conformationally constrained II.  The intrinsic efficacy of some selected ligands was detd. by evaluating the receptor-G protein coupling and the results obtained demonstrated that the nature and the position of substituents play a crit. role in the interaction of these ligands with their receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr3OLUrCRSLVg90H21EOLACvtfcHk0lg5gWDJA5Wrow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVCqurfF&md5=f638b3b57a0130f99d4bd9095e53ce9e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.05.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.05.015%26sid%3Dliteratum%253Aachs%26aulast%3DCastriconi%26aufirst%3DF.%26aulast%3DPaolino%26aufirst%3DM.%26aulast%3DGiuliani%26aufirst%3DG.%26aulast%3DAnzini%26aufirst%3DM.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DMennuni%26aufirst%3DL.%26aulast%3DSabatini%26aufirst%3DC.%26aulast%3DLanza%26aufirst%3DM.%26aulast%3DCaselli%26aufirst%3DG.%26aulast%3DDe%2BRienzo%26aufirst%3DF.%26aulast%3DMenziani%26aufirst%3DM.%2BC.%26aulast%3DSbraccia%26aufirst%3DM.%26aulast%3DMolinari%26aufirst%3DP.%26aulast%3DCosta%26aufirst%3DT.%26aulast%3DCappelli%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationship%2520studies%2520in%2520serotonin%25205-HT4%2520receptor%2520ligands%2520based%2520on%2520a%2520benzo%255Bde%255D%255B2%252C6%255Dnaphthridine%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D82%26spage%3D36%26epage%3D46%26doi%3D10.1016%2Fj.ejmech.2014.05.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spencer, J.P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J.C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medhurst, A.D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehmi, S.S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calver, A.R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Randall, A.D.</span></span> <span> </span><span class="NLM_article-title">Modulation of hippocampal excitability by 5-HT<sub>4</sub> receptor agonists persists in a transgenic model of Alzheimer’s disease</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2004.06.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.neuroscience.2004.06.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=15489027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2cXos1yktbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2004&pages=49-54&author=J.P.+Spencerauthor=J.T.+Brownauthor=J.C.+Richardsonauthor=A.D.+Medhurstauthor=S.S.+Sehmiauthor=A.R.+Calverauthor=A.D.+Randall&title=Modulation+of+hippocampal+excitability+by+5-HT4+receptor+agonists+persists+in+a+transgenic+model+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neuroscience.2004.06.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease</span></div><div class="casAuthors">Spencer, J. P.; Brown, J. T.; Richardson, J. C.; Medhurst, A. D.; Sehmi, S. S.; Calver, A. R.; Randall, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-54</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">5-HT4 receptors are widely distributed in both peripheral and central nervous systems where they couple, via a G-protein, to the activation of adenylate cyclase.  In the brain, the highest 5-HT4 receptor densities are found in the limbic system, including the hippocampus and frontal cortex.  It has been suggested that activation of these receptors may be of therapeutic benefit in diseases that produce cognitive deficits such as Alzheimer's disease (AD).  Previous electrophysiol. studies have shown that the 5-HT4 agonist, Zacopride, can increase population spike amplitude recorded in region CA1 of rat hippocampal slices in a cAMP/cAMP-dependent protein kinase A-dependent manner.  The authors report here that the 5-HT4 agonist, prucalopride, and the 5-HT4 partial agonist, SL65.0155, produce a similar effect in rat hippocampal slices and that the specific 5-HT4 antagonist, GR113808, blocks these effects.  To investigate the potential use of 5-HT4 agonists in the treatment of AD, Prucalopride was applied to hippocampal slices from a transgenic mouse line that overexpresses the Aβ peptide.  Despite the deficit in synaptic transmission present in these mice, the percentage increase of the CA1 population spike induced by Prucalopride was the same as that obsd. in wild-type mice.  These data support 5-HT4 receptors as a target for cognitive enhancement and suggest that a partial agonist would be sufficient to produce benefits, while reducing potential peripheral side effects.  In addn., the authors show that 5-HT4 receptors remain functional in the presence of excess Aβ peptide and may therefore be a useful target in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM0T_aSjIK77Vg90H21EOLACvtfcHk0ljCNa_bEyXG_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXos1yktbo%253D&md5=5f313bb6ae0b51608fffea3c9c6d4eee</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2004.06.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2004.06.070%26sid%3Dliteratum%253Aachs%26aulast%3DSpencer%26aufirst%3DJ.P.%26aulast%3DBrown%26aufirst%3DJ.T.%26aulast%3DRichardson%26aufirst%3DJ.C.%26aulast%3DMedhurst%26aufirst%3DA.D.%26aulast%3DSehmi%26aufirst%3DS.S.%26aulast%3DCalver%26aufirst%3DA.R.%26aulast%3DRandall%26aufirst%3DA.D.%26atitle%3DModulation%2520of%2520hippocampal%2520excitability%2520by%25205-HT4%2520receptor%2520agonists%2520persists%2520in%2520a%2520transgenic%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuroscience%26date%3D2004%26volume%3D129%26spage%3D49%26epage%3D54%26doi%3D10.1016%2Fj.neuroscience.2004.06.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span> </span><span class="NLM_article-title">EPIX Pharmaceuticals Reports Compelling
Clinical Results for PRX-03140
in Alzheimer's Disease</span>. <a href="https://www.fiercebiotech.com/biotech/press-release-epix-pharmaceuticals-reports-compelling-clinical-results-for-prx-03140" class="extLink">https://www.fiercebiotech.com/biotech/press-release-epix-pharmaceuticals-reports-compelling-clinical-results-for-prx-03140</a> (accessed 2021-04-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=EPIX+Pharmaceuticals+Reports+Compelling%0AClinical+Results+for+PRX-03140%0Ain+Alzheimer%27s+Disease.+https%3A%2F%2Fwww.fiercebiotech.com%2Fbiotech%2Fpress-release-epix-pharmaceuticals-reports-compelling-clinical-results-for-prx-03140+%28accessed+2021-04-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DEPIX%2520Pharmaceuticals%2520Reports%2520Compelling%250AClinical%2520Results%2520for%2520PRX-03140%250Ain%2520Alzheimer%2527s%2520Disease" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span> </span><span class="NLM_article-title">Therapeutics PRX-03140</span>. <a href="https://www.alzforum.org/therapeutics/prx-03140" class="extLink">https://www.alzforum.org/therapeutics/prx-03140</a> (accessed 2021-04-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Therapeutics+PRX-03140.+https%3A%2F%2Fwww.alzforum.org%2Ftherapeutics%2Fprx-03140+%28accessed+2021-04-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DTherapeutics%2520PRX-03140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marchetti-Gauthier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumuis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soumireu-Mourat, B.</span></span> <span> </span><span class="NLM_article-title">BIMU1 increases associative memory in rats by activating 5-HT<sub>4</sub> receptors</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1016/S0028-3908(97)00058-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2FS0028-3908%2897%2900058-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=9225296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2sXktlSrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=697-706&author=E.+Marchetti-Gauthierauthor=F.+S.+Romanauthor=A.+Dumuisauthor=J.+Bockaertauthor=B.+Soumireu-Mourat&title=BIMU1+increases+associative+memory+in+rats+by+activating+5-HT4+receptors&doi=10.1016%2FS0028-3908%2897%2900058-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">BIMU1 increases associative memory in rats by activating 5-HT4 receptors</span></div><div class="casAuthors">Marchetti-Gauthier, E.; Roman, F. S.; Dumuis, A.; Bockaert, J.; Soumireu-Mourat, B.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4/5</span>),
    <span class="NLM_cas:pages">697-706</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Olfactory assocn. learning was used to investigate the involvement of 5-HT4 receptors in learning and long-term memory.  The behavioral role of the 5-HT4 receptors was studied by using BIMU1 (3-ethyl-2,3-dihydro-N-[endo-8-methyl-8-azabicyclo(3.2.1)oct-3-yl]-2-oxo-1H-benzimidazole-1-carboxamide, hydrochloride (Boehringer Ingelheim, Italy)); a mixed 5-HT4 agonist/5-HT3 antagonist, and GR125487 (1-[2-[(Me sulfonyl)-amino]ethyl]-4-piperidinyl-Me 5-fluoro-2-methoxy-1H-indole-3-carboxylate; Glaxo Group Research, Hertfordshire, U.K.), a specific 5-HT4 antagonist.  The i.p. injections of BIMU1 at 1, 5, and 10 mg/kg were followed by an substantial improvement (>15% in percentage of correct responses at the dose of 10 mg/kg) in associative memory.  Difficulty rapidly reversing behavioral responses to previously learned assocn., 1 mo later indicated that the BIMU1 effect at 10 mg/kg was not transient, but correlated to long-term memory.  The effects of BIMU1 are most likely to be mediated by 5-HT4 receptors since they were blocked by GR125487 at 10 mg/kg.  These data suggest that activation of 5-HT4 receptors may modulate cognitive processes like learning and memory.  Also, 5-HT4 receptor agonists could be useful for treating mnesic deficits as displayed in patients with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzX-RtVuCgcbVg90H21EOLACvtfcHk0lhmCAD5ONYveA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlSrtLc%253D&md5=c117d4166934db82f0295bc336555a12</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2897%2900058-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252897%252900058-0%26sid%3Dliteratum%253Aachs%26aulast%3DMarchetti-Gauthier%26aufirst%3DE.%26aulast%3DRoman%26aufirst%3DF.%2BS.%26aulast%3DDumuis%26aufirst%3DA.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DSoumireu-Mourat%26aufirst%3DB.%26atitle%3DBIMU1%2520increases%2520associative%2520memory%2520in%2520rats%2520by%2520activating%25205-HT4%2520receptors%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D36%26spage%3D697%26epage%3D706%26doi%3D10.1016%2FS0028-3908%2897%2900058-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eglen, R.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonhaus, D.W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, R.D.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of two novel and potent 5-HT<sub>4</sub> receptor agonists, RS 67333 and RS 67506, <i>in vitro</i> and <i>in vivo</i></span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">1387</span>– <span class="NLM_lpage">1392</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.1995.tb16628.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1111%2Fj.1476-5381.1995.tb16628.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=8564196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2MXns1Wgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=1995&pages=1387-1392&author=R.M.+Eglenauthor=D.W.+Bonhausauthor=L.G.+Johnsonauthor=E.+Leungauthor=R.D.+Clark&title=Pharmacological+characterization+of+two+novel+and+potent+5-HT4+receptor+agonists%2C+RS+67333+and+RS+67506%2C+in+vitro+and+in+vivo&doi=10.1111%2Fj.1476-5381.1995.tb16628.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo</span></div><div class="casAuthors">Eglen, R. M.; Bonhaus, D. W.; Johnson, L. G.; Leung, E.; Clark, R. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1387-92</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Scientific & Medical Division</span>)
        </div><div class="casAbstract">The pharmacol. of two novel 5-HT4 receptor agonists, RS 67333 (1-(4-amino-5-chloro-2-methoxy phenyl)-3-[1(n-butyl)-4-piperidinyl]-1-propanone HCl) and RS 67506 (1-(4-amino-5-chloro-2-methoxy-phenyl)-3-[1-(2-Me sulfonylamino)ethyl-4-piperidinyl]-1-propanone HCl) have been assessed in vitro and in vivo.  RS 67333 and RS 67506 exhibited affinities (pKi = 8.7 and 8.8, resp.) for the 5-HT4 binding sites, labeled with [3H]-GR 113808, in guinea-pig striatum.  The Hill coeffs. from these displacement curves were not significantly different from unity.  The compds. exhibited lower affinities (<6.0) at several other receptors including 5-HT1A, 5-HT1D, 5-HT2A, 5-HT2C, dopamine D1, D2 and muscarinic M1-M3 receptors.  However, RS 67333 and RS 67506 did exhibit affinities for the σ1 (pKi = 8.9 and 7.9, resp.) and σ2 (pKi = 8.0 and 7.3, resp.) binding sites.  At the 5-HT4 receptor mediating relaxation of the carbachol-precontracted esophagus, RS 67333 and RS 67506 acted as potent (pEC50 8.4 and 8.6, resp.) with respect to 5-HT.  Relaxant responses to RS 67333 or RS 67506 were surmountably antagonized by GR 113808 (10 nM), with apparent affinities (pKB) of 9.1 and 9.0, resp.  RS 67333 and RS 67506 induced dose-dependent increases in heart rate of the anesthetized micropig (ED50 4.9 and 5.4 μg kg-1, i.v.), with maximal increases of 35 and 47 beats min-1, resp.  RS 67333 and RS 67506, therefore, acted as potent, partial 5-HT4 receptor agonists in vitro and in vivo.  These compds., by virtue of their high potency and selectivity, may have some utility in elucidating the physiol. role of 5-HT4 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzNOdCScURALVg90H21EOLACvtfcHk0lhmCAD5ONYveA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXns1Wgsrg%253D&md5=c35823f3865d177e00933fd35a779137</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.1995.tb16628.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.1995.tb16628.x%26sid%3Dliteratum%253Aachs%26aulast%3DEglen%26aufirst%3DR.M.%26aulast%3DBonhaus%26aufirst%3DD.W.%26aulast%3DJohnson%26aufirst%3DL.G.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DClark%26aufirst%3DR.D.%26atitle%3DPharmacological%2520characterization%2520of%2520two%2520novel%2520and%2520potent%25205-HT4%2520receptor%2520agonists%252C%2520RS%252067333%2520and%2520RS%252067506%252C%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D115%26spage%3D1387%26epage%3D1392%26doi%3D10.1111%2Fj.1476-5381.1995.tb16628.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moser, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergis, O. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jegham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lochead, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duconseille, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terranova, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berque-Bestel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc'h, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischmeister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumuis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockaert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soubrie, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scatton, B.</span></span> <span> </span><span class="NLM_article-title">SL65.0155, a novel 5-HT<sub>4</sub> receptor partial agonist with potent cognition-enhancing properties</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>302</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1124/jpet.102.034249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1124%2Fjpet.102.034249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=12130738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1OgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2002&pages=731-741&author=P.+C.+Moserauthor=O.+E.+Bergisauthor=S.+Jeghamauthor=A.+Locheadauthor=E.+Duconseilleauthor=J.-P.+Terranovaauthor=D.+Cailleauthor=I.+Berque-Bestelauthor=F.+Lezoualc%27hauthor=R.+Fischmeisterauthor=A.+Dumuisauthor=J.+Bockaertauthor=P.+Georgeauthor=P.+Soubrieauthor=B.+Scatton&title=SL65.0155%2C+a+novel+5-HT4+receptor+partial+agonist+with+potent+cognition-enhancing+properties&doi=10.1124%2Fjpet.102.034249"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">SL65.0155, a novel 5-hydroxytryptamine4 receptor partial agonist with potent cognition-enhancing properties</span></div><div class="casAuthors">Moser, Paul C.; Bergis, Olivier E.; Jegham, Samir; Lochead, Alistair; Duconseille, Elee; Terranova, Jean-Paul; Caille, Dominique; Berque-Bestel, Isabelle; Lezoualc'h, Frank; Fischmeister, Rodolphe; Dumuis, Aline; Bockaert, Joel; George, Pascal; Soubrie, Philippe; Scatton, Bernard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">731-741</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">SL65.0155 [5-(8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-3-[1-(2-phenylethyl)-4-piperidinyl]-1,3,4-oxadiazol-2(3H)-one monohydrochloride] is a novel benzodioxanoxadiazolone compd. with high affinity for human 5-hydroxytryptamine (5-HT)4 receptors (Ki of 0.6 nM) and good selectivity (greater than 100-fold for all other receptors tested).  In cells expressing the 5-HT4(b) and 5-HT4(e) splice variants, SL65.0155 acted as a partial agonist, stimulating cAMP prodn. with a maximal effect of 40 to 50% of serotonin.  However, in the rat esophagus prepn., SL65.0155 acted as a 5-HT4 antagonist with a pKb of 8.81.  In addn., SL65.0155 potently improved performance in several tests of learning and memory.  In the object recognition task, it improved retention at 24 h when administered i.p. or p.o. (0.001-0.1 mg/kg).  This effect was antagonized by the 5-HT4 antagonist SDZ 205,557, itself without effect, demonstrating that the promnesic effects of SL65.0155 are mediated by 5-HT4 agonism.  SL65.0155 also reversed the cognitive deficits of aged rats in the linear maze task and the scopolamine-induced deficit of mice in the water maze task.  Furthermore, the combined administration of an inactive dose of SL65.0155 with the cholinesterase inhibitor rivastigmine resulted in a significant promnesic effect, suggesting a synergistic interaction.  SL65.0155 was devoid of unwanted cardiovascular, gastrointestinal, or central nervous system effects with doses up to more than 100-fold higher than those active in the cognitive tests.  These results characterize SL65.0155 as a novel promnesic agent acting via 5-HT4 receptors, with an excellent preclin. profile.  Its broad range of activity in cognitive tests and synergism with cholinesterase inhibitors suggest that SL65.0155 represents a promising new agent for the treatment of dementia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Fd4FHsnTBrVg90H21EOLACvtfcHk0lheMen3QlqhNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1OgtLs%253D&md5=fdb2129c26cd2aa9bbc0ef4d63fbec1a</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.034249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.034249%26sid%3Dliteratum%253Aachs%26aulast%3DMoser%26aufirst%3DP.%2BC.%26aulast%3DBergis%26aufirst%3DO.%2BE.%26aulast%3DJegham%26aufirst%3DS.%26aulast%3DLochead%26aufirst%3DA.%26aulast%3DDuconseille%26aufirst%3DE.%26aulast%3DTerranova%26aufirst%3DJ.-P.%26aulast%3DCaille%26aufirst%3DD.%26aulast%3DBerque-Bestel%26aufirst%3DI.%26aulast%3DLezoualc%2527h%26aufirst%3DF.%26aulast%3DFischmeister%26aufirst%3DR.%26aulast%3DDumuis%26aufirst%3DA.%26aulast%3DBockaert%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DP.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DScatton%26aufirst%3DB.%26atitle%3DSL65.0155%252C%2520a%2520novel%25205-HT4%2520receptor%2520partial%2520agonist%2520with%2520potent%2520cognition-enhancing%2520properties%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D302%26spage%3D731%26epage%3D741%26doi%3D10.1124%2Fjpet.102.034249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagginapalli, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravella, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kota, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, V. K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of imidazo[1,5-<i>a</i>]pyridine derivatives as 5-HT<sub>4</sub> receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">289</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.08.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.ejmech.2015.08.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=26363507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2nsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2015&pages=289-301&author=R.+Nirogiauthor=A.+R.+Mohammedauthor=A.+K.+Shindeauthor=N.+Bogarajuauthor=S.+R.+Gagginapalliauthor=S.+R.+Ravellaauthor=L.+Kotaauthor=G.+Bhyrapuneniauthor=N.+R.+Muddanaauthor=V.+Benadeauthor=R.+C.+Palacharlaauthor=P.+Jayarajanauthor=R.+Subramanianauthor=V.+K.+Goyal&title=Synthesis+and+SAR+of+imidazo%5B1%2C5-a%5Dpyridine+derivatives+as+5-HT4+receptor+partial+agonists+for+the+treatment+of+cognitive+disorders+associated+with+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2015.08.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease</span></div><div class="casAuthors">Nirogi, Ramakrishna; Mohammed, Abdul Rasheed; Shinde, Anil K.; Bogaraju, Narsimha; Gagginapalli, Shankar Reddy; Ravella, Srinivasa Rao; Kota, Laxman; Bhyrapuneni, Gopinadh; Muddana, Nageswara Rao; Benade, Vijay; Palacharla, Raghava Chowdary; Jayarajan, Pradeep; Subramanian, Ramkumar; Goyal, Vinod Kumar</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">289-301</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disease which has a higher prevalence and incidence in older people.  The need for improved AD therapies is unmet.  The 5-hydroxytryptamine4 receptor (5-HT4R) partial agonists may be of benefit for both the symptomatic and disease-modifying treatment of cognitive disorders assocd. with AD.  Herein, we report the design, synthesis and SAR of imidazo[1,5-a] pyridine derivs. as 5-HT4R partial agonists.  The focused SAR, optimization of ADME properties resulted the discovery of compd. I as potent, selective, brain penetrant 5-HT4 partial agonist as a lead compd. with good ADME properties and efficacy in both symptomatic and disease modifying animal models of cognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy8ulfS2opHrVg90H21EOLACvtfcHk0lheMen3QlqhNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2nsrzO&md5=5d43819ce00762e923aee113fb2721f4</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.08.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.08.051%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DShinde%26aufirst%3DA.%2BK.%26aulast%3DBogaraju%26aufirst%3DN.%26aulast%3DGagginapalli%26aufirst%3DS.%2BR.%26aulast%3DRavella%26aufirst%3DS.%2BR.%26aulast%3DKota%26aufirst%3DL.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DMuddana%26aufirst%3DN.%2BR.%26aulast%3DBenade%26aufirst%3DV.%26aulast%3DPalacharla%26aufirst%3DR.%2BC.%26aulast%3DJayarajan%26aufirst%3DP.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DGoyal%26aufirst%3DV.%2BK.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520imidazo%255B1%252C5-a%255Dpyridine%2520derivatives%2520as%25205-HT4%2520receptor%2520partial%2520agonists%2520for%2520the%2520treatment%2520of%2520cognitive%2520disorders%2520associated%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D103%26spage%3D289%26epage%3D301%26doi%3D10.1016%2Fj.ejmech.2015.08.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiriveedhi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kota, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badange, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R.</span></span> <span> </span><span class="NLM_article-title">Benzamide derivatives and their constrained analogs as histamine H<sub>3</sub> receptor antagonists</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">662</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.12.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.ejmech.2015.12.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=26731168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC28XptFaj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=655-662&author=R.+Nirogiauthor=A.+Shindeauthor=V.+K.+Tiriveedhiauthor=L.+Kotaauthor=S.+K.+Sarafauthor=R.+K.+Badangeauthor=A.+R.+Mohammedauthor=R.+Subramanianauthor=N.+R.+Muddanaauthor=G.+Bhyrapuneniauthor=R.+Abraham&title=Benzamide+derivatives+and+their+constrained+analogs+as+histamine+H3+receptor+antagonists&doi=10.1016%2Fj.ejmech.2015.12.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists</span></div><div class="casAuthors">Nirogi, Ramakrishna; Shinde, Anil; Tiriveedhi, Vinaykumar; Kota, Laxman; Saraf, Sangram Keshari; Badange, Rajesh Kumar; Mohammed, Abdul Rasheed; Subramanian, Ramkumar; Muddana, Nageshwararao; Bhyrapuneni, Gopinadh; Abraham, Renny</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of substituted [(4-piperidinyl)oxy]benzamides and substituted [(4-piperidinyl)oxy]-3,4-dihydro-2H-isoquinolin-1-one derivs. have been synthesized and tested for their binding affinity towards H3 receptor.  Most of these synthesized compds. have displayed potent binding affinity for H3 receptor when tested in in vitro binding assay.  Preliminary SAR studies, functional activity, pharmacokinetic profile and efficacy profile constitute the subject matter of this communication.  The synthesis of the target compds. was achieved using 4-[(4-piperidinyl)oxy]benzoic acid derivs. as intermediates.  Corresponding amide analogs included 1-isoquinolinone derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBGI2izDp8FLVg90H21EOLACvtfcHk0ljE7h-_Kmpw8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptFaj&md5=9d5fe398cfdaab5d6568cebb6aad27fc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.12.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.12.005%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DShinde%26aufirst%3DA.%26aulast%3DTiriveedhi%26aufirst%3DV.%2BK.%26aulast%3DKota%26aufirst%3DL.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26aulast%3DBadange%26aufirst%3DR.%2BK.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DMuddana%26aufirst%3DN.%2BR.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DAbraham%26aufirst%3DR.%26atitle%3DBenzamide%2520derivatives%2520and%2520their%2520constrained%2520analogs%2520as%2520histamine%2520H3%2520receptor%2520antagonists%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D108%26spage%3D655%26epage%3D662%26doi%3D10.1016%2Fj.ejmech.2015.12.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kambhampati, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraf, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badange, R. k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyala, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatta, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bojja, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reballi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasti, V.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylatemonohydrate (SUVN-502): a novel, potent, selective and orally active serotonin 6 (5-HT<sub>6</sub>) receptor antagonist for potential treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1843</span>– <span class="NLM_lpage">1859</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01662</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01662" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislyqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1843-1859&author=R.+Nirogiauthor=A.+Shindeauthor=R.+S.+Kambhampatiauthor=A.+R.+Mohammedauthor=S.+K.+Sarafauthor=R.+k.+Badangeauthor=T.+R.+Bandyalaauthor=V.+Bhattaauthor=K.+Bojjaauthor=V.+Reballiauthor=R.+Subramanianauthor=V.+Benadeauthor=R.+C.+Palacharlaauthor=G.+Bhyrapuneniauthor=P.+Jayarajanauthor=V.+Goyalauthor=V.+Jasti&title=Discovery+and+development+of+1-%5B%282-bromophenyl%29sulfonyl%5D-5-methoxy-3-%5B%284-methyl-1-piperazinyl%29methyl%5D-1H-indole+dimesylatemonohydrate+%28SUVN-502%29%3A+a+novel%2C+potent%2C+selective+and+orally+active+serotonin+6+%285-HT6%29+receptor+antagonist+for+potential+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.6b01662"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Nirogi, Ramakrishna; Shinde, Anil; Kambhampati, Rama Sastry; Mohammed, Abdul Rasheed; Saraf, Sangram Keshari; Badange, Rajesh kumar; Bandyala, Thrinath Reddy; Bhatta, Venugopalarao; Bojja, Kumar; Reballi, Veena; Subramanian, Ramkumar; Benade, Vijay; Palacharla, Raghava Choudary; Bhyrapuneni, Gopinadh; Jayarajan, Pradeep; Goyal, Vinod; Jasti, Venkat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1843-1859</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of a novel series of 3-(piperazinylmethyl) indole derivs. as 5-hydroxytryptamine-6 receptor (5-HT6R) antagonists resulted in identification of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (5al, SUVN-502) as a clin. candidate for potential treatment of cognitive disorders.  It has high affinity at human 5-HT6R (Ki = 2.04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunol. factors, second messengers, and prostaglandins.  It has high selectivity over 5-HT2A receptor.  It is orally bioavailable and brain penetrant with robust preclin. efficacy.  The combination of 5al, donepezil, and memantine (triple combination) produces synergistic effects in extracellular levels of acetylcholine in the ventral hippocampus.  Preclin. efficacy in triple combination and high selectivity over 5-HT2A receptors are the differentiating features which culminated in selection of 5al for further development.  The Phase-1 evaluation of safety and pharmacokinetics has been completed, allowing for the initiation of a Phase-2 proof of concept study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_gw476vRgPbVg90H21EOLACvtfcHk0lirFbq827eIKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislyqsLk%253D&md5=26e4f0c1c34255ce2c2ef3bbf3c06a85</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01662&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01662%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DShinde%26aufirst%3DA.%26aulast%3DKambhampati%26aufirst%3DR.%2BS.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DSaraf%26aufirst%3DS.%2BK.%26aulast%3DBadange%26aufirst%3DR.%2Bk.%26aulast%3DBandyala%26aufirst%3DT.%2BR.%26aulast%3DBhatta%26aufirst%3DV.%26aulast%3DBojja%26aufirst%3DK.%26aulast%3DReballi%26aufirst%3DV.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DBenade%26aufirst%3DV.%26aulast%3DPalacharla%26aufirst%3DR.%2BC.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DJayarajan%26aufirst%3DP.%26aulast%3DGoyal%26aufirst%3DV.%26aulast%3DJasti%26aufirst%3DV.%26atitle%3DDiscovery%2520and%2520development%2520of%25201-%255B%25282-bromophenyl%2529sulfonyl%255D-5-methoxy-3-%255B%25284-methyl-1-piperazinyl%2529methyl%255D-1H-indole%2520dimesylatemonohydrate%2520%2528SUVN-502%2529%253A%2520a%2520novel%252C%2520potent%252C%2520selective%2520and%2520orally%2520active%2520serotonin%25206%2520%25285-HT6%2529%2520receptor%2520antagonist%2520for%2520potential%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1843%26epage%3D1859%26doi%3D10.1021%2Facs.jmedchem.6b01662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagginapally, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kancharla, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middekadi, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogaraju, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravella, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birangal, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarajan, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis, structure–activity relationships, and preclinical evaluation of heteroaromatic amides and 1,3,4-oxadiazole derivatives as 5-HT<sub>4</sub> receptor partial agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4993</span>– <span class="NLM_lpage">5008</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00457</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00457" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsVChsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4993-5008&author=R.+K.+Nirogiauthor=A.+R.+Mohammedauthor=A.+Shindeauthor=S.+R.+Gagginapallyauthor=D.+M.+Kancharlaauthor=V.+R.+Middekadiauthor=N.+Bogarajuauthor=S.+R.+Ravellaauthor=P.+Singhauthor=S.+R.+Birangalauthor=R.+Subramanianauthor=R.+C.+Palacharlaauthor=V.+Benadeauthor=N.+Muddanaauthor=P.+Jayarajan&title=Synthesis%2C+structure%E2%80%93activity+relationships%2C+and+preclinical+evaluation+of+heteroaromatic+amides+and+1%2C3%2C4-oxadiazole+derivatives+as+5-HT4+receptor+partial+agonists&doi=10.1021%2Facs.jmedchem.8b00457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT4 Receptor Partial Agonists</span></div><div class="casAuthors">Nirogi, Ramakrishna; Mohammed, Abdul Rasheed; Shinde, Anil K.; Gagginapally, Shankar Reddy; Kancharla, Durga Malleshwari; Middekadi, Vanaja Reddy; Bogaraju, Narsimha; Ravella, Srinivasa Rao; Singh, Pooja; Birangal, Sumit Raosaheb; Subramanian, Ramkumar; Palacharla, Raghava Choudary; Benade, Vijay; Muddana, Nageswararao; Jayarajan, Pradeep</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4993-5008</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disorder that has a higher prevalence and incidence in people older than 60 years.  The need for improved AD therapies is unmet as the current therapies are symptomatic with modest efficacy.  Partial agonists of the 5-HT4 receptor (5-HT4R) offer both symptomatic and disease-modifying treatments as they shift amyloid-precursor-protein (APP) processing from the amyloidogenic pathway to the nonamyloidogenic pathway by activating the α-secretase enzyme.  In addn., they also offer symptomatic treatment by increasing levels of the neurotransmitter acetylcholine in the brain.  Because of this fascinating dual mechanism of action, several chem. scaffolds having 5-HT4R pharmacophores were designed and evaluated.  Most of the synthesized compds. showed potent in vitro affinities and in vivo efficacies.  Upon anal. of focused structure-activity relationships, compd. 4o was identified as a potent 5-HT4R partial agonist with favorable ADME properties and good in vivo efficacy.  GR-125487, a selective 5-HT4R antagonist, attenuated the activity of compd. 4o in the novel-object-recognition-test cognition model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk2z2YiR_ja7Vg90H21EOLACvtfcHk0lirFbq827eIKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsVChsLk%253D&md5=b8bacee142c07a4dbb433e95b86b1d07</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00457%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%2BK.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DShinde%26aufirst%3DA.%26aulast%3DGagginapally%26aufirst%3DS.%2BR.%26aulast%3DKancharla%26aufirst%3DD.%2BM.%26aulast%3DMiddekadi%26aufirst%3DV.%2BR.%26aulast%3DBogaraju%26aufirst%3DN.%26aulast%3DRavella%26aufirst%3DS.%2BR.%26aulast%3DSingh%26aufirst%3DP.%26aulast%3DBirangal%26aufirst%3DS.%2BR.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DPalacharla%26aufirst%3DR.%2BC.%26aulast%3DBenade%26aufirst%3DV.%26aulast%3DMuddana%26aufirst%3DN.%26aulast%3DJayarajan%26aufirst%3DP.%26atitle%3DSynthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520preclinical%2520evaluation%2520of%2520heteroaromatic%2520amides%2520and%25201%252C3%252C4-oxadiazole%2520derivatives%2520as%25205-HT4%2520receptor%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4993%26epage%3D5008%26doi%3D10.1021%2Facs.jmedchem.8b00457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furlotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alisi, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apicella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capezzone de Joannon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzolla, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuzzucoli Crucitti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrone, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacovo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magaro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miele, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ombrato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pescatori, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polenzani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitiello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Santo, R.</span></span> <span> </span><span class="NLM_article-title">Discovery and pharmacological Profile of New 1H-indazole-3-carboxamide and 2H-pyrrolo[3,4-<i>c</i>]quinoline derivatives as selective serotonin-4 receptor ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9446</span>– <span class="NLM_lpage">9466</span>, <span class="refDoi"> DOI: 10.1021/jm300573d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300573d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOhs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9446-9466&author=G.+Furlottiauthor=M.+A.+Alisiauthor=C.+Apicellaauthor=A.+Capezzone+de+Joannonauthor=N.+Cazzollaauthor=R.+Costiauthor=G.+Cuzzucoli+Crucittiauthor=B.+Garroneauthor=A.+Iacovoauthor=G.+Magaroauthor=G.+Manganoauthor=G.+Mieleauthor=R.+Ombratoauthor=L.+Pescatoriauthor=L.+Polenzaniauthor=F.+Rosiauthor=M.+Vitielloauthor=R.+Di+Santo&title=Discovery+and+pharmacological+Profile+of+New+1H-indazole-3-carboxamide+and+2H-pyrrolo%5B3%2C4-c%5Dquinoline+derivatives+as+selective+serotonin-4+receptor+ligands&doi=10.1021%2Fjm300573d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Pharmacological Profile of New 1H-Indazole-3-carboxamide and 2H-Pyrrolo[3,4-c]quinoline Derivatives as Selective Serotonin 4 Receptor Ligands</span></div><div class="casAuthors">Furlotti, Guido; Alisi, Maria Alessandra; Apicella, Claudia; Capezzone de Joannon, Alessandra; Cazzolla, Nicola; Costi, Roberta; Cuzzucoli Crucitti, Giuliana; Garrone, Beatrice; Iacovo, Alberto; Magaro, Gabriele; Mangano, Giorgina; Miele, Gaetano; Ombrato, Rosella; Pescatori, Luca; Polenzani, Lorenzo; Rosi, Federica; Vitiello, Marco; Di Santo, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9446-9466</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Since the discovery of the serotonin 4 receptor (5-HT4R), a large no. of receptor ligands have been studied.  The safety concerns and the lack of market success of these ligands have mainly been attributed to their lack of selectivity.  In this study we describe the discovery of N-[(4-piperidinyl)methyl]-1H-indazole-3-carboxamide and 4-[(4-piperidinyl)methoxy]-2H-pyrrolo[3,4-c]quinoline derivs. as new 5-HT4R ligands endowed with high selectivity over the serotonin 2A receptor and human ether-a-go-go-related gene potassium ion channel.  Within these series, two mols. (I and II) were identified as potent and selective 5-HT4R antagonists with good in vitro pharmacokinetic properties.  These compds. were evaluated for their antinociceptive action in two analgesia animal models; II showed a significant antinociceptive effect in both models and is proposed as an interesting lead compd. as a 5-HT4R antagonist with analgesic action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnC05jFTxZArVg90H21EOLACvtfcHk0liV-slKT7XSxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOhs7jO&md5=120ddc3595ab221fa97fc1c5da5eccaf</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm300573d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300573d%26sid%3Dliteratum%253Aachs%26aulast%3DFurlotti%26aufirst%3DG.%26aulast%3DAlisi%26aufirst%3DM.%2BA.%26aulast%3DApicella%26aufirst%3DC.%26aulast%3DCapezzone%2Bde%2BJoannon%26aufirst%3DA.%26aulast%3DCazzolla%26aufirst%3DN.%26aulast%3DCosti%26aufirst%3DR.%26aulast%3DCuzzucoli%2BCrucitti%26aufirst%3DG.%26aulast%3DGarrone%26aufirst%3DB.%26aulast%3DIacovo%26aufirst%3DA.%26aulast%3DMagaro%26aufirst%3DG.%26aulast%3DMangano%26aufirst%3DG.%26aulast%3DMiele%26aufirst%3DG.%26aulast%3DOmbrato%26aufirst%3DR.%26aulast%3DPescatori%26aufirst%3DL.%26aulast%3DPolenzani%26aufirst%3DL.%26aulast%3DRosi%26aufirst%3DF.%26aulast%3DVitiello%26aufirst%3DM.%26aulast%3DDi%2BSanto%26aufirst%3DR.%26atitle%3DDiscovery%2520and%2520pharmacological%2520Profile%2520of%2520New%25201H-indazole-3-carboxamide%2520and%25202H-pyrrolo%255B3%252C4-c%255Dquinoline%2520derivatives%2520as%2520selective%2520serotonin-4%2520receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9446%26epage%3D9466%26doi%3D10.1021%2Fjm300573d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulier, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicsic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathé-Allainmat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brémont, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croci, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardamone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aureggi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, M.</span></span> <span> </span><span class="NLM_article-title">New esters of 4-amino-5-chloro-2-methoxybenzoic acid as potent agonists and antagonists for 5-HT<sub>4</sub> receptors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">621</span>, <span class="refDoi"> DOI: 10.1021/jm960320m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm960320m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2sXhsVSktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1997&pages=608-621&author=D.+Yangauthor=J.+L.+Soulierauthor=S.+Sicsicauthor=M.+Math%C3%A9-Allainmatauthor=B.+Br%C3%A9montauthor=T.+Crociauthor=R.+Cardamoneauthor=G.+Aureggiauthor=M.+Langlois&title=New+esters+of+4-amino-5-chloro-2-methoxybenzoic+acid+as+potent+agonists+and+antagonists+for+5-HT4+receptors&doi=10.1021%2Fjm960320m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">New Esters of 4-Amino-5-chloro-2-methoxybenzoic Acid as Potent Agonists and Antagonists for 5-HT4 Receptors</span></div><div class="casAuthors">Yang, Donglai; Soulier, Jean-Louis; Sicsic, Sames; Mathe-Allainmat, Monique; Bremont, Beatrice; Croci, Tiziano; Cardamone, Rosanna; Aureggi, Giulio; Langlois, Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">608-621</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A no. of benzoates derived from 4-amino-5-chloro-2-methoxybenzoic acid and substituted 1-piperidineethanol were prepd. and found to be potent 5-HT4 receptor agonists in the elec.-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum and the rat esophagus muscle.  Monosubstitution of the piperidine ring with Me, OH, NH-Ac, or CONH2 groups gave compds. equipotent to 2-piperidinoethyl-4-amino-2-methoxybenzoate-HCl (I) (ML 10302), a 5-HT4 receptor agonist previously reported to have nanomolar affinity.  I and 2-(3-(S)-hydroxypiperidino)ethyl-4-amino-2-methoxybenzoate-HCl (II) were as potent as serotonin (5-HT) but had maximal responses which were only 60-80% of that of 5-HT, suggesting a partial agonist profile for these compds.  Binding assays were performed with [3H]GR 113808 in the rat striatum, and several of these compds. were found to have nanomolar affinity for 5-HT4 receptors (I, Ki = 1.07; II, Ki = 1.0 nM).  The introduction of 2 Me groups on the piperidine ring brought about a dramatic change in the pharmacol. profile of 2-[(cis- and trans-3,5-dimethylpiperidinyl)ethyl]-4-amino-5-chloro-2-methoxybenzoate (III-cis isomer).  III (Ki = 0.26 nM) inhibited the relaxant action of 5-HT in the rat esophagus muscle with a pA2 value of 8.6.  The advantage of the ester function was demonstrated by comparing the activity of several such compds. at 5-HT4 receptors with those of the corresponding amide derivs.  This difference was less marked when the basic moiety was sterically constrained as in the quinuclidine and tropane moieties.  Structural analyses of I and III were performed by detg. their X-ray crystal structures and by mol. modeling (SYBYL).  A relatively limited no. of min. energy conformers was found for both compds.  They were characterized by the cis folded conformation of the Et chain and by the orientation of the lone pair of the nitrogen atom pointing out of the mol. as seen in conformationally-constrained benzamides such as zacopride and renzapride.  A hypothetical model for the 5-HT4 receptor with 2 sites for the binding of agonist and antagonist mols. was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-i-Mdpx5yirVg90H21EOLACvtfcHk0liV-slKT7XSxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhsVSktb4%253D&md5=9a560dbfd938b39801cea1109316f80c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm960320m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm960320m%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DD.%26aulast%3DSoulier%26aufirst%3DJ.%2BL.%26aulast%3DSicsic%26aufirst%3DS.%26aulast%3DMath%25C3%25A9-Allainmat%26aufirst%3DM.%26aulast%3DBr%25C3%25A9mont%26aufirst%3DB.%26aulast%3DCroci%26aufirst%3DT.%26aulast%3DCardamone%26aufirst%3DR.%26aulast%3DAureggi%26aufirst%3DG.%26aulast%3DLanglois%26aufirst%3DM.%26atitle%3DNew%2520esters%2520of%25204-amino-5-chloro-2-methoxybenzoic%2520acid%2520as%2520potent%2520agonists%2520and%2520antagonists%2520for%25205-HT4%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1997%26volume%3D40%26spage%3D608%26epage%3D621%26doi%3D10.1021%2Fjm960320m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lanthier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallemagne, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lecoutey, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claeysen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochais, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic modulators of the serotonin 5-HT <sub>4</sub> receptor: a patent review (2014-present)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">495</span>– <span class="NLM_lpage">508</span>, <span class="refDoi"> DOI: 10.1080/13543776.2020.1767587</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1080%2F13543776.2020.1767587" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=32400221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSgsLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=495-508&author=C.+Lanthierauthor=P.+Dallemagneauthor=C.+Lecouteyauthor=S.+Claeysenauthor=C.+Rochais&title=Therapeutic+modulators+of+the+serotonin+5-HT+4+receptor%3A+a+patent+review+%282014-present%29&doi=10.1080%2F13543776.2020.1767587"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic modulators of the serotonin 5-HT4 receptor: a patent review (2014-present)</span></div><div class="casAuthors">Lanthier, Caroline; Dallemagne, Patrick; Lecoutey, Cedric; Claeysen, Sylvie; Rochais, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">495-508</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A Review.  IntroductionNumerous chemotypes have been described over time in order to generate potent and selective 5-HT4R ligands.  Both agonists and antagonists have demonstrated their interest in several disease models.  This culminates with the FDA approval of tegaserod and prucalopride in the recent years.  Areas coveredThis review summarizes the patent applications from 2014 to present, dedicated to the use or the description of novel 5-HT4R modulators.  Several novel ligands and scaffolds have been industrially protected mainly in the field of central nervous system (CNS) pathologies as well as gastrointestinal disorders, including the combination with other drugs or for veterinary uses.  Expert opinionThe therapeutic potential of 5-HT4R modulators has been explored for several years in animal models, but also linked to potential safety issues with initial ligands.  The current use of prucalopride in humans demonstrates that its toxicity is not linked to the target and that 5-HT4R modulators are safe in humans.  Therefore, an important no. of studies and patents has continued in the recent years to expand the use of 5-HT4R modulators, not only to treat gastrointestinal disorders, but also for CNS pathologies.  This article details current efforts in this development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Q6zEPQKyZrVg90H21EOLACvtfcHk0ljMgUfdZ3XtfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSgsLbM&md5=c9d6fa1474a9f3242dc0b029b3d2cf05</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1080%2F13543776.2020.1767587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2020.1767587%26sid%3Dliteratum%253Aachs%26aulast%3DLanthier%26aufirst%3DC.%26aulast%3DDallemagne%26aufirst%3DP.%26aulast%3DLecoutey%26aufirst%3DC.%26aulast%3DClaeysen%26aufirst%3DS.%26aulast%3DRochais%26aufirst%3DC.%26atitle%3DTherapeutic%2520modulators%2520of%2520the%2520serotonin%25205-HT%25204%2520receptor%253A%2520a%2520patent%2520review%2520%25282014-present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D495%26epage%3D508%26doi%3D10.1080%2F13543776.2020.1767587" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span>; <span class="NLM_string-name">Mohammed, A. R.</span>; <span class="NLM_string-name">Yarlagadda, S.</span>; <span class="NLM_string-name">Ravella, S. R.</span>; <span class="NLM_string-name">Shinde, A. K.</span>; <span class="NLM_string-name">Kambhampati, R.</span>; <span class="NLM_string-name">Royapalley, P. K.</span>; <span class="NLM_string-name">Jayarajan, P.</span>; <span class="NLM_string-name">Bhyrapuneni, G.</span>; <span class="NLM_string-name">Patnala, S. M.</span>; <span class="NLM_string-name">Ravula, J.</span>; <span class="NLM_string-name">Jasti, V.</span></span> <span> </span><span class="NLM_article-title">Heteroaryl compounds as 5-HT<sub>4</sub> receptor ligands</span>. WIPO patent <span class="NLM_patent">WO2013042135A1</span>, March 28, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=R.+Nirogi&author=A.+R.+Mohammed&author=S.+Yarlagadda&author=S.+R.+Ravella&author=A.+K.+Shinde&author=R.+Kambhampati&author=P.+K.+Royapalley&author=P.+Jayarajan&author=G.+Bhyrapuneni&author=S.+M.+Patnala&author=J.+Ravula&author=V.+Jasti&title=Heteroaryl+compounds+as+5-HT4+receptor+ligands"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26atitle%3DHeteroaryl%2520compounds%2520as%25205-HT4%2520receptor%2520ligands%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span>; <span class="NLM_string-name">Shinde, A. K.</span>; <span class="NLM_string-name">Mohammed, A. R.</span>; <span class="NLM_string-name">Saraf, S. K.</span>; <span class="NLM_string-name">Bogaraju, N.</span>; <span class="NLM_string-name">Subramanian, R.</span>; <span class="NLM_string-name">Jayarajan, P.</span>; <span class="NLM_string-name">Bhyrapuneni, G.</span>; <span class="NLM_string-name">Jasti, V.</span></span> <span> </span><span class="NLM_article-title">Amide compounds as 5-HT<sub>4</sub> receptor agonists</span>. WIPO patent <span class="NLM_patent">WO2016128990A1</span>, Aug 18, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=R.+Nirogi&author=A.+K.+Shinde&author=A.+R.+Mohammed&author=S.+K.+Saraf&author=N.+Bogaraju&author=R.+Subramanian&author=P.+Jayarajan&author=G.+Bhyrapuneni&author=V.+Jasti&title=Amide+compounds+as+5-HT4+receptor+agonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26atitle%3DAmide%2520compounds%2520as%25205-HT4%2520receptor%2520agonists%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Synopsis of some recent tactical application of bioisosteres in drug design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">2529</span>, <span class="refDoi"> DOI: 10.1021/jm1013693</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529&author=N.+A.+Meanwell&title=Synopsis+of+some+recent+tactical+application+of+bioisosteres+in+drug+design&doi=10.1021%2Fjm1013693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lgalxHxg01F2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520some%2520recent%2520tactical%2520application%2520of%2520bioisosteres%2520in%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26doi%3D10.1021%2Fjm1013693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llinas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plowright, A. T.</span></span> <span> </span><span class="NLM_article-title">Oxadiazoles in medicinal chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1817</span>– <span class="NLM_lpage">1830</span>, <span class="refDoi"> DOI: 10.1021/jm2013248</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013248" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1817-1830&author=J.+Bostromauthor=A.+Hognerauthor=A.+Llinasauthor=E.+Wellnerauthor=A.+T.+Plowright&title=Oxadiazoles+in+medicinal+chemistry&doi=10.1021%2Fjm2013248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Oxadiazoles in medicinal chemistry</span></div><div class="casAuthors">Bostrom Jonas; Hogner Anders; Llinas Antonio; Wellner Eric; Plowright Alleyn T</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1817-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms.  Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities.  The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZeneca compound collection.  In virtually all cases, the 1,3,4-oxadiazole isomer shows an order of magnitude lower lipophilicity (log D), as compared to its isomeric partner.  Significant differences are also observed with respect to metabolic stability, hERG inhibition, and aqueous solubility, favoring the 1,3,4-oxadiazole isomers.  The difference in profile between the 1,2,4 and 1,3,4 regioisomers can be rationalized by their intrinsically different charge distributions (e.g., dipole moments).  To facilitate the use of these heteroaromatic rings, novel synthetic routes for ready access of a broad spectrum of 1,3,4-oxadiazoles, under mild conditions, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO9RQiG9xFS2Zyxfu64m4ffW6udTcc2eb_z4BZqukE8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383pt1Oisw%253D%253D&md5=b934995431ced1be297e6f126262f3cb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm2013248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013248%26sid%3Dliteratum%253Aachs%26aulast%3DBostrom%26aufirst%3DJ.%26aulast%3DHogner%26aufirst%3DA.%26aulast%3DLlinas%26aufirst%3DA.%26aulast%3DWellner%26aufirst%3DE.%26aulast%3DPlowright%26aufirst%3DA.%2BT.%26atitle%3DOxadiazoles%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1817%26epage%3D1830%26doi%3D10.1021%2Fjm2013248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drici, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barhanin, J.</span></span> <span> </span><span class="NLM_article-title">Cardiac K+ channels and drug-acquired long QT syndrome</span>. <i>Therapie</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">193</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10860023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A280%3ADC%252BD3czhslKjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2000&pages=185-193&author=M.+D.+Driciauthor=J.+Barhanin&title=Cardiac+K%2B+channels+and+drug-acquired+long+QT+syndrome"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac K+ channels and drug-acquired long QT syndrome</span></div><div class="casAuthors">Drici M D; Barhanin J</div><div class="citationInfo"><span class="NLM_cas:title">Therapie</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">185-93</span>
        ISSN:<span class="NLM_cas:issn">0040-5957</span>.
    </div><div class="casAbstract">The hallmark of long QT syndromes (LQTS) is an abnormal ventricular repolarization characterized by a prolonged QT interval on the electrocardiogram and a propensity to the occurrence of syncopes resulting from polymorphic ventricular tachycardia, called torsades de pointes.  They may degenerate to ventricular fibrillation, possibly causing sudden death.  Congenital LQTS, which implicates at least six chromosomal loci, LQT1 to LQT6, three of them corresponding to mutations concerning the coding of K+ channel proteins, give useful information about the mechanism underlying the arrhythmia.  One of the potassium channel genes implicated in congenital LQTS is HERG, which encodes the IKr current channel protein.  This current has provided a relevant insight into the occurrence of drug-acquired LQTS, since all drugs associated with torsades, such as erythromycin, terfenadine, haloperidol, or cisapride, also block IKr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSpCXQeHUzr0-Q4Pl9hzjQhfW6udTcc2eb_z4BZqukE8Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3czhslKjtg%253D%253D&md5=8acf3350d6b38147e71426f03e20a7dd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrici%26aufirst%3DM.%2BD.%26aulast%3DBarhanin%26aufirst%3DJ.%26atitle%3DCardiac%2520K%252B%2520channels%2520and%2520drug-acquired%2520long%2520QT%2520syndrome%26jtitle%3DTherapie%26date%3D2000%26volume%3D55%26spage%3D185%26epage%3D193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rampe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. M.</span></span> <span> </span><span class="NLM_article-title">A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel hERG</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(97)01249-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2FS0014-5793%2897%2901249-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=9395068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK2sXntVOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=1997&pages=28-32&author=D.+Rampeauthor=M.+L.+Royauthor=A.+Dennisauthor=A.+M.+Brown&title=A+mechanism+for+the+proarrhythmic+effects+of+cisapride+%28Propulsid%29%3A+high+affinity+blockade+of+the+human+cardiac+potassium+channel+hERG&doi=10.1016%2FS0014-5793%2897%2901249-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG</span></div><div class="casAuthors">Rampe, David; Roy, Mary-Louise; Dennis, Adrienne; Brown, Arthur M.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-32</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cisapride (Propulsid) is a gastrointestinal prokinetic agent commonly used to treat nocturnal heartburn as well as a variety of other gastrointestinal disorders.  The use of cisapride has been assocd. with acquired long QT syndrome and ventricular arrhythmias such as torsades de pointes which produces sudden cardiac death.  These cardiotoxic effects can be due to blockade of one or more types of K+ channel currents in the human heart.  For this reason we compared the effects of cisapride on two cloned human cardiac K+ channels, Kv1.5 and the human ether-a-go-go-related gene (HERG) stably transfected into mammalian cells.  Using patch clamp electrophysiol., we found that cisapride was a potent inhibitor of HERG displaying an IC50 value of 44.5 nmol/l when tail currents at -40 mV were measured following a 2 s test depolarization to +20 mV.  When HERG currents were measured at the end of prolonged (20 s) depolarizing steps to +20 mV, the apparent affinity of cisapride was increased and measured 6.70 nmol/l.  The main effect of cisapride was to enhance the rate of HERG current decay thereby reducing current at the end of the voltage clamp pulse.  Furthermore, the potency of cisapride for the HERG channel was similar to that obsd. for the class III antiarrhythmic agent dofetilide (IC50 = 15.3 nmol/l) and the nonsedating antihistamine terfenadine (IC50 = 56.0 nmol/l).  In contrast to its effects on HERG, cisapride inhibited Kv1.5 channel currents weakly displaying an IC50 value of 21.2 μmol/l.  It is concluded that cisapride displays specific, high affinity block of the human cardiac K+ channel HERG.  It is likely that this interaction underlies the proarrhythmic effects of the drug obsd. under certain clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3R8aVmRVtG7Vg90H21EOLACvtfcHk0lhEZDmjTMUQag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXntVOhu74%253D&md5=26afd6fcc7834feab4620055da6376fd</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2897%2901249-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252897%252901249-0%26sid%3Dliteratum%253Aachs%26aulast%3DRampe%26aufirst%3DD.%26aulast%3DRoy%26aufirst%3DM.%2BL.%26aulast%3DDennis%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DA.%2BM.%26atitle%3DA%2520mechanism%2520for%2520the%2520proarrhythmic%2520effects%2520of%2520cisapride%2520%2528Propulsid%2529%253A%2520high%2520affinity%2520blockade%2520of%2520the%2520human%2520cardiac%2520potassium%2520channel%2520hERG%26jtitle%3DFEBS%2520Lett.%26date%3D1997%26volume%3D417%26spage%3D28%26epage%3D32%26doi%3D10.1016%2FS0014-5793%2897%2901249-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walker, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursill, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyse, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzuela, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breit, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, T. J.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the human ether-a-go-go-related gene (hERG) potassium channel by cisapride: affinity for open and inactivated states</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">450</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1038%2Fsj.bjp.0702774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10510456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK1MXmsFWgs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=1999&pages=444-450&author=B.+D.+Walkerauthor=C.+B.+Singletonauthor=J.+A.+Bursillauthor=K.+R.+Wyseauthor=S.+M.+Valenzuelaauthor=M.+R.+Qiuauthor=S.+N.+Breitauthor=T.+J.+Campbell&title=Inhibition+of+the+human+ether-a-go-go-related+gene+%28hERG%29+potassium+channel+by+cisapride%3A+affinity+for+open+and+inactivated+states&doi=10.1038%2Fsj.bjp.0702774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states</span></div><div class="casAuthors">Walker, B. D.; Singleton, C. B.; Bursill, J. A.; Wyse, K. R.; Valenzuela, S. M.; Qiu, M. R.; Breit, S. N.; Campbell, T. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">444-450</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">Cisapride is a prokinetic agent which has been assocd. with QT prolongation, torsades de pointes and cardiac arrest.  The cellular mechanism for these observations is high affinity blockade of IKr (encoded by HERG).  In a chronic transfection model using CHO-K1 cells, cisapride inhibited HERG tail currents after a step to +25 mV with similar potency at room and physiol. temps. (IC50 16.4 nM at 20-22°C and 23.6 nM at 37°C).  Channel inhibition exhibited time-, voltage- and frequency-dependence.  In an envelope of tails test, channel blockade increased from 27±8% after a 120 ms depolarizing step to 50±4% after a 1.0 s step.  These findings suggested affinity for open and/or inactivated channel states.  Inactivation was significantly accelerated by cisapride in a concn.-dependent manner and there was a small (-7 mV) shift in the voltage dependence of steady state inactivation.  Channel blockade by cisapride was modulated by [K+]o, with a 26% redn. in the potency of channel blockade when [K+]o was increased from 1 to 10 mM.  In conclusion, HERG channel inhibition by cisapride exhibits features consistent with open and inactivated state binding and is sensitive to external potassium concn.  These features may have significant clin. implications with regard to the mechanism and treatment of cisapride-induced proarrhythmia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMulDrySVSiLVg90H21EOLACvtfcHk0lhEZDmjTMUQag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmsFWgs7Y%253D&md5=1b8744d3cc1d71832de307061f3ab42a</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702774%26sid%3Dliteratum%253Aachs%26aulast%3DWalker%26aufirst%3DB.%2BD.%26aulast%3DSingleton%26aufirst%3DC.%2BB.%26aulast%3DBursill%26aufirst%3DJ.%2BA.%26aulast%3DWyse%26aufirst%3DK.%2BR.%26aulast%3DValenzuela%26aufirst%3DS.%2BM.%26aulast%3DQiu%26aufirst%3DM.%2BR.%26aulast%3DBreit%26aufirst%3DS.%2BN.%26aulast%3DCampbell%26aufirst%3DT.%2BJ.%26atitle%3DInhibition%2520of%2520the%2520human%2520ether-a-go-go-related%2520gene%2520%2528hERG%2529%2520potassium%2520channel%2520by%2520cisapride%253A%2520affinity%2520for%2520open%2520and%2520inactivated%2520states%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D128%26spage%3D444%26epage%3D450%26doi%3D10.1038%2Fsj.bjp.0702774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Antunes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biala, G.</span></span> <span> </span><span class="NLM_article-title">The novel object recognition memory: neurobiology, test procedure, and its modifications</span>. <i>Cogn. Process.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1007/s10339-011-0430-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1007%2Fs10339-011-0430-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=22160349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A280%3ADC%252BC38zoslWlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=93-110&author=M.+Antunesauthor=G.+Biala&title=The+novel+object+recognition+memory%3A+neurobiology%2C+test+procedure%2C+and+its+modifications&doi=10.1007%2Fs10339-011-0430-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The novel object recognition memory: neurobiology, test procedure, and its modifications</span></div><div class="casAuthors">Antunes M; Biala G</div><div class="citationInfo"><span class="NLM_cas:title">Cognitive processing</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Animal models of memory have been considered as the subject of many scientific publications at least since the beginning of the twentieth century.  In humans, memory is often accessed through spoken or written language, while in animals, cognitive functions must be accessed through different kind of behaviors in many specific, experimental models of memory and learning.  Among them, the novel object recognition test can be evaluated by the differences in the exploration time of novel and familiar objects.  Its application is not limited to a field of research and enables that various issues can be studied, such as the memory and learning, the preference for novelty, the influence of different brain regions in the process of recognition, and even the study of different drugs and their effects.  This paper describes the novel object recognition paradigms in animals, as a valuable measure of cognition.  The purpose of this work was to review the neurobiology and methodological modifications of the test commonly used in behavioral pharmacology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQocv30hVI3YVf1XRtfYM0dfW6udTcc2eZl3Toyzqujr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zoslWlsQ%253D%253D&md5=4f73ed1bafb04056c5aef19b1b86c802</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs10339-011-0430-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10339-011-0430-z%26sid%3Dliteratum%253Aachs%26aulast%3DAntunes%26aufirst%3DM.%26aulast%3DBiala%26aufirst%3DG.%26atitle%3DThe%2520novel%2520object%2520recognition%2520memory%253A%2520neurobiology%252C%2520test%2520procedure%252C%2520and%2520its%2520modifications%26jtitle%3DCogn.%2520Process.%26date%3D2012%26volume%3D13%26spage%3D93%26epage%3D110%26doi%3D10.1007%2Fs10339-011-0430-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayarajan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medapati, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shanmuganathan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandikere, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irappanavar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saralaya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benade, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N.</span></span> <span> </span><span class="NLM_article-title">Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>1453</i></span>,  <span class="NLM_fpage">40</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2012.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.brainres.2012.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=22464882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFeltb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1453&publication_year=2012&pages=40-45&author=R.+Nirogiauthor=R.+Abrahamauthor=P.+Jayarajanauthor=R.+B.+Medapatiauthor=D.+Shanmuganathanauthor=V.+Kandikereauthor=S.+Irappanavarauthor=R.+Saralayaauthor=V.+Benadeauthor=G.+Bhyrapuneniauthor=N.+Muddana&title=Difference+in+the+norepinephrine+levels+of+experimental+and+non-experimental+rats+with+age+in+the+object+recognition+task&doi=10.1016%2Fj.brainres.2012.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Difference in the norepinephrine levels of experimental and non-experimental rats with age in the object recognition task</span></div><div class="casAuthors">Nirogi, Ramakrishna; Abraham, Renny; Jayarajan, Pradeep; Medapati, Rajesh Babu; Shanmuganathan, Dhanalakshmi; Kandikere, Vishwottam; Irappanavar, Shantaveer; Saralaya, Ramanatha; Benade, Vijay; Bhyrapuneni, Gopinadh; Muddana, Nageswararao</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1453</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">40-45</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In the present study, we investigated the performance of adult and juvenile rats in the Object Recognition Task (ORT).  While it is well known that the performance of rat in ORT differs with age, the reason for the difference as well as the underlying neurotransmitter that may have led to these differences were investigated.  In the present study, juvenile rats of postnatal day 40-45 (PND 40-45) and adult rats of postnatal day 60+ (PND 60+) were subjected to a two trial ORT.  The juvenile rats did not discriminate between the novel object and the familiar object, while the adult rats discriminated the novel from the familiar object.  On estg. brain concns. of norepinephrine (NE), it was obsd. that the NE level in MTL (medial temporal lobe) of adult exptl. rats was significantly higher than the adult non-exptl. rats.  In juvenile rats, no significant difference was obsd. in the NE levels of exptl. rats in comparison to its non-exptl. counterparts.  Administration of yohimbine (α2A adrenergic receptor antagonist) enhanced the level of NE in juvenile rats and reversed the difference seen with age.  From the present study, we conclude that the deficit in memory seen is likely due to the difference in NE levels with task and this can be reversed by yohimbine which enhance NE levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzGeFKjEr4j7Vg90H21EOLACvtfcHk0lisV8ptOfRRHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFeltb0%253D&md5=8c0fea2283e6a5f57fd74ae28b94aee8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2012.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2012.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DAbraham%26aufirst%3DR.%26aulast%3DJayarajan%26aufirst%3DP.%26aulast%3DMedapati%26aufirst%3DR.%2BB.%26aulast%3DShanmuganathan%26aufirst%3DD.%26aulast%3DKandikere%26aufirst%3DV.%26aulast%3DIrappanavar%26aufirst%3DS.%26aulast%3DSaralaya%26aufirst%3DR.%26aulast%3DBenade%26aufirst%3DV.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DMuddana%26aufirst%3DN.%26atitle%3DDifference%2520in%2520the%2520norepinephrine%2520levels%2520of%2520experimental%2520and%2520non-experimental%2520rats%2520with%2520age%2520in%2520the%2520object%2520recognition%2520task%26jtitle%3DBrain%2520Res.%26date%3D2012%26volume%3D1453%26spage%3D40%26epage%3D45%26doi%3D10.1016%2Fj.brainres.2012.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olton, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuelson, R. J.</span></span> <span> </span><span class="NLM_article-title">Remembrance of places passed: spatial memory in rats</span>. <i>J. Exp. Psychol. Anim. Behav. Process</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">97</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1037/0097-7403.2.2.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1037%2F0097-7403.2.2.97" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1976&pages=97-116&author=D.+S.+Oltonauthor=R.+J.+Samuelson&title=Remembrance+of+places+passed%3A+spatial+memory+in+rats&doi=10.1037%2F0097-7403.2.2.97"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1037%2F0097-7403.2.2.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1037%252F0097-7403.2.2.97%26sid%3Dliteratum%253Aachs%26aulast%3DOlton%26aufirst%3DD.%2BS.%26aulast%3DSamuelson%26aufirst%3DR.%2BJ.%26atitle%3DRemembrance%2520of%2520places%2520passed%253A%2520spatial%2520memory%2520in%2520rats%26jtitle%3DJ.%2520Exp.%2520Psychol.%2520Anim.%2520Behav.%2520Process%26date%3D1976%26volume%3D2%26spage%3D97%26epage%3D116%26doi%3D10.1037%2F0097-7403.2.2.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Braida, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paladini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamperti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, M.</span></span> <span> </span><span class="NLM_article-title">An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>302</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00072-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2F0014-2999%2896%2900072-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=8790986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADyaK28XjtlSksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=1996&pages=13-20&author=D.+Braidaauthor=E.+Paladiniauthor=P.+Griffiniauthor=M.+Lampertiauthor=A.+Maggiauthor=M.+Sala&title=An+inverted+U-shaped+curve+for+heptylphysostigmine+on+radial+maze+performance+in+rats%3A+comparison+with+other+cholinesterase+inhibitors&doi=10.1016%2F0014-2999%2896%2900072-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors</span></div><div class="casAuthors">Braida, Daniela; Paladini, Emma; Griffini, Pierluigi; Lamperti, Mariapia; Maggi, Antonio; Sala, Mariaelvina</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">13-20</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The potential of heptylphysostigmine tartrate (MF201), a new second-generation cholinesterase inhibitor, to antagonize scopolamine-induced amnesia in rats was assessed in an 8-arm radial maze.  Upon completing the training session, the rats were orally administered increasing doses of MF201 (2, 3, 4, 6 and 8 mg/kg) 60 min prior to a s.c. injection of scopolamine (0.25 mg/kg).  Tacrine (0.25, 0.37, 0.5, 1 and 2 mg/kg), 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]-Me piperidine (E2020) (0.125, 0.18, 0.25 and 0.5 mg/kg) and physostigmine (0.15, 0.25, 0.5 and 1 mg/kg) were orally administered and rats were tested in the same task.  As previously described, scopolamine induced an impairment in radial maze performance, measured in terms of total no. of errors, total time taken to complete the task and the percentage of amnesic animals.  The reversal of scopolamine-induced impairment was characterized by the presence of an inverted U-shaped dose-response curve.  A significant antagonistic effect was achieved with a dose (mg/kg) of 0.25 for E2020, 0.5 for tacrine and physostigmine and 3, 4 and 6 for MF201, the latter manifesting a broader spectrum of activity (3-6 mg/kg).  While the maximal active doses restored the scopolamine-induced modified pattern of arm entry, they were ineffective in reducing hypermotility, suggesting the drugs have a specific effect on cognitive function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR3j3kxkBBC7Vg90H21EOLACvtfcHk0liP97GNRrLVpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtlSksb4%253D&md5=96b226b46ac6bd4470b8a02815f07d1e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900072-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900072-6%26sid%3Dliteratum%253Aachs%26aulast%3DBraida%26aufirst%3DD.%26aulast%3DPaladini%26aufirst%3DE.%26aulast%3DGriffini%26aufirst%3DP.%26aulast%3DLamperti%26aufirst%3DM.%26aulast%3DMaggi%26aufirst%3DA.%26aulast%3DSala%26aufirst%3DM.%26atitle%3DAn%2520inverted%2520U-shaped%2520curve%2520for%2520heptylphysostigmine%2520on%2520radial%2520maze%2520performance%2520in%2520rats%253A%2520comparison%2520with%2520other%2520cholinesterase%2520inhibitors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D302%26spage%3D13%26epage%3D20%26doi%3D10.1016%2F0014-2999%2896%2900072-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sage, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuman, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostaras, S. G.</span></span> <span> </span><span class="NLM_article-title">Psychostimulants and cognition: a continuum of behavioral and cognitive activation</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1124/pr.112.007054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1124%2Fpr.112.007054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=24344115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGnu73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2014&pages=193-221&author=S.+Woodauthor=J.+R.+Sageauthor=T.+Shumanauthor=S.+G.+Anagnostaras&title=Psychostimulants+and+cognition%3A+a+continuum+of+behavioral+and+cognitive+activation&doi=10.1124%2Fpr.112.007054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Psychostimulants and cognition: a continuum of behavioral and cognitive activation</span></div><div class="casAuthors">Wood, Suzanne; Sage, Jennifer R.; Shuman, Tristan; Anagnostaras, Stephan G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">193-221, 29 pp.</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Psychostimulants such as cocaine have been used as performance enhancers throughout recorded history.  Although psychostimulants are commonly prescribed to improve attention and cognition, a great deal of literature has described their ability to induce cognitive deficits, as well as addiction.  How can a single drug class be known to produce both cognitive enhancement and impairment.  Properties of the particular stimulant drug itself and individual differences between users have both been suggested to dictate the outcome of stimulant use.  A more parsimonious alternative, which we endorse, is that dose is the crit. detg. factor in cognitive effects of stimulant drugs.  Herein, we review several popular stimulants (cocaine, amphetamine, methylphenidate, modafinil, and caffeine), outlining their history of use, mechanism of action, and use and abuse today.  One common graphic depiction of the cognitive effects of psychostimulants is an inverted U-shaped dose-effect curve.  Moderate arousal is beneficial to cognition, whereas too much activation leads to cognitive impairment.  In parallel to this schematic, we propose a continuum of psychostimulant activation that covers the transition from one drug effect to another as stimulant intake is increased.  Low doses of stimulants effect increased arousal, attention, and cognitive enhancement; moderate doses can lead to feelings of euphoria and power, as well as addiction and cognitive impairment; and very high doses lead to psychosis and circulatory collapse.  This continuum helps account for the seemingly disparate effects of stimulant drugs, with the same drug being assocd. with cognitive enhancement and impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKUCx_-Q7V6rVg90H21EOLACvtfcHk0liP97GNRrLVpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGnu73E&md5=ec43a4e0babb213d36455c2a070ba16e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1124%2Fpr.112.007054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.112.007054%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DS.%26aulast%3DSage%26aufirst%3DJ.%2BR.%26aulast%3DShuman%26aufirst%3DT.%26aulast%3DAnagnostaras%26aufirst%3DS.%2BG.%26atitle%3DPsychostimulants%2520and%2520cognition%253A%2520a%2520continuum%2520of%2520behavioral%2520and%2520cognitive%2520activation%26jtitle%3DPharmacol.%2520Rev.%26date%3D2014%26volume%3D66%26spage%3D193%26epage%3D221%26doi%3D10.1124%2Fpr.112.007054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kandikere, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saralaya, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajjala, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleti, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rasheed, M. A.</span></span> <span> </span><span class="NLM_article-title"><i>In vivo</i> rat striatal 5-HT<sub>4</sub> receptor occupancy using non-radiolabelled SB207145</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">704</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1111/jphp.12030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1111%2Fjphp.12030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=23600388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1Wks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=704-712&author=R.+Nirogiauthor=V.+Kandikereauthor=G.+Bhyrapuneniauthor=R.+Saralayaauthor=D.+R.+Ajjalaauthor=R.+R.+Aletiauthor=M.+A.+Rasheed&title=In+vivo+rat+striatal+5-HT4+receptor+occupancy+using+non-radiolabelled+SB207145&doi=10.1111%2Fjphp.12030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">In-vivo rat striatal 5-HT4 receptor occupancy using non-radiolabelled SB207145</span></div><div class="casAuthors">Nirogi, Ramakrishna; Kandikere, Vishwottam; Bhyrapuneni, Gopinadh; Saralaya, Ramanatha; Ajjala, Devender Reddy; Aleti, Raghupathi Reddy; Abdul Rasheed, Mohammed</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">704-712</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">The objective of the current investigation was to develop a simple, rapid method for detg. in-vivo 5-hydroxytryptamine type 4 receptor (5-HT4R) occupancy in rat brain using non-radiolabeled SB207145 as a tracer for accelerating the drug discovery process.  In-vivo tracer optimization studies for tracer dose, survival intervals and brain distribution profile were carried out in rats.  The tracer was pharmacol. validated using potent well-characterized 5-HT4R ligands.  The brain regional concns. of tracer (SB207145); plasma and brain concns. of 5-HT4R ligands were quantified using high-performance liq. chromatog. coupled with a tandem mass spectrometric detector (LC-MS/MS).  SB207145 showed a higher specific binding in striatum (1.96 ng/g) and lower binding in cerebellum (0.66 ng/g), which is consistent with findings of other published 5-HT4R expression studies.  Pretreatment with potent 5-HT4 ligands dose-dependently reduced striatal SB207145 concn. and the ED to achieve 50% receptor occupancy (ED50) values were 4.8, 2.0, 7.4, 9.9, 3.8 and 0.02 mg/kg for GR113808, piboserod, prucalopride, RS67333, TD8954 and PF04995274, resp.  Results from the mass spectrometry approach to det. 5-HT4R occupancy in rat brain are comparable with those reported using radiolabeled scintillation spectroscopy methods.  In conclusion, the LC-MS/MS characterization permits use of tracer at a preclin. stage in high-throughput fashion as well as characterization of target expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBAD2h_4wjYrVg90H21EOLACvtfcHk0ljMTEM1GhezDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1Wks7w%253D&md5=fdd50664c69a42cbdf1501a11582e591</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1111%2Fjphp.12030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjphp.12030%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DKandikere%26aufirst%3DV.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DSaralaya%26aufirst%3DR.%26aulast%3DAjjala%26aufirst%3DD.%2BR.%26aulast%3DAleti%26aufirst%3DR.%2BR.%26aulast%3DRasheed%26aufirst%3DM.%2BA.%26atitle%3DIn%2520vivo%2520rat%2520striatal%25205-HT4%2520receptor%2520occupancy%2520using%2520non-radiolabelled%2520SB207145%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2013%26volume%3D65%26spage%3D704%26epage%3D712%26doi%3D10.1111%2Fjphp.12030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grimwood, S.</span>; <span class="NLM_string-name">Drummond, E.</span>; <span class="NLM_string-name">Zasadny, K.</span>; <span class="NLM_string-name">Skaddan, M.</span>; <span class="NLM_string-name">Brodney, M.</span>; <span class="NLM_string-name">Coffman, K.</span>; <span class="NLM_string-name">Nicholas, T.</span>; <span class="NLM_string-name">Duvvuri, S.</span>; <span class="NLM_string-name">Raunig, D. L.</span>; <span class="NLM_string-name">Leurent, C.</span>; <span class="NLM_string-name">Rowinski, C.</span>; <span class="NLM_string-name">Park, Y.-S.</span>; <span class="NLM_string-name">Ogden, A.</span>; <span class="NLM_string-name">Sawant-Basak, A.</span>; <span class="NLM_string-name">Miller, E. L</span>; <span class="NLM_string-name">Rapp, T.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Planeta-Wilson, B.</span>; <span class="NLM_string-name">Ropchan, J.</span>; <span class="NLM_string-name">Carson, R.</span>; <span class="NLM_string-name">Morris, E.</span>; <span class="NLM_string-name">Ding, Y.-S.</span>; <span class="NLM_string-name">Katz, E.</span></span> <span> </span><span class="NLM_article-title">Translational receptor occupancy for the 5-HT<sub>4</sub> partial agonist PF-04995274 in rats, non-human primates and healthy volunteers</span>. Proceedings from the  <i>International Conference on Alzheimer’s Disease</i>, July 16–21, 2011, Paris, France; <span class="NLM_publisher-name">Alzforum</span>: <span class="NLM_publisher-loc">Cambridge, MA</span>, <span class="NLM_year">2011</span>; poster no. 11818.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.jalz.2011.05.1875" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=S.+Grimwood&author=E.+Drummond&author=K.+Zasadny&author=M.+Skaddan&author=M.+Brodney&author=K.+Coffman&author=T.+Nicholas&author=S.+Duvvuri&author=D.+L.+Raunig&author=C.+Leurent&author=C.+Rowinski&author=Y.-S.+Park&author=A.+Ogden&author=A.+Sawant-Basak&author=E.+L+Miller&author=T.+Rapp&author=Y.+Wang&author=B.+Planeta-Wilson&author=J.+Ropchan&author=R.+Carson&author=E.+Morris&author=Y.-S.+Ding&author=E.+Katz&title=Translational+receptor+occupancy+for+the+5-HT4+partial+agonist+PF-04995274+in+rats%2C+non-human+primates+and+healthy+volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2011.05.1875&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26id%3Ddoi%3A10.1016%252Fj.jalz.2011.05.1875%26sid%3Dliteratum%253Aachs%26aulast%3DGrimwood%26aufirst%3DS.%26atitle%3DTranslational%2520receptor%2520occupancy%2520for%2520the%25205-HT4%2520partial%2520agonist%2520PF-04995274%2520in%2520rats%252C%2520non-human%2520primates%2520and%2520healthy%2520volunteers%26jtitle%3DInternational%2520Conference%2520on%2520Alzheimer%25E2%2580%2599s%2520Disease%26pub%3DAlzforum%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robert, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc’h, F.</span></span> <span> </span><span class="NLM_article-title">Distinct functional effects of human 5-HT<sub>4</sub> receptor isoforms on beta-amyloid secretion</span>. <i>Neurodegener. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">163</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1159/000113691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1159%2F000113691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=18322379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1Wht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2008&pages=163-165&author=S.+J.+Robertauthor=F.+Lezoualc%E2%80%99h&title=Distinct+functional+effects+of+human+5-HT4+receptor+isoforms+on+beta-amyloid+secretion&doi=10.1159%2F000113691"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct Functional Effects of Human 5-HT4 Receptor Isoforms on β-Amyloid Secretion</span></div><div class="casAuthors">Robert, Sylvain J.; Lezoualc'h, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">163-165</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: The serotonin 5-HT4 receptor is of potential interest for the treatment of Alzheimer's disease because it increases memory and learning and influences amyloid precursor protein (APP) processing.  Several 5-HT4 receptor isoforms have been cloned in humans.  They all belong to the G-protein-coupled receptor superfamily and differ in compn. and length of their amino acid intracellular C-terminal sequence.  At present, it is still unknown whether 5-HT4 receptor isoforms may have distinct effects on APP processing.  Objective: In this study, we investigated the effect of an ultrashort isoform of the human 5-HT4 receptor (2 amino acids after the splicing site), the 5-HT4(d) receptor isoform (h5-HT4(d)), on APP processing in Chinese hamster ovary cells (CHO cells).  Methods: Non-amyloidogenic sol. sAPPα was detd. by immunoblot and β-amyloid peptides (Aβ1-40 and Aβ1-42) were assayed by ELISA in CHO cells stably expressing h5-HT4(d) and transiently transfected with human APP695.  Results: We show here that activation of h5-HT4(d) strongly stimulates the release of sAPPα and concomitantly decreases extracellular Aβ peptides.  These data contrast with our previous findings showing that the h5-HT4(e/g) receptor isoform, which has 20 amino acids after the splicing site, did not influence Aβ secretion.  Conclusion: We conclude that C-terminal tails of 5-HT4 receptor isoforms may influence their functional effect on Aβ secretion and that the pathways regulating either β- or γ-secretase may be differentially controlled by 5-HT4 receptor isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFF1W64EZATLVg90H21EOLACvtfcHk0ljMTEM1GhezDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Wht7s%253D&md5=c90b7775cd8805e5160a66689b8939ff</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1159%2F000113691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000113691%26sid%3Dliteratum%253Aachs%26aulast%3DRobert%26aufirst%3DS.%2BJ.%26aulast%3DLezoualc%25E2%2580%2599h%26aufirst%3DF.%26atitle%3DDistinct%2520functional%2520effects%2520of%2520human%25205-HT4%2520receptor%2520isoforms%2520on%2520beta-amyloid%2520secretion%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2008%26volume%3D5%26spage%3D163%26epage%3D165%26doi%3D10.1159%2F000113691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cachard-Chastel, M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lezoualc'h, F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewachter, I</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delomenie, C</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croes, S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devijver, H</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, M</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Leuven, F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sicsic, S</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardier, A M</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptor agonists increase sAPPα levels in the cortex and hippo-campus of male C57BL/6j mice</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">892</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1038%2Fsj.bjp.0707178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=17325649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs12ntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2007&pages=883-892&author=M+Cachard-Chastelauthor=F+Lezoualc%27hauthor=I+Dewachterauthor=C+Delomenieauthor=S+Croesauthor=H+Devijverauthor=M+Langloisauthor=F+Van+Leuvenauthor=S+Sicsicauthor=A+M+Gardier&title=5-HT4+receptor+agonists+increase+sAPP%CE%B1+levels+in+the+cortex+and+hippo-campus+of+male+C57BL%2F6j+mice&doi=10.1038%2Fsj.bjp.0707178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptor agonists increase sAPPα levels in the cortex and hippocampus of male C57BL/6j mice</span></div><div class="casAuthors">Cachard-Chastel, M.; Lezoualc'h, F.; Dewachter, I.; Delomenie, C.; Croes, S.; Devijver, H.; Langlois, M.; Van Leuven, F.; Sicsic, S.; Gardier, A. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">883-892</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A strategy to treat Alzheimer's disease (AD) is to increase the sol. form of amyloid precursor protein (sAPPα), a promnesic protein, in the brain.  Because strong evidence supports beneficial effects of 5-hydroxytryptamine 5-HT4 receptor agonists in memory and learning, we investigated the role of 5-HT4 receptors on APP processing in 8 wk-old male C57BL/6j mice.  Mice were given, s.c., prucalopride or ML 10302 (s.c.), two highly selective 5-HT4 receptor agonists and, up to 240 min later, the hippocampus and cortex were analyzed by Western blot for sAPPα detn.  Prucalopride (5 or 10 mg kg-1) significantly increased sAPPα levels in the hippocampus and cortex, but did not modify the expression level of APP mRNA as detected by quant. RT-PCR.  A selective 5-HT4 receptor antagonist, GR125487 (1 mg kg-1, s.c.) inhibited prucalopride induced- increase in sAPPα levels.  In addn., levels of sAPPα were increased by ML10302 only at 20 mg kg-1 and was limited to the cortex.  Also, prucalopride increased sAPPα levels in the cortex of a transgenic mouse model of AD, expressing the London mutation of APP.  Furthermore, the combined injection of a selective acetylcholinesterase inhibitor, donepezil and prucalopride induced a synergic increase in sAPPα levels in the cortex and hippocampus.  The results demonstrate that the 5-HT4 receptor plays a key role in the non-amyloidogenic pathway of APP metab. in vivo and give support to the beneficial use of 5-HT4 agonists for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgDGVLDs3CMLVg90H21EOLACvtfcHk0lgFRa2rfladvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs12ntbo%253D&md5=37636a905d062d15019a151f983ecebc</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707178%26sid%3Dliteratum%253Aachs%26aulast%3DCachard-Chastel%26aufirst%3DM%26aulast%3DLezoualc%2527h%26aufirst%3DF%26aulast%3DDewachter%26aufirst%3DI%26aulast%3DDelomenie%26aufirst%3DC%26aulast%3DCroes%26aufirst%3DS%26aulast%3DDevijver%26aufirst%3DH%26aulast%3DLanglois%26aufirst%3DM%26aulast%3DVan%2BLeuven%26aufirst%3DF%26aulast%3DSicsic%26aufirst%3DS%26aulast%3DGardier%26aufirst%3DA%2BM%26atitle%3D5-HT4%2520receptor%2520agonists%2520increase%2520sAPP%25CE%25B1%2520levels%2520in%2520the%2520cortex%2520and%2520hippo-campus%2520of%2520male%2520C57BL%252F6j%2520mice%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D150%26spage%3D883%26epage%3D892%26doi%3D10.1038%2Fsj.bjp.0707178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Activation of 5-HT<sub>4</sub> receptors inhibits secretion of β-amyloid peptides and increases neuronal survival</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>203</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2006.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.expneurol.2006.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=16978609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Krt73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=203&publication_year=2007&pages=274-278&author=S.+Choauthor=Y.+Hu&title=Activation+of+5-HT4+receptors+inhibits+secretion+of+%CE%B2-amyloid+peptides+and+increases+neuronal+survival&doi=10.1016%2Fj.expneurol.2006.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of 5-HT4 receptors inhibits secretion of β-amyloid peptides and increases neuronal survival</span></div><div class="casAuthors">Cho, Seongeun; Hu, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">203</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">274-278</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Activation of 5-HT4 receptors has been shown to improve memory processes in preclin. cognition models, suggesting potential utility of 5-HT4 agonists for the symptomatic treatment of Alzheimer's disease (AD).  Recent studies have shown that 5-HT4 agonists also increase the secretion of the non-amyloidogenic sol. amyloid precursor protein-alpha (sAPPα).  In the present study, we demonstrated that a selective 5-HT4 partial agonist, RS67333, inhibited the generation of β-amyloid peptide (Aβ) in primary cortical cultures of Tg2576 transgenic mice expressing human APPK670N/M671L.  Furthermore, treatments with RS67333 selectively increased the survival of transgenic neurons in a dose-dependent manner, which was inhibited by 5-HT4 antagonists.  These and previous data collectively suggest that the 5-HT4 receptor may be an effective therapeutic target for AD, providing both symptomatic improvements and neuroprotection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr94iComWBAYLVg90H21EOLACvtfcHk0lgFRa2rfladvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Krt73K&md5=0b90d41ab8f752fb01c09cee2df2a429</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2006.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2006.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DActivation%2520of%25205-HT4%2520receptors%2520inhibits%2520secretion%2520of%2520%25CE%25B2-amyloid%2520peptides%2520and%2520increases%2520neuronal%2520survival%26jtitle%3DExp.%2520Neurol.%26date%3D2007%26volume%3D203%26spage%3D274%26epage%3D278%26doi%3D10.1016%2Fj.expneurol.2006.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdet, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruda, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obedencio, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beattie, D. T.</span></span> <span> </span><span class="NLM_article-title">5-HT<sub>4</sub> receptor agonist mediated enhancement of cognitive function <i>in vivo</i> and amyloid precursor protein processing <i>in vitro</i>: A pharmacodynamics and pharmacokinetic assessment</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2011.02.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.neuropharm.2011.02.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=21392515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslyntrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=69-79&author=F.+Shenauthor=J.+A.M.+Smithauthor=R.+Changauthor=D.+L.+Bourdetauthor=P.+R.+Tsurudaauthor=G.+P.+Obedencioauthor=D.+T.+Beattie&title=5-HT4+receptor+agonist+mediated+enhancement+of+cognitive+function+in+vivo+and+amyloid+precursor+protein+processing+in+vitro%3A+A+pharmacodynamics+and+pharmacokinetic+assessment&doi=10.1016%2Fj.neuropharm.2011.02.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">5-HT4 receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment</span></div><div class="casAuthors">Shen, Fei; Smith, Jacqueline A. M.; Chang, Ray; Bourdet, David L.; Tsuruda, Pamela R.; Obedencio, Glenmar P.; Beattie, David T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">69-79</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">There remains an urgent need for therapeutic agents that provide improved symptomatic treatment and attenuate disease progression in patients with Alzheimer's disease (AD).  5-HT4 receptors are widely expressed in those CNS areas which receive substantial cholinergic input and are involved in cognition.  The ability of 5-HT4 receptor agonists to increase acetylcholine (ACh) release and reduce cognitive impairment in both animals and humans was demonstrated.  In addn., 5-HT4 receptor agonist modulation of levels of the amyloid precursor protein (APP) derived peptides, sol. amyloid precursor protein (sAPPα), and amyloid beta protein (Aβ) in the CNS was reported.  In this study, the preclin. properties of 3 structurally-distinct 5-HT4 receptor selective agonists, PRX-03140, velusetrag, and TD-8954, were studied to assess their potential for symptomatic and disease-modifying benefit in the treatment of AD.  All 3 compds. exhibited high affinity for the rat 5-HT4 receptor but could be discriminated on the basis of their agonist activity.  In cAMP accumulation and sAPPα secretion assays using recombinant HEK293f-5-HT4(d)-APP695 cells, velusetrag and TD-8954 were potent, full agonists, relative to 5-HT, whereas PRX-03140 was a partial agonist (intrinsic activity 18%, relative to 5-HT).  In a guinea pig colon isolated tissue prepn., TD-8954 exhibited lower intrinsic activity than velusetrag, and PRX-03140 had negligible agonist activity.  In the rat Morris water maze (MWM) cognition test, velusetrag and TD-8954 (0.1 mg/kg), but not PRX-03140 (0.03-1 mg/kg), significantly reversed the scopolamine-induced spatial learning deficit via activation of 5-HT4 receptors.  Coadministration of subefficacious doses of the acetylcholinesterase inhibitor (AChEi), donepezil (0.1 mg/kg, i.p.), and either velusetrag or TD-8954 (0.01 mg/kg i.p.) resulted in reversal of the scopolamine-induced cognitive deficit.  Pharmacokinetic data indicated that the CNS penetration for all 3 5-HT4 receptor agonists was relatively low.  However, the pharmacodynamic-pharmacokinetic relationships in the MWM model for velusetrag and TD-8954 were consistent with their resp. receptor pharmacol. (binding affinity and intrinsic efficacy) and CNS penetration properties.  Collectively, these findings support a potential role for potent and efficacious 5-HT4 receptor agonists in the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHch3UQC1H5rVg90H21EOLACvtfcHk0ljqIorEIMF29g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslyntrk%253D&md5=be19e02fdc4c73af70613f43cbc215b0</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2011.02.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2011.02.026%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DF.%26aulast%3DSmith%26aufirst%3DJ.%2BA.M.%26aulast%3DChang%26aufirst%3DR.%26aulast%3DBourdet%26aufirst%3DD.%2BL.%26aulast%3DTsuruda%26aufirst%3DP.%2BR.%26aulast%3DObedencio%26aufirst%3DG.%2BP.%26aulast%3DBeattie%26aufirst%3DD.%2BT.%26atitle%3D5-HT4%2520receptor%2520agonist%2520mediated%2520enhancement%2520of%2520cognitive%2520function%2520in%2520vivo%2520and%2520amyloid%2520precursor%2520protein%2520processing%2520in%2520vitro%253A%2520A%2520pharmacodynamics%2520and%2520pharmacokinetic%2520assessment%26jtitle%3DNeuropharmacology%26date%3D2011%26volume%3D61%26spage%3D69%26epage%3D79%26doi%3D10.1016%2Fj.neuropharm.2011.02.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharif, N. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacological evidence for a functional serotonin-2b receptor in a human uterine smooth muscle cell line</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>317</i></span>,  <span class="NLM_fpage">1254</span>– <span class="NLM_lpage">1261</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.100172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1124%2Fjpet.105.100172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=16517693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD28Xlt1eqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2006&pages=1254-1261&author=C.+R.+Kellyauthor=N.+A.+Sharif&title=Pharmacological+evidence+for+a+functional+serotonin-2b+receptor+in+a+human+uterine+smooth+muscle+cell+line&doi=10.1124%2Fjpet.105.100172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological evidence for a functional serotonin-2B receptor in a human uterine smooth muscle cell line</span></div><div class="casAuthors">Kelly, Curtis R.; Sharif, Najam A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1254-1261</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The present study investigated the serotonin-induced increase in phosphoinositide hydrolysis and mobilization of intracellular Ca2+ ([Ca2+]i) in human uterine smooth muscle cells (HUSMCs) to identify the serotonergic receptor pos. coupled to phospholipase C in these cells.  In phosphoinositide (PI) assays, serotonin (5-HT) and α-methyl-5-HT were potent, full agonists (EC50 = 20 and 4.1 nM, resp.), whereas the phenylethylamine, R-(-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane hydrochloride, was less active (EC50 = 63 nM).  Proposed 5-HT2B-selective agonists, BW-723C86 and (+)-norfenfluramine, exhibited strong agonist potency and efficacy comparable with 5-HT (EC50 = 18 and 33 nM, resp.) and ∼15-fold more potency than (-)-norfenfluramine (EC50 = 500 nM).  5-HT2C receptor agonists m-chlorophenylpiperazine and MK-212 were weak agonists in these cells, with potencies of 110 and 880 nM, resp.  A similar rank order of potency was obsd. in [Ca2+]i mobilization assays (r = 0.9) in the HUSMC and with contraction of rat stomach fundus strips that contain a 5-HT2B receptor (r = 0.9).  Antagonist studies revealed that a 5-HT2B-selective antagonist, RS-127445 (Ki = 0.13 nM), was significantly more effective at inhibiting 5-HT-induced activity than a 5-HT2A antagonist, M-100907 (Ki = 914 nM) and the 5-HT2C antagonists RS-102221 (Ki = 2.5 μM) and SB-242084 (Ki = 42.4 nM) in the HUSMC PI turnover assays.  Taken together, these studies strongly suggest the presence of a functionally active 5-HT2B receptor subtype in HUSMCs.  The physiol. role of this receptor in these cells remains to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWnAOFD_xYkrVg90H21EOLACvtfcHk0ljqIorEIMF29g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xlt1eqtbY%253D&md5=52ea7805fe17184bad2816d80f4fe74a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.100172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.100172%26sid%3Dliteratum%253Aachs%26aulast%3DKelly%26aufirst%3DC.%2BR.%26aulast%3DSharif%26aufirst%3DN.%2BA.%26atitle%3DPharmacological%2520evidence%2520for%2520a%2520functional%2520serotonin-2b%2520receptor%2520in%2520a%2520human%2520uterine%2520smooth%2520muscle%2520cell%2520line%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D317%26spage%3D1254%26epage%3D1261%26doi%3D10.1124%2Fjpet.105.100172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manoharan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinde, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padala, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajjala, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, V. R. C.</span></span> <span> </span><span class="NLM_article-title">Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">105425</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2020.105425</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1016%2Fj.ejps.2020.105425" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=32534194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKntrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=105425&author=R.+Nirogiauthor=G.+Bhyrapuneniauthor=N.+R.+Muddanaauthor=A.+Manoharanauthor=A.+K.+Shindeauthor=A.+R.+Mohammedauthor=N.+P.+Padalaauthor=D.+R.+Ajjalaauthor=R.+Subramanianauthor=V.+R.+C.+Palacharla&title=Absorption%2C+distribution%2C+metabolism%2C+excretion+%28ADME%29%2C+drug-drug+interaction+potential+and+prediction+of+human+pharmacokinetics+of+SUVN-G3031%2C+a+novel+histamine+3+receptor+%28H3R%29+inverse+agonist+in+clinical+development+for+the+treatment+of+narcolepsy&doi=10.1016%2Fj.ejps.2020.105425"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, distribution, metabolism, excretion (ADME), drug-drug interaction potential and prediction of human pharmacokinetics of SUVN-G3031, a novel histamine 3 receptor (H3R) inverse agonist in clinical development for the treatment of narcolepsy</span></div><div class="casAuthors">Nirogi, Ramakrishna; Bhyrapuneni, Gopinadh; Muddana, Nageswara Rao; Manoharan, Arunkumar; Shinde, Anil K.; Mohammed, Abdul Rasheed; Padala, Nagasurya Prakash; Ajjala, Devender Reddy; Subramanian, Ramkumar; Palacharla, Veera Raghava Chowdary</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105425</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SUVN-G3031 is a potent and selective inverse agonist of Histmine-3 (H3) receptor that is being investigated for the treatment of narcolepsy.  SUVN-G3031 has high passive permeability, not a substrate for P-glycoprotein, has high plasma unbound fractions and was equally distributed between blood and plasma.  Major routes of metab. in vitro were cyclization (Metabolite A) in microsomes and dealkylation (Metabolite D) in hepatocytes.  Intrinsic clearance in liver microsomes and hepatocytes was low as monitored by metabolite formation approach.  CYP3A4 and MAO-A were the major enzymes involved in the formation of metabolite A and metabolite D resp.  The human hepatic clearance estd. by well-stirred model from hepatocytes was low (2.7 L.h -1) illustrating the importance of metabolite formation kinetics for prediction of human clearance for SUVN-G3031.  Renal clearance in humans (9.7 L.h -1) was predicted from dog renal clearance and accounts for ∼ 78% of the total clearance.  SUVN-G3031 was neither an inhibitor nor inducer of the P 450 enzymes at clin. relevant concns.  SUVN-G3031 did not inhibit the major uptake transporters and was not a substrate for the uptake transporters.  The potential of SUVN-G3031 as a victim and perpetrator of drug-drug interactions is remote.  The predicted human pharmacokinetic parameters were consistent with those obsd. in the first-in-human study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxMYCrhUw617Vg90H21EOLACvtfcHk0ljqIorEIMF29g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKntrnK&md5=66d29d9d3f72695ac827e19458c16ebd</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2020.105425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2020.105425%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DMuddana%26aufirst%3DN.%2BR.%26aulast%3DManoharan%26aufirst%3DA.%26aulast%3DShinde%26aufirst%3DA.%2BK.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DPadala%26aufirst%3DN.%2BP.%26aulast%3DAjjala%26aufirst%3DD.%2BR.%26aulast%3DSubramanian%26aufirst%3DR.%26aulast%3DPalacharla%26aufirst%3DV.%2BR.%2BC.%26atitle%3DAbsorption%252C%2520distribution%252C%2520metabolism%252C%2520excretion%2520%2528ADME%2529%252C%2520drug-drug%2520interaction%2520potential%2520and%2520prediction%2520of%2520human%2520pharmacokinetics%2520of%2520SUVN-G3031%252C%2520a%2520novel%2520histamine%25203%2520receptor%2520%2528H3R%2529%2520inverse%2520agonist%2520in%2520clinical%2520development%2520for%2520the%2520treatment%2520of%2520narcolepsy%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2020%26volume%3D152%26spage%3D105425%26doi%3D10.1016%2Fj.ejps.2020.105425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nirogi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhyrapuneni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muddana, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goyal, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammed, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravula, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jetta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacharla, V. R. C.</span></span> <span> </span><span class="NLM_article-title">First-in-human studies to evaluate the safety, tolerability, and pharmacokinetics of a novel 5-HT<sub>4</sub> partial agonist, SUVN-D4010, in healthy adult and elderly subjects</span>. <i>Clin. Drug Investig.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1007/s40261-021-01027-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1007%2Fs40261-021-01027-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=33788154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhtVars7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2021&pages=469-482&author=R.+Nirogiauthor=G.+Bhyrapuneniauthor=N.+R.+Muddanaauthor=V.+K.+Goyalauthor=S.+K.+Pandeyauthor=A.+R.+Mohammedauthor=J.+Ravulaauthor=S.+Jettaauthor=V.+R.+C.+Palacharla&title=First-in-human+studies+to+evaluate+the+safety%2C+tolerability%2C+and+pharmacokinetics+of+a+novel+5-HT4+partial+agonist%2C+SUVN-D4010%2C+in+healthy+adult+and+elderly+subjects&doi=10.1007%2Fs40261-021-01027-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects</span></div><div class="casAuthors">Nirogi, Ramakrishna; Bhyrapuneni, Gopinadh; Muddana, Nageswara Rao; Goyal, Vinod Kumar; Pandey, Santosh Kumar; Mohammed, Abdul Rasheed; Ravula, Jyothsna; Jetta, Satish; Palacharla, Veera Raghava Chowdary</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Drug Investigation</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-482</span>CODEN:
                <span class="NLM_cas:coden">CDINFR</span>;
        ISSN:<span class="NLM_cas:issn">1173-2563</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">SUVN-D4010 is a novel, potent, highly selective 5-HT4 partial agonist intended for the treatment of cognitive disorders.  The objective of the clin. study was to characterize the safety, tolerability, and pharmacokinetics of SUVN-D4010 in healthy adults after single and multiple doses, and to evaluate the effect of food, sex, and age on the pharmacokinetics.  Single-ascending dose and multiple-ascending dose studies for 14 days were conducted in healthy adults using a randomized, double-blind design.  The effects of food, sex, and age on SUVN-D4010 pharmacokinetics (25 mg single dose) were evaluated using an open-label, two-period, randomized, fed and fasted, crossover design.  Pharmacokinetics and safety assessments were conducted throughout the study.  SUVN-D4010 at a single dose up to 45 mg and multiple doses up to 40 mg once daily was found to be safe and well tolerated in healthy adults.  The most frequently reported adverse events were headache and nausea.  SUVN-D4010 exposure was dose proportional across the tested doses.  Steady state was achieved on day 2 after once-daily dosing for 14 days.  Food had no significant effect on the exposures but an increase in median time to attain the max. plasma concn. (tmax) from 2 h in a fasted state to 3.5 h in fed state was obsd.  The max. plasma concn. (Cmax) and the area under the concn.-time curve (AUC) of SUVN-D4010 was 37% and 39%, resp., lower in adult females compared to males following administration of a single 25 mg dose.  In the elderly population, Cmax and AUC of SUVN-D4010 were 42% and 37%, resp., lower compared to adult males following administration of a single 25 mg dose.  SUVN-D4010 was well tolerated and safe in elderly subjects (≥ 65 years) following a single 25 mg dose.  Conclusion: SUVN-D4010 was found to be safe and well tolerated in healthy human subjects.  SUVN-D4010 followed linear pharmacokinetics across the dose range.  Accumulation was in the range of 1.3- to 1.4-fold after multiple dosing.  Renal excretion is not the major route of elimination.  Food had no effect on the exposures but increased the tmax of SUVN-D4010.  Exposures were lower in females and elderly subjects suggesting sex and age effects on the pharmacokinetics of SUVN-D4010 and possible dose adjustment in these populations.  SUVN-D4010 was well tolerated and safe in elderly subjects after a single dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKWdz6etmtlLVg90H21EOLACvtfcHk0lg6mszONBaHOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhtVars7nE&md5=1c6620287e3797ccd57aefaa49777e1a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs40261-021-01027-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40261-021-01027-4%26sid%3Dliteratum%253Aachs%26aulast%3DNirogi%26aufirst%3DR.%26aulast%3DBhyrapuneni%26aufirst%3DG.%26aulast%3DMuddana%26aufirst%3DN.%2BR.%26aulast%3DGoyal%26aufirst%3DV.%2BK.%26aulast%3DPandey%26aufirst%3DS.%2BK.%26aulast%3DMohammed%26aufirst%3DA.%2BR.%26aulast%3DRavula%26aufirst%3DJ.%26aulast%3DJetta%26aufirst%3DS.%26aulast%3DPalacharla%26aufirst%3DV.%2BR.%2BC.%26atitle%3DFirst-in-human%2520studies%2520to%2520evaluate%2520the%2520safety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520a%2520novel%25205-HT4%2520partial%2520agonist%252C%2520SUVN-D4010%252C%2520in%2520healthy%2520adult%2520and%2520elderly%2520subjects%26jtitle%3DClin.%2520Drug%2520Investig.%26date%3D2021%26volume%3D41%26spage%3D469%26epage%3D482%26doi%3D10.1007%2Fs40261-021-01027-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santa, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligutti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sithiphong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guoliang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zozulya, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phimmachack, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghetti, A.</span></span> <span> </span><span class="NLM_article-title">Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds</span>. <i>Assay Drug Dev. Technol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1089/adt.2004.2.497</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=10.1089%2Fadt.2004.2.497" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=15671647" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVehtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=497-506&author=H.+Taoauthor=A.+D.+Santaauthor=A.+Guiaauthor=M.+Huangauthor=J.+Liguttiauthor=G.+Walkerauthor=K.+Sithiphongauthor=F.+Chanauthor=T.+Guoliangauthor=Z.+Zozulyaauthor=S.+Sayaauthor=R.+Phimmachackauthor=C.+Sieauthor=J.+Yuanauthor=L.+Wuauthor=J.+Xuauthor=A.+Ghetti&title=Automated+tight+seal+electrophysiology+for+assessing+the+potential+hERG+liability+of+pharmaceutical+compounds&doi=10.1089%2Fadt.2004.2.497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds</span></div><div class="casAuthors">Tao, Huimin; Ana, David Santa; Guia, Antonio; Huang, Mingxian; Ligutti, Joseph; Walker, George; Sithiphong, Khachonesine; Chan, Florence; Tao, Guoliang; Zozulya, Zoya; Saya, Steve; Phimmachack, Rick; Sie, Charles; Yuan, Julian; Wu, Lei; Xu, Jia; Ghetti, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Assay and Drug Development Technologies</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">497-506</span>CODEN:
                <span class="NLM_cas:coden">ADDTAR</span>;
        ISSN:<span class="NLM_cas:issn">1540-658X</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Unintended inhibition of the cardiac potassium channel human ether-a-go-go-related gene (hERG) is considered the main culprit in drug-induced arrhythmias known as torsades de pointes.  Electrophysiol. is the most reliable in vitro screening method for identifying potential cardiac hERG liabilities, but only the recent advent of planar electrode-based voltage clamp electrophysiol. promises sufficient throughput to support the drug testing needs of most drug discovery programs.  The authors have assessed the reliability of this new format of the voltage clamp technol. in measuring the activity of small mols. on the hERG channel.  Based on the results herein of a screening against a panel of well-characterized hERG-active and -inactive mols., the authors demonstrate that planar electrode electrophysiol., utilizing the Sealchip and PatchXpress technol. platform (AVIVA Biosciences Corp., San Diego, CA), is comparable to traditional electrophysiol. based on glass micropipettes in its reliability and data content.  The new technol. will allow significantly higher throughput and more thorough testing of pharmaceutical compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX3rSpyKMUAbVg90H21EOLACvtfcHk0lg6mszONBaHOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVehtb7M&md5=40c3a9569d4e739551db6609173b3c58</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1089%2Fadt.2004.2.497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2004.2.497%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DH.%26aulast%3DSanta%26aufirst%3DA.%2BD.%26aulast%3DGuia%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DLigutti%26aufirst%3DJ.%26aulast%3DWalker%26aufirst%3DG.%26aulast%3DSithiphong%26aufirst%3DK.%26aulast%3DChan%26aufirst%3DF.%26aulast%3DGuoliang%26aufirst%3DT.%26aulast%3DZozulya%26aufirst%3DZ.%26aulast%3DSaya%26aufirst%3DS.%26aulast%3DPhimmachack%26aufirst%3DR.%26aulast%3DSie%26aufirst%3DC.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DGhetti%26aufirst%3DA.%26atitle%3DAutomated%2520tight%2520seal%2520electrophysiology%2520for%2520assessing%2520the%2520potential%2520hERG%2520liability%2520of%2520pharmaceutical%2520compounds%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2004%26volume%3D2%26spage%3D497%26epage%3D506%26doi%3D10.1089%2Fadt.2004.2.497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i99"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00703">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_54701"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00703?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00703</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Characterization data of final compounds, comparative <i>in vitro</i> affinities of 5-HT<sub>4</sub>R reference standards, data from functional assays, selectivity profile and elemental analysis (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Additional data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_002.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_003.csv">CSV</a>)</p></li><li><p class="inline">Additional data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_004.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_001.pdf">jm1c00703_si_001.pdf (947.53 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_002.pdf">jm1c00703_si_002.pdf (637.53 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_003.csv">jm1c00703_si_003.csv (8.84 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00703/suppl_file/jm1c00703_si_004.pdf">jm1c00703_si_004.pdf (216.63 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00703&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00703%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00703" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998ade2b4b3c40","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
